Hypothesis and Speculation Registry

This registry collects all hypotheses, speculations, open questions, and predictions from across the paper, organised by topic — including the speculative mechanistic hypotheses developed in depth in Chapter Speculative Mechanistic Hypotheses, alongside hypotheses from the pathophysiology, neurology, immunology, genetics, and other chapters. Each entry records the type (H=Hypothesis, S=Speculation, OQ=Open Question), certainty level, supporting evidence, source citations, underlying mechanism, chapter reference, testable prediction, treatment implications, and known limitations. The registry distills each hypothesis to a structured, fielded record so that researchers can search, compare, and prioritise hypotheses for testing — it feeds directly into the research protocols in Chapter Entries added 2026-08-26: Central Motor-Drive Fatigability Cascade (Bedard 2026).

1 GWAS/WGS Genetic Architecture

Hypothesis p=0.60Glutamatergic Synaptic Dysfunction as Genetically-Driven Core ME/CFS Mechanism

Evidence: Replicated enrichment of glutamatergic synapse genes across DecodeME (single-gene level: SHISA6, UNC13C) and Maccallini meta-GWAS (gene-set level, Bonferroni-corrected, 19,470 cases) provides convergent evidence that glutamatergic signaling dysfunction is genetically grounded, not an epiphenomenon. aligns with E/I imbalance model (Wirth/Scheibenbogen 2026).
Citations: (Maccallini 2026) (DecodeME Consortium, Ponting, et al. 2025) (Klaus J. Wirth and Scheibenbogen 2026)
Mechanism: Risk variants in glutamatergic synapse genes → altered synaptic transmission → excitation/inhibition imbalance → excessive neural activation → autonomic dysfunction, sensory hypersensitivity, PEM. Glutamatergic vulnerability establishes neuronal hyperexcitability substrate upon which physiological stressors trigger pathological cascade.
Chapter ref: ch12: glutamatergic synaptic dysfunction
Prediction: iPSC-derived neurons from high-risk genotype carriers show altered glutamatergic synaptic transmission vs low-risk. PET with glutamate receptor ligands reveals altered receptor density in ME/CFS, correlating with glutamatergic PRS. Falsified if iPSC neurons show normal glutamatergic function or PET shows normal receptor density.
Treatment: Glutamatergic modulators (memantine, riluzole, lamotrigine) stratified by glutamatergic PRS in a trial – no current clinical recommendation.
Limitation: Maccallini2026 is preprint (not peer-reviewed). Gene-set enrichment reflects cumulative expression across all cell types; cell-type-specific glutamatergic dysfunction not yet demonstrated. Glutamatergic PRS has not been tested for clinical utility.

Hypothesis p=0.55Brain-First Genetic Model – No Peripheral/Immune Tissue Enrichment

Evidence: Maccallini 2026 meta-GWAS demonstrates ME/CFS genetic risk enriched exclusively in 14 brain regions + pituitary across 30 tissues, with zero peripheral enrichment. Absence of genetic correlation with autoimmune diseases (DecodeME) constrains peripheral immune hypothesis. Brain-first architecture does not exclude peripheral pathology – it posits that primary genetic vulnerability operates through neuronal circuits with peripheral consequences via efferent signaling.
Citations: (Maccallini 2026) (DecodeME Consortium, Ponting, et al. 2025)
Mechanism: Genetic liability → primary CNS vulnerability (glutamatergic synapses, subcortical/cerebellar neurons) → efferent autonomic dysregulation, neuroendocrine disruption, altered descending pain modulation → peripheral pathology as downstream consequence. Brain is not merely affected – it is genetically inscribed as the primary locus of risk.
Chapter ref: ch12: brain first genetic
Prediction: Brain tissue-specific PRS should outperform whole-genome PRS in predicting ME/CFS; brain imaging abnormalities detectable in at-risk relatives before illness onset. Falsified if peripheral tissue PRS performs equally well or no brain imaging differences in at-risk relatives.
Treatment: Reframes therapeutic strategy: prioritize CNS-penetrant agents over peripherally-restricted anti-inflammatories. Normal peripheral biomarkers should not be interpreted as evidence against biological causation.
Limitation: GWAS captures common variants only; rare variants affecting peripheral tissues undetected. Brain enrichment does not specify which circuits are primarily affected. Cell-type resolution limited by currently available single-cell reference data.

Hypothesis p=0.55Combinatorial Genetic Architecture – Synergistic SNP Interactions Beyond GWAS

Evidence: Sardell et al. 2026 demonstrated reproducible combinatorial genetic risk factors (synergistic SNP-SNP interactions) across DecodeME and independent cohorts using the PrecisionLife platform – interactions not detectable by standard additive GWAS. Genetic risk operates through multi-SNP interactions in addition to additive effects, explaining some “missing heritability” between twin studies and standard GWAS.
Citations: (Sardell et al. 2026) (DecodeME Consortium, Ponting, et al. 2025) (Das et al. 2022)
Mechanism: Risk SNPs at different loci interact synergistically – each alone sub-threshold but in combination substantially increase ME/CFS risk. This architecture is undetectable by standard GWAS testing single SNPs or simple PRS. Reflects polygenic reality where biological pathways require multiple “hits” to cross disease threshold.
Chapter ref: ch12: genetic variants
Prediction: Combinatorial SNP markers identified in DecodeME replicate at p < 0.05 in independent cohort with OR > 1.5 for top decile vs bottom decile of combinatorial risk score. Combinatorial risk score outperforms standard PRS (AUC difference > 0.10). Falsified if combinatorial markers fail to replicate or show no AUC advantage over PRS.
Treatment: Combinatorial risk profiling could identify highest-risk individuals for post-viral monitoring and early intervention. Requires replication and clinical utility evaluation before any application.
Limitation: Combinatorial approach requires validation in ancestrally diverse populations. Synergistic interactions may be dataset-specific. Sardell2026 is a single study.

Speculation p=0.30Unpublished SynGO Enrichment Raises a Provisional Postsynaptic-Assembly Hypothesis

Evidence: Gene-set enrichment of SynGO synapse ontology terms against DecodeME and DecodeME+MVP GWAS (unpublished single-investigator MAGMA run, blog-documented, no deposited code) provisionally localizes the glutamatergic genetic signal toward synaptic assembly/scaffolding. Reported top terms: synapse adhesion between pre- and post-synapse (GO:0099560), regulation of postsynaptic density assembly (GO:0099151), postsynaptic density membrane (GO:0098839), Bonferroni-significant in the DecodeME run; DecodeME+MVP directionally concordant but not independent (meta incorporates DecodeME). Enriched genes include postsynaptic density/adhesion (LRRC7, NLGN1, SHISA6, DCC) plus genes not cleanly postsynaptic (CACNA1E presynaptic Ca channel, NRXN1 presynaptically anchored, ARFGEF2 trafficking), so the postsynaptic-vs-presynaptic distinction is a testable hypothesis, not an established exclusion. SynGO resource shows synaptic genes are conserved and LoF-intolerant (Koopmans 2019).
Citations: (Koopmans et al. 2019) (Maccallini 2026)
Mechanism: ME/CFS risk variants in synaptic assembly/scaffolding and adhesion genes → possibly altered synaptic structure/wiring rather than (or alongside) altered neurotransmitter release → excitatory/inhibitory imbalance → neuronal hyperexcitability substrate. Refines the glutamatergic-synapse hypothesis by asking which process within the synapse is affected; provisional given unpublished/confound-prone source.
Chapter ref: ch14: subsec-18 Maccallini brain-first genetic architecture — Unpublished SynGO Enrichment Raises a Provisional Postsynaptic-Assembly Hypothesis
Prediction: A pre-registered MAGMA gene-set replication on an independent non-overlapping ME/CFS GWAS cohort will reproduce enrichment of postsynaptic assembly/scaffolding SynGO terms (GO:0099560, GO:0099151, GO:0098839) at family-wise-significant levels, surviving correction for gene length/conservation and exceeding a brain-trait pleiotropy baseline. Falsified if no postsynaptic-assembly enrichment, if signal concentrates in presynaptic vesicle-release terms, or if it attenuates to null after length/conservation correction.
Treatment: If confirmed, directs mechanistic and drug-target research toward postsynaptic scaffolding/adhesion machinery rather than neurotransmitter-release pharmacology. No current clinical recommendation.
Limitation: Direct enrichment result is unpublished (blog MAGMA run, no deposited code), not peer-reviewed or independently replicated. Vulnerable to gene-length/conservation bias (synaptic genes long/conserved/LoF-intolerant) and generic brain-trait pleiotropy (SynGO terms shared with SCZ/ADHD/ASD/BP/intelligence). DecodeME+MVP concordance not fully independent (meta incorporates DecodeME). Gene-set enrichment sensitive to window/background/multiple-testing choices. SynGO is an in silico ontology, translation gap to ME/CFS tissue. Severity not stratified.

Open Question p=n/aSynaptic-Density PET (SV2A) as Testable Imaging Correlate

Evidence: If ME/CFS genetic risk localizes to synaptic assembly/scaffolding, synaptic density may be measurably altered. SV2A PET ([11C]UCB-J, [18F]SynVesT-1) measures in-vivo synaptic density and has been applied in schizophrenia (SV2A reduced in cortex, Onwordi 2020) and couples to glutamatergic markers in health (Onwordi 2021); method reviewed in Asch 2024 and Serrano 2022. No ME/CFS SV2A-PET study exists yet.
Citations: (Onwordi et al. 2020) (Onwordi et al. 2021) (Asch et al. 2024) (Serrano et al. 2022)
Mechanism: Proposed tool: measure SV2A binding (synaptic density) across striatum, hypothalamus, and cortex in ME/CFS vs matched controls to test the synaptic-structure hypothesis indirectly, as a presynaptic proxy of total synapse number.
Chapter ref: ch14: subsec-18 Maccallini brain-first genetic architecture — Synaptic-Density PET as a Presynaptic Proxy for Synaptic Structure
Prediction: An in-vivo [11C]UCB-J or [18F]SynVesT-1 PET study, ideally paired with a glutamatergic-neurochemistry readout (e.g. MRS glutamate), will show a measurable difference in SV2A binding (synaptic density) in one or more brain regions in ME/CFS vs matched controls. Falsified if synaptic density is indistinguishable from controls across all regions; a null SV2A result alone does not rule out a postsynaptic-assembly deficit.
Treatment: If positive, could serve as an objective severity or treatment-response biomarker. Early-stage; untested in ME/CFS.
Limitation: SV2A-PET evidence is from schizophrenia/healthy-volunteer and methodological cohorts, not ME/CFS. Translation gap. Not yet performed in ME/CFS. Critically, SV2A is presynaptic while the genetic signal is postsynaptic, so SV2A-PET is an indirect correlate and a null result cannot falsify a postsynaptic deficit.

ID / Label	Details	Phase / Cert
ach cell-type-enrichment-convergence	Multiple independent post-GWAS enrichment analyses (MAGMA, stratified LDSC) applied to DecodeME+MVP meta-GWAS converge: ME/CFS genetic risk maps to neuronal cell types in CNS, not immune cells. Human Brain Atlas (Siletti 2023 via Duncan 2025 pipeline): eMSN is top cell-type hit. Dropviz mouse atlas: 7/13 significant cell types are striatal neurons. DESCARTES fetal atlas: inhibitory interneurons. ImmGen immune cell enrichment: null. Rare variant analysis (Snyder 2025): independently implicates neuronal genes. Broad neuronal signal robust (cert 0.80); fine MSN/eMSN resolution method-dependent (cert 0.40–0.50). MSN enrichment shared across brain traits (schizophrenia, depression, sleep duration, alcohol consumption). Key limitation: zero functional validation of MSN involvement in fatigue phenotype. Origin: literature integration.	Phase 3 / 0.70
hyp striatal-symptom-signalling	Chaudhuri & Behan (2000) proposed that central fatigue results from dysfunction of the striatal-thalamic-frontal cortical system — heterogeneous upstream pathology (immune, metabolic, infectious) converging on striatal circuits to generate the experience of fatigue. The DecodeME cell-type enrichment findings (eMSN/MSN as top hit) provide the first genetic evidence consistent with this 25-year-old hypothesis. Testable prediction: striatal connectivity patterns in resting-state fMRI will predict fatigue severity in ME/CFS independently of peripheral inflammation markers. Falsified if fatigue severity is predicted by peripheral markers but not striatal connectivity. Limitations: theoretical framework only; no direct measurement of striatal-thalamic-frontal circuit function in ME/CFS. Origin: literature synthesis.	Phase 3 / 0.40
lim cell-type-enrichment-caveats	Broad neuronal enrichment signal is robust; fine cell-type specificity (MSN/eMSN) is method-dependent. Varies with pipeline parameters, LD reference panel, gene window size. Other cell types reach significance depending on atlas (glutamatergic neurons in Seeker 2023, inhibitory interneurons in DESCARTES). MSN enrichment not ME/CFS-specific — shared with schizophrenia, depression, alcohol consumption, sleep duration. Does not undermine core finding: genetic risk maps to neurons, not immune cells, across all methods and atlases. Origin: synthesis blog + Brouwer 2026 methodology review.	Phase 3 / n/a
syn genetic-neuronal-convergence	Three independent evidence lines converge on neuronal biology in ME/CFS: (1) common variant GWAS enrichment in brain tissues and neuronal gene-sets (DecodeME, Maccallini 2026), (2) rare variant burden in neuronal/synaptic genes (Snyder 2025 WES), (3) absence of immune cell-type enrichment despite documented peripheral immune abnormalities (ImmGen null). The immune null suggests that immune dysfunction in ME/CFS may be acquired/environmental or below GWAS detection threshold — not that immune involvement does not exist, but that it is not genetically encoded in common variants. This three-pronged genetic architecture (brain-enriched common variants + rare neuronal variants + immune null) provides a genetic framework for the brain-first model. Origin: literature synthesis.	Phase 3 / 0.65

2 DecodeME-Verifiable Hypotheses

Hypothesis p=0.65Heritability Partitioning: Brain-First Model at the Regulatory Level

Evidence: S-LDSC can partition h²_SNP = 0.095 into functional categories (brain enhancers, immune enhancers, coding regions) using only summary statistics. Schizophrenia and bipolar show brain-enhancer concentration.
Citations: (DecodeME Consortium, Ponting, et al. 2025)
Mechanism: If heritability concentrates in brain-specific enhancers, brain-first model gains regulatory-genomic support. If in immune enhancers, immune model gains support. If diffuse, ME/CFS is genetically unlike psychiatric GWAS.
Chapter ref: ch12: heritability partitioning brain
Prediction: If no functional category enriched (all p > 0.05/97 Bonferroni), brain-first model lacks regulatory support. Prediction: brain enhancers >5x enrichment, immune ~2x, coding depleted.
Treatment: Regulatory targets guide therapeutic development (epigenetic modifiers, enhancer-targeted gene therapy).
Limitation: Requires adequate LD score regression sample size. Annotation quality varies by tissue type.

Hypothesis p=0.60PRS Dose-Response Across ME/CFS Severity Grades

Evidence: PRS predicts psychosis severity in schizophrenia and surgery need in IBD. DecodeME severity classification across 17,000+ participants enables ordinal logistic regression of PRS against severity. Sardell cluster-specific PRS testable for differential severity associations.
Citations: (DecodeME Consortium, Ponting, et al. 2025) (Sardell et al. 2026)
Mechanism: Higher genetic loading = more severe disease. PRS should increase monotonically: mild < moderate < severe < very severe. Distinct pathways (neuronal vs immune vs autophagy) may differentially predict severity.
Chapter ref: ch12: prs severity dose response
Prediction: If PRS does not differ across severity grades (ANOVA p > 0.05, variance explained < 0.5%), genetic loading does not determine severity. Prediction: neuronal-synapse PRS shows strongest severity gradient; immune PRS flat across grades.
Treatment: Genotype-stratified clinical trials could enrich severe-patient arms for specific genetic subtypes.
Limitation: Severity classification is cross-sectional and self-reported. Illness duration confounds severity.

Hypothesis p=0.60Depression Comorbidity: Genetic Predictor or Independent Phenocopy?

Evidence: Depression paradox: rg = 0.60 but no shared causal variants. Depression PRS (from PGC GWAS) applied to DecodeME participants tests whether depression in ME/CFS is genuine comorbidity or shared biology.
Citations: (DecodeME Consortium, Ponting, et al. 2025)
Mechanism: If depression PRS predicts depression comorbidity but NOT ME/CFS core symptoms (PEM, OI), depression is independent comorbidity. If depression PRS predicts specific ME/CFS symptoms, those symptoms share biology with depression.
Chapter ref: ch12: depression comorbidity genetic
Prediction: If depression PRS predicts PEM severity independent of depression status (beta > 0.05, p < 0.01), separate pathology model falsified. Prediction: depression PRS predicts comorbidity (OR ~1.1–1.2) but not PEM or OI (p > 0.1).
Treatment: Distinguishes which ME/CFS symptoms to treat with antidepressants vs which require ME/CFS-specific therapy.
Limitation: Depression comorbidity ascertainment may be crude (yes/no). PRS from general population may not generalise to ME/CFS-specific depression.

Hypothesis p=0.55Sex-Differential Genetic Architecture in ME/CFS

Evidence: ME/CFS ~75% female. Autoimmune diseases show variable sex-differential architecture (SLE yes, RA no). DecodeME n~11,700 female + n~3,900 male cases enables sex-stratified GWAS and cross-sex genetic correlation estimation.
Citations: (DecodeME Consortium, Ponting, et al. 2025)
Mechanism: If qualitative sex difference: distinct loci contribute in each sex. If quantitative: same architecture, lower threshold in females due to hormonal/X-linked modifiers. Cross-sex rg < 0.6 implies partially distinct genetic entities.
Chapter ref: ch12: sex differential architecture
Prediction: Cross-sex rg > 0.8 falsifies sex-differential architecture. rg < 0.6 falsifies sex-shared architecture. Prediction: rg = 0.6–0.8, with immune loci showing more sex differentiation than neuronal loci.
Treatment: Sex-stratified PRS could guide sex-specific treatment approaches.
Limitation: Male n~3,900 limits power for sex-specific loci with modest effects. European ancestry only.

Hypothesis p=0.55Partitioned Genetic Correlation: Biological Basis of rg = 0.75 with IBS

Evidence: rg = 0.75 with IBS is the strongest genetic correlation. Three competing models: shared glutamatergic vulnerability, shared serotonergic variants, shared autonomic regulation. Local genetic correlation (rho-HESS, SUPERGNOVA) can identify which genomic regions drive the correlation.
Citations: (DecodeME Consortium, Ponting, et al. 2025)
Mechanism: If correlation concentrated at glutamatergic loci, enteric glutamatergic model supported. If at serotonergic loci, 5-HT model supported. If uniformly distributed, all mechanistic models oversimplify.
Chapter ref: ch12: partitioned rg ibs
Prediction: If rg uniformly distributed (no region >5% of correlation), no single pathway mediates the overlap. Prediction: concentrated at ~20–50 regions with neuronal/synaptic enrichment and modest serotonergic enrichment.
Treatment: Pathway-specific treatments for ME/CFS+IBS comorbidity (glutamatergic modulators vs serotonergic agents).
Limitation: Local genetic correlation methods require large sample sizes. Annotation of ENS-expressed genes less complete than brain.

Hypothesis p=0.50Non-Infectious Onset as Higher Genetic Loading Subtype

Evidence: Non-infectious-onset ME/CFS (~30–40%) lacks the canonical “second hit.” Higher genetic loading may substitute for environmental trigger. Testable by comparing mean PRS across trigger subgroups.
Citations: (DecodeME Consortium, Ponting, et al. 2025)
Mechanism: Without identifiable trigger, higher genetic loading crosses disease threshold independently. Spectrum model: genetic risk can substitute for environmental trigger.
Chapter ref: ch12: non infectious higher loading
Prediction: If mean PRS not higher in non-infectious-onset vs EBV-triggered (one-sided t-test p > 0.05), high-genetic-loading model falsified. Prediction: ~0.15 SD higher PRS in non-infectious-onset cases.
Treatment: Genetic counselling for families with non-infectious-onset: higher familial risk.
Limitation: Triggers may be unmeasured rather than absent. Self-report limitation.

Hypothesis p=0.5076 Long COVID Shared Genes: Trigger-Specific or Shared Downstream Vulnerability?

Evidence: Sardell 2026 identified 76 genes shared between ME/CFS and Long COVID combinatorial analyses. Shared-gene PRS testable against trigger type within DecodeME.
Citations: (Sardell et al. 2026) (DecodeME Consortium, Ponting, et al. 2025)
Mechanism: If shared-gene PRS preferentially predicts post-respiratory-onset ME/CFS, genes represent respiratory-post-infectious genetic subtype. If trigger-independent, overlap reflects shared downstream pathology.
Chapter ref: ch12: long covid shared genes
Prediction: If shared-gene PRS does not preferentially predict post-respiratory-onset ME/CFS (interaction p > 0.1), overlap is downstream biology, not trigger-specific. Prediction: modest trigger preference (OR ~1.15 respiratory vs ~1.05 EBV), dominant signal trigger-independent.
Treatment: Shared vulnerability genes identify patients at risk for both ME/CFS and Long COVID – post-pandemic screening.
Limitation: 76 genes from combinatorial analysis may not replicate in standard PRS framework. Long COVID phenotype definition heterogeneous.

Speculation p=0.50Amitriptyline Pharmacogenomics: CYP Metaboliser Status and the rg = 0.61 Signal

Evidence: rg = 0.61 between ME/CFS and amitriptyline use. CYP2D6/CYP2C19 metaboliser status imputable from GWAS array. Three competing explanations: prescribing overlap, pharmacogenomic selection, shared biological pathway.
Citations: (DecodeME Consortium, Ponting, et al. 2025)
Mechanism: If rg abolished after conditioning on CYP loci, pharmacogenomic variants drive the correlation. If rg persists, shared synaptic pathway genes more likely – same loci increasing ME/CFS risk also increase probability of amitriptyline prescription via shared pain/neuropathy phenotype.
Chapter ref: ch12: amitriptyline pharmacogenomics
Prediction: If CYP2D6 metaboliser status does not associate with amitriptyline use patterns (p > 0.05), pharmacogenomic selection is not driving the correlation. Falsified if conditioning on CYP loci abolishes the rg.
Treatment: CYP genotyping before amitriptyline prescription in ME/CFS – dose optimisation.
Limitation: CYP imputation from array data has limited accuracy for complex CYP2D6 alleles. Amitriptyline use is binary (yes/no) without dose/duration data.

Speculation p=0.50External PRS as Genetic Modifiers of ME/CFS Symptom Profile

Evidence: PRS from external GWAS (chronic pain, cognitive performance, blood pressure, iron, vitamin D) applied to DecodeME may identify which symptom dimensions are genetically shared with other traits vs ME/CFS-specific.
Citations: (DecodeME Consortium, Ponting, et al. 2025)
Mechanism: High ME/CFS PRS + high pain PRS → fibromyalgia-like phenotype. High ME/CFS PRS + protective cognitive PRS → preserved cognition despite severe PEM. External genetic modifiers explain symptom heterogeneity.
Chapter ref: ch12: external prs symptom modifiers
Prediction: If no external PRS predicts any ME/CFS symptom dimension (all p > 0.01), symptom variation is not genetically correlated with common traits. Prediction: pain PRS predicts pain-dominant phenotype; cognitive PRS inversely predicts cognitive dysfunction; blood pressure PRS predicts OI severity.
Treatment: Modifier PRS could guide personalised symptom management (pain pathway PRS → pain-specific treatment).
Limitation: Symptom phenotyping depth in DecodeME may be insufficient for fine-grained subtyping. External PRS transferability uncertain.

Hypothesis p=0.45Genotype-Trigger Interaction: SNP Effects Differ by Infection Type

Evidence: Two-hit model predicts trigger-specific genetic modulation. DecodeME has infection typing (Bretherick 2023: EBV/IM, non-EBV respiratory, Lyme/Q-fever, non-infectious). Case-only GxE design more powerful than case-control GxE.
Citations: (DecodeME Consortium, Ponting, et al. 2025)
Mechanism: Immune-ambiguous loci should have larger effects in EBV-triggered ME/CFS. Neuronal loci should have equal effects regardless of trigger. Significant GxE implies ME/CFS is a family of genotype-trigger combinations.
Chapter ref: ch12: genotype trigger interaction
Prediction: If no SNP shows genotype-trigger interaction (interaction p > 0.006 for 8 GWS loci), same genetic architecture regardless of trigger – two-hit trigger-specific modulation falsified. Prediction: ≥2 of 8 GWS loci show heterogeneity across trigger groups.
Treatment: Trigger-stratified pharmacogenomics: different treatments for different genotype-trigger combinations.
Limitation: Trigger categories are self-reported. Non-infectious category may contain unrecognised infections.

Hypothesis p=0.45CCC vs IOM: Do Diagnostic Criteria Cut Along Genetic Boundaries?

Evidence: DecodeME accepted CCC, ICC, and IOM criteria. CCC requires PEM + neurological/autonomic/immune criteria; IOM is broader. GWAS separately for each subgroup vs shared controls can compare genetic architecture.
Citations: (DecodeME Consortium, Ponting, et al. 2025)
Mechanism: If CCC patients have different genetic architecture than IOM-only, criteria cut along biological boundary. If identical, criteria differences are clinically but not genetically meaningful.
Chapter ref: ch12: diagnostic criteria genetic
Prediction: If rg between CCC-only and IOM-only > 0.90, criteria do not identify distinct genetic subgroups. Prediction: rg = 0.7–0.85, with CCC-only patients showing higher neuronal-cluster PRS.
Treatment: Genetic validation of diagnostic criteria would end decades of criteria debate.
Limitation: Sample sizes for criteria-exclusive subgroups may be small. Some patients may meet multiple criteria simultaneously.

Speculation p=0.40Between-Cluster Epistasis: Neuronal x Autophagy Synergy

Evidence: Sardell 2026 identified within-cluster epistasis. Between-cluster interactions (neuronal x immune, neuronal x autophagy, immune x autophagy) not yet tested. Cluster-pair interaction PRS testable for synergy beyond additive effects.
Citations: (Sardell et al. 2026) (DecodeME Consortium, Ponting, et al. 2025)
Mechanism: If neuronal x autophagy interaction strongest, mitophagy failure in neurons is the critical convergence. If immune x autophagy strongest, immunometabolic dysfunction is central. Tests whether ME/CFS arises from single-pathway failure or multi-pathway convergence.
Chapter ref: ch12: between cluster epistasis
Prediction: If no between-cluster interaction significant (interaction p > 0.01 for all pairs), clusters act independently. Prediction: neuronal x autophagy synergy coefficient > 1.2; immune cluster acts additively.
Treatment: Multi-pathway targeting (e.g., glutamate modulator + mitophagy enhancer) for patients with convergent genetic risk.
Limitation: Between-cluster interaction testing increases multiple testing burden. Power may be insufficient for three-way interactions.

3 Central Noradrenergic and Neuroimmune

Hypothesis p=0.60Handgrip as Non-Invasive Proxy for Central NE Status

Evidence: NE Pathway correlates with handgrip duration (rho=0.62) in patients (Aregawi et al. 2026). Simple, non-invasive, widely available.
Citations: (Aregawi et al. 2026)
Mechanism: Central NE -> motor output -> handgrip endurance. Reduced NE -> reduced motor sustain. Functional proxy for effort mobilization.
Chapter ref: ch08: catecholamine deficit
Prediction: Handgrip correlates with CSF NE in replication (rho more than 0.5). Falsified if below 0.3.
Treatment: Accessible biomarker. Baseline stratification. Serial monitoring without LP.
Limitation: Single NIH cohort. Confounded by muscle fatigue, motivation, pain. May not track longitudinal NE changes.

Hypothesis p=0.55Central NE Deficiency Impairs Glymphatic Clearance via Vasomotion

Evidence: NE drives slow vasomotion for perivascular CSF flow during NREM. CSF NE deficiency in ME/CFS. DTI-ALPS impaired.
Citations: (Aregawi et al. 2026) (Hauglund et al. 2025)
Mechanism: Low CSF NE -> reduced vasomotion -> impaired glymphatic -> waste accumulation -> microglial activation -> further LC dysfunction. Self-reinforcing loop.
Chapter ref: ch08: cascade neuroinflammatory
Prediction: Lowest NE Pathway patients show reduced DTI-ALPS scores. Falsified if no correlation.
Treatment: Sleep optimization. Slow-wave sleep enhancement. Glymphatic clearance as NE-therapy endpoint.
Limitation: NE-vasomotion link in rodents. DTI-ALPS indirect. Causal direction may be reversed.

Hypothesis p=0.50Selective Central Noradrenergic Deficiency with Preserved Dopaminergic Function

Evidence: NE Pathway (NE+DHPG+MHPG) reduced in PI-ME/CFS and PASC vs HVs; DA Pathway normal (Aregawi et al. 2026). MHPG first report. Prior CSF findings (Walitt, Singh, LaMunion, and others 2024). Certainty 0.70→0.50: adversarial review calibrated — single center, n=16, novel unvalidated composite index, no independent replication. Selectivity claim rests on DA null (not shown normal; not powered). Activity/deconditioning confound not experimentally eliminated.
Citations: (Aregawi et al. 2026) (Walitt, Singh, LaMunion, and others 2024)
Mechanism: ATP-dependent vesicular uptake impairment. DBH requires ATP proton pump. Cytoplasmic DA metabolism normal. NE deficiency impairs arousal, effort, autonomic coordination, glymphatic clearance.
Chapter ref: ch08: catecholamine deficit
Prediction: NE Pathway correlates with LC neuromelanin signal on 7T MRI. Contradiction across 2+ independent centers refutes.
Treatment: NE Pathway as CSF biomarker. Drug candidates: atomoxetine, droxidopa.
Limitation: Same NIH center. n=16 PI-ME/CFS small. Unknown for gradual-onset. Causality unestablished. Activity confound unresolved. Novel index not independently validated.

Speculation p=0.50Central-Peripheral Noradrenergic Mismatch in ME/CFS

Evidence: CSF NE reduced (Aregawi et al. 2026). Peripheral NE elevated. Sympathetic predominance with reduced vagal tone. No simultaneous measurement.
Citations: (Aregawi et al. 2026) (B. Winkler et al. 2016) (Wyller et al. 2007)
Mechanism: Central NE deficiency + peripheral sympathetic overactivity -> pathological dissociation. Explains wired-but-tired paradox and lack of NE-orthostatic correlation.
Chapter ref: ch08: central peripheral mismatch
Prediction: Plasma/CSF NE ratio higher in ME/CFS vs controls. Guanfacine improves tachycardia without worsening fatigue. Falsified if ratio normal.
Treatment: Droxidopa (central) may outperform midodrine (peripheral). Guanfacine for peripheral tone.
Limitation: Separate populations. No simultaneous measurement. Adolescent findings may not generalize.

Hypothesis p=0.45NRI/DNRI Therapy for Central NE Deficiency

Evidence: Selective NE deficiency with normal DA suggests reuptake inhibition over synthesis stimulation. Solriamfetol (DNRI) reduced fatigue in ME/CFS pilot (n=38) (Young et al. 2025). SNRIs effective in FM (Arnold et al. 2004) (A. Malik et al. 2025). Atomoxetine improves BP in nOH via NE augmentation (Mwesigwa et al. 2024).
Citations: (Aregawi et al. 2026) (Young et al. 2025) (Arnold et al. 2004) (A. Malik et al. 2025) (Mwesigwa et al. 2024) (Natelson et al. 2015)
Mechanism: NE reuptake blockade compensates for reduced vesicular NE release. Extends synaptic NE dwell time without requiring increased synthesis. Selective NRI (atomoxetine) preferable to SNRI given serotonergic hypersensitivity risk.
Chapter ref: ch14h: noradrenergic nri therapy; ch15: solriamfetol
Prediction: Atomoxetine 40-80mg over 12 weeks reduces MFI physical fatigue by at least 1 SMD vs placebo. CSF NE Pathway predicts NRI response. Atomoxetine superior to duloxetine on fatigue. Falsified if no NE Pathway-NRI response correlation.
Treatment: Atomoxetine 10-40mg titrated; solriamfetol 75-150mg. Contraindicated in hyperadrenergic POTS (tachycardia). Research-stage only.
Limitation: No ME/CFS atomoxetine trial. Solriamfetol n=38, PEM unmeasured. FM ≠ ME/CFS. POTS risk requires baseline autonomic profiling.

Speculation p=0.40Clonidine Negative RCT — Evidence Against SNS-Overactivity Model

Evidence: Clonidine (α2 agonist) RCT in adolescent CFS (n=120) showed no symptom improvement (Sulheim et al. 2014). 0.65→0.40: adversarial review — null result is non-diagnostic; consistent with mismatch model but equally consistent with wrong dose, wrong population, or NE level being irrelevant to symptoms. Not positive evidence.
Citations: (Sulheim et al. 2014) (Aregawi et al. 2026)
Mechanism: Central NE deficiency → peripheral sympathetic compensation. α2 agonism → removes compensation without fixing deficit → no net benefit. Null is not inconsistent with mismatch model but does not confirm it.
Chapter ref: ch08: central peripheral mismatch
Prediction: Clonidine null replicated in independent adult CFS cohorts. α2 antagonists should be tested. Falsified if α2 antagonist also null.
Treatment: Clonidine not recommended for ME/CFS on current evidence.
Limitation: Clonidine trial in adolescents — generalizability unclear. Null is non-diagnostic. Multiple alternative explanations. Single trial.

Speculation p=0.35ATP-Dependent Vesicular NE Deficiency Explains Selective Noradrenergic Deficit

Evidence: Selective NE reduction with normal DA (Aregawi et al. 2026). VMAT2-mediated vesicular DA uptake requires ATP. Normal DA alongside reduced NE predicted if defect upstream of DBH.
Citations: (Aregawi et al. 2026)
Mechanism: Decreased ATP -> impaired VMAT2 proton gradient -> reduced vesicular DA uptake -> selective NE synthesis failure. Exertion -> ATP depletion -> NE crash with PEM.
Chapter ref: ch08: vesicular ne deficiency
Prediction: VMAT2 assay in patient cells should show ATP-dependent impairment reversible with ATP. Falsified if VMAT2 function normal.
Treatment: Neuronal ATP enhancement (ketogenic diet, creatine CNS penetration, CoQ10) may improve NE Pathway.
Limitation: No direct ATP/pH/VMAT2 data in ME/CFS. LC-specific neuroinflammation alternative. Single-center.

Speculation p=0.35Guanfacine α2A-Selective Agonism for PFC

Evidence: Clonidine null (Sulheim et al. 2014) does not rule out α2A-selective agonism. Guanfacine α2A-selective, binds postsynaptic PFC α2A without suppressing LC. Improves cognition in ADHD/TBI. No ME/CFS data.
Citations: (Sulheim et al. 2014)
Mechanism: Guanfacine XR 1-4mg enhances PFC α2A NE signaling for executive function without reducing CSF NE (unlike clonidine). Targets brain fog locus.
Chapter ref: ch14h: guanfacine a2a pfc
Prediction: Guanfacine improves n-back, Stroop, effort-based decisions vs placebo. CSF NE does NOT decrease. Falsified if NE decreases or cognition unchanged.
Treatment: Generic, low-cost, approved for ADHD. Start 1mg QHS, titrate for hypotension/sedation.
Limitation: No ME/CFS data. Hypotension limits dose. ADHD data may not generalize.

Speculation p=0.30Droxidopa DBH Bypass for NE Synthesis

Evidence: Droxidopa converted directly to NE by LAAAD, bypassing DBH and ATP-VMAT2. FDA-approved for nOH. Increases CNS and peripheral NE without vesicular filling.
Mechanism: L-DOPS to LAAAD to NE without DBH. Bypasses ATP-VMAT2 bottleneck. Complements NRI: more substrate + longer dwell.
Chapter ref: ch14h: droxidopa dbh bypass
Prediction: Droxidopa 200-600mg TID over 4 weeks increases CSF NE and improves fatigue in lowest basal NE. Falsified if NE unchanged.
Treatment: If validated, proves DBH bottleneck is targetable. Contraindicated: supine HTN, hyperadrenergic POTS. Research-stage.
Limitation: No ME/CFS data. Supine HTN risk. LAAAD activity may be impaired in ME/CFS.

Speculation p=0.25Striatal Dopaminergic Terminal Loss as Cross-Condition Pathology in Post-Infectious ME/CFS

Evidence: Liu et al. (2026) used VMAT2 PET [(+)11C-DTBZ] in 24 long COVID patients and 24 age-matched controls, finding 16-20% reduction in VMAT2 binding across ventral striatum, dorsal putamen, and dorsal caudate (P=4×10⁻⁵) — reductions comparable to mild-moderate Parkinson’s disease (Liu et al. 2026). The same Toronto cohort showed striatal TSPO PET (microglial activation) (Braga et al. 2023) and MAO-B PET (astrogliosis) (Braga et al. 2025). COVID-recovered controls had normal VMAT2, confirming specificity to persistent illness. Postmortem evidence shows SARS-CoV-2 infects dopaminergic neurons via ACE2 and induces senescence (Yang et al. 2024). Functional correlate in ME/CFS: ultra-high-field 7T fMRI shows reduced nucleus accumbens functional connectivity in an actual ME/CFS cohort (n=32) (Inderyas et al. 2026), and a solriamfetol RCT in ME/CFS improved fatigue and executive function (Young et al. 2025) — both indicating dopaminergic-circuit involvement extends beyond the SARS-CoV-2 subset, though neither measures structural terminal density. Convergent postviral DA neuron vulnerability evidence from alphavirus (Bantle 2019) and interferon-alpha (Capuron 2012). Direct VMAT2 PET data in ME/CFS are still absent. Aregawi et al. (2026) found normal CSF DA pathway indices in PI-ME/CFS, with selective noradrenergic deficiency (Aregawi et al. 2026).
Citations: (Liu et al. 2026) (Braga et al. 2023) (Braga et al. 2025) (Yang et al. 2024) (Aregawi et al. 2026) (Bantle et al. 2019) (Capuron et al. 2012) (R. Chen et al. 2020) (Inderyas et al. 2026) (Young et al. 2025)
Mechanism: SARS-CoV-2 infection → direct ACE2-mediated DA neuron infection in SN/VTA, OR striatal gliosis (microglial + astroglial activation) → synaptic pruning/ROS damage → dopaminergic terminal loss in ventral striatum (apathy), dorsal putamen (motor slowing), and dorsal caudate (memory decline). Preserved DA synthesis capacity (normal CSF DOPAC/HVA) suggests terminal loss with compensatory synthesis upregulation, or MAO-B hyperactivity increasing DA degradation without structural loss.
Chapter ref: ch08: vmat2 longcovid
Prediction: VMAT2 PET [(18F)AV133] in ME/CFS patients will show reduced striatal binding vs healthy controls in a subset with apathy and motor slowing. Falsified if ME/CFS patients show normal VMAT2 binding in all striatal subregions (P≥0.05 for all) — which would establish that the long COVID VMAT2 finding does not generalize. Also falsified if VMAT2 reduction in ME/CFS is present but does not correlate with apathy or motor slowing.
Treatment: If confirmed: DA augmentation (L-DOPA, MAO-B inhibitors, dopamine agonists) as phenotype-targeted treatment for apathy-predominant post-infectious ME/CFS. VMAT2 PET as stratification tool for clinical trials. The MZ twin discordant proposal (MZ Twin Discordant Design: Striatal Imaging, Microbiome, and LSR in Genetically Controlled ME/CFS) offers a genetically controlled design to test this hypothesis directly. Currently all hypothetical — no ME/CFS-specific evidence.
Limitation: No VMAT2 or DAT PET in ME/CFS. Cross-condition inference only. Aregawi 2026 normal DA pathway indices argue against global DA deficiency. Liu 2026 sample (young, apathy-predominant, n=24) limits generalizability. VMAT2 binding may reflect vesicle density rather than terminal count. Certainty retained at 0.25: the functional-connectivity (Inderyas 2026) and treatment-response (Young 2025) evidence supports dopaminergic-circuit involvement in ME/CFS but does not materially increase the probability of structural VMAT2 terminal loss, which is the central claim of this speculation. Origin: literature inference.

Speculation p=0.20α2-Adrenergic Antagonist Strategy for Central NE Restoration

Evidence: If α2 autoreceptor-mediated inhibition suppresses already-low NE release, blocking α2 receptors (yohimbine, idazoxan, atipamezole) may disinhibit release. No ME/CFS data. Mechanism inferred from clonidine null and NE deficit.
Citations: (Aregawi et al. 2026) (Sulheim et al. 2014)
Mechanism: α2 antagonism -> disinhibited NE release -> increased synaptic NE -> improved arousal, attention, motor output. Limited by ATP-dependent vesicular defect.
Chapter ref: ch14h: alpha2 antagonist noradrenergic
Prediction: Low-dose yohimbine (2.5-5mg) acutely increases CSF NE Pathway activity vs pre-dose. Falsified if NE Pathway unchanged — then deficit is pre-synaptic, not autoinhibition-mediated.
Treatment: None — research-stage only. Yohimbine CV effects dangerous in POTS. Idazoxan/atipamezole research compounds.
Limitation: Zero ME/CFS data. Yohimbine hypertension/tachycardia/anxiety poorly tolerated. ATP-dependent defect limits NE release ceiling. Single-center NE Pathway measurement needed.

Speculation p=0.20Dopaminergic Augmentation as Phenotype-Targeted Treatment in Post-Infectious ME/CFS

Evidence: Contingent on the VMAT2 terminal loss hypothesis. L-DOPA augments dopamine in Parkinson’s disease with established efficacy on motor and motivational symptoms. MAO-B inhibitors (selegiline, rasagiline) prevent dopamine degradation. Rasagiline + tyramine patent filed for long COVID by Meyer (Liu 2026 senior author). Dopamine agonists (pramipexole, ropinirole) bypass terminal integrity. LDA (aripiprazole) already in off-label ME/CFS use as partial D2/D3 agonist with anti-microglial properties. Zero trials of any dopaminergic augmentation strategy in ME/CFS.
Citations: (Liu et al. 2026) (Aregawi et al. 2026)
Mechanism: Dopamine precursors (L-DOPA) provide substrate for surviving terminals; MAO-B inhibitors slow degradation in synapse, particularly relevant if astrogliosis-driven MAO-B hyperactivity (Braga 2025) accelerates turnover; dopamine agonists activate postsynaptic receptors independent of terminal integrity; partial agonists (LDA) modulate rather than augment tone while adding anti-microglial effects.
Chapter ref: ch25: dopaminergic augmentation mecfs
Prediction: L-DOPA/carbidopa trial in apathy-predominant PI-ME/CFS will show greater improvement in Marin Apathy Evaluation Scale and Finger Tapping Test in patients with VMAT2 PET-confirmed reduction vs patients with normal VMAT2 binding. Falsified if L-DOPA shows no differential benefit in VMAT2-low vs VMAT2-normal groups, or if it worsens orthostatic intolerance to the point of trial discontinuation.
Treatment: If confirmed in VMAT2-low ME/CFS phenotype: L-DOPA 25/100 mg at 1/4–1/2 tablet starting dose (far below Parkinson’s dosing) with slow titration. Selegiline 1.25–2.5 mg/day. Rasagiline 0.5–1 mg/day. All require screening for OI/POTS, dietary counseling for MAOIs, and serotonin syndrome risk assessment. Not for severe/very severe patients due to OI risk.
Limitation: No ME/CFS clinical data. Entire hypothesis rests on cross-condition extrapolation. Aregawi 2026 normal DA pathway raises possibility that VMAT2 reduction does not translate to functional DA deficiency. MAOI dietary/serotonin interactions are burdensome in a population with unpredictable dietary tolerance. Impulse control disorder risk from agonists. OI worsening from L-DOPA and agonists. Origin: literature inference.

Hypothesis p=0.35MZ Twin Discordant Striatal VMAT2/DAT Imaging in ME/CFS

Evidence: Monozygotic twin discordant design eliminates genetic and shared-environment confounds: the unaffected co-twin provides the optimal control — identical germline DNA, rearing environment, parental SES, childhood diet (Buchwald et al. 2001) (Koelle et al. 2002). DecodeME cell-type enrichment converges on striatal MSNs as the top cell-type hit (Human Brain Atlas pipeline), replicated in Dropviz (Maccallini 2026) (DecodeME Consortium, Ponting, et al. 2025). Liu 2026 demonstrated 16–20% VMAT2 binding reduction in long COVID striatum across ventral striatum, dorsal putamen, and dorsal caudate (P=4×10⁻⁵), reductions comparable to mild-moderate Parkinson’s (Liu et al. 2026). COVID-recovered controls had normal VMAT2, confirming specificity to persistent illness. Zero VMAT2 PET data exist in ME/CFS. Prior twin studies in ME/CFS used blood biomarkers only (CPET, platelet mitochondrial proteomics, HSV serology), no striatal imaging (Giloteaux, Hanson, and Keller 2016) (Ciregia et al. 2016). Genetically-controlled twin design isolates acquired striatal pathology from shared genetic predisposition.
Citations: (DecodeME Consortium, Ponting, et al. 2025) (Maccallini 2026) (Liu et al. 2026) (Buchwald et al. 2001) (Koelle et al. 2002) (Giloteaux, Hanson, and Keller 2016) (Ciregia et al. 2016) (Braga et al. 2023) (Braga et al. 2025) (Treadway et al. 2012)
Mechanism: ME/CFS genetic risk operates through striatal circuits (MSN enrichment) → environmental trigger (infection, stress) activates this vulnerability → acquired striatal dopaminergic terminal pathology → VMAT2 binding reduction in affected twin vs unaffected co-twin carrying identical genetic vulnerability but lacking illness. DAT availability pattern discriminates vesicular deficit (VMAT2↓ + DAT normal) from structural terminal loss (VMAT2↓ + DAT↓). The unaffected co-twin serves as the ultimate within-subject genetic control — any difference is attributable to the illness or its trigger, not to shared predisposition.
Chapter ref: ch47: mz twin discordant striatal microbiome lsr, mz twin discordant striatal microbiome lsr
Prediction: In MZ twin pairs discordant for ME/CFS, the affected twin shows ≥10% reduction in striatal VMAT2 BP_ND vs unaffected co-twin in at least one subregion (Cohen’s d_z ≥ 0.5, FDR q < 0.05). Unaffected co-twin VMAT2 binding remains within 1 SD of healthy reference pair mean. DAT SBR pattern discriminates concordant (VMAT2↓ + DAT↓) from dissociated (VMAT2↓ + DAT normal) presynaptic pathology. Falsified if: no significant within-pair difference in VMAT2 binding (all P ≥ 0.05), OR DAT null — demonstrating long COVID VMAT2 finding does not generalise to ME/CFS and DecodeME brain enrichment reflects genetic vulnerability without acquired striatal pathology.
Treatment: If confirmed: VMAT2 PET as quantitative biomarker for ME/CFS pathophysiology; striatal circuit-level target for dopaminergic augmentation trials (see Dopaminergic Augmentation for Apathy-Predominant and Motor-Slowing Phenotypes in Post-Infectious ME/CFS); VMAT2-low vs VMAT2-normal stratification tool. If null: redirect field away from striatal dopaminergic imaging toward alternative circuits (brainstem noradrenergic, cortical glutamatergic). No current clinical recommendation.
Limitation: No VMAT2 PET data in ME/CFS — entire hypothesis rests on cross-condition extrapolation from long COVID and genetic enrichment convergence. MZ twin discordant design for ME/CFS with PET imaging has never been attempted. Recruitment feasibility uncertain (requires both twins willing and able to travel). Small sample size inherent to twin design limits power. VMAT2 PET tracer availability limited to research centres. Activity/deconditioning confound: affected twin may be less active.

Speculation p=0.20Gut Microbiome–Striatal VMAT2 Axis in ME/CFS — Twin-Controlled Test

Evidence: Microbiome composition predicts fatigue severity in ME/CFS (Nagy-Szakal et al. 2017). The striatum is a primary target of gut-derived inflammatory signals via the gut-brain axis. Kynurenine pathway links gut microbiome to striatal dopaminergic function: microbial metabolites modulate tryptophan metabolism → kynurenine/tryptophan ratio → quinolinic acid production → striatal microglial activation. Microbial SCFAs (butyrate, propionate) cross BBB and influence dopaminergic gene expression in striatum. The twin design controls for the largest confounds in microbiome research (diet, genetics, early environment, childhood antibiotic exposure), isolating the illness-specific microbiome signal. The gut-microbiome-striatal axis has never been tested with simultaneous measurement of both endpoints in any population.
Citations: (Nagy-Szakal et al. 2017) (DecodeME Consortium, Ponting, et al. 2025) (Liu et al. 2026)
Mechanism: Gut microbiome dysbiosis → altered SCFA production + increased kynurenine pathway metabolites → striatal microglial activation → dopaminergic terminal damage → reduced VMAT2 binding. Alternatively: striatal pathology → altered autonomic output → changes in gut motility and mucosal immunity → microbiome dysbiosis (reverse direction). Both models predict VMAT2-microbiome correlation but with opposite causality — the twin design identifies association but not direction. Severity gradient (VMAT2 difference magnitude correlating with illness severity) would strengthen the case for a shared pathological process rather than independent abnormalities.
Chapter ref: ch47: mz twin discordant striatal microbiome lsr
Prediction: In MZ twin pairs discordant for ME/CFS: affected twin shows reduced α-diversity (Shannon index, Chao1) and altered β-diversity (Bray-Curtis dissimilarity) vs unaffected co-twin, with differentially abundant taxa enriched for butyrate-producing species (Faecalibacterium, Roseburia) in the unaffected twin. Microbiome diversity metrics correlate with striatal VMAT2 binding across all twins (r ≥ 0.3, P ≤ 0.05). Falsified if: no within-pair microbiome difference, OR VMAT2-microbiome correlation absent despite significant individual-group differences in either domain.
Treatment: If confirmed: microbiome composition becomes a stratification and potentially modifiable risk factor for striatal pathology. Gut-targeted interventions (probiotics, diet, FMT) could be tested for effects on downstream striatal imaging endpoints. If null and VMAT2 is reduced: isolates CNS as the primary locus — microbiome changes in prior studies likely downstream of illness behaviour (diet, inactivity). No current clinical recommendation.
Limitation: The gut-striatal axis is mechanistically plausible but never directly measured in any population. VMAT2-microbiome correlation at a single timepoint cannot establish direction of causality. Microbiome is confounded by diet, medications, and GI transit time — partial control by twin design but not eliminated. Single stool sample per participant may not capture temporal microbiome dynamics. Entire association is cross-sectional within the study design.

Prediction p=0.30Combined Striatal-Microbiome-LSR MZ Twin Discordant Design as Definitive ME/CFS Biomarker Study

Evidence: The MZ twin discordant design combining striatal VMAT2+DAT imaging, gut microbiome metagenomics, and LSR measurement eliminates the largest confound in ME/CFS biomarker research — shared genetic and environmental predisposition — in a single study. DecodeME 2025 (n=17,294) identified convergence on striatal MSNs and brain-tissue enrichment (DecodeME Consortium, Ponting, et al. 2025) (Maccallini 2026). Liu 2026 found 16–20% VMAT2 reduction in long COVID striatum vs recovered controls (Liu et al. 2026). The LSR hypothesis proposes a novel ratio-based serological biomarker Lytic-to-Structural IgG Ratio (LSR) as a Diagnostic Biomarker. No study has combined these three measures with genetic control. The combined design has multiple falsification paths: (1) all measures null → VMAT2 finding does not generalise + LSR is not an ME/CFS biomarker; (2) discordant pattern → isolates the locus of pathology (CNS vs gut vs serological); (3) LSR trait pattern → establishes genetic basis for herpesvirus antibody abnormality. Every possible outcome is informative — the design is scientifically self-cleaning.
Citations: (DecodeME Consortium, Ponting, et al. 2025) (Maccallini 2026) (Liu et al. 2026) (Buchwald et al. 2001) (Koelle et al. 2002) (Nagy-Szakal et al. 2017)
Mechanism: Three convergent measurement domains anchored to DecodeME genetic findings: striatal VMAT2+DAT PET/SPECT (tests whether MSN genetic enrichment translates to acquired dopaminergic terminal pathology), gut microbiome (tests whether gut-striatal axis mediates the genotype-to-phenotype gap), LSR (tests whether herpesvirus antibody dysregulation is acquired state or genetic trait). Each domain has independent falsification criteria; the combined design enables cross-domain correlations that individual studies cannot test. The design produces a multi-dimensional biomarker matrix: VMAT2 status (reduced/normal) × DAT status (concordant/dissociated) × microbiome status (dysbiosis/normal) × LSR status (state/trait) = 16 combinatorial patterns mapping to clinical phenotypes.
Chapter ref: ch47: mz twin discordant striatal microbiome lsr
Prediction: The combined design will produce at least one positive finding across the three domains at P ≤ 0.05 (FDR-corrected within each domain). Cross-domain correlations will reveal whether VMAT2-microbiome association (r ≥ 0.3) and VMAT2-LSR association (r ≥ 0.2) exist, indicating shared pathological process vs independent abnormalities. Within-pair VMAT2 difference will correlate with illness severity difference (r ≥ 0.4). Falsified if: all three domains null (the most informative null result in ME/CFS history — redirects the entire field away from striatal imaging, gut-brain axis, and LSR hypotheses simultaneously), OR if no cross-domain correlations exist despite positive individual findings.
Treatment: If confirmed: the study generates a validated multi-domain biomarker panel for ME/CFS diagnosis and stratification. Dominant-domain patterns identify drug targets (VMAT2 primary → dopaminergic augmentation; microbiome primary → gut-targeted interventions; LSR primary → antiviral/immunomodulatory). If null: three major hypotheses are falsified simultaneously by the most rigorous design available — high-value negative result that conserves research resources. No current clinical recommendation.
Limitation: The combined design is unprecedented — no study has simultaneously acquired VMAT2 PET, shotgun metagenomics, and multi-antigen herpesvirus serology from the same participants, let alone discordant MZ twin pairs. Recruitment feasibility is uncertain: discordant MZ twin pairs for ME/CFS willing to travel for PET imaging may be extremely rare. Budget and logistics (PET tracer availability, radiochemistry, microbiome sequencing, serology) are substantial and require multi-centre coordination. Small sample size limits power for cross-domain correlations. Temporal stability of all measures unknown. Entirely a proposal — no funding or infrastructure exists.

4 GPCR Autoantibody and Neuroimmune POTS

Speculation p=0.40SARS-CoV-2 Spike S1 and EBV EBNA-1 Shared Epitope with β2-AR Drives Cross-Reactive GPCR AAb via Molecular Mimicry

Evidence: Blitshteyn 2026 invokes molecular mimicry without specifying epitopes. SARS-CoV-2 spike S1 may contain a linear epitope with homology to β2-AR N-terminus. EBV EBNA-1 may share a different epitope with M2 mAChR.
Citations: (Blitshteyn, Doherty, and Steinman 2026) (Wallukat et al. 2021) (El-Rhermoul et al. 2023)
Mechanism: Infection → B cells primed against viral epitope → cross-react with homologous GPCR sequence → functional autoantibodies → GPCR signaling disruption → autonomic dysfunction.
Chapter ref: ch14d: covid ebv mimicry
Prediction: Computational alignment identifies a candidate 8-15aa peptide with ≥60% identity between spike S1 and β2-AR. Sera from post-COVID POTS binds EBV peptide and vice versa. Mice immunized with candidate peptide generate GPCR AAb and autonomic dysfunction. Falsified if no candidate identified or cross-reactivity absent.
Treatment: If mimicry epitope confirmed, tolerization strategies (peptide immunotherapy, B cell tolerance induction) could prevent post-infectious GPCR AAb generation. Vaccine design could exclude cross-reactive epitopes.
Limitation: No cross-reactivity data in ME/CFS or POTS. Molecular mimicry is a plausible but molecularly underspecified mechanism in Blitshteyn 2026.

Speculation p=0.35GPCR AAb → NTS Baroreflex Reset via Area Postrema Access and Receptor Internalization

Evidence: GPCR autoantibodies (α1, M2, M4) may cross area postrema, bind NTS baroreflex neurons, and trigger β-arrestin-mediated receptor internalization, shifting the baroreflex set point rightward → compensatory sympathetic activation despite normal MAP.
Citations: (Blitshteyn, Doherty, and Steinman 2026) (Blitshteyn 2025) (Sunami et al. 2024) (Fedorowski et al. 2017)
Mechanism: Peripheral GPCR AAb → area postrema (leaky BBB) → NTS GPCR binding → β-arrestin internalization → reduced surface receptor density → blunted baroreflex afferent signal → brainstem perceives low MAP → inappropriate sympathetic activation.
Chapter ref: ch08: gpcr baroreflex nts internalization
Prediction: ME/CFS+POTS patients with GPCR AAb show baroreflex sensitivity deficit (r>0.4 with AAb titer). CSF GPCR AAb correlates with baroreflex impairment. TSPO-PET in dorsolateral medulla correlates with baroreflex deficit. Falsified if no correlation between CSF AAb and baroreflex sensitivity.
Treatment: If confirmed, immunoadsorption or BC007 would be expected to restore baroreflex sensitivity within 1-2 weeks of AAb removal. taVNS may bypass the NTS GPCR blockade by directly activating efferent vagal pathways.
Limitation: No direct evidence in ME/CFS or POTS. NTS GPCR internalization pathway inferred from standard pharmacology, not demonstrated in human NTS tissue. Area postrema access by autoantibodies is hypothetical.

Speculation p=0.35GPCR AAb → Mast Cell Sensitization Loop: Bidirectional Amplification Between Autoimmunity and MCAS

Evidence: GPCR autoantibodies may directly sensitize mast cells via β2-AR and M3 receptors expressed on mast cells, creating a bidirectional amplification loop.
Citations: (Blitshteyn, Doherty, and Steinman 2026) (Blitshteyn 2025)
Mechanism: GPCR AAb → mast cell β2-AR desensitization (removing adrenergic brake) + M3 activation (triggering degranulation) → histamine/tryptase release → increased BBB permeability → more AAb CNS access → brainstem neuroinflammation → autonomic dysregulation.
Chapter ref: ch13: gpcr mast cell loop
Prediction: ME/CFS with elevated GPCR AAb and MCAS show correlation between AAb titer and tryptase (r>0.4). Ex vivo mast cells from AAb+ patients show heightened degranulation to substance P (≥2× histamine release). IA reduces both AAb and tryptase. Falsified if no correlation between AAb and mast cell markers.
Treatment: Dual targeting: IA (remove AAb) + mast cell stabilizers (cromolyn, ketotifen) may show synergy. The loop model predicts monotherapy with either is less effective than combination.
Limitation: No direct evidence of GPCR AAb binding to mast cells from ME/CFS patients. Direction of β2-AR AAb effect on mast cells unknown. Loop model is hypothesis requiring direct cellular testing.

Speculation p=0.30Germinal Center-Like B Cell Aggregates in Dorsolateral Medulla Driving Intrathecal GPCR AAb Synthesis

Evidence: Chronic neuroinflammation in dorsolateral medulla may recruit B cells via CXCL13/CXCR5, forming perivascular plasma cell aggregates that produce GPCR autoantibodies locally within CNS.
Citations: (Blitshteyn 2025) (Moen and Iwasaki 2025)
Mechanism: Chronic medullary neuroinflammation → local CXCL13 → B cell recruitment via CXCR5 → perivascular B cell aggregates → local plasma cells → intrathecal GPCR AAb production → direct action on NTS/RVLM/DMV neurons.
Chapter ref: ch08: brainstem bcell aggregates
Prediction: CSF GPCR AAb index (CSF/serum ratio > albumin ratio) ≥1.5 in ≥20% of ME/CFS. CSF oligoclonal bands in ≥20%. TSPO-PET signal in dorsolateral medulla correlates with AAb index (r>0.5). Falsified if CSF AAb index does not exceed 1.0.
Treatment: Intrathecal AAb production would require CNS-penetrant immunomodulation (high-dose rituximab, mycophenolate, daratumumab). IA alone would be insufficient as peripheral AAb removal does not clear intrathecal pool.
Limitation: Zero direct evidence in ME/CFS. CXCL13 not measured in ME/CFS CSF. No postmortem medulla immunohistochemistry exists. Entirely untested.

Speculation p=0.25Ganglionic AChR Autoantibodies Define a Pan-Autonomic ME/CFS Subtype Overlapping with Autoimmune Autonomic Ganglionopathy

Evidence: A subset of ME/CFS with pan-autonomic COMPASS-31 abnormalities may have ganglionic AChR (α3) autoantibodies impairing ganglionic transmission — an AAG look-alike.
Citations: (Blitshteyn, Doherty, and Steinman 2026) (El-Rhermoul et al. 2023)
Mechanism: Autoantibodies bind α3-nAChR on autonomic ganglia → impaired fast synaptic transmission in both sympathetic and parasympathetic ganglia → pan-autonomic failure (orthostatic, GI, thermoregulatory, pupillary, secretomotor).
Chapter ref: ch10: ganglionic achr mecfs
Prediction: COMPASS-31>60 (severe pan-autonomic) ME/CFS patients: ≥15% positive for ganglionic AChR (α3) autoantibodies vs ≤2% healthy. IVIG (2 g/kg monthly ×3) improves COMPASS-31 ≥30% in α3+ patients. Falsified if under 5% positive in pan-autonomic ME/CFS.
Treatment: Standard AAG treatment (IVIG, immunoadsorption, pyridostigmine) would be directly applicable to α3+ ME/CFS patients. Ganglionic AChR ELISA is commercially available for testing.
Limitation: Ganglionic AChR AAb tested in POTS (mixed results), not in ME/CFS. AAG is rare (1:1,000,000) — even if enriched, absolute prevalence in ME/CFS may be under 5%. Pan-autonomic cutoff COMPASS-31>60 not validated for this purpose.

5 Autoantibody Passive Transfer

Hypothesis p=0.65Four-Group Passive Transfer Establishes IgG Pathogenicity

Evidence: Four independent groups (2021–2026) demonstrated passive IgG transfer from fibromyalgia or long COVID patients reproduces symptomatology in mice: Goebel 2021 (FM, n=8), Mignolet 2026 (LC, n=13), Chen 2026 (LC, n=34), Santos Guedes 2026 (LC, n=55). Cell-published. greater than 21,000 protein array. greater than 70 CNS/PNS autoantigens. IENF damage. BBB crossing 5%. Fatigue-like behaviour, balance/coordination loss, thermal hyperalgesia. Independent replication (three groups). Certainty downgraded 0.75→0.65 after adversarial review: zero ME/CFS-specific passive transfer studies, Germain 2025 comprehensive null counterweight, CNS findings from single group.
Citations: (Santos Guedes de Sa 2026) (Goebel et al. 2021) (Mignolet et al. 2026) (H.-J. Chen et al. 2026) (Wilhelm, Cadamuro, and Mink 2025)
Mechanism: Circulating IgG accesses fenestrated capillaries of sensory ganglia (DRG, nodose) → accumulated IgG activates satellite glial cells → neuronal sensitization → peripheral pain, autonomic dysfunction. Subset of IgG crosses BBB (5%) → CNS protein targeting (MED20, USP5) → balance/coordination loss, fatigue-like behaviour. Long-lived plasma cells maintain autoantibody production → persistent pathogenic IgG greater than 2 years.
Chapter ref: ch07: passive transfer pain ch14b: passive transfer four groups
Prediction: ME/CFS IgG (not FM or LC) passive transfer in mice reproduces fatigue-like behaviour and reduced voluntary wheel running with specific CNS and DRG autoantigen targets. Falsified if IgG depletion fails to abolish effect or if control IgG produces similar behaviour.
Treatment: Immunoadsorption, IVIG, FcRn antagonists should benefit IgG-positive subgroups. Symptom-target correspondence: pain → DRG IgG; balance/fatigue → CNS-targeting IgG. Biomarker-guided patient selection for autoantibody trials.
Limitation: No direct ME/CFS passive transfer performed. LC and FM genetic/immunologic backgrounds differ from ME/CFS. Mouse behavioral outcomes cannot capture PEM or brain fog. BBB crossing 5% may be insufficient. Antigen identity incomplete.

Hypothesis p=0.60Autoantibody-Driven CNS Autoimmunity as ME/CFS Subgroup

Evidence: Santos Guedes 2026 demonstrated de novo autoantibodies targeting greater than 70 CNS proteins persist in LC greater than 1 year. MED20 and USP5 confirmed by proteomics. Autoantibodies cross BBB (5%). Abnormal neuronal activation in pain, fatigue, memory, and emotional regulation circuits. Wilhelm 2025 systematic review: 71% of 44 studies show autoantibody-LC association. Three independent groups replicated IgG pathogenicity.
Citations: (Santos Guedes de Sa 2026) (Wilhelm, Cadamuro, and Mink 2025) (L. Wang et al. 2025)
Mechanism: Viral trigger → extrafollicular B cell activation → de novo autoantibody production → CNS and peripheral nerve protein targeting → functional receptor blockade or activation → autonomic dysfunction (GPCR antibodies) and neurological symptoms (CNS antibodies). Long-lived plasma cell reservoirs sustain autoantibody production → chronic disease persistence.
Chapter ref: ch07: passive transfer igg ch14b: passive transfer four groups
Prediction: ME/CFS patients display elevated autoantibodies against CNS proteins (MED20, USP5, or related) with IgG passive transfer reproducing clinical symptoms in mice. Falsified if comprehensive ME/CFS autoantibody profiling with orthogonal platforms (REAP + CellTrend + protein array) shows complete null, or if passive transfer from ME/CFS donors fails to reproduce any symptom.
Treatment: Autoantibody-positive subset identified by comprehensive panel (ANA, GPCR, tissue-specific CNS/peripheral nerve targets) → candidate for immunoadsorption, plasmapheresis, IVIG, or monoclonal antibody therapy. Stratification required — not all ME/CFS is autoantibody-mediated.
Limitation: No direct ME/CFS passive transfer. Germain 2025: comprehensive null in chronic ME/CFS. CellTrend ELISA specificity questioned (POTS replication failure). LC not identical to ME/CFS. Autoantibody prevalence in non-postviral ME/CFS unknown.

Speculation p=0.55Revised Two-Compartment Model: DRG Pain vs CNS Balance/Fatigue

Evidence: Mignolet 2026 and Chen 2026: no cognitive impairment in passive transfer mice. Santos Guedes 2026: balance/coordination loss and fatigue-like behaviour; CNS protein targeting (MED20, USP5); BBB crossing 5%. Resolution: pain/thermal hypersensitivity = peripheral DRG mechanism (all four groups); balance/coordination/fatigue = CNS autoantibody mechanism (Santos Guedes unique finding).
Citations: (Santos Guedes de Sa 2026) (Mignolet et al. 2026) (H.-J. Chen et al. 2026) (Goebel et al. 2021)
Mechanism: Peripheral DRG (fenestrated capillaries, no BBB): all circulating IgG accessible → pain, thermal hypersensitivity, autonomic dysfunction. CNS compartment: BBB restricts access → only 5% of IgG crosses → balance, coordination, fatigue mediated by CNS-targeting IgG if present. Two distinct IgG populations with different antigen specificities drive different symptom domains.
Chapter ref: ch07: two compartment mecfs
Prediction: CNS-autoantibody-positive LC/ME/CFS patients should show balance/coordination/fatigue improvement after immunoadsorption/IVIG; CNS-autoantibody-negative patients improve only in pain/autonomic measures. No improvement in cognitive endpoints in CNS-negative patients after IgG depletion.
Treatment: IgG-targeted therapy biomarkers: not just autoantibody-positive vs negative but CNS-target-antigen vs peripheral-target-antigen profile. Pairs with precision-medicine stratification for therapeutic trials.
Limitation: CNS symptom transfer from Santos Guedes needs replication (unique finding among four studies). MED20/USP5 as CNS targets need validation. 5% BBB crossing adequacy unproven. Mouse fatigue assays (running wheel, forced swim) may not map to human fatigue. Two-compartment parsimony depends on CNS IgG being minority of pathogenic pool.

Speculation p=0.55Symptom-Symptom Autoantibody Correspondence Defines Clinical Endotypes

Evidence: Santos Guedes 2026 demonstrated 85% symptom-symptom correspondence: pain-phenotype mice predominantly received IgG from pain-reporting donors. Unsupervised clustering of greater than 70 CNS/PNS autoantigen reactivities should identify 3-5 endotypes mapping to clinical clusters (pain-dominant, fatigue/balance-dominant, mixed). Certainty 0.50→0.55 after Phase 4c reinforcement audit: independent convergence with CNS autoimmunity subgroup hypothesis (registry cert 0.60), both argue autoantibody-based patient stratification from different angles (cluster data vs mechanism).
Citations: (Santos Guedes de Sa 2026)
Mechanism: Patient IgG carries a unique autoantibody fingerprint targeting complementary CNS and peripheral circuits. Pain-dominant: IgG targeting DRG nociceptors. Fatigue/balance-dominant: IgG targeting CNS proteins (MED20, USP5). Mixed: both populations present. Same pathological mechanism (circulating IgG) produces different phenotypes depending on which tissue compartment and antigen targets are involved.
Chapter ref: ch07: autoantibody endotype clusters
Prediction: Unsupervised clustering of greater than 70 autoantigen reactivities in n greater than 100 LC patients identifies greater than 3 clusters predicting phenotype with greater than 75% accuracy. Each cluster shows distinct treatment response patterns. Falsified if clustering fails despite validated targets, or if treatment response does not differ between clusters.
Treatment: Precision medicine strategy: autoantibody endotyping guides therapeutic selection — DRG-pain → peripheral IgG reduction; CNS-fatigue → CNS-penetrant therapies; mixed → combination. Moves beyond binary autoantibody stratification.
Limitation: Endotypes inferred from 85% correspondence in single study; multi-phenotype clustering never tested. Greater than 70 autoantigen targets unvalidated beyond MED20 and USP5. Small subgroups unstable in clustering. Requires large independent cohorts.

6 Autonomic and POTS/ME/CFS

Hypothesis p=0.50Cerebral Blood Flow as Unifying Hub of POTS Symptoms

Evidence

Malik 2026: POTS patients show gray matter volume reductions, altered brain network connectivity, and cerebral hemodynamic deficits on MRI — structural brain changes correlate with symptom severity. (b) Miranda-Hurtado 2026 (Raj lab): SV→ETCO2→CBF pathway — reduced SV lowers ETCO2 causing hypocapnic cerebral vasoconstriction independent of MAP. (c) Seeley 2025: brain SPECT shows region-specific hypoperfusion in POTS with cognitive dysfunction; perfusion deficits correlate with domain-specific cognitive scores. (d) van Campen 2020: 27% CBF reduction at 20° tilt in severe ME/CFS. (e) This convergence positions CBF — not HR — as the central mediator of POTS symptoms.

Citations

(V. Malik et al. 2026) (Miranda-Hurtado et al. 2026) (Seeley et al. 2025) (C. L. M. C. van Campen et al. 2020)

Mechanism

Low SV (hypovolemia, SFN, splanchnic pooling) → multiple CBF reduction pathways: reduced perfusion pressure, CO2-mediated vasoconstriction, impaired autoregulation → orthostatic CBF deficits → cognitive symptoms (brain fog, dizziness) → chronic repeated CBF drops → cumulative structural brain changes (gray matter atrophy, altered connectivity). CBF decline determines symptom severity; HR increment is a compensatory response to defend CBF.

Chapter ref

ch10: cbf unifying hub

Prediction

Orthostatic cognitive performance correlates more strongly with ΔMCA velocity (r > 0.6) than with ΔHR (r < 0.3) during HUT. Capnometry-guided CO2 augmentation during standing normalizes orthostatic cognitive performance without affecting HR — confirming CO2→CBF→cognition chain. Falsified if CBF does not outperform HR as cognitive performance predictor or CO2 augmentation fails to improve cognition.

Treatment

Reframe POTS treatment evaluation: assess CBF (transcranial Doppler) and orthostatic cognitive performance, not HR reduction alone. Midodrine may improve CBF without affecting HR; ivabradine may reduce HR but worsen CBF; capnometry biofeedback may improve CBF non-pharmacologically.

Limitation

CBF studies (Malik, Seeley) are moderate n, single-center; cross-sectional — cannot distinguish cause from consequence; structural brain changes could predate POTS or result from comorbid conditions; CO2 augmentation paradigm is experimental, not therapeutic.

Speculation p=0.50Compensatory Tachycardia — HR Reduction as CBF Destabilization in POTS

Evidence

Marchetta 2025: ivabradine reduces HR in POTS but symptom improvement does not correlate with HR reduction magnitude. (b) Chopra 2026: mechanistic argument that POTS tachycardia is compensatory and treatment should target root cause (hypovolemia, venous pooling). (c) Miranda-Hurtado 2026 (Raj lab): reduced SV → lower ETCO2 → hypocapnic cerebral vasoconstriction → impaired CBF, establishing the mechanistic link from low SV to orthostatic cognitive symptoms. (d) Clinical implication: ivabradine/beta-blockers prescribed without first normalizing SV may reduce CO and worsen CBF in low-SV patients.

Citations

(Marchetta et al. 2025) (Chopra 2026) (Miranda-Hurtado et al. 2026)

Mechanism

Low SV → compensatory tachycardia to defend CO and CBF → pharmacological HR reduction without SV support → CO drops → MAP falls → CBF worsens → cognitive and orthostatic symptoms increase. The heterogeneity in ivabradine treatment response corresponds to SV reserve: preserved SV (hyperadrenergic POTS) → benefit; low SV (hypovolemic/neuropathic POTS) → worsening.

Chapter ref

ch10: compensatory tachycardia

Prediction

Pre-treatment SV (impedance cardiography or echo during HUT) predicts treatment response: patients in lowest SV tertile show net worsening of orthostatic cognitive performance after 4 weeks ivabradine; highest SV tertile show improvement. SV-by-treatment interaction significant (p < 0.05) in crossover. Falsified if SV does not predict response or all tertiles show equivalent CBF change.

Treatment

Stratify POTS treatment by SV — ivabradine/beta-blockers only in patients with preserved or elevated SV (hyperadrenergic subtype); avoid in low-SV patients without concurrent volume expansion. Measure SV before prescribing rate-control agents.

Limitation

Marchetta 2025 moderate n (single center); Chopra 2026 is review/opinion (low-medium certainty); compensatory tachycardia hypothesis untested in prospective trial; SV measured by impedance cardiography has moderate accuracy vs gold-standard echo.

Speculation p=0.50Central Sensitization in POTS — CNS Amplification Component

Evidence

Mathew 2026 (Novak lab, JAMA Network Open): 67% of POTS patients meet criteria for central sensitization using validated questionnaires (CSI) — prevalence far exceeding general population. (b) If central sensitization alters processing of autonomic afferent signals at NTS, parabrachial nucleus, and insular cortex, the brain’s interpretation of hemodynamic state is systematically distorted — perceived CBF deficit may exceed actual deficit. (c) Ekman 2025: SFN severity correlates with GI symptoms — peripheral nerve damage provides aberrant afferent input that can trigger or maintain central amplification.

Citations

(Mathew and Novak 2026) (Ekman et al. 2025)

Mechanism

SFN/autonomic nerve damage → aberrant afferent input → central sensitization at brainstem/cortical autonomic nuclei → amplified sympathetic response to orthostatic stimulus → hyperadrenergic state disproportionate to actual hemodynamic deficit → exaggerated HR, symptoms. The peripheral driver (SFN) and CNS amplification (sensitization) are not alternatives — they form a feed-forward loop.

Chapter ref

ch14d: pots central sensitization

Prediction

CSI≥40 POTS patients show exaggerated insula/ACC BOLD activation during graded HUT vs CSI− patients matched for HR, MAP, and SV — confirming CNS amplification of same peripheral signal. CSI score predicts treatment response: high-CSI → better response to CNS-directed (duloxetine, tVNS); low-CSI → better response to peripheral (midodrine, fludrocortisone). Falsified if CSI does not predict differential treatment response.

Treatment

POTS patients with high CSI may benefit from CNS-directed interventions (low-dose duloxetine, cognitive interoceptive retraining, tVNS) rather than or in addition to standard peripheral POTS pharmacotherapy. Stratification by CSI could personalize treatment selection.

Limitation

Mathew 2026 single-center, moderate n, uses self-report CSI (validated for chronic pain, not specifically for dysautonomia). Central sensitization may be consequence (chronic orthostatic stress → CNS remodeling) rather than independent driver. No fMRI or QST validation in this cohort. Treatment stratification entirely untested.

Speculation p=0.35Extracranial Venous Compression Impairs Glymphatic Clearance in ME/CFS

Evidence: 3 ME/CFS studies show abnormal cerebral venous return in 34–48% of patients (Marshall et al. 2022). Glymphatic dysfunction via DTI-ALPS documented in 65% of ME/CFS patients (Patel et al. 2024). IJV flow velocity 36% reduction upright vs supine in MTS (Hartung et al. 2019).
Citations: (Marshall et al. 2022) (Patel et al. 2024) (Hartung et al. 2019) (Neglén and Raju 2008) (Wolpert et al. 2020) (O’Sullivan et al. 2018) (Ferreira et al. 2023)
Mechanism: Extracranial venous compression (MTS, IJV stenosis, CCI) → increased intracranial venous pressure → reduced perivenous CSF drainage → impaired glymphatic clearance → waste accumulation (amyloid-beta, tau, cytokines) → neuroinflammation → fatigue, brain fog, unrefreshing sleep.
Chapter ref: ch14a: venous stasis glymphatic
Prediction: DTI-ALPS index correlates inversely with iliac vein compression severity on CT venography; CSF cytokine/amyloid concentrations higher in patients with compromised cerebral venous return on MRV; stenting in MTS+ ME/CFS improves DTI-ALPS at 6 months.
Treatment: If confirmed: MRV/CT screening for venous compression in ME/CFS patients with predominant brain fog, unrefreshing sleep, and headache. CO₂ challenge or lumbar puncture opening pressure to distinguish ICP elevation from venous obstruction.
Limitation: No study directly measuring MTS-to-glymphatic chain in ME/CFS. Stenting outcomes in MTS general population may not generalize to ME/CFS. Glymphatic dysfunction may persist despite restored venous flow if AQP4 mislocalization or chronic neuroinflammation are irreversible.

Speculation p=0.25May Thurner Syndrome as Contributor to Venous Return Impairment in ME/CFS

Evidence: Anatomical prevalence 22–24% in cadaver studies; female predominance 2–3:1; diagnostic delay 4.2 years (Neglén and Raju 2008) (Ferreira et al. 2023). Fatigue improves in 32–68% after stenting (Wolpert et al. 2020) (O’Sullivan et al. 2018). Autonomic dysfunction documented in MTS (reduced HRV, orthostatic hypotension in 45%) (R. H. Anderson et al. 2021). No study has screened ME/CFS cohorts for MTS.
Citations: (Neglén and Raju 2008) (Wolpert et al. 2020) (O’Sullivan et al. 2018) (Hartung et al. 2019) (R. H. Anderson et al. 2021) (Ferreira et al. 2023) (Marshall et al. 2022) (Patel et al. 2024)
Mechanism: Iliac vein compression → venous pooling → reduced preload + orthostatic intolerance → compounded by existing ME/CFS blood volume deficits + autonomic dysfunction. Extracranial venous obstruction → impaired cerebral venous return → glymphatic impairment pathway.
Chapter ref: ch10: mts venous return; ch14a: glymphatic venous
Prediction: Iliac vein compression severity on CT/MRV correlates with orthostatic symptom severity in ME/CFS; IJV flow velocity (upright TCD) is lower in MTS+ vs MTS− ME/CFS; stenting in confirmed MTS+ ME/CFS improves orthostatic intolerance beyond procedural effect.
Treatment: If confirmed: MRV/CT venography screening in ME/CFS patients with left-leg predominant symptoms, severe OI, or poor response to standard therapy. Stenting as targeted intervention for MTS+ subset.
Limitation: No direct ME/CFS-MTS evidence. All MTS data from non-ME/CFS populations. Anatomical prevalence may mean MTS is incidental. Reversible venous fatigue in MTS is distinct from ME/CFS fatigue. Entirely speculative until screening study conducted.

Speculation p=0.25Orexin→PKA→Tau Phosphorylation: Production-Prevention Pathway in ME/CFS

Evidence: Parhizkar et al. 2025 demonstrated in P301S/E4 tauopathy mice that lemborexant (DORA) reduces tau phosphorylation via cAMP/PKA pathway inhibition, preserving hippocampal volume by 30–40% (Parhizkar et al. 2025). Critical dissociation: zolpidem increased sleep but provided zero neuroprotection, proving orexin signaling (not sleep duration) is the mechanistic driver. Lucey et al. 2023 provided human validation: suvorexant 20 mg reduced CSF p-tau181/T181 ratio by ~10–15% in cognitively unimpaired adults (Lucey et al. 2023). These findings identify a production-prevention pathway (orexin→PKA→tau phosphorylation) mechanistically distinct from glymphatic clearance and HSP70-mediated repair. No ME/CFS data exist.
Citations: (Parhizkar et al. 2025) (Lucey et al. 2023) (J.-E. Kang et al. 2009)
Mechanism: Orexin receptor activation → cAMP elevation → PKA activation → tau phosphorylation at specific residues (Ser202, Ser409, Thr205). DORAs block this pathway. ME/CFS orexin is partially suppressed — endogenous PKA pathway may already be downregulated, or residual orexin tone during fragmented sleep may drive pathological phosphorylation.
Chapter ref: ch15: ch1: 5 orexin pka tau
Prediction: ME/CFS patients with high vs low CSF orexin-A should show proportionally different CSF p-tau181/T181 ratios; DORA-treated ME/CFS patients should show lower p-tau/T-tau ratios than Z-drug-treated patients, matched for sleep duration improvement.
Treatment: If confirmed in ME/CFS: DORAs preferred over Z-drugs for sleep in patients with elevated p-tau biomarkers, pending clinical trials. Z-drugs carry glymphatic impairment (Hauglund 2025) without tau protection. Entirely speculative — no ME/CFS tau data, no DORA-vs-Z-drug human comparison.
Limitation: Single preclinical study (male mice only, tauopathy model). Human validation acute single-dose only, cognitively unimpaired participants. No ME/CFS tau phosphorylation data. All claims cross-disease extrapolation from tauopathy models. Orexin is already suppressed in ME/CFS — adding a DORA may have different (potentially adverse) effects than in tauopathy with normal/high orexin tone.

Open Question p=n/aSystematic Screening for May Thurner Syndrome in ME/CFS Cohorts

Evidence: MTS anatomical prevalence 22–24% (Neglén and Raju 2008); no study has screened ME/CFS patients. Fatigue improves 32–68% after stenting (Wolpert et al. 2020) (Ferreira et al. 2023). Autonomic dysfunction overlaps between MTS and ME/CFS (R. H. Anderson et al. 2021). Screening question: does iliac vein compression prevalence in ME/CFS exceed general population, and if so, does treatment improve ME/CFS symptoms?
Citations: (Neglén and Raju 2008) (Wolpert et al. 2020) (O’Sullivan et al. 2018) (R. H. Anderson et al. 2021) (Ferreira et al. 2023) (Marshall et al. 2022)
Mechanism: CT venography or MRV screening of ME/CFS cohort (n≥500) → MTS prevalence + correlation with symptom severity, orthostatic intolerance, and glymphatic biomarkers → pilot stenting trial in confirmed MTS+ ME/CFS subgroup (n=30) with primary endpoint SF-36 vitality and secondary endpoint DTI-ALPS.
Chapter ref: ch10: mts venous return; ch14a: venous stasis glymphatic
Prediction: MTS prevalence in ME/CFS > 22–24% (general population); stenting improves SF-36 vitality by ≥10 points vs sham; DTI-ALPS improves at 6 months post-stenting.
Treatment: If positive: add CT/MRV to ME/CFS diagnostic workup in patients with suggestive features (left-leg symptoms, severe OI, treatment-refractory). If negative: exclude MTS as a meaningful contributor not worth routine screening.
Limitation: Entirely untested. Anatomical MTS may be incidental and unrelated to ME/CFS. Stenting carries procedural risks (thrombosis, stent migration, bleeding). Placebo effect/regression to mean in unblinded stenting. No funding or trial infrastructure for this research program.

7 Vagal Cholinergic Gastric Denervation

Hypothesis p=0.35Structural Vagal Cholinergic Denervation as an Anatomical Substrate for Post-Viral Dysautonomia and Sustained Inflammation

Evidence: Acanfora et al. 2026 (Acanfora et al. 2026) — first in vivo evidence of selective cholinergic (VIP+) gastric-mucosal denervation in Long COVID (n=12 vs 8), correlating with vagal HRV (LF/HF R=0.50), NT-proBNP and D-dimer; skin IENFD preserved (selectively visceral). Proximal mechanism: Woo 2023 (Woo et al. 2023) (SARS-CoV-2 RNA + monocyte infiltration in vagus nerve) and Llados 2024 (Lladós et al. 2024) (vagus ultrasound thickening + reduced GI peristalsis); predicted by VanElzakker 2013 (VanElzakker 2013). CAP linkage: Tracey 2002 (Tracey 2002), Bonaz 2018 (Bonaz, Bazin, and Pellissier 2018). Extrapolation to ME/CFS indirect — no ME/CFS gastric histology exists; certainty is 0.35 rather than 0.45 (the underlying Long COVID finding) because the hypothesis adds an untested cross-disease inference step. Origin: literature integration.
Citations: (Acanfora et al. 2026) (Woo et al. 2023) (Lladós et al. 2024) (VanElzakker 2013) (Tracey 2002) (Bonaz, Bazin, and Pellissier 2018)
Mechanism: Post-viral vagal injury (viral trafficking / immune-mediated) leads to loss of efferent cholinergic (VIP+) fibers, disengaging the cholinergic anti-inflammatory pathway (vagus, alpha7-nAChR, macrophage TNF-alpha suppression), producing a self-sustaining proinflammatory state maintaining fatigue/autonomic symptoms. Structurally distinct from, and potentially additive with, functional CAP blockade by GPCR autoantibodies (Cholinergic Anti-Inflammatory Pathway Blockade by GPCR Autoantibodies — Potential Mechanism for Vagal Treatment Stratification).
Chapter ref: ch13: structural vagal denervation cap, ch10: vagal structural denervation
Prediction: ME/CFS gastric mucosal biopsy will show reduced VIP+ fiber density vs controls; density will correlate inversely with TNF-alpha/CRP and positively with HF-HRV, independently of GPCR-autoantibody status. Falsified if ME/CFS gastric innervation is normal, or if inflammation tracks autoantibody titre but not fiber density.
Treatment: Mechanistic rationale only (not a recommendation) for vagus-nerve stimulation and cholinergic modulation as investigational approaches; structural denervation argues for early intervention to preserve fibers. No ME/CFS-specific VNS efficacy/safety data.
Limitation: All direct structural evidence is Long-COVID-specific (Acanfora n=12, single-center, dyspeptic controls, no recovered-asymptomatic group). CAP linkage foundational but not ME/CFS-specific. Structural and functional routes not mutually exclusive. Not independently replicated. No ME/CFS gastric-innervation study exists.

Speculation p=0.20Structural Vagal Damage as a Distinct Upstream Node (V_str) in the Causal DAG

Evidence: Motivated by the structural denervation hypothesis (Structural Vagal Cholinergic Denervation as an Anatomical Substrate for Post-Viral Dysautonomia and Sustained Inflammation) and Acanfora 2026 (Acanfora et al. 2026), whose single upstream structural deficit correlated with three downstream readouts (CAP/inflammation, GI motility, HF-HRV). Proposes a slowly-varying structural-capacity variable that bounds functional vagal signaling from above. Origin: brainstorm (ideas 7.1/7.2/7.3/7.5 consolidated).
Citations: (Acanfora et al. 2026) (Tracey 2002)
Mechanism: V_str = surviving vagal cholinergic fiber capacity; functional tone is bounded by V_str, so afferent activation (incl. taVNS) cannot exceed the surviving-fiber ceiling. Distinct time constant from functional signaling (fiber loss slow; signaling fast). One upstream node, three downstream consequences (inflammation, GI, HRV).
Chapter ref: ch13: vstr dag node
Prediction: taVNS-induced TNF-alpha suppression shows a response ceiling correlating with structural fiber density (gastric VIP+ IHC / validated proxy), independent of baseline functional HRV; GI, HRV, and inflammatory readouts load on a common latent factor. Falsified if taVNS response is fully predicted by functional tone with no residual structural term, or if the three readouts share no common factor.
Treatment: If validated, would predict a per-patient ceiling on vagus-stimulation efficacy — useful for trial stratification. Untested modeling proposal, not a recommendation.
Limitation: V_str not parameterized; no ME/CFS structural vagal measurement exists to estimate it. May collapse into functional-tone variables if structural and functional deficits prove empirically inseparable (Five Unresolved Threats to the Structural Vagal Denervation Model).

Open Question p=n/aDoes Post-Viral Small Fiber Pathology Preferentially Target Visceral (Vagal) or Somatic Fibers?

Evidence: Acanfora 2026 (Acanfora et al. 2026) reports selectively visceral cholinergic denervation with preserved skin IENFD in Long COVID (single study, n=12, dyspeptic controls); Oaklander/Joseph 2021 (Joseph et al. 2021) and Azcue 2023 (Néstor Azcue et al. 2023) document somatic small fiber loss in ME/CFS (multiple cohorts, meta-analysis). The evidence bases are asymmetric — Acanfora is unreplicated vs somatic SFN is meta-analytic — so the apparent contradiction may reflect different evidentiary maturity rather than genuine biological divergence. Origin: literature integration (cross-disease contradiction framing).
Citations: (Acanfora et al. 2026) (Joseph et al. 2021) (Néstor Azcue et al. 2023)
Mechanism: Three compatible explanations: (a) Long COVID and ME/CFS differ in fiber tropism (different diseases); (b) different stages of one process; (c) methodological — gastric-mucosal vs lower-leg skin biopsy sample distinct fiber populations not directly comparable.
Chapter ref: ch08: sfn visceral vs somatic, ch08: sfn visceral somatic
Prediction: Paired gastric-mucosal and skin biopsies within one ME/CFS cohort reveal concordant or discordant small fiber loss; the visceral:somatic ratio differs systematically between Long COVID and non-COVID ME/CFS and tracks disease duration. Resolves (a)/(b)/(c).
Treatment: N/A — research direction. Determines whether skin biopsy can miss vagal small fiber neuropathy in post-viral illness (a normal skin biopsy would not exclude visceral denervation).
Limitation: Acanfora small dyspeptic-control sample; no matched skin-vs-mucosa sampling within a single cohort exists; QST/skin and mucosal-biopsy methods are not standardised against each other.

Open Question p=n/aFive Unresolved Threats to the Structural Vagal Denervation Model

Evidence: Critical self-audit (brainstorm categories 10-12) of Structural Vagal Cholinergic Denervation as an Anatomical Substrate for Post-Viral Dysautonomia and Sustained Inflammation. (1) VIP+ IHC cannot separate extrinsic vagal from intrinsic enteric fibers (Acanfora et al. 2026); (2) HRV/fiber changes confounded by deconditioning (uncontrolled in Acanfora); (3) n=12 winner’s-curse inflates R=0.50-0.61 correlations. Origin: brainstorm critical categories.
Citations: (Acanfora et al. 2026)
Mechanism: Confounds/ambiguities that could produce the observed findings without supporting a vagal-specific structural-denervation causal model: enteric-source fiber loss, disuse atrophy, small-sample effect-size inflation.
Chapter ref: ch13: vagal enteric deconditioning
Prediction: Any positive structural finding must survive (a) source attribution (snRNA-seq / retrograde tracing distinguishing vagal from enteric), (b) activity-matched controls, and (c) replication in a larger healthy-controlled cohort before the vagal-denervation causal interpretation is accepted.
Treatment: N/A — methodological caveat; guards against premature clinical use of the structural model or VNS targeting.
Limitation: The confounds are themselves inferred; some (deconditioning, source attribution) are directly testable and should be measured in any future ME/CFS study.

8 Brain Clearance Architecture

Speculation p=0.35DTI-ALPS Measures CSF Flow, Not Parenchymal Clearance

Evidence: Chayama et al. 2026: ICM-injected tracers (50–80% to cervical lymph nodes) distribute to fundamentally different compartments than neuron-derived proteins (dura/skull/nasal, minimal CLN). DTI-ALPS proxy signal may reflect CSF flow rather than actual parenchymal waste extraction → normal DTI-ALPS does not exclude impaired neuronal protein clearance.
Citations: (Chayama et al. 2026)
Mechanism: DTI-ALPS measures water diffusion along perivascular spaces → reflects CSF-convective component of clearance. Endogenous protein clearance may use different routes (dura/skull/nasal) that DTI-ALPS does not measure. The fast CSF-to-lymph pathway dominates tracer studies but is minimally used by brain-derived proteins.
Chapter ref: ch15: ch1: 5 dti alps caveat
Prediction: ME/CFS patients with normal DTI-ALPS but elevated blood NfL or tau would indicate dissociation between CSF-tracer-based and parenchymal clearance. Novel imaging methods tracking endogenous protein movement needed.
Treatment: DTI-ALPS should be interpreted with caveat; complement with blood NfL/tau for direct parenchymal clearance output. Methodological limitation for all glymphatic imaging claims.
Limitation: DTI-ALPS-fibromyalgia/Long COVID correlations are clinically meaningful regardless. Disconnect demonstrated in mice; human validation lacking. Blood NfL rise may have non-clearance causes (neurodegeneration, injury).

Speculation p=0.20Nearest-Exit Compartmentalized Brain Clearance in ME/CFS

Evidence: Chayama et al. 2026 (Cell) demonstrated that neuron-derived proteins drain to dura, skull, and nasal cavity following a "nearest exit" principle — regions drain to proximal border compartments. ME/CFS cognitive phenotypes (executive vs memory vs global brain fog) may reflect regional failure of different clearance compartments.
Citations: (Chayama et al. 2026)
Mechanism: Different brain regions → different clearance routes and kinetics. Impairment in one compartment (e.g., dorsal dura for prefrontal cortex) produces regionally selective waste accumulation → domain-specific cognitive symptoms.
Chapter ref: ch15: ch1: 5 brain clearance architecture
Prediction: DTI-ALPS (regional) in brain fog-predominant vs fatigue-predominant ME/CFS should show different regional patterns; executive dysfunction patients should have worse dorsal clearance vs memory-impaired patients with worse temporal/hippocampal clearance.
Treatment: Compartment-specific therapeutic targeting: dorsal-cortex-predominant brain fog may benefit from supine sleep position; basal/brainstem-predominant OI may need different glymphatic support.
Limitation: No regional glymphatic measurements exist in ME/CFS. Nearest-exit principle demonstrated in mice only; human anatomical differences unknown. DTI-ALPS does not resolve individual clearance compartments.

Speculation p=0.15Inflammatory Rerouting of Brain Antigens Promotes CNS Autoimmunity

Evidence: Chayama et al. 2026: acute LPS inflammation shunts brain-derived proteins directly into blood via vascular leakage, bypassing tolerogenic skull border. ME/CFS neuroinflammation may similarly reroute CNS antigens to systemic circulation → encounter with peripheral immune cells outside the tolerogenic skull environment → breakdown of CNS immune tolerance → autoantibody production.
Citations: (Chayama et al. 2026)
Mechanism: Neuroinflammation → BBB compromised → brain antigens leak into blood → systemic lymphoid organs process CNS proteins in inflammatory context (not tolerogenic skull B cell context) → CNS-directed autoantibodies → autoantibody-positive ME/CFS subsets.
Chapter ref: ch15: ch1: 5 skull bcell tolerance
Prediction: Blood:CSF ratio of neuron-derived proteins should be elevated in autoantibody-positive vs autoantibody-negative ME/CFS; inflammatory biomarker correlations with autoantibody titersb.
Treatment: Anti-inflammatory intervention to restore BBB integrity and reduce antigenic rerouting → may prevent de novo autoantibody emergence. Entirely speculative.
Limitation: LPS is an acute model; ME/CFS neuroinflammation is chronic low-grade. No human data on brain antigen trafficking routes in ME/CFS. BBB integrity status in ME/CFS is contested. Multi-step mechanistic chain with no direct empirical support.

Speculation p=0.15Skull Border B Cell Tolerance Failure as ME/CFS Autoimmune Mechanism

Evidence: Chayama et al. 2026: skull-resident B cells sample brain-derived proteins and mount tolerogenic response (PD-L1, IL10ra, Cd1d1, Ptpn22 upregulation; Tnf, Il1b, type I interferon downregulation). In ME/CFS, neuroinflammatory cytokines may convert these cells from tolerogenic to immunogenic → CNS-directed autoimmunity from within the brain border itself.
Citations: (Chayama et al. 2026)
Mechanism: Neuroinflammation (IL-1beta, TNF-alpha, type I IFN) → downregulation of PD-L1 and IL10ra on skull B cells → loss of tolerogenic B cell programming → brain antigens presented in inflammatory rather than regulatory context → CNS-directed autoantibodies produced locally at the brain border. Skull marrow channels may be remodelled during neuroinflammation, potentially biasing B cell development away from tolerance.
Chapter ref: ch15: ch1: 5 skull bcell tolerance
Prediction: CSF B cell profiles from ME/CFS should show reduced PD-L1 expression and tolerogenic gene module vs controls; skull bone marrow aspirates if available. Null result refutes mechanism.
Treatment: Anti-inflammatory immunomodulation (LDN, microglial modulators) may restore skull B cell tolerogenic programming → reduce autoantibody production. Entirely experimental.
Limitation: No human skull B cell data for any condition. Mouse skull B cell phenotype not studied under chronic neuroinflammation. Connection to clinical autoantibodies is multi-step and speculative. No ME/CFS skull/CSF B cell profiling exists.

Speculation p=0.15Inflammatory vs Obstructive Clearance Failure in ME/CFS Progression

Evidence: Chayama et al. 2026 demonstrated two mechanistically distinct clearance failure modes: LPS inflammation → vascular leakage into blood (rerouting), vs 5XFAD amyloid pathology → parenchymal retention + border obstruction (trapping). In ME/CFS, early disease (higher neuroinflammation, lower protein accumulation) may show rerouting pattern; chronic disease (accumulated protein, progressive barrier dysfunction) may shift toward obstructive pattern.
Citations: (Chayama et al. 2026)
Mechanism: Early ME/CFS: neuroinflammation dominant (microglial activation, cytokine signaling) → BBB compromised → brain antigens leak into blood → elevated blood brain-derived proteins (NfL, tau). Chronic ME/CFS (greater than 10 years): progressive protein accumulation + structural degradation of perivascular spaces → obstructive pattern → reduced blood and border clearance → worsening cognitive symptoms.
Chapter ref: ch15: ch1: 5 neurodegeneration risk
Prediction: Blood:CSF ratio of neuron-derived proteins should be high in early disease (inflammatory rerouting) and low in chronic disease (obstructive trapping); serial measurement over disease course should show transition.
Treatment: Early disease: anti-inflammatory BBB-stabilising strategies. Chronic disease: clearance-enhancing strategies (SWS enhancement, glymphatic position, NE oscillation normalisation). Stratification by clearance failure mode may guide treatment selection.
Limitation: Disease course stratification untested. Protein accumulation in ME/CFS brain unmeasured. Distinction assumes inflammatory and obstructive modes are sequential; they may instead be simultaneous or patient-specific. No human data on brain antigen trafficking evolution in ME/CFS.

ID / Label	Details	Phase / Cert
pem ratchet glymphatic	PEM ratchet hypothesis: exertion → metabolic waste (lactate, ROS, inflammatory mediators) → glymphatic system clearance failure (sleep dysfunction + autonomic impairment + neuroinflammation) → waste accumulation → delayed 12-48h PEM. Ratchet: repeated overexertion → progressive waste accumulation → gradual worsening. Coherent across sleep, autonomic, neuroinflammatory lines. No direct glymphatic measurement in ME/CFS; no exertional glymphatic study. Origin: synthetic inference from existing literature.	Phase 5 / 0.35
csf blood ratio biomarker	CSF:blood concentration ratio of brain-derived proteins (NfL, tau, S100B, GFAP) as glymphatic function biomarker. Normal: CSF proteins drain via meningeal lymphatics → dilute in plasma. Impaired clearance: CSF concentration rises, plasma concentration falls. Ratio reflects clearance efficiency independent of absolute production. Validated in AD/MS; never measured systematically in ME/CFS despite available LP (NIH 2024, Hornig 2017) and peripheral blood data. Origin: Chayama 2026 model prediction.	Phase 5 / 0.40
causal compensatory epiphenomenal	Three interpretations of brain clearance impairment in ME/CFS: (1) causal — primary driver, restoring clearance improves symptoms; (2) compensatory — protective energy-conserving response; (3) epiphenomenal — downstream of sleep/autonomic/neuroinflammatory dysfunction, no independent contribution. Discrimination requires interventional studies.	Phase 5 / n/a
no direct glymphatic imaging mecfs	Zero studies have measured glymphatic function in ME/CFS patients using DTI-ALPS, contrast-enhanced MRI, or CSF tracer studies. Entire brain clearance hypothesis in ME/CFS rests on indirect inference. This is the single most important missing experiment.	Phase 5 / n/a
chayama unreplicated	Chayama 2026 nearest-exit model: paradigm-shifting synthesis of independent components (glymphatic, meningeal lymphatics, sleep-coupled clearance) into unified architecture. Model-dependent components (nearest-exit routing, dual-speed glymphatics, mid-cervical transit node, bioelectric entry, skull-border B-cell tolerance) not independently replicated.	Phase 5 / n/a
pem ratchet speculative	PEM ratchet logically coherent but completely untested. No exertional glymphatic measurement. Appealing connections ≠ evidence. Prediction (glymphatic impairment during post-exertional period with waste metabolite accumulation correlating with symptoms) not tested.	Phase 5 / n/a
convergent narrative confirmation bias	Multiple weak lines of evidence converging on same conclusion feel stronger than they are — known cognitive bias. Each component individually plausible but underdetermined; convergence does not increase collective certainty beyond weakest link. Brain clearance framework = research program, not finding (certainty 0.30).	Phase 5 / n/a
missing negative controls	Brain clearance hypothesis lacks explicit falsification conditions: no specification of what SHOULD NOT happen if true. Currently accommodates any post-hoc result. Sleep apnea/narcolepsy negative control (severe sleep dysfunction without ME/CFS phenotype) problematic for hypothesis. Lactate infusion PEM trigger untested.	Phase 5 / n/a
brain clearance null hypothesis	If brain clearance has no causal role: (1) DTI-ALPS comparable between ME/CFS and inactivity-matched controls; (2) CSF:blood ratios not different; (3) pharmacological enhancement no benefit beyond placebo; (4) PEM severity uncorrelated with glymphatic proxies; (5) CPAP benefit no greater than in non-ME/CFS. All testable; none tested. Pre-experimental mechanism.	Phase 5 / n/a

9 Hypoxia/Altitude/HIF-1α

Hypothesis p=0.55HIF Pathway Inertia in ME/CFS

Evidence: Blunted HIF-1$\alpha$ stabilization and transcriptional programme activation despite chronic tissue hypoxia. miRNA-mediated silencing of HIF targets. Normal basal EPO but impaired inducibility. Certainty increased 0.50→0.55: feed-into from HIF-2alpha sustained endothelial activation provides convergent upstream mechanism for post-viral subtype.
Citations: (Kaczmarek 2023) (A. S. Winkler et al. 2004) (Ribeiro et al. 2026)
Mechanism: Chronic hypoxia → failed HIF-1$\alpha$ response → blunted EPO/VEGF induction → inadequate adaptation → sustained metabolic suppression. In post-viral ME/CFS, endothelial HIF-2alpha sustained activation may further suppress HIF-1alpha inducibility via isoform competition.
Chapter ref: ch14k: hif pathway inertia
Prediction: ME/CFS patients exposed to mild normobaric hypoxia (FiO2 0.14, 2h) will show blunted plasma EPO and VEGF responses vs controls; PBMCs under 1% O2 show reduced HIF target gene induction. Falsified if EPO/VEGF responses are equivalent.
Treatment: Identifies HIF-inducible ME/CFS subtype; motivates HIF-PH inhibitor trials or IHT.
Limitation: HIF-1$\alpha$ protein measurement technically challenging; miRNA-HIF data from in vitro models; basal EPO single-timepoint only.

Hypothesis p=0.55PEM as Hibernation-Mimetic Maladaptation

Evidence: PEM reflects maladaptive persistence of HIF-mediated metabolic suppression after exertion — cells locked in hypoxic metabolic state despite adequate oxygen. Certainty increased 0.50→0.55: convergent feed-into from HIF-2α sustained endothelial activation (Ribeiro2026) provides upstream mechanism — endothelial HIF-2α→VEGF→capillary permeability→tissue hypoxia→muscle HIF-1α persistence.
Citations: (Filip Hoel et al. 2021) (Kell and Pretorius 2022) (Kaczmarek 2023) (Ribeiro et al. 2026)
Mechanism: Viral trigger → endothelial HIF-2α → VEGF → capillary permeability → tissue hypoxia → muscle HIF-1α stabilization post-exertion → PDK1 suppresses PDH, glycolysis persists → sustained lactate, impaired OXPHOS → prolonged recovery. Two independent lines (endothelial HIF-2α sustained activation + muscle HIF-1α persistence) converge.
Chapter ref: ch14k: pem hif maladaptation
Prediction: After exercise, ME/CFS PBMCs show prolonged HIF-1$\alpha$ target gene expression at 24–48h vs 6h in controls; PDH activity remains suppressed; lactate clearance delayed. Falsified if time-courses match controls.
Treatment: Targets HIF deactivation (rather than activation) as therapeutic strategy.
Limitation: Post-exercise HIF time-course not measured in ME/CFS; hibernation-mimetic model from cardiac preconditioning literature; PBMC↔︎tissue generalization untested.

Hypothesis p=0.55HIF-2alpha Sustained Activation as Post-Viral ED Mechanism

Evidence: SARS-CoV-2 spike S1 drives sustained HIF-2alpha nuclear localization in endothelial cells causing VEGF production and barrier disruption. Multiple viruses exploit HIF-2alpha; antiviral IRF3 directly couples viral signaling to HIF pathway.
Citations: (Ribeiro et al. 2026) (Deng et al. 2026) (Couteaudier et al. 2025) (D. Morris et al. 2025)
Mechanism: Spike S1 causes transient HIF-1alpha and sustained HIF-2alpha, increasing VEGF, intercellular gaps, and permeability; belzutifan rescues. IRF3 retains both HIF isoforms; viral infection depletes IRF3.
Chapter ref: ch14k: hif2a sustained postviral
Prediction: Nuclear HIF-2alpha in dermal ECs at 2 fold higher in post-viral ME/CFS vs controls; plasma VEGF and vWF elevated; belzutifan improves FMD by at least 20% in post-viral ME/CFS. Falsified if HIF-2alpha nuclear staining does not differ from controls.
Treatment: Diagnostic subclassification; therapeutic target identification.
Limitation: Direct ME/CFS HIF-2alpha data lacking; all evidence from post-COVID and in vitro studies; EBV/HHV-6 to HIF-2alpha in ECs untested.

Hypothesis p=0.55beta2AR-Negative as HIF-2alpha-Driven ED Subtype

Evidence: The approximately 70% of ME/CFS patients without beta2AR autoantibodies have unexplained endothelial dysfunction; HIF-2alpha-mediated capillary permeability provides a mechanism distinct from autoantibody vasoconstriction.
Citations: (Ribeiro et al. 2026) (Sandvik et al. 2023) (E. Stein et al. 2025) (Shen et al. 2024)
Mechanism: Post-viral trigger leads to HIF-2alpha and VEGF, microvascular barrier disruption, interstitial edema, and impaired O2 diffusion, producing same net tissue hypoxia as vasoconstriction but via permeability rather than constriction.
Chapter ref: ch10: hif2a beta2ar negative
Prediction: beta2AR-autoantibody-negative ME/CFS patients have elevated VEGF, vWF, and EPO compared to autoantibody-positive and healthy controls, with VEGF inversely correlating with FMD. Falsified if VEGF does not differ between subgroups.
Treatment: Therapeutic stratification: belzutifan for beta2AR-negative; immunoadsorption for beta2AR-positive.
Limitation: Sandvik2023 did not measure autoantibodies; Stein2025 did not measure VEGF/vWF. Direct subgroup comparison testing is needed.

Speculation p=0.55NRF2 Exhaustion Permits Pathological HIF-2alpha Dominance

Evidence: Prolonged oxidative stress depletes NRF2 antioxidant reserve, removing the brake on HIF-2alpha transcriptional activity and permitting unchecked VEGF production. Certainty increased 0.50→0.55: independent convergence — Shen2024 (in vitro NRF2-HIF competition) and Zhang2026 (oxidative stress HIF switch) provide convergent mechanistic evidence from different labs.
Citations: (Shen et al. 2024) (Y. Zhang et al. 2026) (Ribeiro et al. 2026)
Mechanism: NRF2 normally competes with HIF-2alpha for CBP/p300 co-activators and maintains EC junction integrity. NRF2 depletion removes this brake, creating a self-sustaining HIF-2alpha dominant state.
Chapter ref: ch10: nrf2 exhaustion hif2a
Prediction: NRF2 target genes (NQO1, HO-1, GCLC) are suppressed relative to HIF-2alpha targets in post-viral ME/CFS ECs; sulforaphane (NRF2 activator) rescues barrier integrity in spike-stimulated ECs. Falsified if NRF2 targets are not suppressed.
Treatment: Identifies NRF2 activators (sulforaphane, DMF, pycnogenol) as therapeutic strategy for HIF-2alpha-driven ED.
Limitation: NRF2-HIF-2alpha competition demonstrated in vitro; not yet confirmed in ME/CFS endothelium.

Hypothesis p=0.50HIF-2alpha to vWF to Microclot Pathway in Post-Viral ME/CFS

Evidence: HIF-2alpha target VEGF induces Weibel-Palade body exocytosis, releasing ultra-large vWF multimers that promote microclot formation without requiring coagulation cascade activation.
Citations: (Ribeiro et al. 2026) (Linden et al. 2023) (K. Wirth and Löhn 2024)
Mechanism: Viral trigger leads to HIF-2alpha, VEGF, Weibel-Palade exocytosis, ultra-large vWF, and platelet adhesion producing fibrinolysis-resistant microclots.
Chapter ref: ch10: hif2a microclot vwf
Prediction: Plasma vWF antigen and vWF propeptide are elevated in post-viral ME/CFS and correlate with microclot burden; belzutifan reduces vWF release from spike-stimulated ECs in vitro. Falsified if vWF does not correlate with microclot burden.
Treatment: Identifies vWF as therapeutic target and biomarker; belzutifan as antithrombotic through HIF-2alpha inhibition.
Limitation: vWF-microclot correlation not tested in ME/CFS; Weibel-Palade assay in patient ECs is in vitro only.

Speculation p=0.50Pycnogenol for Endothelial Protection in ME/CFS

Evidence: Pycnogenol (French maritime pine bark extract) stimulates NRF2, inhibits VEGF signaling, and directly protects EC junctions, increasing ZO-1/occludin expression.
Citations: (Shen et al. 2024) (Ribeiro et al. 2026)
Mechanism: Pycnogenol activates NRF2, competes with HIF-2alpha for CBP/p300, reduces VEGF, and enhances ZO-1/occludin improving barrier integrity.
Chapter ref: ch1: 8: (supplement section)
Prediction: 8 weeks Pycnogenol (150mg/day) in ME/CFS improves FMD by at least 20% and reduces PEM-VAS by at least 25% vs placebo. Falsified if FMD does not improve.
Treatment: Immediate-access OTC endothelial therapy without prescription.
Limitation: No ME/CFS data; effect size estimated from related conditions; moderate cost. No drug interactions known.

Hypothesis p=0.45Post-SLE Remission Fatigue Subgroup

Evidence

Two independent large-cohort studies demonstrate that fatigue persists in a minority of SLE patients after disease remission: 13.6–26.2% of patients in DORIS remission have clinically significant fatigue (Parodis et al. 2025); type 2 fatigue symptoms show no correlation with interferon signatures (Arcani et al. 2023). (b) The majority (74–86%) resolve fatigue with disease control. (c) Whether the persistent-fatigue minority represents autoantibody-mediated neuronal suppression, deconditioning, comorbid depression, sleep disturbance, or a combination is unresolved. (d) If subclinical SLE autoantibodies are present in some ME/CFS patients, this could define a mechanistically distinct subgroup — but PEM has never been assessed in SLE and the fatigue constructs may not be equivalent.

Citations

(Parodis et al. 2025) (Arcani et al. 2023) (Schwarting et al. 2019) (Rubio and Kyttaris 2023)

Mechanism

Subclinical or remission SLE → possible autoantibody-mediated fatigue → may overlap phenotypically with ME/CFS. Causal direction, mechanism, and construct equivalence (PEM vs general fatigue) unestablished.

Chapter ref

ch05: sle remission fatigue subgroup; ch14d: SLE section

Prediction

In a cohort of 200 or more ME/CFS patients, ANA of at least 1:80 plus at least one SLE criterion identifies a subgroup with: (a) elevated anti-NR2 vs seronegative ME/CFS; (b) anti-NR2 correlation with FSS; (c) reduced MRS PCr:ATP ratio in prefrontal cortex; (d) no correlation between anti-NR2 and CRP/ESR. Falsified if anti-NR2 antibodies are absent in ANA-positive ME/CFS.

Treatment

If validated, would define an autoantibody-positive ME/CFS subgroup for clinical trial enrichment. Standard rheumatologic evaluation is existing practice; belimumab/anifrolumab have zero ME/CFS safety data and should not be used outside trials.

Limitation

PEM never assessed in SLE — if SLE remission fatigue lacks PEM, these are distinct clinical entities regardless of molecular overlap. ANA false-positive rate ~5-10%. Schwarting belimumab data is non-randomized observational subgroup. UCTD diagnostic criteria vary.

Speculation p=0.45Intermittent Hypoxic Training for ME/CFS

Evidence: Brief controlled hypoxic exposures (FiO2 0.16, supine, short cycles) may induce beneficial HIF-1$\alpha$-dependent adaptations without triggering PEM.
Citations: (Gangwar et al. 2019) (Janssen Daalen et al. 2025)
Mechanism: Brief hypoxia → HIF-1$\alpha$ stabilization → VEGF, EPO, PGC-1$\alpha$, GLUT1 induction → raised hypoxic threshold → improved exercise tolerance.
Chapter ref: ch18: iht mecfs
Prediction: 8 weeks IHT improves 6MWT distance ≥40m vs sham. Falsified if IHT does not outperform normoxic sham.
Treatment: Non-pharmacological HIF induction for mild-to-moderate ME/CFS.
Limitation: Zero ME/CFS IHT data; protocol parameters untested; PEM risk cannot be eliminated without dose-finding.

Speculation p=0.45Belzutifan for Post-Viral ME/CFS

Evidence: HIF-2$\alpha$ inhibition could rescue endothelial barrier function in post-viral ME/CFS with HIF-2$\alpha$-mediated vascular dysfunction. Updated evidence: Sales2026 (independent HIF-2$\alpha$ barrier rescue via darunavir), Shen2024 (NRF2-HIF2$\alpha$ axis), Deng2026 (IRF3 antiviral-HIF linkage).
Citations: (Ribeiro et al. 2026) (Sales et al. 2026) (Shen et al. 2024) (Deng et al. 2026)
Mechanism: Viral trigger → HIF-2$\alpha$ activation → VEGF production, endothelial gaps, increased permeability → belzutifan inhibits HIF-2$\alpha$ → barrier restoration. Antiviral IRF3 directly retains HIF-$\alpha$ in cytoplasm; viral infection relieves this retention (Deng2026).
Chapter ref: ch18: belzutifan endothelial
Prediction: 8 weeks belzutifan 40mg daily reduces VWF antigen ≥20% and improves 6MWT ≥30m in post-viral ME/CFS with elevated baseline VWF (>150% normal) and β2AR-autoantibody-negative status. Falsified if VWF does not decrease or 6MWT unchanged.
Treatment: Targeted endothelial barrier therapy for post-viral subset; β2AR-negative subgroup predicted to respond preferentially.
Limitation: No ME/CFS data; HIF-2$\alpha$ inhibition could impair erythropoiesis (15-20% anemia risk); isoforms have opposing functions — narrow therapeutic window. Brain penetration unknown.

Speculation p=0.45sFlt-1:PlGF Ratio as ME/CFS Biomarker

Evidence: Elevated sFlt-1:PlGF ratio (validated in preeclampsia) may indicate anti-angiogenic state from HIF-2alpha activation in post-viral ME/CFS, explaining failed angiogenic compensation.
Citations: (Ribeiro et al. 2026) (Flaskamp et al. 2022) (Sales et al. 2026)
Mechanism: HIF-2alpha increases sFlt-1 production trapping VEGF causing functional VEGF deficiency despite normal total VEGF, producing an anti-angiogenic state and impaired capillary repair.
Chapter ref: ch14k: sflt1 plgf biomarker
Prediction: sFlt-1:PlGF ratio is elevated in post-viral ME/CFS vs controls (mean ratio above 38 vs below 38); correlates with PEM severity and impaired angiogenic serum activity. Falsified if ratio does not differ from controls.
Treatment: Non-invasive blood biomarker for endothelial dysfunction subtyping; identifies HIF-2alpha-driven anti-angiogenic state.
Limitation: No ME/CFS sFlt-1 data; preeclampsia mechanism is validated but condition-specific; ratio may differ in men.

Speculation p=0.40Altitude Paradox in ME/CFS

Evidence: Biphasic hypoxia response: moderate altitude (1500–2500m) may induce beneficial hypoxic conditioning; higher altitude (>3000m) may overwhelm impaired cerebral autoregulation.
Citations: (Badhwar et al. 2025) (Medow and Stewart 2024) (Gangwar et al. 2019)
Mechanism: Moderate hypoxia → mild HIF-1$\alpha$ stabilization, mitochondrial efficiency→ benefit. High altitude → CBFv decline, hypocapnia→ harm. Narrow therapeutic window.
Chapter ref: ch14k: altitude paradox
Prediction: 2000m simulated altitude improves cognitive performance and CBFv; 3500m worsens both and triggers PEM at 24h. Falsified if dose-response is monotonic.
Treatment: Identifies altitude risk profile; motivates controlled IHT protocols.
Limitation: No altitude-chamber ME/CFS study exists; dose-response extrapolated from healthy physiology.

Speculation p=0.40Darunavir as HIF-2alpha Blocker for ME/CFS

Evidence: HIV protease inhibitor darunavir blocks HIF-2alpha activation and preserves tight junctions (Sales2026). Repurposing opportunity with 20+ year safety track record.
Citations: (Sales et al. 2026) (Ribeiro et al. 2026)
Mechanism: Darunavir inhibits HIF-2alpha transcriptional activity, preventing VEGF-driven permeability programme and preserving ZO-1/occludin. Mechanism independent of protease inhibition.
Chapter ref: ch18: darunavir hif2a
Prediction: 4 weeks darunavir/ritonavir reduces plasma VEGF and vWF by at least 25% and improves FMD vs placebo in post-viral ME/CFS (double-blind, n=20). Falsified if VEGF does not decrease.
Treatment: Lower-cost alternative to belzutifan for endothelial barrier rescue.
Limitation: No ME/CFS data; substantial drug interactions (CYP3A4 inhibitor); hepatotoxicity risk; low CNS penetration.

Speculation p=0.35Intrapulmonary Shunt as Proximal Cause of Tissue Hypoxia in ME/CFS

Evidence

Intrapulmonary right-left shunt (Qs/Qt, blood bypassing alveolar oxygenation via pre-existing arteriovenous anastomoses — IPAVAs) causes exertional hypoxemia. (b) Post-COVID studies document persistent shunt (~8% vs normal 3–5%) at 6 months with normal PFTs (Farrow2023, Sandhu2026). (c) SARS-CoV-2 impairs HPV, the protective vasoconstriction reflex that normally limits shunt. (d) If HPV impairment generalizes to other viral triggers, post-infectious ME/CFS may involve shunt-driven tissue hypoxia upstream of the microcirculatory and mitochondrial defects documented in ME/CFS. (e) Zero direct ME/CFS shunt measurements exist; this is an inferential cross-disease hypothesis.

Citations

(Farrow et al. 2023) (Sandhu et al. 2026) (Lyne, Camporota, and Montgomery 2024) (Li et al. 2024) (Grist et al. 2022) (Davis et al. 2023) (F. Hoel et al. 2021)

Mechanism

Shunt → reduced arterial O2 content → tissue hypoxia → metabolic strain, lactate, impaired oxygen extraction. Post-viral mechanism with anatomical substrate (IPAVAs) and HPV impairment. Untested in ME/CFS.

Chapter ref

ch06: intrapulmonary shunt mecfs; ch14d: intrapulmonary shunt postviral

Prediction

ME/CFS patients show elevated Qs/Qt (>5%) on 100% FiO2 testing; normal shunt falsifies the hypothesis. Shunt fraction correlates with PEM severity on 2-day CPET. Falsified if Qs/Qt is normal (3–5%) in patients with documented exertional hypoxemia.

Treatment

If confirmed, identifies a treatable upstream target — supplemental O2 during exertion or HPV restoration — for a subset. Until measured, entirely speculative; not a clinical recommendation.

Limitation

Zero ME/CFS data; all evidence from Long COVID or general physiology. Mechanism plausibility supported but unconfirmed for ME/CFS. 100% O2 testing may trigger PEM in sensitive patients.

Speculation p=0.35Anti-NR2 Neuronal Metabolic Suppression as ME/CFS Fatigue Mechanism

Evidence

Anti-NR2 (NMDAR) autoantibodies in SLE correlate with fatigue severity independent of neuropsychiatric lupus (n=426, cross-sectional) and downregulate neuronal energy metabolism without cytotoxicity (Schwarting et al. 2019). (b) Belimumab reduces both anti-NR2 titers and fatigue in an observational treatment subgroup (n=86, non-randomized for this endpoint), suggesting but not proving a causal relationship. (c) Anti-NR2 antibodies have never been measured in ME/CFS; the hypothesis that analogous anti-neuronal receptor autoantibodies could produce ME/CFS fatigue through metabolic suppression is entirely inferential.

Citations

(Schwarting et al. 2019) (Weissman-Tsukamoto, Carroll, and Diamond 2025)

Mechanism

Anti-NR2 (or analogous anti-neuronal) autoantibodies → competitive or allosteric NMDAR modulation → reduced neuronal glucose utilisation and ATP synthesis → impaired cognitive and motor network function → fatigue. Entirely speculative in ME/CFS context.

Chapter ref

ch14d: SLE section; ch07: autoantibodies

Prediction

Anti-NR2 antibodies are detectable in at least 15 percent of ANA-positive ME/CFS patients vs under 3 percent of ANA-negative ME/CFS; anti-NR2 titer correlates with MRS PCr:ATP ratio in prefrontal cortex. Falsified if anti-NR2 antibodies are absent across 100+ ME/CFS patients irrespective of ANA status.

Treatment

If validated, would define an autoantibody-positive ME/CFS subgroup for clinical trial enrichment. Zero data for any treatment recommendation; belimumab (approximately USD 35k/year) has no ME/CFS safety data and is not approved for ME/CFS.

Limitation

No anti-NR2 data in ME/CFS; mechanism inferred from SLE; Schwarting belimumab data is observational subgroup (n=86), not randomised comparison for fatigue; anti-NR2 ELISA not validated for ME/CFS; normal brain MRI is compatible with many mechanisms, not specific to autoantibody hypothesis.

Speculation p=0.35SLE-NK Mitochondrial Dysfunction as Shared ME/CFS Mechanism

Evidence

SLE NK cells accumulate enlarged dysfunctional mitochondria with impaired mitophagy leading to defective cytotoxicity (Fluder et al. 2026). (b) ME/CFS NK cells show well-established functional impairment (reduced cytotoxicity, TRPM3 channelopathy). (c) Whether ME/CFS NK impairment involves a comparable mitochondrial component is entirely untested; SLE NK cells operate in a distinct pro-inflammatory milieu (type I IFN, BAFF, immune complexes) absent in ME/CFS.

Citations

(Fluder et al. 2026)

Mechanism

Mitochondrial dysfunction → NK cell metabolic exhaustion → reduced killing capacity. Demonstrated in SLE; testable hypothesis in ME/CFS. Different immunological contexts may produce different patterns of NK mitochondrial impairment.

Chapter ref

ch14d: SLE section; ch07: NK cell section

Prediction

ME/CFS NK cells show mitochondrial structural abnormalities on MitoTracker staining and reduced mitophagy markers vs controls, correlating with reduced K562 killing. Falsified if ME/CFS NK cell mitochondria are structurally and functionally normal.

Treatment

If validated, mitochondria-targeting interventions (rapamycin, urolithin A) could be investigated as NK-modulating strategies in ME/CFS clinical trials — not a clinical recommendation.

Limitation

No ME/CFS NK cell mitochondrial data; Fluder 2026 is SLE-specific (sample size unspecified); SLE NK inflammatory environment differs from ME/CFS; mitophagy enhancer data limited to non-NK tissues.

Speculation p=0.30HIF-PH Inhibitors for ME/CFS

Evidence: Pharmacological HIF stabilization (roxadustat, daprodustat) could restore blunted hypoxic adaptation. Low-dose to avoid excessive erythropoiesis.
Citations: (A. S. Winkler et al. 2004) (Little et al. 2023) (Ribeiro et al. 2026)
Mechanism: PHD inhibitor → stabilizes HIF-1$\alpha$/2$\alpha$ → full transcriptional programme (EPO+VEGF+glycolytic enzymes+mitophagy) → metabolic adaptation. Risk: Th17 promotion, VEGF-mediated permeability, viscosity.
Chapter ref: ch18: hif ph inhibitors
Prediction: Low-dose daprodustat (1mg TIW) improves constant-workload cycling time without hematocrit >45% in ME/CFS with blunted hypoxia-challenge EPO. Falsified if no improvement or adverse events exceed sham.
Treatment: Pharmacological HIF stabilization for HIF-inert ME/CFS subtype; repurposed existing drugs.
Limitation: No ME/CFS safety data; all HIF-PH inhibitor literature from CKD populations; autoimmune and endothelial risks uncharacterized.

Speculation p=0.25Shunt as HIF Isoform Imbalance Driver in Post-Viral ME/CFS

Evidence

This paper proposes HIF isoform imbalance (HIF-2α dominance in endothelium, HIF-1α blunting in other tissues) in post-viral ME/CFS. (b) Intrapulmonary shunt → chronic mild arterial hypoxemia (PaO2 ~75–85 mmHg). (c) Chronic mild hypoxia preferentially activates endothelial HIF-2α (which responds to sustained mild signals) over ubiquitous HIF-1α (which responds to acute severe hypoxia). (d) Shunt may thus drive the HIF-2α-dominant state — unifying the endothelial and metabolic arms of ME/CFS HIF pathology under one upstream mechanism. (e) Bidirectional: HIF-2α-driven endothelial dysfunction may itself impair pulmonary HPV signaling → worsen shunt. Origin: brainstorm.

Citations

(Farrow et al. 2023) (Ribeiro et al. 2026) (Sandvik et al. 2023) (Li et al. 2024)

Mechanism

Shunt → chronic mild hypoxemia → HIF-2α-skewed isoform ratio → endothelial VEGF/permeability programme + blunted HIF-1α metabolic adaptation. Positive feedback: HIF-2α worsens shunt via HPV impairment.

Chapter ref

ch14d: shunt hif imbalance

Prediction

Shunt-positive ME/CFS patients (Qs/Qt >6%) show lower nuclear HIF-2α:HIF-1α ratio in PBMCs vs shunt-normal patients and controls. Falsified if isoform ratios do not differ by shunt status.

Treatment

If confirmed, correcting shunt (O2, HPV restoration) could normalize HIF signaling across tissues — single intervention for multiple arms of pathology. Currently speculative; no clinical data.

Limitation

No HIF isoform-shunt correlation data; PaO2 range from 8% shunt is theoretical (O2-Hb curve); HIF activation dynamics in chronic mild hypoxemia not directly studied in humans; PBMC HIF ratios may not reflect tissue-specific isoforms.

Speculation p=0.20RBC Deformability IPAVA Routing Synergy as Shunt Amplifier

Evidence

ME/CFS RBCs have impaired deformability (stiffer membranes, slower capillary transit, elevated ROS; Saha 2025, Guo 2025). (b) Stiff RBCs that cannot deform for alveolar capillaries (~5–7 μm) may preferentially route through low-resistance IPAVAs (~25–50 μm) — bypassing oxygenation. (c) Creates a self-reinforcing loop: stiff RBCs → IPAVA routing → reduced O2 uptake → tissue hypoxia → oxidative RBC damage → more stiffness. (d) The two abnormalities (RBC stiffness + IPAVA anatomy) have never been measured in the same ME/CFS patients. Origin: brainstorm.

Citations

(A. K. Saha et al. 2025) (Yuanbin Guo et al. 2025) (Lyne, Camporota, and Montgomery 2024) (Davis et al. 2023)

Mechanism

Stiff RBCs → IPAVA preference → shunt amplification. Self-reinforcing via oxidative damage. Individual components documented; interaction untested.

Chapter ref

ch06: rbc ipava synergy

Prediction

Within ME/CFS, RBC deformability inversely correlates with Qs/Qt on 100% O2 testing (r > 0.5) independent of age, sex, BMI. Falsified if R2 < 0.10.

Treatment

If confirmed, RBC health and shunt are two sides of one problem — antioxidant strategies could reduce shunt indirectly. Currently mechanistic; no clinical application.

Limitation

No data on RBC deformability-shunt correlation; IPAVA routing preference for stiff RBCs is theoretical; flow partitioning depends on unmeasured variables (pressure gradients, viscosity, vasomotor tone).

Speculation p=0.20Post-Exertional Shunt Window as Delayed PEM Trigger

Evidence

IPAVAs open during exercise in nearly all adults (Lyne 2024). (b) In health, HPV closes them promptly post-exertion. (c) If HPV remains impaired post-virally (Li 2024), IPAVAs may stay patent for hours after exercise — creating a persistent shunt window. (d) This prolonged arterial hypoxemia during the recovery period would amplify all downstream PEM mechanisms by impairing ATP regeneration and tissue repair. (e) IPAVA closure kinetics post-exercise have never been measured in any post-viral population. Origin: brainstorm.

Citations

(Lyne, Camporota, and Montgomery 2024) (Li et al. 2024) (Farrow et al. 2023)

Mechanism

Exercise → IPAVA opening → impaired HPV prevents closure → persistent shunt for hours → prolonged hypoxemia → delayed PEM at 24–48h. Timing matches PEM kinetics but mechanism untested.

Chapter ref

ch06: post exertional shunt window

Prediction

ME/CFS patients show Qs/Qt >5% at 1h and 6h post-exercise (vs ≤30 min in controls), with 6h Qs/Qt correlating with Day 2 PEM severity. Falsified if post-exercise Qs/Qt normalizes within 30 min in all patients.

Treatment

If confirmed, the first 1–6 hours post-exertion become a therapeutic window for PEM prevention — supplemental O2 or positional strategies in this window may reduce crash severity.

Limitation

Zero post-exercise shunt data in any post-viral population; all healthy-physiology data shows IPAVA closure within minutes; alternative shunt sources (bronchopulmonary anastomoses, fixed anatomical shunts) would not respond to HPV restoration.

Prediction p=n/aHIF-2alpha CPET Dynamic Test for ME/CFS Subtyping

Evidence: Serial PBMC nuclear HIF-1alpha/HIF-2alpha measurement before and after CPET (baseline, 0, 2, 6, 24, 48h) to define temporal signature distinguishing post-viral from gradual-onset ME/CFS.
Citations: (Ribeiro et al. 2026)
Mechanism: Post-exertional nuclear HIF dynamics: controls show transient HIF-1alpha peak at 0h; post-viral ME/CFS shows delayed HIF-2alpha rise at 24-48h persisting at 48h; gradual-onset shows intermediate.
Chapter ref: ch14k: hif2a cpet dynamics
Prediction: HIF-2alpha AUC over 0-48h at 2 fold controls in post-viral ME/CFS, with sustained elevation at 48h (p less than 0.01). Falsified if HIF-2alpha time-courses do not differ between groups.
Treatment: Diagnostic subtyping tool; defines objective post-exertional molecular signature.
Limitation: Protocol requires PBMC nuclear fraction at 6 timepoints; HIF nuclear translocation may not reflect transcriptional activity.

Prediction p=n/aEPO Stimulation Test as ME/CFS Biomarker

Evidence: Standardized 2h mild hypoxia (FiO2 0.14) with serial EPO measurement over 48h as dynamic functional test of HIF pathway integrity.
Citations: (A. S. Winkler et al. 2004)
Mechanism: Hypoxia challenge → EPO AUC over 48h → blunted response indicates HIF inertia. Analogous to ACTH stimulation test for adrenal insufficiency.
Chapter ref: ch18: epo stimulation test
Prediction: EPO AUC over 48h is ≥40% lower in ME/CFS vs age/sex-matched controls; abnormal test (>2 SD below control) identifies HIF-inert subtype. Falsified if AUC is equivalent.
Treatment: Diagnostic subtyping tool; identifies candidates for HIF-targeted therapies.
Limitation: Protocol needs validation in ME/CFS; FiO2 0.14 may trigger PEM in some patients; 48h sampling burden.

Open Question p=n/a100% FiO2 Shunt Testing as ME/CFS Research Tool

Evidence: Is intrapulmonary shunt measurement (Qs/Qt on 100% O2, a well-established pulmonary function test) feasible and informative in ME/CFS patients? Would shunt fraction correlate with exertional desaturation, PEM severity, or metabolic phenotypes (lactate, impaired oxygen extraction)? The test exists, the anatomical substrate (IPAVAs) is known, and the post-COVID precedent is established — but it has never been applied to ME/CFS.
Citations: (Farrow et al. 2023) (F. Hoel et al. 2021) (Walitt, Singh, LaMunion, Hallett, et al. 2024)
Mechanism: 100% FiO2 → measure A-a gradient → calculate shunt fraction → correlate with CPET desaturation, PEM, metabolic markers. Directly testable with existing clinical equipment.
Chapter ref: ch06: intrapulmonary shunt mecfs
Prediction: If Qs/Qt is normal (3–5%) in ME/CFS → shunt ruled out; mechanism pursuit ends. If elevated (>5%) → opens new research pathway: PEM-shunt dynamics, HPV impairment, therapeutic O2 trials.
Treatment: If elevated, could open a new therapeutic axis — O2 supplementation during exertion for shunt-positive patients. Until tested, direction unknown.
Limitation: No ME/CFS data; equipoise is complete — the test could be positive or negative. 100% O2 testing may trigger PEM in some patients; safety protocol needed.

10 Corticosteroid Failure and Steroid Avoidance

Hypothesis p=0.60CNS-Confined Fatigue Persists Despite Normal Peripheral Inflammatory Biomarkers

Evidence: Omdal et al. 2026 (n=96, 48 LC vs 48 recovered): severe fatigue (fVAS 63 vs 5, FACIT-F 21.5 vs 49) with zero differences in CRP, TNF-α, IL-6, HSP90α, Serpin F1, hémopexine, APOA4. Multivariable regression: no biomarker-fatigue association. Fatigue in LC/ME/CFS is driven by CNS-confined mechanisms that do not spill into peripheral circulation — neuroinflammation compartmentalised behind BBB, epigenetic maintenance of microglial activation, or mitochondrial-derived danger signals trapped in CNS. The null is positive evidence for CNS compartmentalisation, not evidence against biological causation.
Citations: (Omdal et al. 2026)
Mechanism: Acute viral/inflammatory trigger → microglial priming + hypothalamic sickness behavior activation → fatigue maintained via CNS circuits (microglial cytokine production, epigenetic H3K4me1 marks, cGAS-STING activation from mtDNA leak) → peripheral cytokines normalise but CNS signal persists → chronic fatigue with normal bloodwork.
Chapter ref: ch15: ch1: 5 cytokine fatigue ch06: selective energy
Prediction: CSF IL-1β, TNF-α, quinolinic acid, C4d, or sC5b-9 will be elevated in ME/CFS/LC patients despite normal plasma cytokines. Falsified if CSF is also normal — fatigue mechanism must be non-inflammatory (epigenetic, metabolic, or predictive processing).
Treatment: CNS-penetrant anti-inflammatories (LDN, minocycline) should outperform peripherally-restricted anti-inflammatories (NSAIDs, colchicine) on fatigue endpoints. Normal CRP with disabling fatigue is not a diagnostic exclusion — it is characteristic of the disease and should not be used to rule out ME/CFS or LC diagnosis.
Limitation: No paired CSF-plasma cytokine study in ME/CFS to date. Omdal measured peripheral biomarkers only. CNS compartmentalisation inferred from peripheral null, not directly demonstrated. Alternative explanations (epigenetic maintenance, metabolic fatigue, predictive processing noise) equally consistent with the data.

Hypothesis p=0.55Corticosteroid-induced HPA “Trust-Breaking” in Post-Viral Fatigue

Evidence: Acute corticosteroid administration may disrupt endogenous HPA axis feedback in post-viral ME/CFS and Long COVID via GR downregulation and CRH suppression, creating iatrogenic dependency. Negative PoCoVIT trial suggests initial corticosteroid benefit transitions to HPA dysregulation without addressing core pathology.
Citations: (Adam 2024)
Mechanism: Corticosteroid suppresses CRH → downregulates GR → blunts endogenous cortisol response → creates artificial dependency cycle.
Chapter ref: steroid hpa trust breaking
Prediction: Longitudinal cortisol profiles pre/post corticosteroid treatment will show blunted diurnal variation and increased post-treatment fatigue severity vs baseline.
Treatment: Corticosteroids contraindicated; focus on HPA axis restoration (circadian rhythm, stress response training, low-dose hydrocortisone if CRH confirmed low).
Limitation: Mechanism inferred from negative trial; direct HPA axis measurements in corticosteroid-treated Long COVID patients not yet available.

Hypothesis p=0.55Corticosteroid-Induced NK Cell Suppression Facilitates Viral Reactivation

Evidence: Methylprednisolone dose-dependently suppresses NK cell cytotoxicity and IFN-γ production, potentially enabling EBV/HHV-6 reactivation in Long COVID and ME/CFS. PoCoVIT trial adverse events may reflect viral reactivation rather than pure immunosuppression.
Citations: (Adam 2024)
Mechanism: Corticosteroids suppress NK cells → reduced viral surveillance → EBV/HHV-6 reactivation → sustained immune activation → chronic fatigue.
Chapter ref: steroid nk viral reactivation
Prediction: Corticosteroid-treated patients will show increased EBV/HHV-6 viral load and decreased NK cell activity vs placebo at 3-month follow-up.
Treatment: Antiviral protocols (valacyclovir) + NK-boosting supplements (beta-glucan, medicinal mushrooms) preferred over corticosteroids.
Limitation: PoCoVIT trial did not measure viral load or NK cell activity; mechanism inferred from corticosteroid pharmacology.

Hypothesis p=0.55Systemic Innate-Immune Hyperactivation as a Drug-Addressable Driver of Fatigue/PEM

Evidence: Che et al. 2025 (Lipkin multi-site multi-omics + ex-vivo microbial stimulation) (Che et al. 2025) and Hornig et al. 2015 plasma immune signatures (Hornig et al. 2015) document an exaggerated innate immune response that worsens after exercise and correlates with fatigue/PEM. Consistent with ch18 TLR4/NF-$\kappa$B PEM amplification TLR4/NF-$\kappa$B Activation as PEM Cytokine Amplifier. Cohort overlap: Che 2025 and Hornig 2015 share the Columbia multi-site program — these are overlapping sources, not independent replications.
Citations: (Che et al. 2025),(Hornig et al. 2015)
Mechanism: Infectious/microbial-antigen trigger → exaggerated innate TLR/NF-$\kappa$B and NLRP3-inflammasome response → systemic chronic inflammation → downstream metabolic (TCA/beta-oxidation/urea-cycle) and tryptophan-kynurenine amplification → fatigue and PEM worsened by exercise.
Chapter ref: ch34 sec-08 innate-immune-hyperactivation-cascade (β-blocker benefit declines at a stable dose and a weekend drug holiday restores it); ch08 Innate Immunity Immune Activation and Inflammation; ch18 TLR4/NF-$\kappa$B Activation as PEM Cytokine Amplifier; ch17 Integrated Hypothesis: The Multi-Lock Trap
Prediction: Qualitatively different drug-response patterns separate an innate-immune driver from metabolic-triage and CNS-confined neuroinflammation: (a) if systemic innate immunity is rate-limiting, broad anti-inflammatories give partial relief and inflammasome/IL-1 blockers (colchicine, anakinra, canakinumab) improve a subset; (b) if metabolic-triage dominates (Pacing prevents progressive decline), anti-inflammatories fail to relieve fatigue; (c) if the driver is CNS-confined (cf. Omdal CNS-compartment hypothesis), peripherally-restricted anti-inflammatories (NSAIDs, colchicine) fail while CNS-penetrant agents (LDN, minocycline) succeed. Falsified if anti-inflammatory response patterns are uniform across all ME/CFS patients in all three scenarios.
Treatment: Sequential, mechanism-probing trial of broad anti-inflammatory → inflammasome/IL-1 blocker → CNS-penetrant immunomodulator, each with the monitoring, interaction, and stopping guidance in medication reference. Research-stage; no clinical recommendation.
Limitation: Che 2025 is cross-sectional with severity distribution unstated (severity coverage unknown) and uses ex-vivo blood/plasma to infer systemic tissue inflammation (compartment gap, Doc C). Competes with the CNS-confined-peripheral-null hypothesis — differential drug response is the deciding test, not inflammatory-marker presence alone. Origin: /integrate-topic innate-immunity-che2025 (scoped cascade micro-add).

Hypothesis p=0.50Corticosteroid-Induced Transcriptional Reprogramming Creates Pathological “Stuck State”

Evidence: Glucocorticoid receptor (GR) signaling induces rapid transcriptional reprogramming via chromatin remodeling. In post-viral contexts, acute corticosteroid exposure may lock immune cells into pathological gene expression patterns that persist after drug clearance, explaining PoCoVIT’s lack of durability and adverse events.
Citations: (Adam 2024)
Mechanism: GR binding to GREs → chromatin remodeling → persistent transcriptional “memory” even after corticosteroid clearance → pathological immune state.
Chapter ref: steroid transcriptional lock
Prediction: Single-cell RNA-seq of PBMCs pre/post corticosteroid treatment will show persistent gene expression changes at 6-month follow-up despite drug clearance.
Treatment: Epigenetic modulators (HDAC inhibitors, DNA methylation agents) may reverse corticosteroid-induced transcriptional locking.
Limitation: Single-cell transcriptomics not performed in PoCoVIT; mechanistic inference from GR biology.

Hypothesis p=0.45GR Isoform Imbalance (GRα/GRβ) Underlies Corticosteroid Resistance and Adverse Outcomes

Evidence: Chronic inflammation in Long COVID and ME/CFS may shift GR isoform expression toward GRβ (dominant-negative) and away from GRα (functional), creating corticosteroid resistance and paradoxical pro-inflammatory effects. PoCoVIT trial failure may reflect undetected GR isoform imbalance.
Citations: (Adam 2024)
Mechanism: Inflammation → increased GRβ:GRα ratio → corticosteroid resistance → paradoxical GRβ-mediated inflammation → adverse outcomes.
Chapter ref: gr isoform imbalance
Prediction: GRβ:GRα mRNA ratio > 0.5 in peripheral blood monocytes will predict corticosteroid non-response and increased adverse events.
Treatment: GRα-selective agonists or GRβ silencing approaches may restore corticosteroid responsiveness; GR isoform screening before corticosteroid use.
Limitation: GR isoform expression not measured in PoCoVIT; mechanism inferred from inflammatory disease literature.

Hypothesis p=0.45Corticosteroids May Exacerbate T Cell Exhaustion in Post-Viral Fatigue

Evidence: Glucocorticoids modulate T cell function through GR-mediated transcriptional reprogramming, PD-1 pathway modulation, metabolic suppression, and subset-specific CD8+ preference. In ME/CFS, where CD8+ T cells already show epigenetic locking of exhaustion programs and failed metabolic reprogramming, corticosteroids may lock cells deeper into exhausted states rather than restoring function.
Citations: (Adam 2024) (Derek S. Iu et al. 2024) (Mandarano et al. 2020)
Mechanism: GR activation → transcriptional reprogramming + PD-1 upregulation + metabolic suppression + CD8+ preference → deeper T cell exhaustion → impaired viral clearance → worse outcomes.
Chapter ref: steroid tcell exhaustion
Prediction: ME/CFS/Long COVID patients receiving corticosteroids will show increased PD-1/Tim-3/CTLA-4 on CD8+ T cells, deeper transcriptional exhaustion shifts, reduced viral clearance, and in vitro dexamethasone will increase checkpoint expression more than in healthy controls.
Treatment: Corticosteroids contraindicated in post-viral fatigue; if unavoidable, combine with T cell support (checkpoint modulation, metabolic support) and monitor exhaustion markers.
Limitation: Direct evidence for corticosteroid effects on ME/CFS T cell exhaustion lacking; mechanistic inference from GR biology and negative methylprednisolone trial.

Speculation p=0.45GR Signaling Bifurcation in Post-Viral vs Acute Inflammation

Evidence: The immune response in post-viral ME/CFS and Long COVID may have bifurcated away from standard acute inflammation model that guides corticosteroid use. Altered cofactor availability, epigenetic reprogramming at GR binding sites, shifted GR isoform balance, and exhausted immune cell phenotypes may cause GR activation to produce different effects in chronic post-viral states vs acute inflammation, explaining why steroids work in acute COVID pneumonia but fail in Long COVID/ME/CFS.
Citations: (Adam 2024)
Mechanism: Chronic inflammation → altered GR signaling context → different transrepression/transactivation ratio → unexpected steroid effects → treatment failure.
Chapter ref: gr bifurcation
Prediction: Single-cell ATAC-seq will show different chromatin accessibility at GR binding sites in ME/CFS vs acute inflammation; GR activation will produce different gene expression signatures; transrepression/transactivation ratio altered; acute inflammation biomarkers (IL-6, CRP) won’t predict steroid response in post-viral fatigue.
Treatment: Corticosteroids generally contraindicated in post-viral fatigue unless compelling indication; need GR signaling phenotyping before any steroid use.
Limitation: Direct evidence for GR signaling bifurcation in ME/CFS lacking; mechanistic inference from negative methylprednisolone trial and GR biology.

Speculation p=0.45Post-Steroid Recovery Protocol for HPA Axis Restoration

Evidence: Patients who received corticosteroids for Long COVID or ME/CFS may require structured HPA axis recovery including circadian rhythm optimization, adrenal support (adaptogens, licorice), and gradual weaning of any iatrogenic dependency. PoCoVIT trial participants likely need recovery support.
Citations: (Adam 2024)
Mechanism: Circadian alignment + adrenal support + gradual weaning → HPA axis restoration → reduced iatrogenic fatigue.
Chapter ref: post steroid recovery
Prediction: Structured recovery protocol will improve fatigue scores and normalize cortisol rhythm in corticosteroid-exposed patients vs standard care.
Treatment: Morning light exposure, sleep schedule regularity, ashwagandha 300mg BID (caution: may affect thyroid function), licorice root 200mg AM (caution: pseudohyperaldosteronism — monitor blood pressure and potassium), magnesium 400mg PM for 8 weeks.
Limitation: No trials of post-steroid recovery specifically in ME/CFS or Long COVID; protocols adapted from adrenal fatigue literature; licorice root carries hypertension and hypokalemia risk with prolonged use; ashwagandha may interfere with thyroid medication.

Speculation p=0.40Steroid-Sparing Anti-Inflammatory Protocol for Post-Viral Fatigue

Evidence: Given corticosteroid failure, a protocol combining mast cell stabilizers (cromolyn, ketotifen), low-dose colchicine, and omega-3 fatty acids may provide anti-inflammatory benefits without HPA axis disruption. This addresses ME/CFS/Long COVID neuroinflammation while avoiding corticosteroid risks.
Citations: (Adam 2024)
Mechanism: Mast cell stabilization + anti-fibrotic (colchicine) + anti-inflammatory (omega-3) → reduced neuroinflammation without HPA disruption.
Chapter ref: steroid sparing protocol
Prediction: Steroid-sparing protocol will reduce inflammation markers (IL-6, TNF-α) and improve fatigue scores without altering cortisol rhythm.
Treatment: Cromolyn 100mg QID, ketotifen 1mg BID, colchicine 0.5mg daily (monitor renal function; narrow therapeutic index), omega-3 2g daily for 12 weeks.
Limitation: No clinical trials of this specific combination in ME/CFS or Long COVID; individual components have mixed evidence; colchicine narrow therapeutic index requires renal monitoring; ketotifen causes sedation.

Hypothesis p=0.35Corticosteroid Timing Paradox: Early Harm, Late Benefit

Evidence: The timing of corticosteroid administration relative to viral infection may determine outcomes. Early administration (less than 4 weeks post-infection) may impair viral clearance and immune priming, increasing chronic sequelae risk. Late administration (greater than 6 months) might provide anti-inflammatory benefits without compromising viral clearance, as viral reservoir is established and immune dysregulation is primary pathology. Explains why steroids work in acute COVID pneumonia but fail in Long COVID.
Citations: (Adam 2024)
Mechanism: Early steroids → NK suppression + T cell priming disruption + GR reprogramming → viral reservoir establishment → chronic sequelae. Late steroids → established reservoir + chronic inflammation → anti-inflammatory benefit without viral clearance compromised.
Chapter ref: steroid timing paradox
Prediction: Retrospective analysis will show worse Long COVID outcomes with steroids less than 4 weeks vs greater than 6 weeks; animal models will show higher viral load/chronic sequelae with early vs late steroids; biomarker profiles differ (viral markers early, inflammation markers late).
Treatment: Steroids generally contraindicated in post-viral fatigue; timing-dependent effects uncertain; avoid unless compelling indication.
Limitation: Timing hypothesis speculative; no prospective trials comparing early vs late steroid administration in post-viral syndromes.

Speculation p=0.35Corticosteroids May Worsen Long-Term Outcomes in Post-Viral Fatigue

Evidence: Despite acute anti-inflammatory effects, corticosteroids may impair viral clearance, disrupt tissue repair, and induce endocrine dependency that prolongs recovery. PoCoVIT trial’s early termination and high adverse event rate suggest net harm in Long COVID. Similar concerns apply to ME/CFS.
Citations: (Adam 2024)
Mechanism: Corticosteroids impair viral clearance + disrupt tissue repair + induce endocrine dependency → prolonged recovery → net harm despite acute inflammation reduction.
Chapter ref: corticosteroid mechanism
Prediction: Corticosteroid-treated patients will have lower recovery rates and higher symptom burden at 12-month follow-up vs untreated controls.
Treatment: Corticosteroids contraindicated in post-viral fatigue; focus on viral clearance (antivirals) and tissue repair (growth factors, collagen support).
Limitation: Long-term outcomes not measured in PoCoVIT (trial terminated early); mechanism speculative.

Speculation p=0.35Vagus Nerve Stimulation as Corticosteroid Alternative for Neuroinflammation

Evidence: Transcutaneous vagus nerve stimulation (tVNS) may provide anti-inflammatory and autonomic benefits in ME/CFS and Long COVID without HPA axis disruption. Unlike corticosteroids, VNS enhances cholinergic anti-inflammatory pathway via parasympathetic activation, addressing neuroinflammation mechanism. Controlled tVNS trials in the most closely analogous condition (PCC) are null for clinical efficacy despite confirmed HRV engagement — sham outperformed active in the best-powered RCT ((Balan et al. 2026)). 0.50→0.35: contradictory controlled evidence from PCC.
Citations: (Adam 2024)
Mechanism: tVNS → parasympathetic activation → cholinergic anti-inflammatory pathway → reduced neuroinflammation without HPA disruption.
Chapter ref: vns steroid alternative
Prediction: tVNS 15min BID will reduce inflammation markers and improve fatigue scores without altering cortisol rhythm or causing adverse events.
Treatment: tVNS devices (gammaCore, Nemos) 15min BID on neck, targeting auricular branch for 12 weeks.
Limitation: Small pilot studies in rheumatoid arthritis and Crohn’s disease show benefit; no trials in ME/CFS or Long COVID yet. All PCC controlled tVNS trials null for clinical efficacy ((Balan et al. 2026)); CAP blockade by GPCR autoantibodies may explain ineffectiveness (Candidate Explanations for the tVNS Sham-Superior Paradox and Implication for Trial Design).

11 Tick-Borne Infections × ME/CFS

Speculation p=0.70Borrelia burgdorferi Directly Activates Human Microglia — Bacterial Counterpart to Viral Microglial Coverage

Evidence: Six+ independent studies across three labs: Bb directly activates human and primate microglia via TLR1/TLR2/MyD88→NF-κB→TNF-α, IL-1β, IL-6, chemokines (Myers, Kaushal, and Philipp 2009) (PLoS Pathog, cert 0.70) (Parthasarathy and Philipp 2015) (J Neuroinflamm, cert 0.70) (Cassiani-Ingoni et al. 2006) (J Neuropathol Exp Neurol, cert 0.65, human microglia) (Kuhlow et al. 2005) (J Neuroimmunol, cert 0.65). Non-viable Bb debris suffices to sustain microglial activation (Parthasarathy and Gadila 2022) (cert 0.65) — explains post-antibiotic neuroinflammation. In vivo human PET confirms glial activation persists years after treatment in PTLDS (Coughlin et al. 2018) (n=12, cert 0.60).
Citations: (Myers, Kaushal, and Philipp 2009) (Parthasarathy and Philipp 2015) (Cassiani-Ingoni et al. 2006) (Kuhlow et al. 2005) (Parthasarathy and Gadila 2022) (Coughlin et al. 2018)
Mechanism: Bb→TLR1/TLR2 on human microglia→MyD88→NF-κB + MAPK→proinflammatory cytokine release (TNF-α, IL-1β, IL-6, CCL2, CXCL10). Microglia are necessary intermediaries — Bb alone does not directly kill neurons; microglial inflammatory response is required. Non-viable bacterial debris sustains this activation → convergent neuroimmunological endpoint for viral and bacterial post-infectious ME/CFS triggers. Complement to the existing viral microglial coverage in Sleep EEG Delta/Alpha Ratio as a Non-Invasive Thalamic Calcium Proxy.
Chapter ref: ch07: tick borne; ch08: glial (microglial activation paragraph)
Prediction: Not a hypothesis — established finding. Would be refuted if a well-powered study found Bb does not activate human microglia, but evidence against this scenario is strong (6+ studies, 3 labs, human and primate cells).
Treatment: The activation mechanism explains post-antibiotic symptom persistence (non-viable debris sustains inflammation) — clinically useful for patient education but no direct therapeutic target identified at this stage. Research-stage only.
Limitation: In vitro microglial studies (primate and human cell lines/primary); in vivo human evidence is a single pilot PET study (n=12). No ME/CFS-specific microglial data; evidence is from neuroborreliosis/PTLDS models. Does not establish that microglial activation is present in ME/CFS patients with a tick-borne trigger — only that Bb can cause it and that PTLDS patients show it.

Speculation p=0.40Infection-Driven Oxidative Consumption as a Contributor to CoQ10 Depletion

Evidence: Every component separately documented in ME/CFS: low plasma CoQ10 (Maes et al. 2009) (cert 0.55); elevated lipid peroxidation (Maes and Leunis 2014) (Maes et al. 2021); viral-reactivation mitochondrial ROS (Schreiner et al. 2020) (in vitro); post-viral antioxidant depletion in Long COVID Al-Hakeim et al. (2023). Biochemical framework for oxidative CoQ10 consumption (Gerwyn Morris et al. 2013) (cert 0.65). Unified causal chain never directly tested.
Citations: (Maes et al. 2009) (Gerwyn Morris et al. 2013) (Gerwyn Morris and Maes 2014) (Maes and Leunis 2014) (Maes et al. 2021) (Schreiner et al. 2020) Al-Hakeim et al. (2023)
Mechanism: Persistent/reactivating infection → sustained ROS load → oxidative consumption of CoQ10 (a regenerable lipophilic antioxidant quenching lipid peroxyl radicals) faster than ETC/GSH/vitamin-E regeneration → contributes to documented CoQ10 deficiency. Self-amplifying via ROS→ETC damage→more ROS feed-forward loop.
Chapter ref: ch07: coq10 infection consumption
Prediction: Pathogen-burden markers (EBV/HHV-6 load or composite infection-activity index) correlate inversely with plasma/tissue CoQ10 and positively with lipid-peroxidation markers; suppression of viral reactivation is followed by a rise in CoQ10 / fall in lipid-peroxidation markers. Refuted if CoQ10 deficiency occurs without elevated oxidative-consumption markers or if pathogen burden and CoQ10 are uncorrelated after adjustment.
Treatment: If confirmed, controlling infection/oxidative source may matter as much as CoQ10 repletion (leaking-tank logic); not a clinical recommendation — inference only. No direct evidence antiviral therapy restores CoQ10.
Limitation: Causal arrow untested; competing biosynthesis-defect mechanism (Laredj, Licitra, and Puccio 2014) (cert 0.70) not excluded (see Is ME/CFS CoQ10 Deficiency Driven by Oxidative Consumption or Impaired Biosynthesis?). HHV-6 evidence in vitro only; Long COVID analogy not ME/CFS-replicated. All CoQ10 data plasma, not tissue.

Hypothesis p=0.35Tick-Borne Pathogen-Driven Glycolytic Reprogramming as a Compounding Immunometabolic Insult in a Post-Infectious ME/CFS Subset

Evidence: Borrelia (strongest): LDHA/TXN upregulation with glucose depletion and lactate accumulation in human THP-1 monocytes (Dong et al. 2026) (in vitro, cert 0.50); persistent trained-immunity glycolytic macrophage memory with mitochondrial downregulation, reversed in vivo by glycolysis inhibition (Barriales et al. 2021) (mouse + in vitro, cert 0.65, PLoS Biol); cell-type-specific trained immunity (Bernard and Hu 2020) (cert 0.50); Borrelia obligately glycolytic, LDH druggable (Lynch et al. 2023) (cert 0.45). Bartonella: B. henselae stabilises HIF-1α → cellular hypoxia → decreased host ATP → VEGF (Kempf et al. 2005) (cert 0.70, Circulation). Babesia (weakest): increased de-novo glucose uptake in infected murine RBCs (Ohmori et al. 2004) (cert 0.35, single animal study). Contradiction: Kerstholt2022BorreliaLactate found DECREASED baseline glycolysis in primary monocytes (cert 0.60) — context/timepoint-dependent, bidirectional. Null: PTLDS serum metabolomics found NO glycolytic signature (Fitzgerald et al. 2021) (cert 0.65) — consistent with cell-type-restricted reprogramming. 0 direct ME/CFS studies.
Citations: (Dong et al. 2026) (Barriales et al. 2021) (Kempf et al. 2005) (Ohmori et al. 2004) (Kerstholt et al. 2022) (Fitzgerald et al. 2021) (Mandarano et al. 2020) (Naviaux et al. 2016)
Mechanism: Asymmetric evidence: Borrelia (moderately-evidenced) drives a Warburg-like glycolytic shift via LDHA/trained-immunity macrophage memory; Bartonella HIF-1α/ATP depletion is consistent-with but does not measure glycolysis (single cell-line study); Babesia RBC glucose uptake is a transporter-level effect in anucleate cells, NOT transcriptional reprogramming. In a tick-borne-triggered or co-infected subset a Borrelia-type shift may compound the pre-existing ME/CFS immunometabolic defect (failed CD8+ Warburg (Mandarano et al. 2020); cell-danger-response glycolysis (Naviaux et al. 2016)) and, if epigenetically stabilised as trained immunity, may persist after pathogen clearance to sustain chronic symptoms — mirroring the post-viral glial mechanism (Post-Viral CNS Reprogramming Hypothesis).
Chapter ref: ch07: tickborne glycolytic reprogramming
Prediction: In a tick-borne-triggered ME/CFS subset with serology/PCR-confirmed infection, isolated monocytes/macrophages will show a trained-immunity glycolytic signature (elevated LDHA/lactate, downregulated mitochondrial transcripts, enhanced ex-vivo cytokine responses) exceeding non-tick-borne ME/CFS patients and controls; attenuated in patients whose infection was eradicated early. Falsified if tick-borne-triggered ME/CFS monocytes show no glycolytic/mitochondrial transcriptional difference from other ME/CFS patients.
Treatment: If confirmed: identifies a subset potentially addressable by metabolic (glycolysis-modulating) rather than purely antimicrobial approaches. Currently a research direction, not a treatment basis. No human data.
Limitation: No study has measured tick-borne pathogen-driven glycolytic reprogramming in any ME/CFS patient — ME/CFS relevance is mechanistic parallel only. Strongest evidence (Borrelia trained immunity) is mouse/human-cell; Bartonella/Babesia thinner (Babesia = single animal study). PTLDS serum metabolomics null for glycolysis. Subset size and severity applicability unknown. Direction of effect (↑ vs ↓ glycolysis) context-dependent, unresolved in vivo.

Speculation p=0.35Combinatorial Immune Signatures Behind Cross-Study Inconsistency in ME/CFS

Evidence: PTLD immunophenotyping separated patients from controls only with a multi-parameter classifier, not any single marker (Girgis et al. 2025); ME/CFS immune studies are chronically inconsistent at the single-marker level.
Citations: (Girgis et al. 2025)
Mechanism: If the discriminating immune signal is inherently combinatorial in both PTLD and ME/CFS, univariate studies would disagree across cohorts while multivariate classifiers on the same data recover a reproducible signal.
Chapter ref: ch07: tickborne combinatorial immune
Prediction: A multivariate (elastic-net) classifier on published ME/CFS immunophenotyping datasets separates patients from controls at materially higher AUC than the best single marker. Refuted if multivariate ≈ univariate, or if the signal fails to replicate across cohorts.
Treatment: None directly; a diagnostic/analysis-method insight, not a treatment.
Limitation: Combinatorial finding solid for PTLD; transfer to ME/CFS is inference, not measurement. Origin: brainstorm.

Open Question p=0.35Serum Exosomal mtDNA + Tick Serology Stratification Panel

Evidence: Post-exercise exosomal mtDNA elevated in ME/CFS (Tsilioni, Natelson, and Theoharides 2022) (cert 0.55) but never stratified by trigger type. If tick-borne-triggered ME/CFS involves a separate NO $\rightarrow$ mito $\rightarrow$ mtDNA pathway, seropositive patients with elevated post-exercise exosomal mtDNA might identify the subgroup for microglial-targeted trials. Panel: exosomal mtDNA post-exercise + Borrelia C6 peptide IgG + Bartonella IgG (approximately USD 150). PPV untested. Origin: brainstorm (idea 9.2).
Citations: (Tsilioni, Natelson, and Theoharides 2022)
Mechanism: Not a mechanistic claim — a stratification/biomarker proposal. Hypothesis: tick-borne-triggered ME/CFS patients will show higher post-exercise exosomal mtDNA than viral-triggered, and mtDNA reduction will correlate with response to microglial-targeted interventions.
Chapter ref: ch07: exosomal mtdna tick serology panel
Prediction: In a cohort with documented tick-exposure history + ME/CFS, seropositive patients (Borrelia C6 IgG+) will show ≥30% higher post-exercise exosomal mtDNA than seronegative patients. Panel AUC ≥0.75 for predicting response to a microglial-targeted intervention. Falsified if mtDNA does not differ by serostatus or does not correlate with treatment response.
Treatment: Research-stage stratification tool only; not for clinical use. Could identify who to enroll in trials of microglial-targeted agents.
Limitation: mtDNA trigger-type stratification completely untested. Borrelia serology has known sensitivity/specificity limitations. Panel PPV for treatment-response prediction is nil — unmeasured. No data on whether mtDNA response to exercise differs between tick-borne and viral ME/CFS. Serial pharmacodynamic application (pre/post-intervention mtDNA) is also untested. Origin: brainstorm.

Speculation p=0.30Weak HLA–Antigen Binding as a Shared Vulnerability Across Post-Infectious Illness

Evidence: In-silico HLA binding-affinity analysis reports ME/CFS-susceptibility alleles (C*07:04, DQB1*03:03) bind Borrelia burgdorferi antigens weakly while protective alleles (B*08:01, DPB1*02:01) bind strongly — same pattern reported for herpesvirus and SARS-CoV-2 antigens. Computational only; no wet-lab or functional validation; few alleles tested.
Citations: (Georgopoulos, James, and Peterson 2025)
Mechanism: Weak HLA presentation → inefficient antigen clearance → antigen persistence → chronic immune activation, offering one reason the same host could develop ME/CFS, PTLDS, or Long COVID depending on the arriving pathogen.
Chapter ref: ch07: hla shared susceptibility
Prediction: In an HLA-genotyped cohort, carriers of the “weak-binding” susceptibility alleles show higher rates of chronic post-infectious illness after documented tick-borne or viral infection than carriers of “strong-binding” protective alleles. Refuted if chronic-illness incidence is independent of HLA-binding class, or if measured binding does not match the in-silico predictions.
Treatment: None. A genetic risk marker, if validated, would inform risk stratification — not treatment. Not usable for individual risk prediction at present.
Limitation: In-silico only; binding affinity does not guarantee functional immune outcome; small allele set; no prospective genotype–outcome cohort exists. Origin: literature-derived.

Speculation p=0.30Tick-Borne Pathogens Converge on Glycolytic Reprogramming — A Post-Infectious Metabolic-Memory Synthesis

Evidence: Synthesis (not a new claim) condensing Tick-Borne Pathogen-Driven Glycolytic Reprogramming as a Compounding Immunometabolic Insult in a Post-Infectious ME/CFS Subset (0.40), Non-Viral Tick-Borne Pathogens May Drive Comparable Glial and Immune Glycolytic Reprogramming (0.30), Borrelia-Trained Immune Glycolysis May Reverse the Astrocyte–Neuron Lactate Gradient (0.20), Metformin as a Hypothetical Trained-Immunity Metabolic Reset — Research-Stage Only (0.22), and Testing Tick-Borne Glycolytic Reprogramming in ME/CFS: A Research Programme, cross-referenced to Post-Viral CNS Reprogramming Hypothesis. Convergence of Borrelia ((Barriales et al. 2021), (Dong et al. 2026)), Bartonella ((Kempf et al. 2005)), Babesia ((Ohmori et al. 2004)) on a glycolytic endpoint. 0 direct ME/CFS data; direction-of-effect unresolved; PTLDS serum null (Fitzgerald et al. 2021).
Citations: (Barriales et al. 2021) (Dong et al. 2026) (Kempf et al. 2005) (Ohmori et al. 2004) (Fitzgerald et al. 2021)
Mechanism: Asymmetric evidence — one moderately-evidenced pathogen (Borrelia trained-immunity glycolysis) plus a weaker Bartonella analogy (HIF-1α, glycolysis not measured); Babesia excluded from “reprogramming” (transporter-level, anucleate). The Borrelia case, if it holds, reaches the same endpoint as viral glial reprogramming — motivating a broader “post-infectious” (not merely post-viral) metabolic-memory model for mechanisms with post-clearance persistence, with downstream reach to the ANLS and a metabolic therapeutic corollary.
Chapter ref: ch07: tickborne glycolytic reprogramming model
Prediction: The synthesis stands or falls on the research programme (Testing Tick-Borne Glycolytic Reprogramming in ME/CFS: A Research Programme): the central testable claim is that tick-borne-triggered ME/CFS shows a monocyte trained-immunity glycolytic signature exceeding viral-triggered ME/CFS. Falsified if no such signature exists.
Treatment: Unifies post-viral and tick-borne ME/CFS under a metabolic-memory framework IF confirmed — would support metabolic (not antimicrobial) intervention. Not a current clinical recommendation.
Limitation: Aggregative synthesis at certainty 0.30 (below the 0.35 hypothesis it summarises because it also spans lower-certainty speculations). 0 direct ME/CFS measurement; direction-of-effect unresolved; closest human data (PTLDS serum) null. Origin: brainstorm-derived aggregation.

Speculation p=0.30Two-Hit Microglial Priming: Borrelia as Primer, Exercise mtDNA as Second Hit

Evidence: Priming: Bb upregulates TLR1/TLR2 and NLRP3/pro-IL-1β in human microglia (Cassiani-Ingoni et al. 2006) (cert 0.65) (Myers, Kaushal, and Philipp 2009) (cert 0.70). Second hit: exercise-induced exosomal mtDNA activates human microglia to secrete IL-1β in ME/CFS (Tsilioni, Natelson, and Theoharides 2022) (cert 0.55). Two-hit NLRP3 biology established in macrophages; not specifically demonstrated in Bb-exposed human microglia. Origin: brainstorm (idea 1.3).
Citations: (Cassiani-Ingoni et al. 2006) (Myers, Kaushal, and Philipp 2009) (Tsilioni, Natelson, and Theoharides 2022)
Mechanism: Bb exposure primes microglia (TLR/NLRP3 upregulation) but does not alone trigger IL-1β secretion (canonical NLRP3 requires priming + activation). The second hit — exercise-induced exosomal mtDNA — activates NLRP3, producing mature IL-1β and the PEM crash. Pacing prevents mtDNA release from exercise, thus preventing the second hit. Molecular mechanism for PEM in tick-borne-triggered ME/CFS specifically.
Chapter ref: ch07: microglial two hit priming
Prediction: Bb-exposed primary microglia (24 h): elevated NLRP3/pro-IL-1β mRNA but minimal mature IL-1β. Addition of mtDNA (10 μg/mL) at 24 h → 5–10× IL-1β increase vs mtDNA alone or Bb alone, blocked by MCC950 (NLRP3) and DNase. Falsified if Bb alone drives full IL-1β (single-hit) or mtDNA does not amplify.
Treatment: Pacing justified by a specific molecular mechanism (prevents exercise mtDNA second-hit on primed microglia), not just by general energy conservation. No direct treatment implication beyond pacing.
Limitation: NLRP3 two-hit biology in Bb-exposed human microglia not specifically demonstrated; priming-by-Bb inferred from TLR upregulation studies, not from a direct Bb-primed + mtDNA-triggered experiment. Applies to tick-borne-triggered ME/CFS specifically; viral-triggered PEM may involve different priming signals. Certainty 0.30 — inferential assembly of separately-plausible components. Origin: brainstorm.

Speculation p=0.28Infection-Driven Kynurenine Shunt as a Route to Post-Lyme Fatigue

Evidence: IDO activation by sustained interferon-γ is established in Lyme disease; ME/CFS peripheral-serotonin depletion and the kynurenine trap are documented separately. The specific post-Lyme tryptophan → serotonin → fatigue chain has not been measured directly.
Citations: (Nawrocki et al. 2025)
Mechanism: Tick-borne infection → sustained IFN-γ → IDO activation → tryptophan diverted down kynurenine pathway → lower peripheral serotonin + reduced NAD⁺ substrate → persistent fatigue as the non-normalising post-Lyme domain.
Chapter ref: ch07: tickborne kynurenine fatigue
Prediction: Post-Lyme patients with persistent fatigue show elevated kynurenine:tryptophan ratios and lower peripheral serotonin than recovered controls, magnitude tracking fatigue severity. Refuted if KYN:TRP and serotonin do not differ by fatigue status, or if any difference is fully explained by acute-phase inflammation.
Treatment: If validated, IDO-pathway or serotonin-substrate strategies become candidates — research-stage only, no current clinical action.
Limitation: Links two separately-documented mechanisms; never measured as a chain in post-Lyme cohorts. Contingent on Peripheral Serotonin Depletion as Multi-System Convergence Point remaining supported (cert 0.60). Origin: brainstorm.

Speculation p=0.25Non-Viral Tick-Borne Pathogens May Drive Comparable Glial Glycolytic Reprogramming

Evidence: Extension of the post-viral glial reprogramming hypothesis (Post-Viral CNS Reprogramming Hypothesis, cert 0.40) to non-viral tick-borne pathogens. Peripheral (non-glial) evidence: Borrelia trained-immunity glycolytic macrophage memory reversible in vivo (Barriales et al. 2021) (cert 0.65); Bartonella HIF-1α stabilisation + host ATP depletion (Kempf et al. 2005) (cert 0.70). Analogous to microglial trained-immunity reprogramming (Wendeln et al. 2018) (Nirakis et al. 2025) and viral glial reprogramming (Rodrigues et al. 2025). NO glial-specific data for any tick-borne pathogen; 0 ME/CFS glial data.
Citations: (Barriales et al. 2021) (Kempf et al. 2005) (Wendeln et al. 2018) (Nirakis et al. 2025) (Rodrigues et al. 2025)
Mechanism: If Borrelia/Bartonella reprogram glia (as they reprogram peripheral macrophages) toward glycolysis with epigenetic stabilisation, the same self-sustaining cycle proposed for viruses (metabolic shift → epigenetic stabilisation → chronic neuroinflammation) would apply. Bartonella is neurotropic (encephalopathy-capable), making CNS access plausible.
Chapter ref: ch08: tickborne glial reprogramming
Prediction: Microglia/astrocytes exposed to Borrelia or Bartonella antigens in vitro will show a sustained OXPHOS-to-glycolysis shift (elevated LDHA/lactate, downregulated mitochondrial transcripts, H3K4me1/H3K27ac at inflammatory loci) persisting after antigen removal, comparable to viral glial reprogramming. Falsified if bacterial/protozoal antigen exposure produces only transient metabolic change with no epigenetic stabilisation in glia.
Treatment: If confirmed, broadens “post-viral” to “post-infectious” glial reprogramming — tick-borne-triggered patients could benefit from metabolic/epigenetic-reversal strategies proposed for post-viral ME/CFS. Untested research direction.
Limitation: No glial glycolytic-reprogramming data for any tick-borne pathogen; all evidence from peripheral macrophages/monocytes or non-CNS tissue; no ME/CFS glial data. Whether these pathogens reprogram glia specifically (vs peripheral immune cells) untested. Compound speculation (cert 0.25): peripheral tick-borne hypothesis (0.35) × untested glial extrapolation.

Speculation p=0.22Metformin as a Hypothetical Trained-Immunity Metabolic Reset in Tick-Borne-Triggered ME/CFS — Research-Stage Only

Evidence: Corollary of Tick-Borne Pathogen-Driven Glycolytic Reprogramming as a Compounding Immunometabolic Insult in a Post-Infectious ME/CFS Subset. Barriales2021 showed glycolysis inhibition in vivo reversed the Borrelia-trained macrophage phenotype (cert 0.65). Metformin opposes trained-immunity establishment via AMPK / reduced acetyl-CoA in other models (general immunometabolism literature, not tick-borne-specific). 0 human data in ME/CFS or any tick-borne fatigue population. Origin: brainstorm (idea 3.1).
Citations: (Barriales et al. 2021)
Mechanism: Metformin → AMPK activation + reduced acetyl-CoA for histone acetylation → opposes trained-immunity glycolytic epigenetic imprint → may reverse the pathogen-imprinted glycolytic macrophage memory. Metabolic, NOT antimicrobial — distinct from and not in tension with the rejection of prolonged antimicrobials for “seronegative chronic Lyme” (“Seronegative Chronic Lyme” as a Claimed Cause of ME/CFS — Not Supported).
Chapter ref: ch07: metformin trained immunity reset
Prediction: Open-label pilot in tick-borne-triggered ME/CFS with documented, treated prior infection: metformin reduces ex-vivo monocyte glycolytic output (ECAR/OCR) and raises mitochondrial-transcript expression vs baseline. Falsified if monocyte metabolism and fatigue unchanged.
Treatment: Explicitly NOT a treatment recommendation. Harms: GI intolerance, B12 depletion, rare lactic acidosis (relative contraindication in renal impairment; ironic given lactate-centred rationale). No human efficacy/dosing data for this indication.
Limitation: Untested in ME/CFS or any tick-borne fatigue population. Whole chain (tick-borne glycolytic reprogramming → reversibility → metformin as the reversing agent in humans) unvalidated at every link. Certainty 0.22. Origin: brainstorm.

Speculation p=0.20Borrelia-Trained Immune Glycolysis May Reverse the Astrocyte–Neuron Lactate Gradient

Evidence: Bridges two separately-documented mechanisms: Borrelia-trained macrophage glycolytic lactate output (Barriales et al. 2021) (cert 0.65) and ANLS gradient-dependence (Brainstem Glial Senescence as a Self-Reinforcing Autonomic Trap). Contrast with failed-Warburg immune deficit (Mandarano et al. 2020). Entirely inferential; 0 direct measurement. Origin: brainstorm (idea 1.1).
Citations: (Barriales et al. 2021) (Mandarano et al. 2020)
Mechanism: Chronically elevated systemic lactate from widely-distributed trained-immune cells reduces the serum-to-brain lactate gradient driving the astrocyte–neuron lactate shuttle, depriving neurons of a fuel supplying 30–50% of neuronal ATP — a mechanism distinct from and potentially compounding the failed-Warburg immune deficit.
Chapter ref: ch08: tickborne anls gradient reversal
Prediction: In tick-borne-triggered ME/CFS: resting venous lactate and arterial-to-venous lactate difference elevated vs non-tick ME/CFS; CSF-to-serum lactate ratio reduced from ~0.6–0.8 toward ~0.4. Falsified if lactate gradients do not differ by tick-exposure history.
Treatment: Motivates ketone-body bypass (ANLS-independent neuronal fuel) as symptomatic strategy; no direct treatment implication established.
Limitation: No measurement of immune-derived lactate flux, ANLS function, or lactate gradients in tick-borne ME/CFS. Magnitude of trained-immune lactate contribution unquantified, may be negligible. Inherits the Borrelia direction-of-effect contradiction. Certainty 0.20 — below both parent mechanisms. Origin: brainstorm.

Speculation p=0.20Microglial Mitochondrial Dysfunction After Bb/Bartonella — Untested Deductive Hypothesis

Evidence: Upstream: Bb→TLR→microglial activation well-established (cert 0.70, 6+ studies). Bb drives M1 microglial polarisation with iNOS induction (Akinlusi et al. 2025) (cert 0.45). Bb induces oxidative stress in host cells, likely mitochondrial targets (Peacock et al. 2015) (cert 0.50). Bb OMVs induce ROS in neuronal cells (Wawrzeniak et al. 2020) (cert 0.50, ROS in dermal fibroblasts/keratinocytes). Downstream: ME/CFS exosomal mtDNA activates human microglia to produce IL-1β (Tsilioni, Natelson, and Theoharides 2022) (cert 0.55). Middle: NO study has measured mitochondrial function in microglia after Bb/Bartonella exposure — the central link is a complete blank. Bartonella microglial infection: single 2001 feline study (Munana et al. 2001) (cert 0.55).
Citations: (Myers, Kaushal, and Philipp 2009) (Parthasarathy and Philipp 2015) (Akinlusi et al. 2025) (Peacock et al. 2015) (Wawrzeniak et al. 2020) (Tsilioni, Natelson, and Theoharides 2022) (Munana et al. 2001) (Parthasarathy and Gadila 2022)
Mechanism: Sustained TLR→NF-κB→iNOS→NO→mitochondrial complex inhibition→mtDNA release→NLRP3/cGAS-STING→sustained IL-1β. M1 polarisation→Warburg-like glycolytic shift→impaired mitophagy→accumulation of damaged mitochondrial mass. A deductive assembly: the upstream (Bb→microglia TLR) and downstream (mtDNA→microglia IL-1β) are separately documented; the middle (mitochondrial dysfunction in microglia after bacterial infection) has never been measured.
Chapter ref: ch07: microglial mitochondrial borrelia
Prediction: Primary/iPSC-derived human microglia exposed to live and non-viable B. burgdorferi in vitro will show reduced mitochondrial respiration (Seahorse OCR), elevated ECAR, and detectable mtDNA release within 24 h. Falsified if microglia maintain normal respiration and produce no mtDNA after 48 h Bb exposure at any MOI. Experimentally straightforward, never done.
Treatment: Pure basic science — no clinical application at this stage. Identifies a specific, testable gap rather than an undifferentiated “neuroinflammation” construct.
Limitation: The central step (microglial mitochondrial dysfunction) is unmeasured — this is a gap-identification hypothesis, not a finding. M1 polarisation data from HMC3 cell line only; Bb oxidative stress studies in non-microglial cell types; Bartonella microglial data in feline cells only, 2001, no human replication; whole chain deductive not empirical. Certainty 0.20 reflects the weight of separately-documented components but zero direct evidence for the assembled mechanism.

Speculation p=0.18Babesia Hemolysis → Haptoglobin Depletion as a Fatigue-Amplifying Pathway

Evidence: Babesia lyses erythrocytes releasing free hemoglobin; ME/CFS patients show post-exertional haptoglobin depletion tracking cognitive severity (Moezzi et al. 2025); Nrf2/HO-1 axis linked to fibromyalgia fatigue (Luo et al. 2025). Each link documented separately; the full Babesia→haptoglobin→fatigue chain never measured in a single cohort.
Citations: (Breitschwerdt et al. 2025) (Moezzi et al. 2025) (Luo et al. 2025) (Locke et al. 2023)
Mechanism: Chronic Babesia infection → persistent low-grade hemolysis → free hemoglobin/heme release → haptoglobin depletion + heme oxygenase-1 upregulation via Nrf2 → oxidative stress (Fenton chemistry from free iron) and impaired hemoglobin clearance → fatigue amplification. Converges with documented ME/CFS haptoglobin deficit rather than proposing a separate pathway.
Chapter ref: ch07: babesia hemolysis haptoglobin
Prediction: In tick-exposed ME/CFS cohort, plasma haptoglobin inversely proportional to Babesia parasitemia; free hemoglobin/heme proportional to parasitemia after controlling for confounders. Refuted if no relationship exists or if haptoglobin suppression is Babesia-independent.
Treatment: If validated, haptoglobin could serve as a monitoring marker during anti-Babesia treatment — research-stage only, not a basis for current clinical decisions.
Limitation: Theoretical chain of individually-documented links, never measured as a pathway. Enrichment culture (BAPGM) specificity unresolved. No treatment data. Origin: brainstorm.

Speculation p=0.15Bartonella Endotheliotropism as a Non-Autoantibody Route to Microclots

Evidence: Bartonella characteristically infects and dysregulates vascular endothelium (vasculitis-like presentations); ME/CFS/Long COVID microclot and endothelial-dysfunction pathology is developed elsewhere. Direct link to measured microclots untested.
Citations: (Bush et al. 2024)
Mechanism: Chronic endotheliotropic Bartonella infection → direct endothelial injury/activation → microclot formation via a route distinct from autoantibody or fibrin(ogen)-conformation mechanisms.
Chapter ref: ch07: bartonella endothelial microclot
Prediction: Post-tick-exposure ME/CFS patients with Bartonella evidence show higher endothelial-activation markers (vWF, soluble thrombomodulin) and microclot burden than tick-exposed Bartonella-negative patients. Refuted if microclot burden is independent of Bartonella status.
Treatment: If confirmed, identifies a subset in whom treating chronic infection addresses vascular pathology — not current grounds for antibiotics.
Limitation: Endotheliotropism established; link to measured microclots is untested extrapolation. Origin: brainstorm.

Open Question p=n/aWhat Would Falsify the Babesia–ME/CFS Hypothesis?

Evidence: Breitschwerdt 2025: 24% Babesia PCR in n=50 chronic fatigue patients, no controls, COI. 95% CI 12-36% overlaps background seroprevalence in endemic areas. MacDonald 1996: 0/47 CFS Babesia-seropositive vs 2/47 controls — directionally neutral, only controlled comparison. Babesia detection in immunocompetent adults is typically transient. No controlled Babesia serosurvey exists for ME/CFS.
Citations: (Breitschwerdt et al. 2025) (MacDonald et al. 1996) (Locke et al. 2023) (Moezzi et al. 2025)
Mechanism: Epistemic framing — not a mechanistic hypothesis. Identifies conditions that would reject the null (Babesia prevalence ≤ background) and methodological concerns (enrichment culture contamination risk, Berkson’s referral bias, no independent positive replication, BAPGM long culture incubation). Flags trigger-vs-driver distinction: even if Babesia acts only as an acute trigger that clears, a persistent-driver framework would miss it.
Chapter ref: ch07: babesia falsification
Prediction: Null rejected if: (a) Babesia PCR+serology is materially higher in ME/CFS vs matched endemic controls at a statistically significant level, (b) evidence of active infection associated with current symptoms, whether via persistent parasitemia or acute-trigger-then-clear with post-infectious sequelae, (c) haptoglobin/LDH tracks PCR positivity, all from an independent lab. Specific numerical thresholds are illustrative, not prescriptive. Proposed highest-yield studies: (1) controlled serosurvey, (2) independent Breitschwerdt replication, (3) Hp/LDH screening study.
Treatment: None — epistemic framing; treatment premature pending rejection of null.
Limitation: Open question, not a positive claim. Origin: brainstorm critical categories 10–12.

Open Question p=n/aBabesia–ME/CFS Research Priorities

Evidence: Five research proposals drawn from brainstorm: (1) three-arm serosurvey with 2-day CPET, (2) Hp/LDH ratio as screening triage, (3) ODE model of parasitemia→haptoglobin→PEM, (4) RBC deformability as functional biomarker, (5) diagnostic equity program. Each anchored in the Babesia evidence base from this cycle.
Citations: (Breitschwerdt et al. 2025) (MacDonald et al. 1996) (Moezzi et al. 2025) (Luo et al. 2025)
Mechanism: Aggregate research proposals, not a mechanistic hypothesis. Covers serosurvey design (n at least 200 per arm, IFA+PCR+hemolytic panel+CPET), Hp/LDH screening (threshold ratio below 0.5, sensitivity/specificity validation pending), ODE modeling (parasitemia → haptoglobin depletion → exercise threshold), RBC deformability (ektacytometry, elongation index at 3 Pa), and diagnostic equity (subsidized PCR in endemic areas).
Chapter ref: ch07: babesia research priorities
Prediction: Research proposals, not predictions — the proposals themselves are the output. The predicted finding from the serosurvey: Babesia detection rate higher in ME/CFS than matched controls, seropositive predicts greater day-2 VO2max decline. Hp/LDH: sensitivity above 80% for Babesia PCR at ratio below 0.5, reducing PCR testing by roughly 4-fold. ODE: predicts parasitemia at 0.3% infected RBCs depletes haptoglobin below 50 mg/dL within 6–8 weeks.
Treatment: None — none of the proposed tests or models should be ordered outside research protocols until validated.
Limitation: Aggregate proposals, each with its own limitations (small-n prediction for serosurvey, unvalidated Hp/LDH thresholds, ODE calibration against scarce parasitemia kinetic data, no RBC deformability data in ME/CFS, diagnostic equity contingent on funding). Origin: brainstorm.

Open Question p=n/aResearch Programme to Test Tick-Borne Glycolytic Reprogramming in ME/CFS

Evidence: Consolidated research agenda for Tick-Borne Pathogen-Driven Glycolytic Reprogramming as a Compounding Immunometabolic Insult in a Post-Infectious ME/CFS Subset. Motivated by the 0-direct-evidence gap and the Dong (Dong et al. 2026) / Kerstholt (Kerstholt et al. 2022) direction contradiction and the Fitzgerald (Fitzgerald et al. 2021) serum null. Origin: brainstorm (ideas 2.1, 2.2, 2.3, 6.1, 9.1).
Citations: (Dong et al. 2026) (Kerstholt et al. 2022) (Fitzgerald et al. 2021) (Barriales et al. 2021)
Mechanism: Not a mechanistic claim — a testability agenda. Four priority studies: (1) ex-vivo monocyte Seahorse ECAR/OCR (tick-borne vs viral ME/CFS vs controls); (2) systematic replication resolving Borrelia glycolysis direction across cell substrates/timepoints; (3) CSF (not serum) metabolomics in PTLDS; (4) post-hoc stratification of existing ME/CFS trial datasets by documented tick-exposure history.
Chapter ref: ch07: tickborne glycolytic research programme
Prediction: Study (1) predicts tick-borne-triggered ME/CFS monocytes show elevated ECAR/OCR vs viral-triggered and controls (AUC ≥0.75 for tick-exposure stratification). Study (2) resolves whether the contradiction is cell-type or timepoint driven. Each is individually falsifiable.
Treatment: No treatment implication — determines whether the hypothesis is worth pursuing therapeutically.
Limitation: An agenda, not a finding. Respects “Seronegative Chronic Lyme” as a Claimed Cause of ME/CFS — Not Supported (documented exposure, not “chronic Lyme” labels). Origin: brainstorm.

Open Question p=n/aIs ME/CFS CoQ10 Deficiency Driven by Oxidative Consumption or Impaired Biosynthesis?

Evidence: Documented low CoQ10 (Maes et al. 2009) consistent with two untested-against-each-other mechanisms: oxidative consumption (Infection-Driven Oxidative Consumption as a Contributor to CoQ10 Depletion) vs impaired biosynthesis (Laredj, Licitra, and Puccio 2014) (COQ genetics, biogenesis downregulation, statins, malabsorption).
Citations: (Maes et al. 2009) (Laredj, Licitra, and Puccio 2014) (Gerwyn Morris et al. 2013)
Mechanism: Not a mechanistic claim — a discrimination agenda. Consumption-dominant predicts high CoQ10 turnover + elevated oxidative markers + intact biosynthesis-gene expression; biosynthesis-dominant predicts low turnover + reduced biosynthetic-gene expression.
Chapter ref: ch07: coq10 consumption vs biosynthesis
Prediction: A single cohort measuring CoQ10 turnover kinetics, pathogen-activity biomarkers, COQ-biosynthesis gene expression, and tissue CoQ10 would separate the two mechanisms. Each arm is individually falsifiable.
Treatment: Determines whether priority is infection/oxidative control vs straightforward repletion for a CoQ10-deficient patient.
Limitation: No study has co-measured turnover, pathogen burden, and biosynthesis genes in ME/CFS. All existing CoQ10 data are static plasma levels.

12 Herpesvirus and LSR Cascade

Hypothesis p=0.85Herpesvirus Antibody Titres Reflect Long-Lived Plasma Cell Output, Not Necessarily Ongoing Viral Replication

Evidence: Amanna 2007 (NEJM) — antiviral antibody half-lives >200 yr for EBV, >50 yr for VZV, n=45 followed ≤26 yr. Hammarlund 2017 (Nat Commun) — LLPCs survive >10 yr without memory B cells in primate model. Robinson 2022 (Sci Immunol) — LLPCs accrue in bone marrow at ~1 cell/hr, number determined by initial GC response duration. Slifka 2019 (Front Immunol) — multivalent antigen arrays (viral capsids) preferentially drive LLPC generation. Chackerian 2020 (Viruses) — antigen structure, not persistence, determines antibody longevity.
Citations: (Amanna, Carlson, and Slifka 2007) (Hammarlund et al. 2017) (Robinson et al. 2022) (Slifka and Amanna 2019) (Chackerian and Peabody 2020)
Mechanism: LLPCs migrate to bone marrow survival niches after primary infection, constitutively secrete antibody for host lifetime without antigen re-exposure, cell division, or memory B cell replenishment. Herpesviruses present multivalent repetitive epitopes (capsids, envelope glycoproteins) that are structurally optimised for LLPC induction. Antibody titre reflects initial infection magnitude + individual niche capacity, not current viral activity.
Chapter ref: ch07: herpesvirus antibody persistence, herpesvirus antibody interpretation
Prediction: ME/CFS patients with elevated structural antigen IgG (VCA, EBNA-1, gB) but normal viral DNA loads will not differ in clinical outcomes from those receiving antiviral therapy vs placebo. Falsified if structural-antigen IgG elevation without viral DNA predicts antiviral response.
Treatment: Clinicians should not diagnose “chronic EBV” or initiate antiviral therapy based on structural antigen IgG titres alone. Antiviral treatment decisions require viral DNA (qPCR), viral mRNA, or early lytic gene product antibody data.
Limitation: The LLPC biology is settled in healthy populations; the formal demonstration that the same principles hold in ME/CFS immune context has not been done (no ME/CFS bone marrow LLPC study exists). Structural antigen IgG CAN be boosted by clinical reactivation (e.g., VZV IgG rises during shingles), so the LLPC baseline is a dominant but not exclusive contributor. The prediction that structural-antigen IgG does not predict antiviral response conflicts with the two controlled positive antiviral trials (Lerner 2007, Montoya 2013) that enrolled on elevated titres and found clinical benefit.

Hypothesis p=0.45Lytic-to-Structural IgG Ratio (LSR) as a Diagnostic Biomarker in ME/CFS — Distinguishing LLPC Output from Reactivation-Driven Antibody

Evidence: Cliff 2019 — structural-antigen seroprevalence identical (null, but measured seroprevalence not titre — cannot detect titre differences in universally seropositive population). Palomo 2026 — lytic-antigen dUTPase IgG elevated (positive, but findings from a single research group without independent replication). Loebel 2017 — EBNA-6 repeat region enhanced, overall pattern “quite similar” (mixed). Apostolou 2022 — salivary lytic-cycle antigen antibodies elevated. This contradictory pattern could be explained by the LSR: structural antibodies normal, lytic antibodies elevated — but the pattern is inferred from incompatible methodologies across studies and has never been directly measured.
Citations: (Cliff et al. 2019) (Blomberg et al. 2019) (Palomo et al. 2026) (Loebel et al. 2017) (Apostolou et al. 2022) (Lanz et al. 2022)
Mechanism: In normal LLPC biology, the ratio of lytic-cycle to structural-antigen IgG is stable (same LLPC pool produces both). Abortive lytic reactivation (→ preferential boosting of lytic antigens via short-lived plasmablasts) OR epitope-specific autoimmune drift (→ selective elevation of cross-reactive lytic epitopes) would elevate the LSR. Each patient serves as their own internal control, eliminating confounding by infection timing, age, and initial antigen load.
Chapter ref: ch07: lytic structural igg ratio
Prediction: The LSR (anti-BZLF1 IgG / anti-VCA-p18 IgG ratio) will discriminate ME/CFS from healthy seropositive controls (AUC ≥ 0.75) and correlate with symptom severity (r ≥ 0.3 with fatigue score). IgG avidity will be uniformly high in ME/CFS (avidity index >0.6, consistent with remote past infection). Falsified if: structural-antigen IgG is equally elevated, OR low-avidity IgG ($<$ 0.4) is detected (indicating recent reactivation rather than LLPC maintenance).
Treatment: If validated, the LSR would provide a low-cost blood test using existing clinical serology assays to stratify ME/CFS patients by mechanism (LLPC-driven vs reactivation-driven). Patients with elevated LSR may benefit from different treatment approaches (B cell-targeted vs antiviral) — but this is presently a research question, not a clinical recommendation.
Limitation: No study has simultaneously measured lytic-cycle and structural-antigen IgG in the same ME/CFS cohort and computed the LSR. The LSR hypothesis is inferred from comparing results across studies with different populations, methods, and antigens (positive studies used ELISA with specific antigens; Cliff measured seroprevalence, which cannot detect titre differences in universally seropositive populations). The dUTPase findings the hypothesis depends on derive from a single research group without independent replication. There is no mechanistic reason grounded in herpesvirus biology why abortive lytic replication would selectively boost lytic-cycle antibodies without also boosting structural-antigen antibodies — the lytic cascade is sequential, not selective. The MS cross-reactivity precedent (one epitope in one disease) is structurally different from the LSR (a quantitative ratio of broad antigen-class IgG). Origin: brainstorm.

Speculation p=0.30B Cell Dysregulation as Driver of Elevated Herpesvirus Antibodies in ME/CFS — Not Viral Reactivation

Evidence: Sun 2024 (J Transl Med) — scRNA-seq, n=4 ME/CFS, n=4 controls. Memory B cells in ME/CFS show unique subtype early in pseudotime, increased trajectory toward plasma cell differentiation. Single study, very small n.
Citations: (Y. Sun et al. 2024)
Mechanism: Intrinsic B cell dysregulation → biased memory B cell → plasma cell differentiation → elevated antibody output across all specificities, including herpesvirus antigens, without requiring antigenic stimulation. Would explain elevated antibody in the absence of viral DNA.
Chapter ref: ch07: antibody elevation bcell dysregulation
Prediction: ME/CFS patients with elevated herpesvirus antibodies will show increased frequencies of antibody-secreting cells (CD19^low CD27^high CD38^high) in peripheral blood AND increased plasma cell numbers in bone marrow aspirates, independent of viral DNA load. Falsified if antibody elevation always correlates with detectable viral DNA.
Treatment: If confirmed: antiviral therapy would not be expected to reduce antibody titres; B cell-targeted interventions (rituximab, BAFF inhibitors) might be more appropriate. Currently entirely speculative — no clinical implication.
Limitation: n=4 patients, single study, single time point, peripheral blood only. No direct measurement of herpesvirus antibody titres in the same patients. The increased plasma cell differentiation trajectory is an inference from pseudotime analysis, not a direct observation. Entirely unvalidated. Origin: brainstorm.

Speculation p=0.15LSR Cascade Interpretation — What Valacyclovir Response Reveals About the Mechanism Driving Elevated LSR

Evidence: Derived from mechanistic cascade tracing. Valacyclovir inhibits EBV DNA polymerase (BALF5) at the DNA replication step — it does not block immediate-early or early gene expression (BZLF1, dUTPase). The following interpretive schema is inferred: (a) if valacyclovir works AND LSR declines → abortive lytic reactivation (ALR) is likely the driver, though poly-herpesvirus antiviral activity limits specificity; (b) if valacyclovir fails AND LSR unchanged → LLPC autoimmune drift is the more likely mechanism, though early-gene-only ALR cannot be excluded (if the lytic cascade stalls before DNA replication, valacyclovir has no target). If both valacyclovir and valganciclovir fail with LSR confirmed elevated, this is the strongest available negative evidence that LSR is NOT driven by ongoing viral replication. No clean discriminating probe exists — all intercepting drugs have ≥3 targets. Origin: brainstorm — cascade trace.
Mechanism: Two candidate mechanisms for elevated LSR: (1) ALR → EBV immediate-early/early gene expression → BZLF1/dUTPase produced → SLPB response adds lytic IgG on top of LLPC baseline → LSR rises. Valacyclovir blocks DNA replication (step 3 of 5 in the cascade) — effective if ALR proceeds through DNA replication, irrelevant if ALR stalls at early gene expression. (2) B cell dysregulation → selective LLPC clonal expansion producing cross-reactive lytic-epitope antibodies → LSR rises. Valacyclovir has no target in this cascade — LLPCs do not require viral replication to maintain antibody output.
Chapter ref: ch07: lsr valacyclovir response; ch31: lsr cascade interpretation
Prediction: In a cohort of ME/CFS patients with elevated LSR, pre- and post-valacyclovir (6 months, therapeutic dose) LSR measurements will show: (a) LSR decline only in clinical responders; (b) no decline in non-responders. Falsified if LSR declines in non-responders (ALR continues despite absent clinical benefit), OR if LSR unchanged in responders (valacyclovir benefit independent of ALR suppression).
Treatment: Research-stage only — no clinical recommendation. Elevated LSR that does not budge after valacyclovir would indicate LLPC-driven antibody abnormality, directing treatment toward B cell-targeted research rather than antiviral escalation. This could spare patients from years of empirically escalated antiviral therapy.
Limitation: Cascade model is a linear simplification. Valacyclovir specificity is low (active against VZV, HSV in addition to EBV — clinical improvement could reflect non-EBV suppression). Cannot distinguish LLPC drift from early-gene-only ALR. The valacyclovir substudy is proposed as a nested cohort within a larger LSR validation study that has not yet been performed — the prediction’s validity depends on the LSR demonstrating AUC ≥0.75 first. Origin: brainstorm — cascade trace.

Hypothesis p=n/aLSR Diagnostic Biomarker Validation — Prospective Cross-Sectional and Antiviral-Response Study

Evidence: Proposed study (Lytic-to-Structural IgG Ratio (LSR) Diagnostic Biomarker Validation). The LSR concept has never been measured in any disease — this is a first-ever study of the lytic-to-structural herpesvirus IgG ratio. Existing evidence: Palomo 2026 (dUTPase elevated, single-group), Cliff 2019 (structural seroprevalence null), Blomberg 2019 (multiplex null), Apostolou 2022 (salivary), Loebel 2017 (EBNA-6 repeat enhanced), Maes 2025 (partial independent dUTPase replication in RRMS). None computed LSR. Origin: brainstorm — proposal derived from Lytic-to-Structural IgG Ratio (LSR) as a Diagnostic Biomarker.
Citations: (Palomo et al. 2026) (Cliff et al. 2019) (Blomberg et al. 2019) (Apostolou et al. 2022) (Loebel et al. 2017) (Maes et al. 2025)
Mechanism: Two-phase design. Phase 1: cross-sectional LSR (anti-BZLF1 ÷ anti-VCA-p18) measurement in n=200 (100 ME/CFS + 100 controls) to establish the normal range and test discriminant validity. Phase 2: nested valacyclovir substudy (n=40, 6 months) measuring pre- and post-LSR to distinguish ALR-driven (LSR declines) from LLPC-driven (LSR stable) elevation. Avidity index measurement (urea-wash ELISA) to exclude recent primary infection confound. Poly-herpesvirus LSR (HHV-6 anti-U45 ÷ anti-gB) to test EBV-specificity.
Chapter ref: ch39: lsr diagnostic biomarker; ch40: lsr biomarker validation study
Prediction: Primary: LSR AUC $≥$ 0.75 for ME/CFS vs healthy controls, while VCA-p18 IgG alone achieves AUC $<$ 0.55. IgG avidity uniformly $>$ 0.6 in ME/CFS (excludes recent primary infection). Valacyclovir-responsive patients show declining LSR; non-responders show stable LSR. Falsified if LSR AUC $<$ 0.60, OR structural-antigen IgG shows equivalent discrimination, OR low-avidity IgG ($<$ 0.4) detected in $>$ 10% of ME/CFS (would refute LLPC model).
Treatment: If validated: first serological biomarker to stratify ME/CFS patients by mechanism (ALR vs LLPC), directing antiviral therapy to the ALR group. Deployable on existing clinical ELISA platforms within 2–3 years. Null result would close the LSR hypothesis definitively and redirect herpesvirus research toward whole-proteome serology.
Limitation: Custom anti-dUTPase ELISA required — not commercially available. Anti-BZLF1/anti-VCA-p18 ELISA kits validated for qualitative (seropositive/seronegative) detection, not quantitative ratio computation — reference range unknown. Valacyclovir substudy is observational (confounding by indication). Poly-herpesvirus LSR profiling requires custom antigens for each virus’s dUTPase — multiplies assay development bottleneck. IgG avidity assays not commercially standardized. Phase 2 (n=40) underpowered if valacyclovir response rate $<$ 50%. Origin: brainstorm — proposal.

Open Question p=n/aAntigen-Specific (Not Global) Herpesvirus Antibody Elevation in ME/CFS — Lytic-Cycle and Cross-Reactive Epitopes Selectively Elevated

Evidence: Cliff 2019 (Front Immunol, n=251) — no seroprevalence difference for 6 herpesviruses. Blomberg 2019 (Front Immunol) — overall HHV-1-7 IgG no significant difference. Palomo 2026 (J Med Virol, n=40+16) — elevated dUTPase IgG. Loebel 2017 (PLOS ONE, n=92+50) — EBNA-6 repeat region enhanced, overall pattern “quite similar”. Apostolou 2022 (Front Immunol, n=95+110) — salivary EBNA-1 elevated.
Citations: (Cliff et al. 2019) (Blomberg et al. 2019) (Palomo et al. 2026) (Loebel et al. 2017) (Apostolou et al. 2022)
Mechanism: Total IgG against structural antigens (VCA, EBNA-1, gB) is driven by LLPCs and may not differ between ME/CFS and controls. Lytic-cycle antigens (dUTPase, EA-D) and latency proteins with human homology (EBNA-6 repeat) may be selectively elevated because they reflect: (a) recent abortive lytic events not captured by structural-antigen serology; (b) epitope spreading targeting cross-reactive epitopes; or (c) altered B cell regulation amplifying responses to specific epitopes.
Chapter ref: ch07: herpesvirus antibody universal
Prediction: A study measuring IgG against structural antigens AND lytic-cycle antigens AND latency-protein repeat regions simultaneously in the same ME/CFS cohort should find elevations only in lytic and repeat-region categories, not in structural antigen IgG. Falsified if structural antigen IgG is equally elevated.
Treatment: If confirmed, clinical herpesvirus serology panels should include dUTPase and EA-D IgG, not just VCA/EBNA-1. Total IgG panels — the most commonly used clinical test — are uninformative for ME/CFS.
Limitation: No study has simultaneously measured all three categories of herpesvirus antibodies in the same ME/CFS cohort. The antigen-specificity model is inferred from comparing results across studies with different populations, methods, and antigens. The Palomo and Cliff cohorts are from different countries.

Open Question p=n/aLSR–Valacyclovir Discordant Pattern — What if LSR is Elevated but Valacyclovir Succeeds Clinically?

Evidence: A third possible pattern beyond the positive-response and null-response scenarios: valacyclovir produces clinical improvement but LSR stays elevated. This would suggest viral reactivation is rate-limiting for symptoms, while the LSR is maintained by a mechanism valacyclovir does not touch — either (a) LLPCs produce the lytic IgG baseline while SLPB-derived lytic IgG from ALR events is too small a fraction to move the ratio, or (b) clinical benefit comes from suppressing a different herpesvirus (VZV, HSV) contributing to symptoms without affecting EBV LSR. Neither possibility can be resolved without a prospective study. Origin: brainstorm — cascade trace.
Mechanism: Two non-exclusive explanations: (1) the LLPC lytic IgG pool is the dominant component of the LSR signal, and valacyclovir-suppressible SLPB-derived lytic IgG is a negligible fraction — valacyclovir reduces symptoms by blocking ALR without moving the antibody ratio. (2) The clinical benefit comes from suppressing a co-infecting herpesvirus whose antibodies are not captured by the EBV-specific LSR — if VZV or HSV reactivation is contributing to symptoms, valacyclovir resolves that without affecting EBV LSR.
Chapter ref: ch07: lsr valacyclovir discordant
Prediction: A prospective study measuring LSR, viral DNA (qPCR for each herpesvirus), and clinical symptoms simultaneously before/during/after valacyclovir will resolve this question by showing whether LSR change correlates with (a) EBV DNA suppression, (b) clinical improvement, (c) both, or (d) neither.
Treatment: N/A — methodological research question. Resolution requires data that does not yet exist.
Limitation: Pure methodological observation — no empirical data, no predictive claim. The discordant pattern may not occur if LSR and clinical response are tightly coupled, making this a hypothetical edge case. Origin: brainstorm — cascade trace.

Speculation p=0.25LSR as Trait-vs-State Discriminator Using the MZ Twin Discordant Design

Evidence: The LSR (anti-BZLF1 IgG / anti-VCA-p18 IgG) hypothesis proposes that elevated lytic-to-structural herpesvirus IgG ratio reflects acquired antibody dysregulation — abortive lytic reactivation (ALR) selectively boosting lytic-cycle antibodies via short-lived plasmablasts while long-lived plasma cells maintain stable structural-antigen output Lytic-to-Structural IgG Ratio (LSR) as a Diagnostic Biomarker. The twin design directly tests the mechanism: if LSR is elevated in the affected twin but NOT in the unaffected co-twin, ALR-driven acquired dysregulation is supported; if LSR is elevated in BOTH twins vs population controls, LSR reflects a genetic (or shared-early-environment) predisposition to herpesvirus antibody production — a trait, not a state marker. Koelle 2002 found no HSV antibody difference between discordant twins (n=22 pairs) (Koelle et al. 2002) — consistent with either scenario. The LSR has never been measured in any twin study or in any disease. Zero data exist on the heritability of herpesvirus antibody ratios.
Citations: Lytic-to-Structural IgG Ratio (LSR) as a Diagnostic Biomarker (Koelle et al. 2002) (Palomo et al. 2026) (Cliff et al. 2019)
Mechanism: Two competing models, both testable by within-pair comparison: (1) State model (acquired): ALR → SLPB-derived lytic IgG added onto LLPC baseline → LSR elevated only in affected twin. This validates LSR as an illness-specific biomarker and supports antiviral or B-cell-targeted treatment approaches for LSR-high patients. (2) Trait model (genetic/shared-environmental): shared immune response genotype or shared early-life EBV infection → both twins have elevated LSR vs population controls but not different from each other. LSR remains useful as a diagnostic biomarker (if elevated in both twins vs population) but loses its proposed mechanism (ALR-driven acquired dysregulation). Consistent with Koelle 2002 null. Intermediate pattern (elevated in both twins but higher in affected) would suggest genetic predisposition with illness-related amplification — consistent with the two-hit model.
Chapter ref: ch47: mz twin discordant striatal microbiome lsr, ch07: lytic structural igg ratio
Prediction: In MZ twin pairs discordant for ME/CFS, within-pair LSR difference (affected – unaffected) will be significantly > 0 (one-sample paired t-test, P ≤ 0.05), with LSR in affected twins elevated vs healthy reference pairs and LSR in unaffected twins normal. Falsified if: LSR elevated in both twins equally → trait model confirmed — LSR reflects genetic/shared-environment predisposition. Complementary falsification: LSR normal in affected twin → LSR hypothesis refuted outright. Both outcomes are informative and advance the LSR biomarker programme.
Treatment: If state model confirmed: LSR becomes a validated illness-specific biomarker, supporting ALR-mechanism interpretation and accelerating the LSR biomarker validation study (Lytic-to-Structural IgG Ratio (LSR) Diagnostic Biomarker Validation). Antiviral/B-cell-targeted trials enriched for LSR-high patients. If trait model confirmed: LSR still potentially useful as diagnostic biomarker but targets a different mechanism (genetic predisposition, not acquired dysregulation — may not respond to antivirals). No current clinical recommendation.
Limitation: LSR has never been measured in any population — the normal range and test-retest reliability are unknown. Absence of within-pair LSR difference could reflect true genetic trait OR insufficient assay sensitivity to detect a state marker — the null is ambiguous. MZ twins share early environment (same household, same EBV exposure timing) in addition to genes — the design cannot distinguish genetic from shared-early-environmental trait. Koelle 2002 null used total HSV antibody titres, not an LSR-type ratio. Entirely untested. Origin: proposal-derived.

13 Herpesvirus and HSV

Speculation p=0.20HSV Outbreak Frequency × PEM Timing as Endogenous Viral Reactivation Probe

Evidence: The mechanistic rationale is coherent but every ME/CFS-specific link is untested. Stress→HSV reactivation link is established in general population (Chida 2009 meta-analysis, 11 prospective studies, r=0.083, p=0.005 (Chida and Mao 2009)). PEM→catecholamine pathway is established in ME/CFS CPET literature. However: no prospective study has tracked HSV outbreak timing relative to PEM episodes; the Treg→CD8+ T cell→HSV latency mechanism demonstrated in mice (Yu et al. 2018) has not been tested in human ME/CFS; the null serology literature (Buchwald 1996 n=548 (Buchwald et al. 1996); Koelle 2002 22 twin pairs (Koelle et al. 2002)) found no HSV-1/2 serological differences between ME/CFS and controls. HSV recurrence epidemiology from general-population review: 67% global prevalence, 20–40% of seropositive individuals experience recurrent outbreaks (Gopinath et al. 2023). Origin: brainstorm.
Citations: (Chida and Mao 2009) (Yu et al. 2018) (Buchwald et al. 1996) (Koelle et al. 2002) (Gopinath et al. 2023)
Mechanism: PEM → sympathetic activation → catecholamine surge → Treg-mediated CD8+ T cell suppression at trigeminal ganglion → HSV exit from latency → visible cold sore. This is a patient-reportable, timestamped viral reactivation event. The probe is falsifiable, inexpensive, and patient-owned — no laboratory testing required.
Chapter ref: ch08: hsv pem probe
Prediction: Prospective diary study (n $≥$ 100 HSV-1 seropositive ME/CFS, 12 months, powered for 15–25 events) with home lesion-swab PCR + photo documentation: $≥$ 60% of HSV-PCR-confirmed outbreaks within 24–96h post-exertion exceeding anaerobic threshold, vs chance-expectation given observation-day proportions; per-patient outbreak frequency higher during PEM-heavy vs PEM-light months; stress (PSS), sleep, menstrual cycle, UV exposure do not independently predict outbreak timing after controlling for exertion; bidirectional lag analysis excludes HSV prodrome→PEM-like flare. Falsified if PCR-confirmed outbreaks equally distributed around exertion vs non-exertion windows, OR if stress/sleep/UV predict better than exertion.
Treatment: N/A — research tool, not a clinical recommendation. If validated, HSV outbreak diaries become a secondary endpoint for antiviral trials and a patient-owned biomarker. If HSV outbreaks cluster with PEM but valacyclovir suppression does not reduce PEM severity, HSV reactivation is a downstream consequence, not a driver — still useful as probe, not as therapeutic target.
Limitation: Every ME/CFS-specific link is untested. HSV recurrence is multifactorial (UV, fever, menstruation, sleep disruption, stress independent of PEM) — these confounds must be controlled in any prospective design. Patient-reported diaries have recall bias and variable sensitivity for detecting prodromal/minor outbreaks. Photographic documentation recommended for validation. The 20–40% recurrence rate means only a minority of HSV-seropositive patients would contribute data. Origin: brainstorm.

Open Question p=n/aTreg-Mediated CD8+ T Cell Suppression at HSV Latency Sites Explains PEM-Associated HSV Outbreaks

Evidence: Synthesis of two independent lines never connected in the same study: (1) Treg→CD8+ T cell→HSV latency maintenance axis in mice (Yu 2018, cert 0.30 discounted (Yu et al. 2018)); (2) Treg-herpesvirus-immune hyperactivation model of ME/CFS (Sepúlveda 2019, cert 0.50, computational only (Sepúlveda et al. 2019)). Neither has been tested in human ME/CFS nor in the context of PEM-provoked HSV reactivation. Origin: brainstorm.
Citations: (Yu et al. 2018) (Sepúlveda et al. 2019)
Mechanism: PEM-associated catecholamine surges lower the Treg-dependent threshold for HSV reactivation at trigeminal ganglia. ME/CFS patients with elevated Treg percentages experience more frequent/more PEM-coupled HSV outbreaks because Treg-mediated CD8+ T cell suppression at latency sites is more easily triggered by stress signals.
Prediction: In HSV-1 seropositive ME/CFS with prospective diary: Treg% correlates with monthly HSV outbreak frequency (r ≥ 0.3); PEM-associated outbreaks show higher pre-outbreak Treg% than PEM-independent outbreaks; CD8+ T cell frequency and HSV-specific CD8+ T cell functionality lower in patients with more frequent outbreaks. Falsified if no Treg–outbreak correlation, OR if CD8+ T cell function does not differ by outbreak frequency.
Treatment: N/A — mechanistic hypothesis with zero clinical implication.
Limitation: Mouse-to-human translation gap for Treg–CD8–HSV mechanism. Sepúlveda 2019 is a computational model, not an observational finding — no empirical evidence that Treg-mediated immune hyperactivation occurs in ME/CFS. The Treg phenotype in ME/CFS is itself contested (some studies find elevation, others find normal percentages). Origin: brainstorm.

Open Question p=n/aHSV-Specific Analog of the LSR — Anti-ICP0 ÷ Anti-gB Ratio as Cross-Viral Validation

Evidence: The EBV LSR (anti-BZLF1 ÷ anti-VCA-p18) has never been measured in any disease. The proposed HSV analog (anti-ICP0 ÷ anti-gB) would be a replication construct — same logic (lytic-cycle ÷ structural), different virus, different latency compartment (neuronal instead of B cell). But ICP0 is not a clinical antigen: anti-ICP0 serology has never been developed for human diagnostic use, its immunogenicity profile in natural infection is unknown, and there is zero literature on ICP0-specific antibody responses in any disease context. Origin: brainstorm.
Mechanism: Compare immediate-early (ICP0, expressed at reactivation initiation) to late structural (gB, LLPC-maintained) HSV-1/2 IgG. If HSV reactivation follows abortive lytic replication pattern: ICP0-to-structural IgG ratio elevated in patients with frequent PEM-associated outbreaks because ICP0 expression occurs even when reactivation is abortive. If HSV-LSR elevated but EBV-LSR normal → reactivation is compartmentalized (trigeminal ganglion-specific), not systemic B cell-driven.
Prediction: Not currently testable — requires anti-ICP0 IgG ELISA development and validation. If developed: HSV-LSR should correlate with patient-reported HSV outbreak frequency and decline during valacyclovir suppression. Falsified if HSV-LSR is normal in patients with frequent PEM-associated outbreaks.
Treatment: N/A — assay does not exist. Years from implementation.
Limitation: Anti-ICP0 serology does not exist. No commercial or research-grade ICP0 ELISA exists. The entire construct is model-dependent — it assumes HSV follows the same ALR immunogenicity pattern as EBV, which has not been demonstrated. The pragmatic near-term alternative is the patient-reported outbreak diary — no assay development required. Origin: brainstorm.

Open Question p=n/aLSR–HSV Outbreak Pattern Intersection — Do Elevated EBV-LSR Patients Show Different HSV Recurrence Profiles?

Evidence: Requires two prior validations that do not yet exist: (1) LSR discriminates ME/CFS from controls (foundational LSR validation study, never performed), and (2) HSV outbreaks cluster with PEM (HSV probe framework, never tested). Only if both are affirmative does the cross-viral intersection become testable. Origin: brainstorm.
Mechanism: If elevated EBV-LSR reflects systemic immune dysregulation affecting multiple herpesvirus reservoirs (not just EBV B cell latency), patients with elevated LSR should show: (a) higher HSV outbreak frequency; (b) stronger temporal coupling between HSV outbreaks and PEM; (c) elevated HSV-specific LSR analog (if assay developed). If LSR elevated but HSV outbreak patterns unremarkable: LSR reflects EBV-specific B cell compartment process, not systemic. If HSV outbreaks PEM-correlated but LSR normal: viral reactivation is compartmentalized (trigeminal), not captured by EBV-serological ratios.
Prediction: In a nested analysis within the LSR validation study (Lytic-to-Structural IgG Ratio (LSR) Diagnostic Biomarker Validation): HSV-1 seropositive patients with elevated EBV-LSR will report higher HSV outbreak frequency than those with normal LSR. Falsified if LSR and HSV outbreak frequency are independent.
Treatment: N/A — entirely speculative. Requires both LSR and HSV probe to be validated first.
Limitation: The LSR has never been measured. The HSV outbreak probe has never been tested. This is a conjecture about the relationship between two unvalidated constructs — it is a hypothesis about hypotheses. Origin: brainstorm.

LIM p=n/a“Seronegative Chronic Lyme Disease” as a Driver of ME/CFS — Claim Not Supported by High-Quality Evidence

Evidence: Adjudication of the proposition (most-cited source: a retrospective uncontrolled single-author chart review, n=210, claiming 99% “seronegative Lyme” and 62–88% antibiotic response (Shor 2011), certainty 0.20). Refuted on two independent grounds. Therapeutic: three double-blind RCTs found prolonged antibiotics no better than placebo for persistent symptoms attributed to Lyme (Berende et al. 2016) (Klempner et al. 2001) (Fallon et al. 2008). Diagnostic: the “seronegative Lyme” markers used (single WB band, low CD57, elevated C4a/C6, co-infection serologies) are not validated tests of active Borrelia (Lantos 2015) (Feder et al. 2007); patients labelled “chronic Lyme” by such methods are phenotypically CFS with no objective Borrelia (Patrick et al. 2015); genuine seronegative Lyme is confined to documented prior acute Lyme (Dattwyler et al. 1988). Harm: prolonged antibiotics for this indication cause documented septic shock, C. difficile, and fatal outcomes (Marzec et al. 2017).
Citations: (Shor 2011) (Berende et al. 2016) (Klempner et al. 2001) (Fallon et al. 2008) (Lantos 2015) (Feder et al. 2007) (Patrick et al. 2015) (Dattwyler et al. 1988) (Marzec et al. 2017)
Mechanism: The claimed mechanism — persistent seronegative Borrelia infection driving CFS, reversible by long-course antimicrobials — is directly testable and fails the test. The uncontrolled “response” is attributable to placebo effect, regression to the mean (highest-vs-lowest scoring), co-intervention for comorbidities, and unblinded observer bias by a declared advocacy-position clinician (past ILADS president). This limitation is scoped to the seronegative-chronic-Lyme claim only; it does not bear on confirmed tick-borne infection, whose ME/CFS overlap is discussed at Viral-Gene-Product Surveillance of Peripheral Compartments Is Null; Anellovirus Burden May Be an Immune-State Marker and Tick-Borne Illness as an ME/CFS Trigger — Convergent Model.
Chapter ref: ch07: seronegative chronic lyme cfs
Prediction: Falsifiable: a future double-blind RCT enrolling internationally case-defined CFS patients meeting “seronegative Lyme” criteria and randomising to prolonged antimicrobials vs placebo would show no QoL/fatigue benefit over placebo. The claim would be resurrected only if such a trial (adequately powered, independent lab, pre-registered) showed benefit — none has.
Treatment: Do not initiate prolonged antimicrobial therapy for ME/CFS on the basis of “seronegative Lyme” markers. Confirmed, serologically or PCR-documented tick-borne infection — not inferred “chronic Lyme” — is the appropriate threshold for antimicrobial treatment. Replication: null therapeutic result independently replicated across three RCTs.
Limitation: The rejection rests on high-quality contradicting evidence rather than on a study directly enrolling Shor’s exact “seronegative Lyme” phenotype into an RCT; such a trial has not been done, but the PLEASE population (persistent symptoms attributed to Lyme) is the closest available and is null. The diagnostic critique is drawn from reviews and one prospective comparison rather than a single definitive head-to-head. Clinical relevance: MEDIUM (cautionary — protects patients from ineffective, harmful treatment).

14 Mast Cell IgE → Connective Tissue

Hypothesis p=0.65Post-COVID Ocular Syndrome as a Dysautonomia–SFN–Immune Triad Instance in Accessible Tissue

Evidence: Moustardas et al. (2026, Nature Communications, n=100 post-COVID ocular, n=32 controls) found: standard eye exam normal, yet specialised testing revealed corneal neurodegeneration + dendritic/T-cell activation (confocal microscopy), weakened pupillary reflexes, adult-onset strabismus, and a tear CD4+ T-cell dysregulation proteomic signature matching severe/fatal COVID tissue patterns. Two diagnostic models (77–91% accuracy). Smit et al. (2026, n=397 PCS, n=129 controls) confirmed pupillary autonomic dysregulation (IPA/LHIPA reduced, $p < 0.001$) (Smit et al. 2026). Already corroborated by Cañadas 2023 (corneal confocal long COVID) Cañadas et al. (2023) and Azcue 2025 (corneal tortuosity ME/CFS) (Néstor Azcue et al. 2025). Origin: literature-derived.
Citations: (Moustardas et al. 2026) (Smit et al. 2026) Cañadas et al. (2023; Néstor Azcue et al. 2025) (Johansson et al. 2022) (Naseri et al. 2025)
Mechanism: Mild COVID-19 → chronic T-cell-mediated neuroinflammation → (a) corneal small-fiber degeneration, (b) autonomic pupillary/oculomotor dysfunction, (c) immune dysregulation detectable in tear fluid. Triad = dysautonomia + small fiber neuropathy + T-cell dysregulation — the same three-chamber cascade the paper’s causal hierarchy identifies as propagating CNS energy failure to end-organs (Chapter Causal Hierarchy: Root Causes, Amplifiers, and Consequences). Eye = tissue where all three are non-invasively measurable.
Chapter ref: ch08: postcovid ocular syndrome, ch03: sec 10 ocular, ch07: tear tcell readout
Prediction: A criteria-defined ME/CFS cohort subjected to the same multimodal protocol (corneal confocal, pupillometry, tear proteomics) will show reduced corneal nerve fibre density (≥20% below matched controls), reduced pupillary light-reflex amplitude or constriction velocity (≥25% below controls), and a tear proteomic classifier separating patients from controls at AUC ≥0.75. Falsified if patients with documented dysautonomia and SFN have corneal nerve density, pupillary reflexes, and tear proteomes statistically indistinguishable from controls.
Treatment: No treatment tested. Diagnostic models (77–91% accuracy) suggest objective biomarkers are feasible.
Limitation: Moustardas cohort was selected for ocular symptoms, not ME/CFS criteria. Tear proteomics not performed in any ME/CFS cohort. Single study, unreplicated. Dry eye and convergence insufficiency are confounders (e.g. increased screen use post-virally). No causative mechanism established — correlational.

Hypothesis p=0.60Peripheral Serotonin Depletion as Multi-System Convergence Point in ME/CFS

Evidence: Wong et al. (Cell, 2023) identified 3 converging serotonin depletion mechanisms in Long COVID (IFN-γ-IDO diversion, enterochromaffin cell damage, platelet storage defects). Che et al. (2025, Lipkin group) confirmed innate immune-driven tryptophan→kynurenine diversion in ME/CFS away from serotonin. Gunning et al. (2016, n=181) found 81% of POTS patients have platelet serotonin storage pool deficiency. Mar et al. (2014, RCT crossover) showed SSRI worsens POTS hemodynamics — clinically consistent with peripheral serotonin depletion. Peripheral serotonin regulates mitochondrial biogenesis, vagal tone, vascular stability, gut motility, and immune function. Origin: literature-derived.
Citations: (Wong et al. 2023) (Che et al. 2025) (Thorpe et al. 2026) (K. J. Wirth and Scheibenbogen 2026) (Raij and Raij 2024) (Gunning et al. 2016) (Mar et al. 2014) (G. M. Anderson et al. 2024) (Loçasso et al. 2024) (Paredes et al. 2019)
Mechanism: Inflammation → IDO activation → tryptophan diversion → reduced serotonin synthesis + enterochromaffin cell damage + impaired platelet serotonin uptake → multi-system consequences: mitochondrial dysfunction, reduced vagal tone, orthostatic intolerance, GI dysmotility, immune dysregulation, pain amplification. Cross-disease convergence across ME/CFS, Long COVID, POTS, fibromyalgia.
Chapter ref: ch13: peripheral serotonin convergence
Prediction: ME/CFS patients show reduced platelet serotonin content (HPLC, controlled platelet preparation) vs sedentary controls (effect size ≥0.5 SD). Platelet serotonin inversely correlates with kynurenine/tryptophan ratio and positively with HRV. Falsified if platelet serotonin levels do not differ or differences explained by diet/medication confounds.
Treatment: Caution with serotonergic drugs (SSRIs may worsen POTS-like symptoms). Butyrate + 5-HTP as mechanistic support targeting serotonin restoration — not yet proven as ME/CFS treatment. Platelet serotonin measurement may identify patients most likely to benefit from serotonin-targeted interventions.
Limitation: Platelet serotonin not systematically measured in large ME/CFS cohort with adequate controls. Causality unresolved — depletion may be consequence, not cause. SSRI harm data from POTS, not ME/CFS directly. Central vs peripheral serotonin are separate pools. Methodological challenges with platelet serotonin assays (sample handling, circadian variation).

Speculation p=0.60Cardiac ECM Remodelling as Mast Cell-MMP Degradation Prototype

Evidence: Janicki 2006 established cardiac mast cells regulate MMP-mediated collagen degradation in ventricular remodelling (Janicki et al. 2006). The same mediators (tryptase, chymase, TNF-α) that degrade cardiac collagen are proposed to degrade ligamentous ECM in MCAS-associated hypermobility. Conserved ECM substrates across tissues. This is the strongest cross-disease mechanistic precedent. Origin: brainstorm.
Citations: (Janicki et al. 2006) (Lind et al. 2022) (Y. Guo et al. 2021)
Mechanism: Cardiac mast cells → tryptase/chymase/TNF-α → MMP activation → collagen degradation → ventricular remodelling. Same mediators target same ECM substrates in ligaments. MC→MMP→ECM degradation chain is a conserved pathological programme across tissues with MC hyperplasia. Translation to ligament/joint capsule requires tissue-specific demonstration.
Chapter ref: ch14d: cardiac ecm mc prototype
Prediction: Serum MMP-3, MMP-9, TIMP levels in MCAS-hEDS patients should parallel cardiac MC-activation model profiles (adjusted for age/sex). Ligament biopsy MMP expression should mirror cardiac MMP profiles. Falsified if MCAS-hEDS MMP profiles fundamentally differ from cardiac MC models.
Treatment: Establishes translational precedent for MC-targeted CT preservation therapies. No direct clinical recommendation.
Limitation: Cardiac ECM physiology differs from ligamentous ECM in mechanical loading, repair rate, and resident cell populations. Cardiac MC studies focus on TNF-α remodelling not IgE-driven degranulation.

Speculation p=0.55Periodontitis as Human Model of IgE-Mediated CT Degradation

Evidence: Periodontitis is the best-established human model: IgE against oral bacteria → local MC activation → MMP-mediated periodontal ligament and alveolar bone degradation → measurable clinical attachment loss. Subantimicrobial doxycycline 20mg BID preserves periodontal attachment by inhibiting MMP-2/9. Causal chain (IgE→MC→MMP→CT degradation) identical to MCAS-hEDS proposal. Origin: brainstorm.
Citations: (Janicki et al. 2006)
Mechanism: IgE against P. gingivalis → MC activation in gingival tissue → MMP release → collagen degradation in periodontal ligament → clinical attachment loss → tooth loss. Subantimicrobial doxycycline interrupts the MMP step. Parallel: IgE → MC → MMP → ligament CT degradation → hypermobility.
Chapter ref: ch14d: periodontitis ige ct model
Prediction: MCAS-hEDS patients show elevated IgE to periodontal pathogens vs non-MCAS hEDS. Treatments reducing MC activation or MMP activity (doxycycline, ketotifen, omalizumab) should slow Beighton score progression analogous to periodontal attachment-loss preservation.
Treatment: Establishes precedent for repurposing subantimicrobial doxycycline + MC stabiliser combination for CT preservation. No clinical recommendation without trial data specific to hypermobility.
Limitation: Periodontal CT differs from ligamentous CT mechanically. IgE against oral bacteria is luminal; IgE in MCAS-hEDS may target systemic/self-antigens. Periodontal trials used doxycycline only; MC stabiliser component lacks human CT outcome data.

Hypothesis p=0.45Adult-Onset Strabismus as Clinical Sign of Oculomotor Nerve Involvement in Post-Infectious Syndromes

Evidence: Moustardas et al. (2026) found adult-onset strabismus (normally a childhood condition) in a subset of post-COVID patients and attributed it to oculomotor nerve involvement (Moustardas et al. 2026). Strabismus and double vision (diplopia) are documented clinical features of ME/CFS (Chapter 3, sec-10-ocular). Origin: literature-derived.
Citations: (Moustardas et al. 2026)
Mechanism: Oculomotor (CN III), trochlear (CN IV), or abducens (CN VI) nerve dysfunction → impaired extraocular muscle coordination → eye misalignment. Consistent with α3-nAChR autoantibody-mediated autonomic ganglionopathy (Chapter Cardiovascular Dysfunction) and SFN affecting nerve control.
Chapter ref: ch03: sec 10 ocular, ch08: postcovid ocular syndrome
Prediction: A proportion of ME/CFS patients reporting diplopia (predicted $\geq 15%$) will show measurable strabismus ($gt 5$ prism dioptres deviation on cover test) on orthoptic examination with normal extraocular muscle anatomy on imaging (nerve, not muscle). Falsified if $lt 5%$ show measurable deviation, or if diplopia in ME/CFS consistently traces to accommodation fatigue rather than oculomotor misalignment.
Treatment: May respond to prism correction or botulinum toxin, as in conventional strabismus. No ME/CFS-specific trial data.
Limitation: Strabismus in Moustardas cohort is a minority finding — core ocular phenotype is corneal neuropathy + pupillary dysautonomia. Diplopia in ME/CFS more commonly fatigue-related (accommodation failure) than structural misalignment. Nerve-vs-muscle distinction requires specialist orthoptic testing, not available in routine exams. Single study.

Hypothesis p=0.45Corneal Confocal Microscopy as Cross-Disease Validated SFN Biomarker with Normative Data

Evidence: Corneal confocal microscopy (CCM) has been validated across ≥7 disease groups (diabetic neuropathy, fibromyalgia, MS, PD, SLE, POTS, chemotherapy-induced) for small-fiber neuropathy detection. Multinational normative data (CNFD, CNBD, CNFL, tortuosity) available from Tavakoli et al. (2015, multicenter, n>340) (Tavakoli et al. 2015) with ethnic-specific reference values (Cao et al. 2022). Ranathunga et al. (2026, Pain) meta-analysis confirmed transdiagnostic SFN in chronic pain (Ranathunga et al. 2026). Oreskovic et al. (2026) scoping review mapped CCM across neurodegenerative disease (Oreskovic et al. 2026). In ME/CFS, Azcue et al. (2025) found increased corneal nerve tortuosity as primary discriminator (AUC=0.720) with non-length-dependent distribution (Néstor Azcue et al. 2025). Azcue 2023 documented C-fiber dysfunction with 31% meeting POTS criteria (Néstor Azcue et al. 2023). Origin: literature-derived cross-disease synthesis.
Citations: (Tavakoli et al. 2015) (Cao et al. 2022) (Ranathunga et al. 2026) (Oreskovic et al. 2026) (Néstor Azcue et al. 2025) (Néstor Azcue et al. 2023) (Sommer and Üçeyler 2025) (Akowuah et al. 2025) (Ghadban et al. 2025) (Gharib et al. 2025) (Cantrell et al. 2025)
Mechanism: CCM images the corneal subbasal nerve plexus (Aδ and C fibers) non-invasively. Corneal nerve loss reflects systemic small-fiber pathology across diseases. In ME/CFS, tortuosity increase (not density loss) is the primary finding — consistent with immune-mediated rather than metabolic neuropathy. Non-length-dependent distribution distinguishes from diabetic neuropathy. CCM and skin biopsy (IENFD) show moderate correlation — they measure partially distinct aspects of SFN (morphology vs density).
Chapter ref: ch10: sfn interface failure, ch14d: ccm cross disease patterns, ch08: retinal corneal cns window
Prediction: A cross-disease CCM study (ME/CFS, fibromyalgia, post-COVID, healthy controls, n≥50 per group) would identify disease-specific CCM patterns (tortuosity-dominant in ME/CFS, DC-density-dominant in MS, density-dominant in diabetic neuropathy). ME/CFS corneal nerve tortuosity should correlate with IENFD reduction, autonomic dysfunction severity, and CNS symptoms. Falsified if CCM parameters are indistinguishable across conditions or within-group variance exceeds between-group difference.
Treatment: CCM is a diagnostic/monitoring tool, not treatment. Could serve as non-invasive longitudinal outcome measure for SFN-targeted treatment trials (IVIG, LDN) — repeatable without biopsy-related morbidity.
Limitation: Only one ME/CFS CCM study exists (Azcue 2025). No head-to-head cross-disease CCM comparison including ME/CFS. CCM-vs-IENFD correlation is moderate (Ghadban 2025) — CCM does not replace skin biopsy. Automated vs manual image analysis significantly affects results (Raasing 2023, method heterogeneity). No normative comparison of ME/CFS CCM parameters against the Tavakoli database. Publication bias toward positive CCM findings — negative CCM studies under-published.

Speculation p=0.35Acquired Progressive Hypermobility via Mast Cell Mediator-Mediated Connective Tissue Degradation

Evidence: Individual mechanistic steps well-supported (tryptase→MMP-3/-13 cert 0.70 (Magarinos et al. 2013), chymase→MMP-1 cert 0.75 (Saarinen et al. 1994), mast cell→collagen degradation cert 0.70 (Janicki et al. 2006), histaminylation→collagen mechanics cert 0.70 (Zhu et al. 2026)). Causal chain assembled from separate literatures; not demonstrated end-to-end. No gene identified for most hEDS (Martin 2019). Origin: brainstorm.
Citations: (Magarinos et al. 2013) (Saarinen et al. 1994) (Janicki et al. 2006) (Zhu et al. 2026) (Martin 2019) (Vazquez et al. 2022) (F. C. Wilson et al. 2026) (Imanaka et al. 2026)
Mechanism: Triggering event (infection, new allergy) → chronic mast cell activation → sustained tryptase/chymase + histaminylation → cumulative collagen/ECM degradation → progressive ligament/joint capsule laxity → increased hypermobility (Beighton score, new instability, worsening POTS). Constrained by three null findings: HaT does NOT cause hypermobility; random tryptase not elevated; no hEDS gene identified.
Chapter ref: ch14d: acquired progressive hypermobility mc
Prediction: Prospective study (n≥30 post-infectious hypermobility): MC stabiliser treated → Beighton score stable over 12 months; untreated → ≥1-point increase. Stronger: provoked tryptase (>20%+2 ng/mL above baseline) elevated. Falsified if treatment does not alter progression or provoked MC markers normal.
Treatment: Mast cell stabilizers (cromolyn, ketotifen) or anti-IgE (omalizumab, if IgE-mediated) may slow hypermobility progression — entirely untested. No clinical recommendation without trial data.
Limitation: Full causal chain not demonstrated end-to-end. Progressive hypermobility may reflect cumulative mechanical joint damage from proprioceptive dysfunction rather than direct CT degradation. hEDS molecular basis undefined — field open to non-genetic mechanisms but not yet demonstrated. Beighton ceiling effects. TNXB haploinsufficiency competing mechanism for ~5-10% (Imanaka et al. 2026).

Speculation p=0.30Histaminylation as MMP-Independent Collagen Weakening Mechanism

Evidence: Histaminylation — covalent histamine attachment to collagen via transglutaminase 2 — directly alters collagen matrix mechanics in vitro (certainty 0.70) (Zhu et al. 2026). Mechanism is independent of the established tryptase/chymase→MMP pathway, providing a second route by which mast cell histamine release could weaken connective tissue. Origin: brainstorm.
Citations: (Zhu et al. 2026)
Mechanism: Mast cell degranulation → histamine release → TG2-mediated histaminylation of collagen glutamine residues → altered collagen fibril assembly and matrix stiffness → reduced biomechanical quality of ligaments/joint capsules. Independent of MMP-mediated degradation; both pathways operate simultaneously.
Chapter ref: ch07: histaminylation collagen
Prediction: Skin biopsy collagen from MCAS+ME/CFS hypermobile patients shows elevated histaminylation (anti-histaminyl-glutamine Ab or mass spectrometry) vs non-MCAS controls. Histaminylation inversely correlates with collagen stiffness (AFM) and positively with disease duration. Falsified if histaminylation is not elevated or does not correlate with stiffness.
Treatment: H1 antihistamines may reduce ongoing histaminylation — distinct from MMP inhibition. Possibly explains anecdotal hypermobility improvement on sustained antihistamines. No clinical recommendation.
Limitation: In vivo detection requires specialised mass spectrometry. Relationship between histaminylation levels and clinical hypermobility severity not tested. TG2 upregulation in ME/CFS tissue not measured. Net effect of TG2 on tissue mechanics context-dependent (stabilising in some contexts).

Speculation p=0.30Tear-Fluid Proteomics as Low-Burden Immune Biomarker Window for Severe ME/CFS

Evidence: Moustardas et al. (2026) demonstrated that tear CD4+ T-cell dysregulation proteomics matches blood/tissue signatures from severe/fatal COVID (Moustardas et al. 2026). Tear fluid is collectable non-invasively — no needle, no clinic visit required. T-cell exhaustion and immune dysregulation are documented in ME/CFS blood (Derek S. Iu et al. 2024) (Walitt, Singh, LaMunion, Hallett, et al. 2024) but no tear study exists. Origin: literature-derived inference.
Citations: (Moustardas et al. 2026) (Derek S. Iu et al. 2024) (Walitt, Singh, LaMunion, Hallett, et al. 2024)
Mechanism: Systemic T-cell dysregulation → spillover into lacrimal gland/tear fluid → detectable proteomic signature. Tear fluid mirrors systemic immune state for some compartments (shown for post-COVID; unverified for ME/CFS).
Chapter ref: ch07: tear tcell readout, ch08: postcovid ocular syndrome
Prediction: Tear proteomics in ME/CFS shows CD4+/CD8+ dysregulation signature correlating with blood T-cell exhaustion markers (PD-1 expression, TCF7 state) within individuals at within-subject $r \geq 0.4$, or a tear-only classifier separating patients from controls at AUC $\geq 0.70$. Falsified if the within-subject tear–blood correlation is below 0.4 and no tear classifier reaches AUC 0.70 in an adequately powered sample.
Treatment: No treatment proposed. If validated, tear biomarkers would enable home-collection immune monitoring in trials enrolling severe/bedbound patients normally excluded by phlebotomy burden.
Limitation: Entirely untested in ME/CFS. Tear-blood concordance shown only for a selected post-COVID ocular-symptom cohort. Tear composition varies with ocular surface condition (dry eye, blepharitis), diet, environment, and sleep — all confounders in ME/CFS. Mechanism of spillover (active secretion vs passive leakage vs local ocular immune response) unknown.

Speculation p=0.30CCM as Non-Invasive SFN Treatment-Response Monitor for ME/CFS Trials

Evidence: CCM detected chemotherapy-induced polyneuropathy earlier than clinical assessment (Baghdasaryan et al. 2026). SNRI treatment partially reversed corneal nerve changes in fibromyalgia (Kubat et al. 2026). CCM is non-invasive, radiation-free, repeatable every few months (skin biopsy requires healing time). In ME/CFS, if SFN-targeted treatments (IVIG, corticosteroids, immunomodulators) reduce small-fiber pathology, serial CCM could provide the first repeatable tissue-level treatment-response biomarker. Origin: literature-derived inference.
Citations: (Baghdasaryan et al. 2026) (Kubat et al. 2026) (Néstor Azcue et al. 2025) (Néstor Azcue et al. 2023)
Mechanism: Treatment of SFN → reduced immune-mediated nerve damage → corneal nerve regeneration (increased CNFD/CNFL, reduced tortuosity) → detectable by serial CCM within 3–6 months. CCM regeneration signals precede symptom improvement, analogous to diabetic neuropathy CCM monitoring protocols.
Chapter ref: ch10: sfn interface failure, ch14d: ccm cross disease patterns
Prediction: In a 12-month IVIG trial for autoimmune SFN in ME/CFS, CCM parameters (CNFD, tortuosity) will show detectable improvement at 6 months (≥10% CNFD increase), preceding symptom improvement at 9–12 months. Falsified if CCM is static despite clinical improvement, or if CCM improvement is dissociated from IENFD improvement.
Treatment: If validated, CCM could serve as early-response biomarker for SFN-targeted trials, enabling shorter trial durations and dose-finding without repeat skin biopsy. No clinical use outside trials.
Limitation: Only one ME/CFS CCM study. Treatment-response CCM data in ME/CFS entirely absent. Regeneration timelines in immune-mediated vs metabolic neuropathy may differ — extrapolation from fibromyalgia/chemo-neuropathy uncertain. CCM cannot distinguish between regeneration of existing nerves and compensatory sprouting. Regeneration signal may reflect corneal-specific recovery not generalizable to somatic small fibers.

Speculation p=0.30Pupillometry as ME/CFS Autonomic Biomarker

Evidence: Sander 2025 validated handheld pupillometer in autonomic failure (certainty 0.70) (Sander et al. 2025). Master 2020 validated PLR as objective biomarker in n=352 concussion patients (certainty 0.75) (Master et al. 2020). Szklarski 2021 demonstrated elevated M3/α1 autoantibodies in ME/CFS (certainty 0.65) (Szklarski et al. 2021). Azcue 2026 replicated α1 autoantibody elevation in PCS+CFS (certainty 0.70) (N. Azcue et al. 2026a). Lisowski 2025 reviewed pupil autonomic anatomy (Lisowski et al. 2025). Rizzuto 2025 reviewed hippus as autonomic biomarker (Rizzuto et al. 2025). Sendrowski 1997 (certainty 0.25) — only direct CFS pupillometry study. Origin: brainstorm.
Citations: (Sander et al. 2025) (Master et al. 2020) (Szklarski et al. 2021) (N. Azcue et al. 2026a) (Lisowski et al. 2025) (Rizzuto et al. 2025) (Sendrowski, Buker, and Gee 1997) (Egg et al. 2002) (Parmak Yener et al. 2026)
Mechanism: M3 muscarinic receptors (iris sphincter, parasympathetic constriction) and α1-adrenergic receptors (iris dilator, sympathetic dilation) are targets of GPCR autoantibodies elevated in ME/CFS. If antibodies are functionally pathogenic, end-organ effect should be measurable as slowed constriction velocity, reduced dilation velocity, or both. Pupillometry is noninvasive, brief (30s), performable supine — accessible to severe patients.
Chapter ref: ch30: pupillometry biomarker, ch30: pupillometry pem, ch30: plr gpcr bioassay
Prediction: ME/CFS patients with elevated α1/M3 autoantibodies will show slower PLR constriction velocity and/or reduced dilation velocity vs ME/CFS without autoantibodies and controls. PLR parameters will correlate with COMPASS-31 and orthostatic intolerance measures. PEM provocation will alter PLR dynamics. Falsified if autoantibody-positive patients show normal PLR, or if PLR does not differ from controls after accounting for age/medication confounds.
Treatment: No treatment proposed. If validated, pupillometry could serve as functional autoantibody bioassay and treatment-response monitor for immunomodulatory trials — distinguishing functionally pathogenic from non-pathogenic autoantibodies.
Limitation: No modern ME/CFS pupillometry data. Egg 2002 found pupillary unrest inversely correlated with fatigue in MS (null result). PLR sensitive to medications, ambient light, alertness, age. Day-to-day reliability in ME/CFS unknown.

Speculation p=0.25Pupillometry as Noninvasive LC Functional Readout

Evidence: Drummond 2022 demonstrated LC deficit via pupil dilation asymmetry in CRPS (Drummond and Finch 2022). Aregawi 2026 documented CSF NE deficiency in ME/CFS (Aregawi et al. 2026). LC → IML → SCG → α1-adrenergic iris dilator pathway is well-characterized (Lisowski et al. 2025). Origin: brainstorm.
Citations: (Drummond and Finch 2022) (Aregawi et al. 2026) (Lisowski et al. 2025)
Mechanism: LC functional output → pupil dilation velocity via α1-adrenergic dilator muscle innervation. CSF NE deficiency predicts reduced baseline pupil diameter (low tonic LC output) and slower dilation to arousal stimuli (impaired phasic LC bursts). Provides noninvasive proxy for central noradrenergic state — safer and repeatable vs lumbar puncture.
Chapter ref: ch08: pupillometry lc readout
Prediction: ME/CFS patients will show slower pupil dilation velocity to auditory arousal vs controls. Dilation velocity will correlate positively with CSF NE Pathway index in patients with both pupillometry and LP. Atomoxetine (NRI) will increase pupil dilation velocity, with magnitude predicting clinical response. Falsified if dilation velocity is normal in ME/CFS, or if no correlation with CSF NE exists.
Treatment: If validated, pupillometry could serve as bedside LC function monitor for NRI treatment trials — avoiding repeat lumbar puncture. No clinical use until validated.
Limitation: No direct ME/CFS pupillometry-LC correlation data. Peripheral sympathetic dysfunction could produce pupil abnormalities independent of LC. Medications, light adaptation, age, alertness all affect pupil dynamics. Baseline pupil diameter has poor specificity — multiple conditions produce smaller pupils.

Open Question p=n/aIgE-Specific Pathway in MCAS-Connective Tissue Interaction

Evidence: Wilson 2026 (n=2141, certainty 0.45): IgE elevated in high-MC-score hEDS/HSD (p=0.0004) while random tryptase normal. Omalizumab safe/effective for refractory MCAS (Matheny 2025, certainty 0.55). No study has examined omalizumab effect on CT integrity or hypermobility outcomes. The IgE→FcεRI pathway is under-explored relative to MRGPRX2 in MCAS-CT research.
Citations: (F. C. Wilson et al. 2026) (Matheny, Craig, and Al-Shaikhly 2025)
Mechanism: If IgE-mediated sensitisation drives MC activation in hEDS subset → IgE sequestration by omalizumab → reduced FcεRI pathway activation → reduced mast cell degranulation → potential slowing of CT degradation. Anti-IgE therapy serves as therapeutic probe: pathway-specific hypothesis testing using an approved drug with established safety profile.
Chapter ref: ch07: ige pathway ct mcas
Prediction: Omalizumab-treated hEDS/MCAS patients with progressive hypermobility should show reduced provoked MC mediators (tryptase, urinary N-methylhistamine/LTE4/PGD2 metabolite) and stabilised Beighton score at 12 months vs pre-treatment trajectory. Falsified if hypermobility progresses despite effective IgE sequestration (normalised IgE, reduced MC mediators).
Treatment: Omalizumab as therapeutic probe for IgE→MC→CT pathway. Specialist prescribing only. No clinical recommendation — entirely research-stage for CT outcomes.
Limitation: No study of omalizumab with CT/hypermobility endpoints. Most MCAS literature focuses on non-IgE pathway (MRGPRX2). Omalizumab only targets IgE pathway — ineffective if dominant degranulation is MRGPRX2/complement/TLR-mediated. Dynamic biomarker monitoring required; random labs insufficient.

Open Question p=n/aOmalizumab as Therapeutic Probe for IgE→MC→CT Hypothesis

Evidence: Omalizumab safe/effective for refractory MCAS (Matheny2025, 28 patients, 61% partial, 18% complete (Matheny, Craig, and Al-Shaikhly 2025)). Wilson2026 found IgE elevated in high-MC-score hEDS/HSD (n=2141, p=0.0004 (F. C. Wilson et al. 2026)). No study has examined CT integrity or hypermobility outcomes with any anti-IgE therapy. Omalizumab’s IgE-specific mechanism makes it an ideal therapeutic probe: if it reduces MC activation AND slows hypermobility, IgE→MC→CT is supported. Origin: brainstorm.
Citations: (Matheny, Craig, and Al-Shaikhly 2025) (F. C. Wilson et al. 2026)
Mechanism: Omalizumab → IgE sequestration → reduced FcεRI activation → reduced MC degranulation. If IgE pathway drives CT degradation: reduced degranulation → reduced MMP/histaminylation → CT degradation slowed. If non-IgE pathway dominant: MC activation unchanged despite IgE suppression. If MC→CT wrong: MC activation reduced but CT degradation continues.
Chapter ref: ch14d: omalizumab ct therapeutic probe
Prediction: 12-month open-label omalizumab in IgE-elevated hEDS/MCAS: provoked tryptase reduced, serum MMP-3/9 reduced, histaminylation markers reduced, Beighton score stabilised vs pre-treatment progression. Falsified if CT outcomes unchanged despite reduced MC activation, or if neither changes.
Treatment: Proof-of-mechanism trial is immediately feasible using approved drug with established MCAS safety. Positive result would justify an RCT; negative result would redirect research away from IgE pathway. No clinical recommendation outside trial setting.
Limitation: Therapeutic probe only tests IgE pathway, not MC→CT chain itself. If dominant degranulation is MRGPRX2/complement/TLR-mediated, omalizumab will be negative even if MC→CT chain is correct. Single-arm open-label design limits causal inference.

Open Question p=n/aPupillometry During PEM Provocation

Evidence: ME/CFS autonomic function often normal at rest but deranged after provocation. Sander 2025 (Sander et al. 2025) validated methodology. No PEM provocation pupillometry study exists. Origin: brainstorm.
Citations: (Sander et al. 2025)
Mechanism: Exercise/orthostatic provocation → autonomic decompensation → measurable PLR changes reflecting dynamic sympathetic/parasympathetic failure. Handheld pupillometer enables serial measurements at rest, during orthostasis, and at multiple timepoints post-exertion.
Chapter ref: ch30: pupillometry pem
Prediction: PLR constriction velocity and dilation velocity measured 2h post-exertion will be significantly slower than pre-exertion baseline in ME/CFS, with slowing magnitude proportional to PEM severity. Healthy controls show no change or faster recovery. Falsified if PLR is stable across pre/post-exertion timepoints, or if within-subject variability exceeds between-state differences.
Treatment: N/A — research direction only.
Limitation: No pilot data. Optimal timing for post-exertion measurement unknown. PEM onset is delayed (12–72h); single 2h measurement may miss the window. Repeated testing itself may be a PEM trigger. Medication half-lives may confound serial PLR.

Open Question p=n/aPLR as GPCR Autoantibody Functional Bioassay

Evidence: Szklarski 2021 (Szklarski et al. 2021) and Azcue 2026 (N. Azcue et al. 2026a) demonstrate GPCR autoantibodies in ME/CFS. In vitro ELISA/bioassay measures binding to recombinant receptors; binding does not establish functional impairment at native tissue. Pupil is native tissue with M3/α1 receptors at physiological densities. Origin: brainstorm.
Citations: (Szklarski et al. 2021) (N. Azcue et al. 2026a) (Lisowski et al. 2025)
Mechanism: ME/CFS patients with GPCR autoantibodies → functional impairment of M3/α1 receptor-mediated pupil dynamics IF antibodies are pathogenic. Pupillometry measures end-organ function, distinguishing neutralizing from non-pathogenic autoantibodies — a distinction in vitro binding assays cannot make.
Chapter ref: ch30: plr gpcr bioassay
Prediction: Among ME/CFS patients with anti-α1 or anti-M3 antibodies, PLR constriction/dilation velocity will be slower in patients who later show clinical improvement after IVIG than same patients’ post-treatment values. Antibody titers alone will not predict treatment response. Falsified if PLR does not change post-treatment, or if PLR change is dissociated from clinical improvement.
Treatment: If validated, PLR-based bioassay could identify which autoantibody-positive patients benefit from immunomodulatory therapy — stratifying IVIG/plasmapheresis trials. No clinical use until validated.
Limitation: Entirely untested. PLR impairment may have causes beyond autoantibodies (medications, age, comorbid conditions). Cutoff between “functionally impaired” and “normal” PLR in the context of positive serology is undefined. Pupil receptors represent one tissue — autoantibody effects may be tissue-specific.

15 Connective Tissue and Extracellular Matrix

Hypothesis p=0.65Glymphatic-Capillary Clearance Enhancement

Evidence

Sleep-based glymphatic dysfunction documented in ME/CFS (alpha-delta sleep, impaired vasomotion coupling). Glymphatic clearance role in ECM homeostasis established in healthy brain. Positional effects on glymphatic flow documented.

Mechanism

Glymphatic system clears metabolic waste, including extracellular matrix fragments, from the interstitial space during sleep. (b) ME/CFS sleep architecture abnormalities impair glymphatic clearance (alpha-delta sleep, impaired LC-NE-vasomotion coupling). (c) Diminished glymphatic removal of ECM fragments may contribute to elevated circulating ECM biomarkers and chronic inflammation. (d) Glymphatic function may be modulated by positional factors (supine vs upright), sleep quality, and cerebrospinal fluid dynamics.

Chapter ref

ct glymphatic capillary

Treatment

Enhanced glymphatic clearance via sleep optimization, positional therapy (supine sleep), or direct glymphatic modulation could reduce circulating ECM burden in ME/CFS.

Hypothesis p=0.60Structural-Autonomic Stratification

Evidence

CTD prevalence 30-57% in ME/CFS vs 10-15% general population. Hypermobility, CCI, POTS comorbidity documented. Vascular connective tissue interactions established in physiology.

Mechanism

Connective tissue disorders (CTDs) and autonomic dysfunction (POTS, NMH) may co-occur as distinct but interacting subtypes. (b) Structural features (hypermobility, CCI, ligament laxity) may predispose to autonomic dysfunction via craniospinal instability, mechanical strain, or impaired vascular compliance. (c) Conversely, autonomic dysfunction may exacerbate connective tissue pathology through impaired tissue perfusion, oxidative stress, and inflammatory cascades. (d) Distinguishing these subtypes requires combined structural (MRI, Beighton score) and autonomic testing (tilt table, HRV) to guide targeted treatment.

Chapter ref

ct structural autonomic stratification

Treatment

Combined structural and autonomic phenotyping to identify CTD + autonomic subtypes requiring different therapeutic approaches (mechanical stabilization vs autonomic modulation vs combination).

Hypothesis p=0.55Vagal-Mast Cell-Connective Tissue Axis

Evidence

Vagal control of mast cell activity established in neuroimmunology. Vagal afferent signaling via connective tissue mechanoreceptors documented. ME/CFS vagal dysfunction documented.

Mechanism

Vagal tone modulates mast cell degranulation and inflammatory responses; high vagal activity suppresses mast cell release. (b) Connective tissue integrity may influence vagal afferent signaling via mechanoreceptors and nociceptors. (c) ME/CFS may involve impaired vagal control of mast cells, contributing to MCAS prevalence. (d) Vagus nerve stimulation or vagal tone modulation could reduce mast cell activation and improve connective tissue inflammation.

Chapter ref

ct vagal mast cell ecm

Treatment

Vagal modulation therapies (tVNS, breathwork, biofeedback) to reduce mast cell activation and improve connective tissue inflammation in ME/CFS with MCAS features.

Hypothesis p=0.50Mechanical Stress-Modulated Mast Cell Threshold

Evidence

Mast cell mechanosensitivity documented in mast cell biology literature. Mechanical stress triggers degranulation in experimental models. ME/CFS MCAS prevalence elevated in hypermobile subgroups.

Mechanism

Mast cells are mechanically sensitive; mechanical stress (stretch, compression, vibration) can trigger degranulation. (b) Mechanosensitive ion channels (Piezo1/2) and integrin-mediated signaling transduce mechanical forces into mast cell activation signals. (c) Connective tissue weakness or hypermobility may lower the mechanical threshold for mast cell activation, particularly in tissues with poor connective tissue support (joints, ligaments, vasculature). (d) ME/CFS patients with CTD or hypermobility may have mechanically primed mast cells, explaining high MCAS prevalence in this subgroup.

Chapter ref

ct mechanical mast cell

Treatment

Mechanical stability interventions (physical therapy, cervical stabilization, joint support) may reduce mast cell activation in ME/CFS patients with mechanically primed mast cells.

Hypothesis p=0.50Senescence-Associated CT Decline

Evidence

Senescence-associated ECM degradation established in aging and fibrosis literature. SASP cytokines (IL-6, TGF-β) degrade ECM components. ME/CFS accelerated aging phenotype documented.

Mechanism

Cellular senescence contributes to connective tissue aging through senescence-associated secretory phenotype (SASP) production of inflammatory cytokines and proteases. (b) ME/CFS may show accelerated connective tissue aging and senescent cell burden in skin, tendon, or ligament tissues. (c) Senolytic or senomorphic therapies targeting senescent fibroblasts could improve connective tissue integrity in ME/CFS. (d) Skin or tendon biopsies could quantify senescence burden (p16^INK4a, SA-β-gal) as biomarker of connective tissue aging.

Chapter ref

ct senescence

Treatment

Senolytic or senomorphic therapies to reduce senescent fibroblast burden and improve connective tissue integrity in ME/CFS. Senescence biomarkers as outcome measures.

Hypothesis p=0.50Circadian Collagen Resynchronization

Evidence

Circadian regulation of collagen synthesis established in connective tissue physiology. ME/CFS circadian disruption well-documented. Melatonin effects on collagen documented.

Mechanism

Collagen synthesis exhibits circadian rhythms, with peak production during nighttime hours. (b) ME/CFS circadian disruption (phase delay, fragmented sleep, abnormal melatonin secretion) may impair collagen synthesis efficiency, contributing to connective tissue weakness over time. (c) Circadian optimization (light therapy, sleep schedule stabilization, melatonin supplementation) could restore collagen production patterns. (d) Circadian markers (melatonin, cortisol rhythm) may predict collagen synthesis capacity and connective tissue healing potential.

Chapter ref

ct circadian collagen

Treatment

Circadian rhythm optimization to restore collagen synthesis capacity in ME/CFS, with circadian markers as biomarkers of connective tissue health.

Hypothesis p=0.50Glycine-Proline Collagen Optimization

Evidence

Glycine and proline requirements for collagen synthesis established in biochemistry literature. ME/CFS nutritional deficiencies documented. Collagen peptide supplementation effects documented.

Mechanism

Glycine and proline are primary amino acids in collagen structure; deficiencies impair collagen synthesis. (b) ME/CFS patients may have suboptimal glycine/proline intake or impaired utilization, contributing to connective tissue weakness. (c) Supplementation with glycine, proline, or collagen peptides could improve collagen production and connective tissue integrity. (d) Circadian timing of supplementation may align with collagen synthesis peaks.

Chapter ref

ct collagen peptides

Treatment

Glycine-proline or collagen peptide supplementation to improve collagen synthesis and connective tissue integrity in ME/CFS, with circadian timing for maximal effect.

Hypothesis p=0.45Chronobiological Prolyl Hydroxylase Optimization

Evidence

Wirth 2026 CTD-MECFS study on ROS-prolyl hydroxylase-HIF-1alpha connection; circadian regulation of prolyl hydroxylases in collagen synthesis literature; ascorbic acid deficiency causing scurvy via collagen crosslinking failure.

Mechanism

Prolyl hydroxylases (P4H, P3H) exhibit circadian rhythms essential for collagen crosslinking. (b) ROS-mediated inhibition of these enzymes in ME/CFS impairs ligament stability, particularly in hypermobile patients. (c) Timed cofactor supplementation (ascorbic acid, alpha-ketoglutarate) at circadian peak times may maximize enzymatic activity and improve collagen crosslinking efficiency. (d) This addresses the connective tissue weakness observed in ME/CFS hypermobility through timed nutritional intervention.

Chapter ref

Ch. 14a — prolyl hydroxylase circadian section

Treatment

Circadian optimization of prolyl hydroxylase activity to improve collagen crosslinking in hypermobile ME/CFS patients. Nutritional timing strategy to overcome ROS inhibition.

Hypothesis p=0.45Basal Lamina-Targeted Capillary Restoration

Evidence

Basement membrane thickening documented in ME/CFS and Long COVID microvascular pathology. Capillary pericyte biology established in angiogenesis. ME/CFS microvascular dysfunction documented.

Mechanism

Capillary basement membrane thickening impairs endothelial function and microvascular perfusion. (b) ME/CFS may show basement membrane pathology contributing to orthostatic intolerance and tissue hypoperfusion. (c) Targeted restoration of basal lamina integrity (MMP inhibition, collagen IV support, growth factor modulation) could improve capillary function. (d) Pericyte-mediated capillary stabilization may support basement membrane repair.

Chapter ref

ct arb capillary

Treatment

Basement membrane-targeted therapies to restore capillary function and improve tissue perfusion in ME/CFS with microvascular dysfunction.

Hypothesis p=0.45Matrix Stiffness-Mast Cell Priming

Evidence

Matrix stiffness effects on immune cell activation established in tissue engineering. Mast cell mechanosensitivity documented. ME/CFS ECM accumulation hypothesized.

Mechanism

Matrix stiffness influences immune cell phenotype and activation; stiffer ECM environments promote pro-inflammatory phenotypes. (b) ME/CFS may show increased tissue stiffness due to ECM accumulation or crosslinking, potentially priming mast cells for hyperreactivity. (c) Mechanoreceptors (Piezo1/2, integrins) on mast cells may sense ECM stiffness and trigger degranulation. (d) Softening of ECM or mechanoreceptor blockade could reduce mast cell activation in stiff-tissue ME/CFS subtypes.

Chapter ref

ct matrix stiffness mast cell

Treatment

ECM softening or mechanoreceptor blockade to reduce mast cell activation in ME/CFS patients with stiff-tissue phenotypes or elevated mast cell mediators.

Hypothesis p=0.40LOX-Mediated Collagen Stabilization

Evidence

LOX function essential for collagen crosslinking established in connective tissue biology. ROS inhibition of LOX documented in oxidative stress pathophysiology. ME/CFS ROS elevation documented.

Mechanism

LOX (lysyl oxidase) enzymes catalyze collagen and elastin crosslinking, essential for tissue strength and stability. (b) ROS-mediated inhibition of LOX in ME/CFS may impair collagen crosslinking, contributing to ligament laxity and connective tissue weakness. (c) Co-factors (ascorbic acid, copper) are required for LOX activity; deficiency may exacerbate the defect. (d) Supplementation with LOX cofactors or modulation of LOX activity could improve connective tissue integrity.

Chapter ref

ct lox collagen

Treatment

LOX cofactor supplementation (ascorbic acid, copper, vitamin C) to restore collagen crosslinking in ME/CFS with connective tissue weakness or hypermobility.

Hypothesis p=0.40ECM Microbiome Interaction

Evidence

ECM microenvironment influences microbial colonization established in tissue engineering. Microbial metabolites modulate collagen and fibronectin expression documented. ME/CFS gut dysbiosis well-documented.

Mechanism

Extracellular matrix provides structural scaffold and bioactive niches for host cells and microorganisms. (b) Microbial products (LPS, bacterial peptidoglycan) can bind to ECM components, modulating inflammation and immune cell recruitment. (c) Gut microbiome dysbiosis in ME/CFS may influence ECM composition via microbial metabolites (short-chain fatty acids, indoles) that modulate ECM production and remodeling. (d) ECM microenvironment may selectively promote pathogenic microbial communities, creating a bidirectional dysbiosis-ECM interaction.

Chapter ref

ct ecm microbiome

Treatment

Microbiome-targeted interventions (probiotics, antimicrobial peptides, diet) may modulate ECM composition and reduce inflammation in ME/CFS via microbiome-ECM cross-talk.

Hypothesis p=0.40Elastin-Specific Degradation

Evidence

Elastin degradation mechanisms established in connective tissue biology. MMP-12 and MMP-9 elastolytic activity documented. Elastin fragment biomarkers developed.

Mechanism

Elastin provides elastic recoil to connective tissues; its degradation contributes to tissue laxity and structural weakness. (b) Elastin-specific MMPs (MMP-12, MMP-9) may be dysregulated in ME/CFS, leading to elastin breakdown. (c) Elastin fragments (sVTI) may serve as diagnostic biomarkers of connective tissue degradation. (d) Elastin-specific protection strategies (MMP inhibitors, elastin stabilizers) could preserve tissue integrity.

Chapter ref

ct elastin degradation

Treatment

Elastin-specific biomarkers (sVTI) to detect connective tissue degradation in ME/CFS, with elastin-protective therapies for tissue preservation.

Hypothesis p=0.40HIF-1alpha Isoform Targeting

Evidence

HIF-1alpha vs HIF-2alpha isoform specificity documented in hypoxia biology. HIF-1alpha-driven MMP-3 expression established. Isoform-selective inhibitors in development.

Mechanism

HIF-1alpha and HIF-2alpha have distinct target gene profiles; HIF-1alpha preferentially induces MMP-3 and ECM degradation. (b) ME/CFS may show HIF-1alpha-dominant activation driving connective tissue pathology. (c) Selective HIF-1alpha inhibition could reduce ECM degradation without affecting beneficial HIF-2alpha functions (erythropoiesis, angiogenesis). (d) Isoform-specific modulation may provide connective tissue benefits while minimizing off-target effects.

Chapter ref

ct hif isoform

Treatment

Isoform-selective HIF-1alpha inhibition to reduce MMP-3 and ECM degradation in ME/CFS with connective tissue pathology.

Hypothesis p=0.35Periostin-Targeted ECM Restoration

Evidence

Periostin mutations cause connective tissue disorders; periostin-deficient mice show ligament laxity and impaired wound healing; TGF-beta dysregulation documented in ME/CFS.

Mechanism

Periostin (POSTN) is a matricellular protein critical for collagen crosslinking and tissue remodeling. (b) ME/CFS may involve periostin deficiency or dysregulation, impairing connective tissue repair. (c) Recombinant periostin or TGF-beta modulators could restore ECM integrity in hypermobile patients. (d) This addresses the molecular basis of connective tissue weakness in ME/CFS.

Chapter ref

periostin ecm restoration

Treatment

Targeted biological approach to connective tissue pathology using recombinant periostin or TGF-beta modulators to restore collagen crosslinking.

Hypothesis p=0.35Post-Infectious Acquired Chiari

Evidence

Post-infectious CCI documented in Long COVID, post-viral meningoencephalitis, and infectious mononucleosis. Cervical symptoms common in ME/CFS. MRI screening guidelines established.

Mechanism

Chiari malformation type I can develop post-infectiously, particularly following infections causing significant inflammation or swelling. (b) Post-infectious CCI may occur via chronic inflammation-induced swelling of cerebellar tonsils or ligamentous laxity at craniovertebral junction. (c) Clinical presentation (headache, neck pain, dizziness) overlaps with ME/CFS, contributing to diagnostic confusion. (d) MRI evaluation should be considered in ME/CFS patients with unexplained orthostatic symptoms, cervical pain, or neurological abnormalities.

Chapter ref

ct acquired chiari

Treatment

MRI-based screening for CCI in ME/CFS patients with cervical symptoms to identify post-infectious structural subtype requiring decompression or rehabilitation.

16 Antigen-Specific IgE and Mast Cell Activation

Speculation p=0.30Infection-Triggered Allergic Sensitization as Shared Upstream of Post-Viral Illness

Evidence: COVID-19 raises incident allergic disease at population scale (HR 1.20; asthma 2.25), replicated; epithelial alarmin→Th2 route plausible; ME/CFS shows Th2 bias but WITHOUT IgE elevation (a dissociation).
Citations: (Oh et al. 2024) (Clarion et al. 2026) (Filippatos et al. 2025) (Skowera et al. 2004)
Mechanism: Epithelial injury → IL-33/IL-25/TSLP alarmins → Th2 polarization + ILC2 expansion → epigenetic Th2 scars → increased allergic disease incidence; in ME/CFS the Th2 shift appears IgE-independent.
Chapter ref: ch14b: infection allergic sensitization
Prediction: Prospective post-COVID / post-tick cohorts: those who develop ME/CFS show higher new clinician-diagnosed allergic disease incidence than recoverers, driven by Th2-axis symptoms not total-IgE rises. Falsified if incidence equal or fully explained by total-IgE elevation.
Treatment: Reframes intuition: infection→allergic disease is general-population evidence, not an ME/CFS-IgE-allergy claim. No treatment implication.
Limitation: Population-level studies show ANY allergic disease, not antigen-specific IgE. Link to ME/CFS inferred, not demonstrated. Th2-bias study small (n=32).

Speculation p=0.20Minority Post-Infectious Subset Carries Antigen-Specific IgE to Spike or Tick Antigens

Evidence: Spike-specific IgE exists in acute COVID and correlates with severity; alpha-gal proves tick→antigen-specific IgE; both invisible to standard total/common-allergen IgE panels which are normal in ME/CFS.
Citations: (Tan et al. 2022) (Meltendorf et al. 2022) (Portilho et al. 2024) (Platts-Mills et al. 2025) (J. M. Wilson et al. 2024) (Nunen 2015) (Cabezas-Cruz et al. 2021) (Giménez-Orenga et al. 2025)
Mechanism: Triggering infection (SARS-CoV-2 or tick) → Th2 (IL-4/IL-13) → antigen-specific IgE → persistent FcεRI sensitization of mast cells in a subset → chronic mediator release.
Chapter ref: ch14b: ige antigen subset
Prediction: Antigen-specific IgE panels (anti-spike S1, anti-RBD, anti-alpha-gal) elevated in ≥15% subset of post-infectious ME/CFS vs controls and correlating with mast-cell symptom burden. Falsified if no elevation vs controls or if present but uncorrelated.
Treatment: If a real subset exists, antigen-specific (not standard) IgE testing could identify it; anti-IgE or mast-cell-targeted strategies are research-stage only — no clinical action implied.
Limitation: Never measured in ME/CFS. Total/allergen-specific IgE replicated-normal in ME/CFS. Giménez-Orenga 2025 suggests anti-spike IgE tracks COVID exposure, not ME/CFS state. Entirely unstudied.

Open Question —Mast-Cell Neuroinflammation in ME/CFS: IgE-Mediated vs Non-IgE Activation

Evidence: Histamine→H1R→microglia neurotoxicity, mast-cell→BBB/tryptase/PAR2→microglia, and CRH→intracranial mast-cell degranulation are all established in animal/in-vitro models; FcεRI vs non-IgE contribution in ME/CFS is unmeasured.
Citations: (Rocha et al. 2016) (Lakatos and Rosta 2025) (Theoharides et al. 1995) (Repka-Ramirez et al. 2001) (K. Kowal et al. 2002)
Mechanism: Mast cell activation (route unknown) → histamine/tryptase/CRH-amplified mediators → BBB disruption + microglial activation → neuroinflammation → brain fog / mood lability / dysautonomia.
Chapter ref: ch14b: ige vs nonige neuroinflammation
Prediction: Direct measurement of FcεRI-cross-linking vs non-IgE (substance P, CRH, IL-33, MRGPRX2) mast-cell activation in ME/CFS blood/brain; replicated-normal IgE tilts toward non-IgE. Falsified-direction depends on which route dominates.
Treatment: Distinguishing routes prevents futile anti-IgE trials in a non-IgE-dominant population; no current clinical action.
Limitation: No study has measured the FcεRI-vs-non-IgE contribution in ME/CFS, in blood or brain. All mechanistic evidence is animal/in-vitro.

Open Question —Three-Group Anti-Spike IgE Serosurvey to Resolve Disease-Marker vs Exposure-Marker

Evidence: Anti-spike IgE assays exist (tan2022, meltendorf2022); three comparator groups exist; Giménez-Orenga 2025 already suggests signal tracks COVID exposure not ME/CFS state. Decisive, low-cost test of the IgE-as-driver hypothesis.
Citations: (Tan et al. 2022) (Meltendorf et al. 2022) (Giménez-Orenga et al. 2025)
Mechanism: Measure anti-spike (S1/S2/RBD) IgE, anti-nucleocapsid IgE, IgG4 across post-COVID ME/CFS vs post-COVID recovered vs prepandemic ME/CFS; correlate with severity + mast-cell mediators + neurocognition.
Chapter ref: ch14b: antispike ige serosurvey
Prediction: Anti-spike IgE titres do NOT differ between post-COVID ME/CFS and post-COVID recovered after controlling for acute severity + time-since-infection → confirms exposure-marker, closes hypothesis. Higher in ME/CFS correlating with severity → re-opens it.
Treatment: Determines whether antihistamine/anti-IgE approaches are worth trialling at all; no current clinical action.
Limitation: Must control time-since-infection, acute severity, atopy, vaccination. Must use native conformational spike (denatured-antigen artifacts) and objective IgE (not self-report).

17 Thermoregulation and Heat/Cold Exposure

Hypothesis p=0.55ME/CFS-Heat Stroke Shared Pathway Vulnerability Explains Heat Intolerance

Evidence: Stanculescu et al. 2021 identified at least 9 shared pathophysiological mechanisms between heat stroke and ME/CFS: gut permeability/endotoxemia, systemic inflammation (IL-6, TNF-alpha, NLRP3), endothelial dysfunction, mitochondrial dysfunction, HSP deficiency, CNS neuroinflammation, splanchnic vasoconstriction, coagulation disorders, and similar transcriptomic profiles (downregulated respiratory chain genes, glycolysis switch). Female predominance, viral reactivation, and cumulative stress are shared predisposing factors.
Citations: (Stanculescu et al. 2021)
Mechanism: Environmental heat exposure activates existing vulnerable pathways in ME/CFS rather than imposing a new stressor. Gut barrier already compromised (40-67% elevated LPS antibodies) → heat stress further increases permeability → endotoxemia spike → systemic inflammatory response → PEM. This explains why heat, a universal stressor, is disproportionately harmful in ME/CFS.
Chapter ref: ch02: autonomic; ch14: autonomic management; ch17: isr lifestyle misc
Prediction: ME/CFS patients exposed to standardized environmental heat (30°C, 50% humidity, 2 hours) will show greater increases in LPS, IL-6, and fatigue scores vs healthy controls and vs ME/CFS patients at thermoneutral. Gastric permeability testing (lactulose/rhamnose) will show worsening post-heat in ME/CFS but not controls.
Treatment: Heat avoidance during heat waves and hot environments is justified by shared vulnerability pathways. Pre-cooling strategies and gut barrier support (butyrate, glutamine) prior to unavoidable heat exposure may reduce PEM risk. Research-stage.
Limitation: Narrative review (no systematic methodology); no new primary data. Shared mechanism inference from heat stroke → ME/CFS, not direct experimental evidence from ME/CFS patients. No prospective ME/CFS heat-challenge data. Certainty lowered from review mechanism strength due to absence of direct ME/CFS validation.

Hypothesis p=0.55HMGB1 as Central DAMP Sustaining Neuroinflammation in ME/CFS

Evidence

HMGB1 translocates from nucleus to extracellular space under cellular stress, signaling via TLR4/TLR9/RAGE (Ibrahim, Wasim, and Rahman 2026). (b) HMGB1 redox state determines bioactivity: disulfide-HMGB1 pro-inflammatory, fully reduced chemotactic (Ibrahim, Wasim, and Rahman 2026). (c) Exercise-induced oxidative stress may shift HMGB1 toward disulfide form, triggering PEM. (d) HMGB1-pCTS-L (cathepsin L) complex amplifies inflammation (W. Chen et al. 2026). (e) HMGB1 binds immunogenic DNA, enhancing cGAS-STING type I interferon induction. (f) No study has measured extracellular HMGB1 or redox isoforms in ME/CFS.

Citations

(Ibrahim, Wasim, and Rahman 2026) (W. Chen et al. 2026)

Mechanism

Stress $\rightarrow$ HMGB1 release $\rightarrow$ TLR4/RAGE $\rightarrow$ neuroinflammation. Exertion $\rightarrow$ disulfide-HMGB1 $\rightarrow$ PEM. BBB disruption $\rightarrow$ peripheral HMGB1 enters CNS $\rightarrow$ microglial amplification.

Chapter ref

ch17: um resolution

Prediction

Total HMGB1 elevated in ME/CFS. Disulfide:reduced ratio increases post-exertion, correlating with PEM. HMGB1 correlates with TLR4 activation and IL-$ 1$ in CSF.

Treatment

HMGB1 Box A antagonists or TLR4 inhibitors candidate.

Limitation

No ME/CFS HMGB1 data. Chronic inflammation role less established than acute. Redox isoform ELISA specialised.

Hypothesis p=0.55S100A8/A9 (Calprotectin) as Microglial Priming Signal and NET Proxy

Evidence

Nunes et al. (2024) demonstrated significant S100-A9 upregulation in ME/CFS plasma (Nunes et al. 2024). (b) S100A8/A9 signals via TLR4/RAGE to activate microglia. (c) Calprotectin correlates with NET burden ($r \geq 0.745$) (Hetland et al. 2022). (d) Serial measurement pre/post CPET could serve as low-cost exertion biomarker.

Citations

(Nunes et al. 2024) (Hetland et al. 2022)

Mechanism

S100A8/A9 from neutrophils $\rightarrow$ TLR4/RAGE on microglia $\rightarrow$ neuroinflammation. Post-CPET calprotectin rise $\rightarrow$ NET activation $\rightarrow$ PEM prediction.

Chapter ref

ch17: um resolution; ch07: innate immunity

Prediction

Calprotectin rises 6-24h post-CPET in ME/CFS, correlates with PEM. Correlates with NET markers (MPO-DNA, H3cit). Highest responders show highest TSPO PET microglial activation.

Treatment

Calprotectin as low-cost exertion biomarker.

Limitation

Single-cohort proteomics. NET correlation from VITT, not ME/CFS. No serial exertion data.

Speculation p=0.55Endothelin-1-Mediated Vascular Tone Dysregulation Underlies Thermoregulatory Failure in ME/CFS

Evidence: Cambras et al. 2023 demonstrated skin temperature circadian rhythm alterations in ME/CFS significantly associated with ET-1 levels (p < 0.01). ET-1 is a potent vasoconstrictor; its association with temperature rhythm stability links vascular tone dysregulation directly to thermoregulatory symptoms. Self-reported symptom severity correlated with both ET-1 and temperature rhythm disruption.
Citations: (Cambras et al. 2023)
Mechanism: ET-1 → vasoconstriction → impaired peripheral blood flow regulation → disrupted skin temperature circadian rhythms → heat/cold intolerance symptoms. Autonomic dysfunction + ET-1 dysregulation = dual-hit thermoregulatory failure.
Chapter ref: ch09: circadian; ch02: autonomic; ch14: autonomic management
Prediction: ME/CFS patients with documented heat intolerance will show elevated ET-1 and disrupted skin temperature rhythm amplitude vs ME/CFS without heat intolerance and vs healthy controls. ET-1 receptor antagonists should improve thermal tolerance.
Treatment: ET-1 receptor antagonists (bosentan, macitentan) as candidate thermoregulatory therapy. Endothelin pathway as biomarker for thermal intolerance severity.
Limitation: Single study; sample size unclear from available abstract; causality not established (ET-1 as marker vs driver). No ET-1 antagonist data in ME/CFS.

Hypothesis p=0.50Distinct GPCR Autoantibody Profiles Discriminate ME/CFS from PCC

Evidence

Azcue et al. (2026, $n=59$ ME/CFS, $n=96$ PCC, $n=36$ HCs) found distinct GPCR AAb profiles: ME/CFS patients had significantly higher $\beta_2$-adrenergic AAb titers ($F_{2,186}=3.15$, $p=0.046$), while PCC patients showed more borderline/pathological M3 muscarinic AAb results. (b) These distinct profiles suggest that the immunological mechanisms driving autoantibody production differ between post-infectious conditions despite shared clinical features. (c) The finding implies that PCC is not simply a larger-sample replication of ME/CFS mechanisms — trigger-specific immunological trajectories may produce condition-specific autoantibody repertoires. (d) Certainty moderated to 0.50: single study, ELISA methodology, sample size moderate, not yet independently replicated.

Citations

(N. Azcue et al. 2026b)

Mechanism

$\beta_2$-adrenergic AAbs (elevated in ME/CFS) may reflect chronic sympathovagal dysregulation in longer-duration illness, while M3 muscarinic AAbs (trending in PCC) may reflect early-stage immune activation in more recent-onset disease. Different viral triggers (SARS-CoV-2 vs unknown/enhant pathogens in classic ME/CFS) may programme distinct B cell repertoires.

Chapter ref

ch07: autoantibodies; ch14d: cross disease

Prediction

Independent replication in separate cohort ($n >= 100$ per condition) using blinded ELISA + confirmatory functional assay will reproduce the ME/CFS > PCC $\beta_2$-AAb and PCC > ME/CFS M3-AAb profile differences with similar effect sizes. Falsified if pooled analysis of 3+ independent cohorts shows no significant profile differences or if functional assays show no activity of differentially elevated AAbs.

Treatment

$\beta_2$ vs M3 AAb ratio could serve as a biomarker for distinguishing post-COVID ME/CFS from non-COVID ME/CFS in clinical settings where trigger history is uncertain. Could also guide therapy selection: $\beta_2$-predominant → $\beta$-blocker trials; M3-predominant → anticholinergic or muscarinic modulation. Research-stage only; no clinical recommendation.

Limitation

Single study, moderate sample size, CellTrend ELISA specificity concerns, no independent replication. Distinct profiles may reflect illness duration confound (ME/CFS longer duration → $\beta_2$ accumulation) rather than distinct pathophysiology. Germain 2025 null in chronic ME/CFS cohort using different platform weakens confidence.

Hypothesis p=0.50$\beta_2$-Adrenergic Autoantibodies Drive Sympathovagal Imbalance in ME/CFS

Evidence

Azcue et al. (2026) found $\beta_2$-adrenergic AAb titers correlated with sympathovagal imbalance in ME/CFS as measured by HRV frequency-domain parameters ($r=0.45$, $p=0.001$, $n=59$). (b) This is the strongest quantitative autonomic-autoantibody correlation in ME/CFS to date. (c) $\beta_2$-adrenergic receptors are expressed in cardiac sinoatrial node, vasculature, and sympathetic ganglia — autoantibody binding at any of these sites could produce sympathovagal imbalance. (d) Functional activity of the antibodies (agonistic vs antagonistic) has not been determined in this cohort.

Citations

(N. Azcue et al. 2026b) (Freitag et al. 2021) (Elisa Stein et al. 2025)

Mechanism

$\beta_2$-adrenergic AAbs $\rightarrow$ receptor binding (agonist or antagonist effect depending on epitope) $\rightarrow$ altered sympathetic signaling to heart and vasculature $\rightarrow$ HRV power shifts between LF and HF bands $\rightarrow$ sympathovagal imbalance measurable as elevated LF/HF ratio or reduced total HRV power.

Chapter ref

ch10: autonomic; ch07: autoantibodies

Prediction

Longitudinal study ($n >= 50$): immunoadsorption → $\beta_2$-AAb reduction → normalization of HRV sympathovagal parameters within 4 weeks post-treatment, with effect size proportional to pre-treatment $\beta_2$-AAb titre. Falsified if $\beta_2$-AAb depletion does not produce HRV normalization despite successful titre reduction.

Treatment

If $\beta_2$-AAbs are causally driving sympathovagal imbalance, autoantibody-targeted therapies (immunoadsorption, BC007, daratumumab) should improve HRV parameters and autonomic symptoms. $\beta_2$-AAb titre could serve as a biomarker for selecting patients for autoantibody-reduction trials and monitoring treatment response.

Limitation

Cross-sectional correlation; causality not established. CellTrend ELISA specificity concerns. Correlation $r=0.45$ is moderate — explains ~20% of HRV variance. Other mechanisms (central autonomic dysfunction, baroreflex impairment, peripheral denervation) likely contribute to remaining variance. Not yet replicated in independent cohort.

Hypothesis p=0.50IgG Subclass Profiling Resolves GPCR Autoantibody Contradictions in ME/CFS

Evidence

Pollak 2014 meta-analysis of NMDAR autoantibodies in schizophrenia: 7.98% positive any Ig class, only 1.46% IgG (Pollak et al. 2014). (b) Schou 2016 (n=925): 11.6% anti-neuronal Ab overall, only 0.5% NMDAR IgG (Schou et al. 2016). (c) Hartwig 2020: ME/CFS IgG fails to activate beta2-AdR in functional assay (Hartwig et al. 2020). (d) The IgG subclass paradox: total IgG autoantibodies are often non-pathogenic; the pathogenic fraction may be restricted to IgG1/IgG3 (complement-fixing, high FcgammaR affinity) while IgG4 (non-classical, Fab-arm exchange) may be protective or epiphenomenonal. (e) GPCR ELISA studies (Azcue 2026, Wirth 2021) measure total IgG — mixing pathogenic and non-pathogenic subclasses, diluting the signal. (f) If ME/CFS GPCR AAbs are predominantly IgG4, ELISA positivity without functional pathogenicity is expected; if IgG1/IgG3, pathogenicity is more likely.

Citations

(Pollak et al. 2014) (Schou et al. 2016) (Hartwig et al. 2020) (N. Azcue et al. 2026b)

Mechanism

GPCR AAb subclass profiling (IgG1-4) will reveal that the apparent contradiction between CellTrend ELISA positivity and Germain REAP null is partly explained by different IgG subclass detection. Hypothesis: ELISA detects IgG4-dominated response (conformational epitopes, non-pathogenic); REAP detects IgG1/IgG3 (linear epitopes, potentially pathogenic).

Chapter ref

ch14d: igg subclass profiling; ch07: autoantibodies

Prediction

IgG1/IgG3 subclass titers correlate more strongly with autonomic symptom severity than total IgG; IgG4 anti-GPCR titers negatively correlate with severity; IgG1/IgG4 ratio discriminates immunoadsorption responders from non-responders. Falsified if IgG subclass profiling does not outperform total IgG in predicting severity or treatment response in a cohort of n ≥ 100 ME/CFS patients.

Treatment

IgG subclass profiling prior to autoantibody-targeted therapy (immunoadsorption, BC007) — IgG1/IgG3-predominant patients selected for treatment, IgG4-predominant patients deferred.

Limitation

No ME/CFS GPCR IgG subclass data. Cross-disease analogy from schizophrenia subclass prevalence. Hartwig 2020 ME/CFS functional null consistent with IgG4 dominance but not tested.

Hypothesis p=0.45SPM Deficiency as Chronicity Switch in ME/CFS

Evidence

Engert et al. (2026) propose sleep disturbance dysregulates SPM biosynthesis (resolvins, protectins, maresins) in Long COVID, producing failed resolution rather than excessive inflammation (Engert et al. 2026). (b) Rauf et al. (2026) characterize PASC as a disorder of impaired innate immune resolution with persistent TLR/RIG-I/NLR/cGAS-STING signaling (M. Rauf, Naveed, and Asghar 2026). (c) Gracia Aznar et al. (2024) showed SPM-enriched marine oil improved resolution markers in a 12-week open-label PCS trial (Gracia Aznar et al. 2024). (d) SPMs have not been measured in ME/CFS plasma or CSF. (e) Cholinergic anti-inflammatory pathway (vagal alpha7-nAChR) stimulates resolvin production, linking reduced HRV in ME/CFS to resolution deficit.

Citations

(Engert et al. 2026) (Serhan, Libreros, and Nshimiyimana 2022) (M. Rauf, Naveed, and Asghar 2026) (Gracia Aznar et al. 2024)

Mechanism

SPM deficiency $\rightarrow$ failed resolution $\rightarrow$ every trigger converts to sustained event. Vagal tone reduction $\rightarrow$ impaired SPM synthesis $\rightarrow$ compounds resolution failure.

Chapter ref

ch17: um resolution

Prediction

Targeted SPM lipidomics (RvD1-6, RvE1-3, LXA4, MaR1, PD1) in ME/CFS plasma vs controls pre/post CPET: lower baseline, blunted post-exertion rise, correlation with PEM duration.

Treatment

SPM supplementation or vagal-SPM enhancement (tVNS) candidate.

Limitation

No ME/CFS SPM data. Specialised LC-MS/MS required. One open-label PCS trial only.

Hypothesis p=0.45Schizophrenia Autoantibody Discovery Arc as a Model for ME/CFS

Evidence: Schizophrenia autoantibody trajectory (Bartley & Ross 2020) as cross-disease analogy for ME/CFS autoantibody subgroup discovery. Nemani 2026 (preprint): 2× autoantibody burden in schizophrenia via REAP. Dalmau 2007: anti-NMDAR encephalitis as treatable autoimmune psychosis. Key disanalogies: IA-PACS-CFS was autoantibody-enriched yet null (challenges simple selection narrative); Germain 2025 REAP in ME/CFS found null (may reflect domain-fragment limitation, unresolved). Cross-disease analogy, not direct evidence. Certainty 0.45.
Citations: (Bartley and Ross 2020) (Nemani et al. 2026) (Dalmau et al. 2008)
Mechanism: Cross-disease analogy: unbiased screening reveals hidden autoantibody subgroups.
Chapter ref: ch14d: schizophrenia mecfs autoantibody parallel
Prediction: REAP screening of ME/CFS plasma will identify autoantibody targets beyond GPCR panels. Falsified if total burden equivalent to controls.
Treatment: Unbiased screening highest-yield experiment.
Limitation: Cross-disease analogy; no ME/CFS data.

Speculation p=0.45CRPS GPCR Autoantibody Parallel to ME/CFS Autonomic Dysfunction

Evidence

Blaes et al. (2011) demonstrated functionally active $\beta_2$-adrenergic and M2 muscarinic autoantibodies with agonistic properties in CRPS using cardiomyocyte bioassays. (b) CRPS shares small fiber neuropathy, autonomic dysregulation, and hyperalgesia with ME/CFS. (c) Key difference: CRPS AAbs are functionally validated agonistic; ME/CFS AAbs are ELISA-detected with undetermined functional status. (d) CRPS proves GPCR AAbs can cause autonomic dysfunction in humans (existence proof) but does not directly validate ME/CFS AAb pathogenicity — different functional class, different assay methodology for pathogenicity demonstration. Certainty 0.55→0.45 after adversarial review addressing “natural positive control” overstatement.

Citations

(Blaes, Wallukat, et al. 2011) (N. Azcue et al. 2026b)

Mechanism

CRPS → functionally validated GPCR AAb pathogenicity → ME/CFS parallel possible but unproven due to divergent functional profiles (CRPS agonistic vs ME/CFS unknown) and different detection platforms. Immunoadsorption benefit in both is consistent with shared GPCR-AAb pathology OR non-specific immune benefit.

Chapter ref

ch14d: crps gpcr parallel; ch07: autoantibodies

Prediction

Functional GPCR AAb assays (cardiomyocyte bioassays, receptor internalization) on ME/CFS sera will demonstrate a distinct functional profile from CRPS (desensitization/antagonism vs agonism). Falsified if ME/CFS sera show identical functional profile to CRPS.

Treatment

If ME/CFS GPCR AAbs are functionally validated, therapeutic strategies from CRPS (immunoadsorption, beta-blockade) transfer. If distinct, ME/CFS-specific strategies (receptor resensitization, Fc$\gamma$R blockade) required.

Limitation

CRPS n=20; indirect comparison to ME/CFS via different assay platforms. No head-to-head functional comparison of CRPS vs ME/CFS sera. Opposite functional effects weaken rather than strengthen the direct parallel.

Speculation p=0.45ME/CFS Autoantibody Subgroup Discovery Trajectory Prediction

Evidence

If the schizophrenia trajectory is a model for ME/CFS: (1) unbiased proteome-wide screening (REAP) will identify novel autoantibody targets enriched in a subset of ME/CFS patients; (2) autoantibody-positive subgroup will show preferential immunomodulatory therapy response; (3) initial discovery from infection-triggered cohort with clinical autoimmune features. (b) Germain 2025 null may reflect either genuine absence or REAP individual-domain limitation for conformational epitopes — schizophrenia’s decades of negative targeted screening before REAP discovery suggests option (b) cannot be excluded. Certainty 0.40.

Citations

(Germain et al. 2025) (Nemani et al. 2026) (Bartley and Ross 2020)

Mechanism

Unbiased screening likely to reveal autoantibody targets missed by GPCR ELISA; Germain null is not the final word unless confirmed by complementary platforms using full-length native proteins.

Chapter ref

ch14d: schizophrenia trajectory mecfs

Prediction

Head-to-head comparison of three platforms (CellTrend GPCR ELISA, REAP with full-length native protein libraries, multi-tissue Western blot) in same ME/CFS cohort (n≥100) will identify different but partially overlapping signatures — unbiased platforms detect targets missed by GPCR ELISA alone. Falsified if all three platforms converge on equivalent null.

Treatment

Multi-platform autoantibody screening strategy recommended; single-platform nulls should not be accepted as definitive.

Limitation

Zero ME/CFS studies using proteome-wide unbiased screening. Cross-disease prediction only.

Hypothesis p=0.40GPCR Autoantibody-Based Autonomic Phenotyping Defines Treatable ME/CFS Subtypes

Evidence

Azcue et al. (2026) provides the first study combining GPCR AAb measurement ($\beta_2$, M1, M3, M4) with comprehensive autonomic (HRV, tilt-table, COMPASS-31, hemodynamics) and cognitive (7 domains) testing in the same ME/CFS patients ($n=59$). (b) Proposed four-subtype taxonomy: $\beta_2$-dominant (reduced HRV, POTS → beta-blocker/immunoadsorption candidates), M3-dominant (orthostatic intolerance → tVNS candidates), M1/M4-low-cognitive (impaired cognition → cognitive remediation candidates), AAb-negative (alternative pathophysiology). (c) Subtypes are provisional — constructed from single dataset without formal cluster analysis. (d) No treatment-response data exist for any stratified indication; Stein 2025/Fluge 2025 enrolled without subtype testing. Certainty 0.40 (from 0.50 after adversarial review).

Citations

(N. Azcue et al. 2026b) (Freitag et al. 2021) (Elisa Stein et al. 2025)

Mechanism

AAb profiling + autonomic/cognitive phenotyping → biologically distinct endotypes → differential therapeutic targeting → improved response rates. Untested in any trial.

Chapter ref

ch07: gpcr aab autonomic phenotyping; ch10: hrv

Prediction

Prospective stratified trial ($n >= 150$): AAb-matched arms (e.g., $\beta_2$-dominant → immunoadsorption) show higher response rates than mismatched arms ($\beta_2$-dominant → tVNS). Falsified if matching does not improve over unstratified treatment.

Treatment

Precision medicine strategy: select patient subpopulation most likely to respond to each intervention. Could reduce trial sample size requirements by enriching for responders. Research-stage only; no clinical recommendation.

Limitation

Single GPCR AAb dataset ($n=59$); subtypes constructed without formal clustering; no RCT testing; Germain 2025 null unsettles platform selection; Stein/Fluge trial data do not test stratified vs unselected response.

Speculation p=0.40The Many Schizophrenias Lesson for ME/CFS Subtyping

Evidence: Kraepelin and Bleuler concluded schizophrenia is a group of diseases — we should speak of schizophrenias in the plural. The same diagnostic heterogeneity may mask treatable subgroups in ME/CFS. Autoantibody-based subgrouping controversial but may prove as fruitful as in schizophrenia. Certainty 0.40.
Citations: (Bartley and Ross 2020)
Mechanism: Diagnostic heterogeneity masks subgroups; cost of pursuing single unifying models is delayed treatment discovery; solution requires biological subgrouping.
Chapter ref: ch14d: many mecfss lesson
Prediction: Four autoantibody-defined subgroups show non-equivalent immunotherapy response (interaction p < 0.05); double-negative subgroup shows no response (effect size < 0.2). Falsified if interaction non-significant or double-negative shows effect size≥0.3.
Treatment: Subgroup stratification in immunotherapy trials; autoantibody profiling standard.
Limitation: Cross-disease analogy only; no ME/CFS subgroup-stratified RCT. Well-established schizophrenia precedent.

Speculation p=0.40BBB Disruption and Autoantibody Access as Dual-Hit Feed-Forward Loop in ME/CFS

Evidence

ME/CFS involves BBB dysfunction (Chapter Neurological and Neurocognitive Dysfunction). (b) If ME/CFS autoantibodies are pathogenic, BBB disruption enables their CNS access — autoantibodies can then target BBB antigens themselves, further disrupting barrier integrity. (c) Autoantibodies against brain endothelial antigens are documented in neuropsychiatric SLE, where anti-NR2/NMDAR antibodies cross a compromised BBB (C. Kowal et al. 2004). (d) No study has measured anti-BBB autoantibodies in ME/CFS.

Citations

(C. Kowal et al. 2004)

Mechanism

Infection/inflammation → initial BBB disruption → peripheral autoantibodies enter CNS → some target BBB endothelium → further disruption → more autoantibody CNS access → feed-forward amplification.

Chapter ref

ch14d: bbb autoantibody feedforward; ch08: bbb

Prediction

Anti-BBB endothelial antigen autoantibodies enriched in ME/CFS vs controls; associated with elevated Q_Alb (>7.0); IgG from ME/CFS patients increases endothelial monolayer permeability in vitro. Falsified if anti-BBB AAbs are not significantly elevated or do not correlate with BBB permeability markers.

Treatment

If validated, BBB stabilization (statins, corticosteroids — research-stage) becomes a therapeutic target to break the feed-forward loop.

Limitation

Zero ME/CFS anti-BBB autoantibody data. BBB disruption in ME/CFS is inferred from CSF/serum albumin ratio, not molecularly characterized.

Speculation p=0.40Conformational Epitope Hypothesis Resolves Germain REAP Null in ME/CFS

Evidence

Germain 2025 used REAP (protein microarray) and found no significant autoantibody differences between ME/CFS and controls (Germain et al. 2025). (b) REAP uses recombinantly expressed protein fragments — linear epitopes only. (c) Most GPCR ELISA assays (CellTrend) use full-length, membrane-embedded receptors with native conformation — capturing conformational epitopes. (d) The discrepancy between REAP null and ELISA positivity may reflect that ME/CFS autoantibodies predominantly target conformational epitopes requiring full-length protein in native membrane context — not captured by REAP linear fragments. (e) Schizophrenia parallel: decades of targeted autoantibody negativity resolved only when unbiased full-length protein screens revealed hidden burden.

Citations

(Germain et al. 2025) (Nemani et al. 2026)

Mechanism

If ME/CFS autoantibodies target conformational (3D) epitopes on native GPCRs, REAP using linear protein fragments would systematically miss them. Cell-based ELISA using full-length membrane-embedded receptors would detect them. The REAP null is therefore not a refutation of the GPCR AAb hypothesis — it is a methodological constraint.

Chapter ref

ch14d: conformational epitope germain; ch07: autoantibodies

Prediction

Head-to-head comparison of three platforms (CellTrend GPCR ELISA, REAP, and cell-based functional assay) in same ME/CFS cohort (n >= 100) will show correlation between CellTrend and functional assay (both use native conformation) but not between either and REAP. Falsified if all three platforms converge on equivalent null.

Treatment

Multi-platform autoantibody screening strategy recommended; REAP-only nulls should not be accepted as definitive. Cell-based functional assays should be the gold standard for GPCR AAb detection.

Limitation

Conformational epitope hypothesis is untested in ME/CFS. REAP may capture some conformational epitopes if proteins are properly folded. Platform comparison study has not been conducted.

Speculation p=0.35Controlled Passive Heat Therapy Benefit Despite Heat Intolerance

Evidence: Soejima et al. 2015: Waon far-infrared sauna (60°C, 15 min, 5x/week × 4 weeks, n=10, uncontrolled, unblinded) reported reduced fatigue; cannot distinguish treatment from placebo. Hochecker et al. 2025: whole-body hyperthermia (39°C, n=9, single center, unreplicated) reduced autophagy and improved PBMC mitochondrial respiration (basal +66.60%, ATP +61.41%, spare +112.35%); no clinical outcomes measured. Whether these two observations are causally connected is unknown.
Citations: (Soejima et al. 2015) (Hochecker et al. 2025)
Mechanism: Passive heat → vasodilation → improved tissue perfusion and oxygen delivery → reduced hypoxia-induced autophagy + enhanced mitochondrial respiration (in PBMCs only — extrapolation to thermoeffector cells untested).
Chapter ref: ch14: controlled heat paradox; ch17: heat hsat2 caution
Prediction: Blinded sham-controlled RCT (n ≥ 30): Waon therapy vs thermoneutral rest → significant improvement in fatigue and mitochondrial respiration with PEM incidence not exceeding control. Refuted if blinded design eliminates signal seen in open-label studies.
Treatment: If confirmed: medically supervised heat therapy protocol for selected ME/CFS patients who pass heat tolerance screening in a clinical trial. Until confirmed: research-stage only; NOT a clinical recommendation.
Limitation: Two small uncontrolled pilots only (n=9, n=10); clinical benefit unestablished; PBMC findings don’t demonstrate whole-body thermoregulatory improvement; HSAT2 risk in susceptible patients uncharacterized. Not replicated.

Speculation p=0.35Muscarinic Autoantibodies Positively Correlate with Memory in ME/CFS

Evidence

Azcue et al. (2026) found M1, M3, and M4 muscarinic AAb titers positively correlated with verbal and working memory performance in ME/CFS. (b) Counterintuitive direction: higher autoantibodies associated with better cognition. (c) Possible explanations: partial agonism compensating for low acetylcholine tone, compensatory receptor upregulation tracking antibody production, or ELISA artifacts. (d) Without functional validation, this remains a statistical observation only.

Citations

(N. Azcue et al. 2026b)

Mechanism

M1/M3/M4 receptor autoantibodies → partial agonism → weak compensatory cholinergic stimulation → improved memory encoding and working memory. Alternatively: cognitive impairment → cholinergic compensatory upregulation → more receptor targets for autoantibody binding → correlation without causation.

Chapter ref

ch08: muscarinic cognition; ch07: autoantibodies

Prediction

Functional calcium flux or impedance assays on M1/M3/M4-expressing cell lines with purified ME/CFS IgG will demonstrate agonistic signaling (if partial agonism correct), antagonistic signaling (if pathogenic but correlation spurious), or no effect (if ELISA artifact). Falsified if functional assays show no receptor activity despite positive ELISA titers.

Treatment

If muscarinic AAbs are compensatory partial agonists, their depletion (immunoadsorption) could transiently worsen cognition — a clinically important warning for autoantibody-targeted trials. Monitoring verbal/working memory pre/post immunoadsorption essential.

Limitation

Single study, $n=59$, not replicated. Counterintuitive direction. CellTrend ELISA specificity concerns. No functional validation. Positive correlation could be statistical artifact — requires independent replication with functional confirmation before any mechanistic interpretation.

Speculation p=0.35Early Autoantibody Intervention Within Reversible Therapeutic Window

Evidence

Autoantibody pathogenicity may be time-dependent: early in the disease course, autoantibody-driven pathology may be reversible; chronic exposure may produce irreversible tissue damage, synaptic loss, or epigenetic modifications that self-sustain even after autoantibody removal. (b) Schizophrenia autoantibody trajectory supports time-dependent pathogenicity: early-stage anti-NMDAR encephalitis responds to immunotherapy; chronic schizophrenia with NMDAR antibodies shows variable response (Bartley and Ross 2020). (c) In ME/CFS, immunoadsorption trials (Stein 2025, Scheibenbogen 2018) show response in some but not all patients — duration of illness may be a response predictor. (d) No study has stratified immunoadsorption response by illness duration in ME/CFS.

Citations

(Bartley and Ross 2020) (E. Stein et al. 2025) (Scheibenbogen et al. 2018b)

Mechanism

Autoantibody-targeted therapy effective only within a reversible therapeutic window — after chronicity exceeds a threshold (tau_epi), tissue damage is self-sustaining via epigenetic or structural changes. Illness duration predicts immunoadsorption response.

Chapter ref

ch14d: autoantibody therapeutic window; ch07: autoantibodies

Prediction

Illness duration stratifies immunoadsorption response: patients treated within 3 years of onset show =50% improvement; patients treated after >=10 years show 20% improvement. Falsified if no response-duration gradient exists in pooled immunoadsorption trial data.

Treatment

If validated, early autoantibody screening and intervention become urgent — the therapeutic window may close within years. Research-stage.

Limitation

No prospective immunoadsorption results stratified by illness duration. Retrospective analysis of Stein 2025 and Scheibenbogen 2018 data could test this. Cross-disease analogy only.

Speculation p=0.30ER Stress / UPR as Feed-Forward Inflammatory Mechanism in ME/CFS

Evidence

Kawano et al. (2023) showed ER proteostasis dysfunction in peripheral tissues regulates sleep via UPR signaling (Kawano et al. 2023). (b) Chronic UPR activation drives inflammation via IRE1alpha-XBP1 (IL-6, TNF-alpha), PERK-eIF2alpha (NF-kappaB), ATF6 (complement). (c) UPR provides feed-forward mechanism linking protein-folding disturbance to sustained inflammation without ongoing antigenic stimulation. (d) No study has measured UPR activation markers in ME/CFS.

Citations

(Kawano et al. 2023)

Mechanism

Stress $\rightarrow$ ER misfolding $\rightarrow$ UPR $\rightarrow$ IRE1alpha/PERK/ATF6 $\rightarrow$ cytokines $\rightarrow$ more stress. UPR $\rightarrow$ sleep disruption $\rightarrow$ glymphatic impairment $\rightarrow$ metabolite accumulation $\rightarrow$ more UPR.

Chapter ref

ch17: um resolution

Prediction

Phospho-PERK, spliced XBP1, nuclear ATF6 elevated in ME/CFS PBMCs at rest and post-CPET. UPR markers correlate with fatigue and sleep disruption.

Treatment

IRE1alpha inhibitors (MKC8866) or chemical chaperones (TUDCA, 4-PBA) research-stage.

Limitation

No ME/CFS UPR data. Kawano in C. elegans, mammalian pending.

Speculation p=0.30Contrast Hydrotherapy for Vasomotor Training with UPR Hormesis and SPM Induction

Evidence

Contrast hydrotherapy (warm 38–40°C alternating with cool 15–20°C) operates through three complementary mechanisms: vasomotor training via repeated vasodilation-constriction cycles, UPR hormesis via heat-induced HSP70 upregulation (Hochecker et al. 2025), and TRPV1/TRPA1-mediated SPM induction from heat→cold transitions. (b) Hochecker 2025 demonstrated hyperthermia improves PBMC mitochondrial respiration in ME/CFS. (c) No ME/CFS contrast hydrotherapy data exist.

Citations

(Hochecker et al. 2025)

Mechanism

Heat → HSP70/UPR hormesis + cold → FGF21 anti-inflammatory + heat→cold transition → TRPV1/TRPA1 → SPM release. Combined vasomotor + UPR + resolution effects from single protocol.

Chapter ref

ch17: contrast hydrotherapy

Prediction

12-week contrast hydrotherapy vs thermoneutral control increases cutaneous perfusion range by >30%, PBMC HSP70 by ≥20%, plasma FGF21 by ≥30%, reduces IL-6 by ≥15%, and improves SF-36 PF by ≥5 points. Falsified if any primary endpoint not met.

Treatment

Accessible, low-cost adjunct. Contraindicated in severe POTS (orthostatic intolerance), severe temperature dysregulation, bedbound patients. Requires graduated introduction.

Limitation

No ME/CFS data. Extrapolated from sports medicine vasomotor conditioning, general HSP70/sauna literature, and TRPV1/TRPA1-SPM biology.

Speculation p=0.25Intravenous Albumin for Triple-Mechanism DAMP Clearance and Iron Buffering

Evidence

Intravenous albumin infusion (25% albumin, 100 mL weekly × 4) binds free iron (reducing Fenton chemistry-driven ROS and ferroptosis). (b) Albumin directly binds and neutralizes extracellular HMGB1, the central DAMP implicated in PEM amplification (Ibrahim, Wasim, and Rahman 2026). (c) Albumin’s free cysteine (Cys34) is a major plasma thiol reservoir with radical-scavenging antioxidant activity. (d) Three complementary mechanisms — iron buffering, DAMP neutralization, antioxidant activity — from a single well-established intervention. (e) No ME/CFS data exist.

Citations

(Ibrahim, Wasim, and Rahman 2026)

Mechanism

Albumin infusion → iron buffering + HMGB1 sequestration + thiol antioxidant → breaks ferroptosis-DAMP-oxidative stress loop.

Chapter ref

ch18: albumin damp iron clearance

Prediction

4 weekly infusions reduce serum free iron and HMGB1 by ≥25%, isoprostanes by ≥20%, and improve SF-36 PF by ≥5 points in pre/post pilot. Falsified if free iron or HMGB1 do not decrease or fatigue does not improve.

Treatment

Research-stage only. Albumin is FDA-approved, widely available; pilot study (n=10, pre/post) feasible.

Limitation

Zero ME/CFS data. Volume expansion may worsen POTS. Contraindicated in CHF, severe anemia.

Speculation p=0.20Salivary Metabolomic Fingerprint of Chronic Unrefreshing Sleep in ME/CFS

Evidence: Scholz et al. (2026, n=20 healthy males, cross-over RCT) demonstrated that 24h acute sleep deprivation produces a detectable salivary metabolic fingerprint (94% classification accuracy, 12 features, LC-HRMS) but four nights of chronic sleep restriction to 6h produced no exploitable metabolic changes — the primary experimental constraint. ME/CFS unrefreshing sleep is chronic (months to decades); the Scholz chronic restriction null suggests homeostatic adaptation may render peripheral metabolic signatures undetectable. Oishi et al. (2025, n=100, PSQI-defined) found 13 metabolites altered in chronic poor sleep (2-hydroxybutyrate 36% higher; 86.6% classification) but is cross-sectional, self-report-based, and derives from general population without ME/CFS metabolic derangements — supportive but non-definitive. Maksoud et al. (2021, systematic review, 20 studies, n≈1,000) confirmed 91–100% unrefreshing sleep prevalence with near-normal PSG architecture. No direct ME/CFS salivary metabolomics data.
Citations: (Scholz et al. 2026) (Oishi et al. 2025) (Maksoud et al. 2021)
Mechanism: Primary constraint from Scholz chronic null: ME/CFS unrefreshing sleep (months to years) may produce no peripheral metabolic signature due to homeostatic adaptation. Oishi chronic poor-sleep finding suggests chronic signals can exist but is methodologically limited (PSQI self-report, no objective sleep). Alternative: peripheral signature absent but sleep pathology real (CNS orexin/glymphatic dysfunction) — requires independent falsifiable predictions, not just null fallback.
Chapter ref: ch20: saliva sleep metabolomics; ch02: sleep
Prediction: ME/CFS salivary metabolomic profile will differ from healthy rested and acute deprivation controls, and will most closely resemble the Oishi chronic poor-sleep profile if peripheral detectable. Falsified if ME/CFS profile is indistinguishable from rested controls — does not automatically confirm CNS model unless CNS model has independent positive predictions (e.g., orexin levels correlate with unrefreshing sleep severity).
Treatment: Non-invasive, at-home saliva collection for sleep quality monitoring. Research-stage only; clinical utility requires validation of single-timepoint detectability before time-series or composite indices.
Limitation: All evidence from healthy populations; no ME/CFS data. Scholz n=20 all-male; Oishi cross-sectional, self-report sleep quality. No replication in independent lab for Scholz panel. Scholz chronic null is most directly relevant constraint and may predict null ME/CFS outcome.

Speculation p=0.20ADHD and ME/CFS as Same-Root Etiology — Inflammation-Driven Energy Failure

Evidence

ADHD and ME/CFS share all known metabolic disturbances: mitochondrial OXPHOS impairment (cybrid evidence (Verma et al. 2016); PBMC spare respiratory capacity reduction in ME/CFS), neuroinflammatory-dopaminergic co-localisation (Yokokura 2021 dual-tracer PET (Yokokura et al. 2021); Walitt 2024 CSF catecholamine reduction in ME/CFS), prefrontal cerebral hypoperfusion (Berthier 2025 systematic review (Berthier et al. 2025)), BH4/GCH1 bottleneck (Williams 2025 case series (Williams et al. 2025)), and overlapping mtDNA haplogroup effects (haplogroup U protective in ADHD (Chang et al. 2020), symptom-modifying in ME/CFS). (b) Convergent pharmacology: 77.1% of ME/CFS patients report stimulant benefit for brain fog (Eckey et al. 2025), and both conditions respond to dopamine-norepinephrine reuptake inhibition. (c) Epidemiological: 29.7% of adult CFS patients had childhood ADHD (Sáez-Francàs et al. 2012); ADHD traits predict 2× fatigue risk (Quadt et al. 2024) with IL-6 mediation. (d) The unifying model: both conditions reflect the same mitochondrial energy failure, differing in tissue compartment affected (CNS-limited in ADHD, systemic in ME/CFS) and temporal profile (trait-like in ADHD, state-like in ME/CFS). The brain’s high energy demand makes it the first system to decompensate as mitochondrial ATP output declines — ADHD cognitive symptoms should precede systemic ME/CFS in patients with converging energy deficits.

Citations

(Yokokura et al. 2021) (Berthier et al. 2025) (Williams et al. 2025) (Verma et al. 2016) (Almutairi et al. 2024) (Chang et al. 2020) (Fanet et al. 2021) (Quadt et al. 2024) (Sáez-Francàs et al. 2012) (Eckey et al. 2025)

Mechanism

Mitochondrial energy failure → CNS energy deficit (ADHD phenotype) when compartmentalised; → systemic energy deficit (ME/CFS phenotype) when generalised. The same root process determines which threshold is crossed: CNS $R_\text{crit}$ is lower (higher vulnerability), explaining why ADHD-like cognitive symptoms precede ME/CFS in prospective cohorts. Tissue specificity may be determined by mtDNA haplogroup, tissue-specific heteroplasmy, or differential inflammatory exposure.

Chapter ref

ch14d: adhd mecfs same root; ch14d: architecture c metabolic reserve

Prediction

PBMC spare respiratory capacity (Seahorse assay) will form a gradient across groups: controls > ADHD-only > ME/CFS-only > ADHD+ME/CFS. Falsified if ADHD-only patients show normal PBMC mitochondrial function indistinguishable from controls.

Treatment

If validated, ADHD and ME/CFS would not be separate comorbidities but the same disease in different tissue compartments — shifting clinical practice from treating two conditions to targeting the shared mitochondrial root. Research-stage only.

Limitation

No head-to-head metabolic comparison of ADHD vs ME/CFS has ever been performed. All evidence is cross-condition inference. The compartment-specific model is untestable with current data. ADHD mitochondrial evidence is mostly preclinical. The 30% ADHD-ME/CFS comorbidity is consistent with predisposition, same-root, or diagnostic confusion — cannot distinguish without direct metabolic phenotyping.

Open Question p=n/aET-1 as Thermoregulatory Impairment Biomarker in ME/CFS

Evidence: Cambras et al. 2023 demonstrated that endothelial-1 is associated with skin temperature circadian rhythm disruption and symptom severity. ET-1 measurement is clinically available (ELISA). Could ET-1 levels and/or temperature rhythm monitoring serve as objective biomarkers for thermoregulatory impairment severity and treatment response in ME/CFS?
Citations: (Cambras et al. 2023)
Mechanism: ET-1 → serial measurement + skin temperature ambulatory monitoring → thermoregulatory impairment index → prediction of heat intolerance severity + therapeutic response monitoring.
Chapter ref: ch09: circadian; ch20: biomarker overview
Prediction: ET-1 levels will correlate with heat intolerance severity (thermal comfort questionnaire) and predict PEM risk during thermal stress. Falsified if ET-1 does not correlate with thermal symptom severity in adequately powered study (n ≥ 40).
Treatment: ET-1 + temperature monitoring as objective measure of thermoregulatory function for clinical assessment and treatment response tracking.
Limitation: Single study; sample size unclear; ET-1 as marker vs mediator not established. No serial ET-1 data in ME/CFS. Commercial ELISAs for ET-1 have variable precision.

Open Question p=n/aWaon Therapy / Passive Hyperthermia as CDR and Autophagy Reset in ME/CFS

Evidence: Hochecker et al. 2025 demonstrated WBH acutely reduces autophagy markers and improves mitochondrial respiration in ME/CFS PBMCs. Soejima et al. 2015 showed clinical benefit with Waon therapy. Would a protocol of repeated mild hyperthermia sessions over weeks produce sustained metabolic improvement and quality-of-life benefit? What is the optimal temperature, duration, frequency, and patient selection? Can heat-tolerant patients be identified prospectively?
Citations: (Hochecker et al. 2025) (Soejima et al. 2015)
Mechanism: Mild hyperthermia → improved perfusion → reduced hypoxia → autophagy normalization + mitochondrial respiratory improvement → accumulated cellular benefit over repeated sessions → sustained symptom improvement. Requires patient stratification by thermal tolerance.
Chapter ref: ch17: hyperthermia protocol; ch17: heat hsat2 caution
Prediction: Dose-finding trial (n=40, 4-arm): Waon at 3 temperature levels (45°C, 52°C, 60°C) + thermoneutral control → optimal temperature balancing mitochondrial benefit vs intolerance. Responder analysis: pre-treatment ET-1, HRV, and HSAT2 levels predict thermal therapy response.
Treatment: If confirmed: medically supervised hyperthermia as prescribed treatment for selected patients. If null: abandon thermal therapy in ME/CFS. Until confirmed: research-stage only with stringent safety monitoring.
Limitation: Small uncontrolled pilots only. Heat intolerance may make most patients ineligible. HSAT2 risk in susceptible patients uncharacterized. Core temperature of 39°C may be too high for severe ME/CFS. Optimal parameters unknown.

Speculation p=0.25Pharmacodiagnostic Negative-Control Class — Hypothesis Falsification by Drug Failure

Evidence: Fluge 2019 Phase III RCT (n=151, (Ø. Fluge et al. 2019)) found rituximab no better than placebo — a null result that constrains the B-cell-dependent GPCR-AAb hypothesis. Immunoadsorption response heterogeneity ((Tölle et al. 2020), (E. Stein et al. 2025)) reveals negative-control boundary: IA removes only circulating IgG1/IgG2/IgG4, not tissue-bound IgG, IgG3, or IgA/IgM. The formal negative-control class concept does not exist in any published biomedical literature — this is a novel contribution.
Citations: (Ø. Fluge et al. 2019) (Tölle et al. 2020) (E. Stein et al. 2025) (Scheibenbogen et al. 2018a) (Øystein Fluge et al. 2011)
Mechanism: A medication is a negative-control for a hypothesis when the hypothesis predicts the drug must work (specific, directional, cascade-intercepted node), the drug’s mechanism is narrow, and the null result is obtained under adequate parameters. Under these conditions, a null result falsifies the hypothesis at the mechanism level, not just eliminates it for one patient. Class I (source-level, e.g., rituximab → CD20+ B cells) carries higher evidentiary weight than Class II (pathway-level, e.g., IA → circulating IgG only). The negative-control ladder optimizes trial sequencing for population-level mechanism falsification, complementing the null ladder’s patient-level hypothesis elimination.
Chapter ref: ch34: negative control class; ch34: negative control principle; ch34: negative control taxonomy; ch34: negative control ladder; ch34: negative control decision heuristic; ch34: negative control asymmetric evidence
Prediction: Retrospective audit of existing ME/CFS drug trial results: classify each negative result by the decision heuristic (5-condition checklist) → estimate the proportion of published nulls that qualify as genuine negative-control results vs. underdetermined failures. Falsified if negative-control classification produces zero convergent constraint patterns across independently studied drug—mechanism pairs.
Treatment: The framework reframes treatment failures as diagnostic data — not therapeutic recommendations. Negative-control classification informs which drug trials are most informative for mechanism-level inference, and which nulls should be treated as evidence against a mechanism vs. evidence of inadequate trial parameters.
Limitation: Novel conceptual framework. No validation against a known-false mechanism (impossible to obtain — no ethics committee would approve a trial targeting a known-false mechanism, and no patient would volunteer). Inference chain from null response to hypothesis falsification adds uncertainty scaled by drug specificity, compartment coverage, and alternative-explanation count. Classification is human-judgment-driven, not algorithmic — the 5-condition heuristic requires pharmacological and clinical knowledge to apply correctly.

Open Question p=0.25TRPV1-Thermal Autonomic Stress Test as At-Home Diagnostic Probe

Evidence: Nelson 2021 (n=16 ME/CFS): HRR impaired post-exercise (HRR ≤34.5 bpm discriminatory, ROC AUC 74.8%). Ruijgt 2026 (n=121 LC): wearable HRV suppressed 24h post-exercise, predicts PEM threshold. De Becker 1998: cold pressor reveals sympathetic overactivity in CFS.
Citations: (M. J. Nelson et al. 2021) (Ruijgt et al. 2026) (De Becker et al. 1998)
Mechanism: Post-thermal autonomic recovery time (T90 — time to 90% baseline HR after standardized sauna or cold-water challenge) may serve as at-home autonomic stress test for ME/CFS. TRPV1 sensory neurons → sympathetic outflow → HR/BP response; parasympathetic reactivation during recovery reflects autonomic integrity. Thermal challenge avoids exercise confounds (muscle damage, metabolites). Testable at home with pulse oximeter + thermometer.
Chapter ref: ch15: trpv1 thermal autonomic stress test; ch47: trpv1 thermal autonomic stress test
Prediction: Prospective cohort (n=40 ME/CFS, n=20 healthy): post-thermal T90 significantly prolonged in ME/CFS vs controls. Falsified if no between-group difference in recovery slope after controlling for baseline HR.
Treatment: If validated, T90 recovery time serves as low-burden autonomic biomarker. Abnormal result triggers full autonomic testing (tilt table, QSART). Normal result reduces diagnostic uncertainty but does not rule out ME/CFS.
Limitation: No direct TRPV1-thermal-autonomic study in ME/CFS. Nelson/Ruijgt/De Becker provide indirect evidence from exercise, cold pressor, and HRV domains. Thermal challenge dose not calibrated. Home measurement introduces compliance variability.

Speculation p=0.20Cold Pressor Recovery Kinetics as Autonomic Discriminator — Existing Dataset Re-Analysis

Evidence: De Becker 1998 cold pressor study (n=21 CFS, foot immersion 4°C × 90s) measured acute HR/BP response but not recovery kinetics. Wyller 2007 studied thermoregulatory hand cooling (n=15 adolescent CFS). Both datasets contain raw time-series data suitable for re-analysis.
Citations: (De Becker et al. 1998) (Wyller et al. 2007)
Mechanism: Recovery slope (time from challenge end to 90% baseline HR) is the discriminating parameter, not acute response magnitude. If recovery time is prolonged irrespective of acute response → autonomic recovery deficit is independent of provocation magnitude.
Chapter ref: ch15: cold pressor recovery convergence
Prediction: Re-analysis of De Becker 1998 and Wyller 2007 datasets → T90 recovery time significantly prolonged in CFS vs. controls (p < 0.05). Acute HR/BP response magnitude does not predict T90 (r < 0.3).
Treatment: If confirmed, recovery slope becomes the preferred cold-pressor readout. Existing datasets provide free, immediate data. If null, attention shifts to other autonomic challenge modalities.
Limitation: Retrospective re-analysis. Original studies not designed for recovery-slope measurement. Time-series sampling rate may be insufficient for precise T90 estimation. Wyller 2007 studied adolescents — generalizability to adults uncertain.

Speculation p=0.25Thermal Recovery Time as PEM Threshold Predictor

Evidence: Ruijgt 2026 (LC) established HRV→PEM correlation: wearable HRV suppressed 24h post-exercise predicts PEM threshold. Mancini 2026 null on 2-day CPET (n=58 — no Day 1→Day 2 VO2 decline) motivates alternative PEM threshold tests.
Citations: (Ruijgt et al. 2026) (Mancini et al. 2026)
Mechanism: Post-thermal autonomic recovery time (T90) may correlate with PEM threshold measured by next-day actigraphy (r ≥ 0.4, n ≥ 40). Thermal challenge as calibrated, repeatable, non-exercise stressor — no muscle damage, controllable dose, home-achievable.
Chapter ref: ch15: thermal recovery pem threshold
Prediction: Prospective study (n=40): post-thermal T90 correlates with next-day actigraphy step-count decline (r ≥ 0.4). Falsified if r < 0.2 or circadian phase (Williams 1996) explains >50% of T90 variance, making autonomic specificity low.
Treatment: If confirmed, home thermal challenge provides calibrated PEM threshold estimate without exercise. Informs activity pacing. If null (circadian-dominant), thermal challenge not useful for PEM prediction — attention shifts to circadian phase measurement.
Limitation: Thermal challenge dose-response uncalibrated. Correlation with PEM threshold inferred from exercise HRV data, not directly measured. Circadian phase confounding (Williams 1996 thermoregulatory decoupling) requires explicit measurement. No existing thermal-PEM correlation study.

Speculation p=0.25Post-Thermal vs Post-Exercise HRR Congruence — General Autonomic Deficit Test

Evidence: Post-exercise HRR impairment documented in ME/CFS (Nelson 2021, n=16). If the recovery deficit reflects parasympathetic infrastructure damage rather than exercise-specific mechanisms, post-thermal HRR should mirror post-exercise HRR.
Citations: (M. J. Nelson et al. 2021)
Mechanism: Within-subject comparison of post-thermal vs post-exercise HRR. If recovery deficit reflects parasympathetic infrastructure damage rather than exercise-specific mechanisms, post-thermal HRR should mirror post-exercise HRR (within-subject r ≥ 0.5). Distinguishes general autonomic deficit from muscle-damage-driven recovery delay.
Chapter ref: ch15: hrr thermal extension
Prediction: Within-subject crossover (n=30 ME/CFS): post-thermal HRR correlates with post-exercise HRR (r ≥ 0.5). Falsified if r < 0.3 — then HRR deficits are modality-specific and thermal challenge is not a general autonomic probe.
Treatment: If congruence confirmed: thermal HRR serves as exercise-independent autonomic biomarker. If decoupled: exercise HRR reflects muscle-specific damage, not autonomic infrastructure. Each test answers a different question.
Limitation: Small sample (n=16) in Nelson HRR study. No existing within-subject thermal-vs-exercise HRR comparison. Exercise confounds (muscle soreness, metabolic disturbance) may persist into recovery period and influence HRR independently of autonomic status.

18 Exercise Modality and Physical Activity

Speculation p=0.68Hydrostatic Pressure Augments Orthostatic Reserve via Parasympathetic Shift

Evidence: Chest-deep thermoneutral water immersion increases central venous pressure, decreases HR ~10 bpm (vagal activation), decreases peripheral vascular resistance 21–30% in cardiac populations. Post-MI patients fail to utilize hydrostatic preload during upright exercise, suggesting horizontal position + immersion required for benefit.
Citations: (Schmid et al. 2007) (Hanna, Sheldahl, and Tristani 1993)
Mechanism: Hydrostatic pressure → increased CVP → increased preload → increased stroke volume → decreased compensatory sympathetic drive → parasympathetic shift. Most reliable in horizontal positions (swimming, supine floating).
Chapter ref: aquatic hydrostatic
Prediction: Aquatic exercise (thermoneutral 32°C, 10 min) → standing HR reduction ≥5 bpm post-immersion vs. land; increased HF-HRV ≥30 min post; reduced orthostatic symptoms on stand-test 1h post.
Treatment: Aquatic exercise may provide autonomic benefit beyond buoyancy alone. Thermoneutral water and horizontal posture maximize the hydrostatic effect.
Limitation: Testing in cardiac populations, not ME/CFS. ME/CFS autonomic physiology differs from heart failure/MI. Single direct study (Schmid 2007, n=30). Some patients report pool worsening. Not replicated in ME/CFS.

Hypothesis p=0.55Engineered Exosome-Mediated HSP70 mRNA Delivery Reverses Sleep-Deprivation Neuroinflammation — Proof-of-Principle for CNS mRNA Therapy

Evidence: Kang et al. 2026 demonstrated that RVG-targeted exosomes carrying HSP70 mRNA reverse cognitive deficits and hippocampal neuroinflammation in sleep-deprived mice. BBB crossing mechanisms for EVs documented in Ramos-Zaldívar et al. 2022 review of primary data; engineering platform context from Sanadgol et al. 2025 review of brain-targeted nucleic acid delivery. Single preclinical study in mice; not yet replicated; RVG targeting and HSP70 cargo specific to this study; no human or ME/CFS data.
Citations: (Z. Kang et al. 2026)
Mechanism: RVG-Lamp2b exosomes → HSP70 mRNA delivery across BBB → HSP70 translation in CNS cells → reduced TNF-α, IL-6, IL-1β; increased IL-10, BDNF, pCREB → neuroinflammation reversal + synaptic repair.
Chapter ref: engineered exosome bbb mrna
Prediction: ME/CFS iPSC-derived neurons and microglia treated with HSP70@ExoRVG exosomes will show reduced inflammatory cytokine production and improved metabolic function vs untreated cells; ME/CFS CSF EV subpopulations will show cargo profiles distinct from healthy controls.
Treatment: If validated, engineered exosomes could deliver anti-inflammatory/neuroprotective mRNA cargo directly to CNS targets, bypassing the BBB delivery bottleneck. Research-stage only; no human trials exist.
Limitation: Single preclinical study in mice; no human data; no ME/CFS data; exosome manufacturing standardization, scalability, and regulatory pathways do not exist; immunogenicity and repeated dosing safety unknown.

Speculation p=0.55Thermoneutral Water (31–32°C) as Prerequisite for Safe Aquatic Exercise

Evidence: ME/CFS patients exhibit impaired thermoregulation and sympathetic response to temperature stress. Cold water (below 29°C) triggers vasoconstriction and sympathetic activation. Warm water (greater than 35°C) causes vasodilation and potential hypotension in POTS. Thermoneutral avoids both extremes. Schmid 2007: all aquatic testing at 32°C. Cardiac rehab guidelines: 31–33°C.
Citations: (Schmid et al. 2007)
Mechanism: Temperature deviation from thermoneutral → autonomic stress (vasoconstriction or vasodilation) → counteracts hydrostatic benefit. Only thermoneutral water provides pure hemodynamic benefit without thermal autonomic cost.
Chapter ref: ch17: thermoneutral water
Prediction: Crossover: cold (28°C) → increased HR, catecholamines; warm (35°C) → increased lightheadedness, orthostatic symptoms; thermoneutral (32°C) → optimal parasympathetic shift, lowest PEM.
Treatment: Verify pool temperature before entry. If only non-thermoneutral pools available: restrict to 5–8 min sessions. Post-pool warming to prevent chill-induced vasoconstriction.
Limitation: No ME/CFS temperature-comparison data. Individual temperature sensitivity varies. Optimal window may be narrower for some patients. Starting recommendation, not rigid absolute.

Speculation p=0.55Orthostatic-Demand-Based Exercise Modality Classification

Evidence: Five-tier taxonomy based on body position, orthostatic demand, and positional transition frequency. Tier 1: supine isometric/stretching (all severities). Tier 2: constant seated/horizontal with hydrostatic benefit (water rowing, recumbent bike, backstroke, resistance bands). Tier 3: upright constant position (cycling). Tier 4: positional transitions (walking, standard yoga). Tier 5: contraindicated (GET protocols, AT-exceeding).
Citations: (Oka et al. 2014) (Oka, Wakita, and Kimura 2017)
Mechanism: Modality orthostatic demand = f(body position, transition frequency, hydrostatic factor). Matching modality to individual orthostatic tolerance reduces PEM risk.
Chapter ref: ch17: modality classification
Prediction: Patients selecting modalities from matched severity tier → ≥50% lower PEM incidence vs above-tier selection in 12-week observational comparison (N=60).
Treatment: Clinically applicable taxonomy for matching exercise modality to patient severity. Start at matching tier; progress to next tier only after ≥4 weeks tolerance with zero PEM for 2 consecutive weeks.
Limitation: Tier boundaries theoretically derived, not empirically calibrated. Conflates orthostatic demand with fall/intensity risk. No validation study. Individual variation may exceed predicted tier. Classification is hypothesis, not validated clinical tool.

Speculation p=0.55Post-Exercise Horizontal Rest Reduces Delayed PEM

Evidence: Exercise produces blood redistribution from splanchnic circulation to working muscles. In ME/CFS with global hypoperfusion, this may exceed compensatory capacity. Mandatory 5–10 min horizontal rest post-exercise maximizes venous return and accelerates perfusion recovery. Extends Klimas program’s supine-rest concept to all modalities.
Citations: (Ussher 2025)
Mechanism: Post-exercise postural transition from active to horizontal rest → maximized venous return → accelerated splanchnic/cerebral perfusion recovery → reduced sympathetic carryover → lower delayed PEM risk.
Chapter ref: ch17: post exercise horizontal rest
Prediction: Within-subject crossover (4-week phases, N≥20): post-exercise horizontal rest → reduced HR recovery time, reduced orthostatic symptom duration, and PEM incidence OR below 0.5 vs. no-post-exercise-rest phase.
Treatment: Mandatory 5–10 min horizontal rest after every exercise session, independent of subjective recovery. Rest duration needed to meet completion criteria serves as intensity calibration metric for subsequent sessions.
Limitation: Post-exercise rest not isolated as independent intervention variable. Benefit may derive from any rest, not specifically horizontal. Time commitment may reduce adherence. No ME/CFS-specific trial.

Hypothesis p=0.50Constant Body Position as Primary PEM-Safety Criterion for POTS+ME/CFS

Evidence: Constant body position eliminates orthostatic demand fluctuations that drive autonomic compensation. Water immersion decreases HR (vagal activation) while maintaining cardiac output. Recumbent isometric formats are PEM-safe in CFS and feasible in severe ME/CFS. Leeds POTS protocol validates recumbent-to-upright progression.
Citations: (Schmid et al. 2007) (Oka et al. 2014) (Oka, Wakita, and Kimura 2017)
Mechanism: Positional transitions → baroreflex stress → autonomic reserve depletion → PEM threshold reduction. Constant-position activities maintain stable hemodynamics throughout.
Chapter ref: ch17: constant body position
Prediction: Crossover trial: constant-position vs. varying-position exercise at matched intensity → constant-position shows lower PEM (OR below 0.5), lower catecholamines, and shorter recovery time.
Treatment: Prefer constant-position modalities (recumbent bike, seated rowing, backstroke, resistance bands seated) over activities with frequent positional transitions.
Limitation: No RCT directly testing constant-vs-varying position exercise. Individual orthostatic tolerance variability. Cert anchored in POTS physiology; not ME/CFS-validated.

Hypothesis p=0.50Fitness Maintenance as a Distinct Goal from Fitness Improvement in ME/CFS

Evidence: (0.60→0.50: Mancini/Natelson 2026 NIH-funded null replication brings CPET evidence to equipoise — one positive study and one equivalently powered null. Incoming evidence certainty 0.60). Energy envelope theory (Jason 2008) and CPET evidence (contested: Keller 2024 positive vs. Mancini/Natelson 2026 null) demonstrate that ME/CFS patients experience disproportionate physiological burden from exertion. Exercise physiology distinguishes fitness maintenance (preventing loss from baseline) from fitness improvement (building capacity above baseline). In healthy populations these coexist; in ME/CFS they are fundamentally decoupled — any protocol intended to produce adaptation instead produces deterioration. The only achievable goal is fitness maintenance: calibrated movement preventing deconditioning complications without triggering PEM. Note: framework re-anchored from objective VO₂ decline to elevated RPE + energy envelope + GET harms — RPE is a subjective self-report measure and should not be equated with objective metabolic biomarkers.
Citations: (Leonard A. Jason, Muldowney, and Torres-Harding 2008) (Keller et al. 2024) (Mancini et al. 2026) (Braeden T. Charlton et al. 2026a) (Kindlon 2011)
Mechanism: Metabolic dysfunction underlying PEM (2-day CPET: 5–8% declines in VO₂ peak, recovery 13+ days) means exercise produces training de-adaptation, not adaptation. GET produced 51% harm rates because it applied fitness-improvement model to physiology that cannot accommodate it. Fitness must be redefined as functional capacity within the energy envelope — ADL capacity, baseline stability, PEM threshold, deconditioning prevention — not VO₂max or maximal strength.
Chapter ref: ch17: fitness maintenance
Prediction: 12-week RCT: fitness-maintenance-targeted activity (pacing + deconditioning-prevention movement, explicit “stability is success” messaging) vs. standard pacing → equivalent or better functional stability, reduced PEM frequency, reduced exercise-related psychological distress.
Treatment: Explicit expectation-setting at treatment initiation replaces improvement culture with stability-as-success. Reduces goal-behavior mismatch that drives overexertion. Connects to ACT frameworks for living meaningfully within limitation.
Limitation: Conceptual framework; no trial. “Recovery of latent capacity” vs. “acquisition of new capacity” cannot be distinguished in individuals without knowing pre-illness ceiling. Fitness redefinition is semantical — useful for communication but not subject to hypothesis testing. Not yet replicated as structured protocol.

Speculation p=0.50Severity-Stratified Rowing Protocol Improves Tolerability Over Uniform Protocol

Evidence: ME/CFS severity spans mild to very severe. A uniform rowing protocol (same start intensity for all) simultaneously under-stimulates mild patients and over-stresses severe patients. Severity-stratified parameters — modality selection, start intensity, progression speed, duration ceiling — match the intervention to baseline functional capacity. Leeds protocol’s 59 percent community attrition suggests uniform protocols fail across the functional spectrum.
Citations: Consensus severity classification; FUNCAP-27; Bell Disability Scale
Mechanism: Severity → baseline metabolic reserve → maximum tolerable rowing intensity. Uniform protocol → mismatch at both ends of spectrum → dropout from over-stress (severe) and under-stimulus (mild). Stratification → appropriate starting parameters → higher completion rate.
Chapter ref: ch17: severity stratified rowing
Prediction: Stratified vs uniform protocol (n=120, 12 weeks): stratified shows lower PEM in moderate/severe arms, higher ceiling in mild arm. Refuted if no PEM advantage in any tier, or mild arm shows no ceiling advantage.
Treatment: Four-tier table: mild (8-10 spm/3 min/weekly/30 min), moderate (5-8 spm/2 min/biweekly/15 min), severe (isometric primary, rowing 5 spm/1 min/monthly/5 min), very severe (passive ROM, rowing contraindicated). Printable for home logs and clinic charts.
Limitation: Severity bins are consensus, not empirically calibrated for rowing tolerance. Start parameters are reasoned estimates. Severity-to-modality mapping may misclassify. Progression speeds assume linear tolerance accumulation. Zero ME/CFS stratified trial data.

Speculation p=0.50Cross-Disease Fitness-Maintenance Protocols from COPD and Heart Failure Adapt to ME/CFS

Evidence: COPD pulmonary rehabilitation and heart failure exercise programs have explicit maintenance-phase protocols distinct from conditioning phases. Both conditions feature pathophysiological exercise intolerance (ventilatory limitation in COPD, cardiac output limitation in HF). In COPD, maintenance protocols emphasize submaximal interval training + monitoring; in HF, maintenance focuses on symptom-limited steady-state exercise. Both fields have adopted maintenance-as-success framing.
Citations: Puhan 2011 COPD maintenance trial; O’Connor 2009 HF-ACTION; Taylor 2014 Cochrane review of exercise-based cardiac rehab. No ME/CFS-adapted protocol exists.
Mechanism: COPD and HF share with ME/CFS the feature that exercise intolerance is pathophysiological, not behavioral. Both have developed standardized maintenance protocols accepting that capacity-building is not always achievable. ME/CFS can adopt the protocol structure (interval-based, submaximal, monitored, maintenance-framed) while substituting ME/CFS-specific limits (HR below AT, PEM tracking, severity-adjusted intensity).
Chapter ref: ch17: cross disease maintenance
Prediction: ME/CFS patients following COPD-adapted maintenance protocol (submaximal interval, HR-monitored, “maintenance” framed) → equivalent or better 12-month FUNCAP stability with reduced PEM frequency vs. standard pacing, when adapted for ME/CFS severity.
Treatment: Provides structured protocol template where none exists. Reduces ad-hoc pacing decisions. Gives clinicians a named framework (adapted from established fields) to justify maintenance approach. Maintenance framing from respected rehabilitation fields may persuade skeptics.
Limitation: Cross-disease analogy not validated for ME/CFS. COPD/HF mechanisms differ from ME/CFS — transferability unknown. Protocol adaptation requires empiric testing. No ME/CFS-adapted trial exists. Maintenance protocols in COPD/HF still include moderate exertion that may exceed ME/CFS thresholds.

Speculation p=0.45Positioning and Postural Management Prevents Contractures and Pressure Injuries in Bedbound ME/CFS

Evidence: Well-established in ICU nursing, palliative care, and spinal cord injury rehabilitation. Prolonged single-position immobility causes contractures, pressure injuries, dependent edema, and chest wall restriction. Structured repositioning protocols prevent these complications with zero patient metabolic cost.
Citations: ICU nursing standards; palliative care guidelines; extrapolated to ME/CFS by analogy
Mechanism: Every-2-hour repositioning → muscle shortening prevention → contracture prevention. Joint positioning (neutral angles) + pressure relief (mattress, heel protectors) → pressure injury prevention. Position rotation (supine/lateral/semi-recumbent) → dependent edema + chest wall restriction prevention.
Chapter ref: ch17: bedbound positioning
Prediction: Bedbound ME/CFS receiving structured positioning protocol → lower contracture incidence (goniometry at 12 weeks) and lower pressure injury rate vs. unstructured controls; PEM frequency unchanged.
Treatment: Repositioning schedule: every 2h waking, every 3–4h sleep. Joint neutral positioning. Pressure-relieving surfaces. Micromovement (finger wiggles, toe curls) within tolerance at each repositioning. Active PEM → reduce to essential changes only (every 4h).
Limitation: Requires caregiver present — significant access barrier for patients living alone without 24-hour care. Repositioning may trigger autonomic symptoms. No ME/CFS position-management trial exists. Extrapolation from ICU/palliative care; applicability to ME/CFS-specific pathophysiology unverified.

Speculation p=0.40Land-Based Rowing as Tier 2 Safe Modality — Leeds Protocol Precedent, No Hydrostatic Component

Evidence: Land rowing retains seated constant body position and compound upper+lower body movement distribution from water rowing but loses hydrostatic pressure benefit. Gains home accessibility: eliminates pool transport PEM risk. Dallas/Leeds POTS protocol explicitly uses seated rowing as starting modality. Caution: 59 percent community dropout for Dallas protocol in POTS patients (who lack PEM) constrains extrapolation to ME/CFS. Water-resistance machines may offer smoother loading vs. air flywheels — theoretical only. Zero ME/CFS rowing trial data.
Citations: (Fu et al. 2010) (Fu and Levine 2018)
Mechanism: Seated constant position + compound movement + rhythmic reciprocal pattern → low orthostatic demand + reduced local metabolic demand. No hydrostatic preload. Home accessibility eliminates transport energy cost.
Chapter ref: ch17: land rowing
Prediction: Land rowing (home-based, sub-AT) → PEM incidence below 30% in mild-moderate POTS+ME/CFS over 8 weeks; non-inferior to recumbent cycling (margin ≤5%). PEM above 30% refutes hypothesis.
Treatment: Home-based land rowing as a Tier 2 modality. 2 min/session start, min water resistance, progression one parameter at a time. Consider only for patients with adequate equipment budget, technique coaching access, and stable orthostatic tolerance.
Limitation: Zero ME/CFS rowing data. Economic access barrier (€800–1500). Technique errors may skew intensity. 59% POTS community dropout constrains generalizability. Water-vs-air resistance advantages are theoretical only.

Speculation p=0.40Hybrid Rowing-Isometric Protocol Permits Longer Duration Without PEM

Evidence: Alternating rowing (compound, cardiovascular) with isometric yoga (localized, isometric, parasympathetic) within a single session may distribute metabolic stress across tissue compartments, prevent local metabolite accumulation in rowing-specific muscles, and use isometric phases as active recovery that maintains muscle engagement and vagal tone. Total session can extend without PEM because no single metabolic pathway is continuously stressed. Zero hybrid protocol data.
Citations: (Oka et al. 2014)
Mechanism: Rowing → metabolic demand on rowing-specific muscle groups → local metabolite accumulation → ↑ PEM risk. Isometric interlude → different muscle groups → maintained vagal tone → active metabolite clearance → ↓ local accumulation → ↑ total session duration before PEM threshold.
Chapter ref: ch17: hybrid rowing isometric
Prediction: Three-arm RCT (n=60, 8 weeks): hybrid vs rowing-only vs isometric-only, all 15 min/session. Hybrid predicted PEM below 15 percent vs 25-30 percent single-modality. Refuted if hybrid shows no advantage over rowing-only (isometric adds no synergy). Refuted if hybrid worse than rowing-only (active recovery hypothesis contradicted).
Treatment: 15-min session: 5 min rowing → 5 min isometric yoga → 5 min rowing → 5 min supine rest. Progression one parameter at a time. Patient needs: rowing machine + mat/chair. Cognitive load manageable — fixed structure, no real-time decisions.
Limitation: Zero hybrid data. Active recovery in athletes may not translate to ME/CFS metabolic defect. Modality transition (stand from rower to mat) introduces brief orthostatic demand. 5-min isometric segment may be insufficient for clearance. Completely untested in ME/CFS.

Speculation p=0.40Rowing Stroke Rate as Precision PEM-Threshold Calibration Dial

Evidence: Rowing allows incremental intensity adjustment via stroke rate alone — approximately 15–20% power change per stroke/min at competition speeds. At ultra-low stroke rates (5–10 spm as used in the ME/CFS protocol), the relationship may be nonlinear or discontinuous, and day-to-day threshold variability limits calibration validity. The concept extends generic sub-threshold pacing: start low, increase gradually, monitor PEM, roll back on PEM. The rowing-specific parameterization adds a convenient titration metric but does not constitute a novel treatment principle.
Citations: (Kleshnev 2004)
Mechanism: Linear power-stroke rate + incremental titration + PEM monitoring = generic pacing applied to rowing-specific parameter. Precision advantage over other modalities is asserted but undefended.
Chapter ref: ch17: rowing stroke rate dial
Prediction: Patients at calibrated threshold minus 1 spm → will not reliably stay below PEM threshold on days when threshold varies by greater than 15-20% from calibration. PEM incidence below 15% predicted only under the stable-threshold assumption.
Treatment: Individual calibration: start 5 spm/2 min, +1 spm every 2–3 weeks if zero PEM, re-test periodically. Threshold stability assumption is clinically dubious — day-to-day variation may exceed 1 spm step size, rendering calibrated rate unreliable on bad days.
Limitation: Zero ME/CFS titration data. Threshold varies day-to-day. Kleshnev kinetics from competitive rowers at 18-36 spm — relationship at 5-10 spm may not hold. Technique errors introduce nonlinearity. Completely untested in ME/CFS.

Speculation p=0.40Resistance Bands Produce Lower HR Than Equivalent-Load Free Weights in ME/CFS

Evidence: Resistance bands eliminate gravitational stabilization demands that free weights impose (continuous muscle co-contraction to stabilize against gravity). Very slow tempo (5-2-5) prevents rapid force development that requires explosive motor unit recruitment. Seated/supine positioning reduces orthostatic demand. hEDS/HSD comorbidity: mid-range loading without end-range subluxation risk.
Citations: (Oka et al. 2014) (Zabriskie 2022)
Mechanism: Reduced stabilization demand + slow tempo (no explosive recruitment) + accommodating resistance (matches strength curve) + seated position → lower HR response and lower PEM risk vs equivalent-load free weights.
Chapter ref: ch17: resistance band hr
Prediction: Seated band exercises (2 × 8 reps, 30% 1RM, 5-2-5 tempo) → ≥5 bpm lower peak HR vs. matched free-weight protocol; lower PEM incidence at equivalent volume over 4 weeks.
Treatment: Resistance bands as preferred loading modality for ME/CFS patients needing strength maintenance. Combine with compound movement preference. 30% 1RM, 5-2-5 tempo, seated/supine only.
Limitation: No ME/CFS band vs. free-weight trial. Max resistance limited by band availability. Non-linear tension complicates precise progressive overload. Some movements difficult to replicate with bands. Not yet replicated.

Speculation p=0.40Compound Movements May Produce Lower HR Than Isolated Movements in ME/CFS

Evidence: ME/CFS patients show impaired perfusion redistribution and reduced cardiac output. Compound movements distribute metabolic load across larger muscle mass, potentially reducing peak local demand and ischemic stress. Isolated movements concentrate demand in small muscle groups, risking local perfusion failure and compensatory sympathetic HR elevation. This inverts the healthy pattern where compound > isolated HR. Zero direct comparative data.
Citations: Mechanistic: global hypoperfusion literature (Chapter Cardiovascular Dysfunction); cardiac output limitation in ME/CFS.
Mechanism: Global hypoperfusion → regional load distribution matters → compound movement = lower per-gram-tissue metabolic demand → reduced local ischemia → reduced compensatory sympathetic HR elevation. Isolated movement = concentrated demand → local perfusion failure → sympathetic activation → disproportionate HR.
Chapter ref: ch17: compound vs isolated hr
Prediction: Matched-RPE crossover: seated row (compound) → ≥5 bpm lower HR vs. bicep curl (isolated); isolated → greater NIRS deoxygenation; compound → lower PEM over 4-week trial.
Treatment: When prescribing resistance exercise, prioritize compound movements (seated row, chest press, leg press) over isolation (bicep curl, tricep ext, leg curl) at equivalent intensity. Applies to bands, free weights, and machines.
Limitation: Completely untested in ME/CFS. Assumes local perfusion failure, not total metabolic demand, is dominant HR driver. Compound movements require more motor coordination (increased cognitive demand). Individual perfusion reserve varies.

Speculation p=0.40Passive Range-of-Motion Protocols Prevent Contractures Without Triggering PEM in Bedbound ME/CFS

Evidence: ICU patients immobilized greater than 7 days and astronauts during microgravity show PROM reduces contracture development and muscle atrophy compared to no intervention. Large ICU studies confirm safety and feasibility even in mechanically ventilated patients. Energy cost borne by caregiver; patient muscles remain inactive, eliminating the metabolic PEM trigger.
Citations: (P. E. Morris et al. 2008) (W. Bao et al. 2022)
Mechanism: Caregiver-administered PROM → no patient muscle contraction → no metabolic PEM trigger → contracture prevention from passive joint movement through range. Risk is positional (subluxation, pain, autonomic activation), not metabolic.
Chapter ref: ch17: bedbound passive rom
Prediction: Bedbound ME/CFS patients receiving PROM (2–3 sessions/week × 12 weeks) → slower joint ROM decline (goniometry) and lower contracture incidence vs. matched bedbound controls; PEM frequency unchanged.
Treatment: PROM as the safest movement intervention for bedbound ME/CFS. Caregiver-administered, supine position, pain-free range, very slow tempo (5-second per movement), 5–8 min/session. Monitor at 6h, 24h, 48h post-session for PEM.
Limitation: Not tested in ME/CFS. Extrapolation from critical care/space medicine populations. Even passive movement may trigger PEM in very severe patients. Caregiver availability is access barrier. Hypermobility requires mid-range only.

Speculation p=0.40Bed-Based Isometric Holds as Lowest-Intensity Safe Movement Tier for Severe ME/CFS

Evidence: Isometric exercises already in Ch. 17 (wall sits, plank holds, leg presses) — appropriate for mild-to-moderate. For severe/bedbound, lowest possible intensity tier: supine single-muscle 3-second holds, HR ≤5 bpm above resting, no respiratory rate increase, no effort sensation. Extends existing framework to explicit severity stratification.
Citations: (Oka et al. 2014) (Oka, Wakita, and Kimura 2017)
Mechanism: Supine single-muscle isometric contraction (3 seconds) → minimal metabolic demand → ≤5 bpm HR increase → no respiratory rate change → no PEM trigger. Progressive: 3→5→10 seconds over weeks if tolerated.
Chapter ref: ch17: bedbound isometric
Prediction: Bedbound ME/CFS performing supine single-muscle 3-second isometric holds (2–3 min/day total contraction time) → slower quadriceps CSA decline (ultrasound at 12 weeks) vs. bedbound controls; PEM frequency unchanged.
Treatment: Single-muscle unilateral only. Submaximal intensity (can talk during contraction). 1 session/day, 2–3 min total contraction. HR monitor. Symptom tracking at 6h, 24h, 48h. Not on active PEM days. Progress only after 2 weeks zero-PEM tolerance.
Limitation: Even minimal isometrics may trigger PEM in very severe patients — not guaranteed safe. 3-second, single-muscle, sub-5-bpm thresholds are clinician-estimated, not empirically validated. May be too minimal for measurable muscle preservation. Oka 2017 (n=12 pilot) was severe but not bedbound-severe.

Speculation p=0.40Engineered Exosomes as CNS-Targeted Therapeutic Delivery Vehicles for ME/CFS Neuroinflammation

Evidence: Endogenous EVs traffic bidirectionally across BBB in ME/CFS (Ramos-Zaldívar et al. 2022 review of EV BBB crossing mechanisms). Kang et al. 2026 proof-of-principle: engineered exosomes can deliver functional mRNA cargo across BBB to reverse neuroinflammation in mice. Engineering platform context from Sanadgol et al. 2025 review of brain-targeted nucleic acid delivery. Platform generalisable but ME/CFS-specific cargo, targeting, pharmacokinetics, and safety entirely unknown.
Citations: (Z. Kang et al. 2026)
Mechanism: Patient-derived or engineered exosomes + CNS-targeting ligand (RVG, Lamp2b) + therapeutic mRNA cargo (anti-inflammatory cytokines, neurotrophic factors, mitophagy enhancers) → systemic administration → BBB crossing → CNS cell uptake → therapeutic protein expression → neuroinflammation reduction + neural repair.
Chapter ref: engineered exosome bbb mrna
Prediction: Radiolabeled engineered exosomes will show measurable CNS uptake in ME/CFS animal models; iPSC-derived ME/CFS neurons treated with anti-inflammatory mRNA-loaded exosomes will show reduced cytokine production and improved mitochondrial respiration vs untreated cells.
Treatment: Research direction — no near-term clinical application. Characterizing endogenous EV trafficking in ME/CFS would illuminate inter-compartment signaling regardless of whether therapeutic exosomes ever reach the clinic.
Limitation: No ME/CFS data of any kind; single preclinical proof-of-principle study; CNS delivery fraction typically less than one percent of injected dose; manufacturing and regulatory pathways do not exist; cost and complexity prohibitive; immunogenicity concerns in immune-dysregulated patients.

Speculation p=0.40Point-of-Care Ultrasound and Urinary Creatinine as Bedside Muscle Monitoring in Bedbound ME/CFS

Evidence: POCUS quadriceps CSA validated against DXA/CT in ICU. Urinary creatinine correlates with muscle mass (r≥0.7 with DXA) but confounded by diet/renal function. Bedbound patients cannot travel for DXA/CT — bedside alternatives are essential for monitoring intervention efficacy.
Citations: ICU POCUS validation literature; urinary creatinine validation against DXA.
Mechanism: POCUS → mid-thigh transverse CSA → 5-min supine scan → detects ≥5% CSA change. Urinary creatinine → 24h collection → serial measurements track muscle mass trends. Both are radiation-free, low-cost, bedside.
Chapter ref: ch17: muscle mass monitoring
Prediction: Ultrasound CSA decline rate → correlates with Bell Disability Scale change; detects intervention effects with sensitivity comparable to DXA-measured lean mass over 24 weeks in bedbound ME/CFS.
Treatment: Baseline POCUS + urinary creatinine at intervention start. POCUS every 6 weeks. Urinary creatinine at 12-week intervals. Both at 12-week endpoint for any intervention trial.
Limitation: Non-ME/CFS validation only. Ultrasound operator-dependent. Urinary creatinine confounded by diet, renal function, collection completeness. Neither measures bone density. Floor effects at very low muscle mass. Reliable 24h collection challenging in severe patients.

Speculation p=0.40Caregiver Training and Protocol Fidelity Improves Muscle Preservation Outcomes in Bedbound ME/CFS

Evidence: All bedbound interventions depend on caregiver execution. Standardized training (PROM technique, repositioning procedure, nutritional preparation, PEM recognition) may improve protocol fidelity and reduce adverse events. Established in chronic disease management; no ME/CFS caregiver trial.
Citations: Caregiver education literature in chronic disease management; extrapolated to ME/CFS by analogy.
Mechanism: Structured caregiver training → higher protocol adherence (validated by observation) → better muscle preservation outcomes → lower adverse event rate. Training elements: correct joint positioning/range limits (PROM), safe position transitions/pressure inspection (repositioning), small frequent meals/GI monitoring (nutrition), standardized symptom logs (PEM recognition).
Chapter ref: ch17: caregiver training
Prediction: Trained caregivers → higher protocol adherence (validated) and patients → better muscle CSA preservation vs. untrained caregivers over 12 weeks.
Treatment: Caregiver training as prerequisite for any PROM or NMES protocol in severe ME/CFS. Direct observation or video review for fidelity monitoring. Standardized checklists for each intervention component.
Limitation: No ME/CFS caregiver trial. Training may increase caregiver burden. Training availability is socioeconomic access barrier. Fidelity measurement is inherently intrusive — may not be acceptable to severely ill patients.

Speculation p=0.40Bifurcation Model of Exercise Dose-Response in ME/CFS

Evidence: Standard exercise models treat dose-response as monotonic (more exercise = more adaptation). In ME/CFS, the evidence suggests a bifurcation: below the PEM threshold (AT), movement prevents atrophy (maintenance); above threshold, it produces deterioration (PEM). This can be formalized as dF/dt = maintenance_rate for exertion ≤ threshold, dF/dt = deterioration_rate for exertion > threshold, where F = functional capacity. Note: the group-average CPET-2 decline that anchors the deterioration regime is contested — Keller 2024 (positive) vs. Mancini/Natelson 2026 (null (Mancini et al. 2026)). The model remains valid if deterioration is individually variable rather than group-average, since elevated RPE and chronotropic incompetence are consistent across all CPET studies.
Citations: (Keller et al. 2024) provides threshold data (AT as bifurcation point); (Mancini et al. 2026) provides null group-average result but corroborates elevated RPE and chronotropic incompetence. No formal mathematical model exists for this pattern in ME/CFS.
Mechanism: Exercise in ME/CFS exhibits a bifurcated dose-response curve — the sign of dF/dt flips at a threshold exertion level. This contrasts fundamentally with the monotonic dose-response assumed by GET and standard exercise physiology. The bifurcation point is individually calibrated to the patient’s anaerobic threshold.
Chapter ref: ch17: bifurcation model
Prediction: Piecewise function (maintenance below AT, deterioration above AT) will better fit longitudinal FUNCAP trajectories (R² improvement ≥0.10) than linear dose-response model, when tested with wearable HR + activity data over 24 weeks in n≥30 ME/CFS patients.
Treatment: Formalizes the clinical intuition that “movement within envelope helps, movement above harms.” Provides mathematical justification for HR-based pacing thresholds. If validated: objective threshold calibration protocol for each patient.
Limitation: Model is conceptual with CPET grounding but no longitudinal validation. AT as bifurcation point assumed but PEM may have additional determinants (cognitive load, emotional stress). dF/dt sign change may be gradual, not binary at threshold. Individual calibration requires CPET which many patients cannot access or tolerate.

Speculation p=0.35Adapted Swimming Protocol for ME/CFS — Backstroke, Thermoneutral, No Turns

Evidence: Backstroke swimming: face always out of water (eliminates breath-holding), cervical spine supported, horizontal constant position, hydrostatic pressure benefit. Standard lap swimming introduces PEM risks from Valsalva, cervical stress, and wall turns. Adapted protocol eliminates these. NCT07454395 registered — no results yet.
Citations: (Schmid et al. 2007)
Mechanism: Horizontal position (constant) + hydrostatic pressure + no breath-holding (no Valsalva) + no positional transitions (no turns) → minimized autonomic stress during aquatic exercise.
Chapter ref: ch17: adapted swimming
Prediction: Adapted backstroke protocol → PEM incidence below 20% in mild-to-moderate POTS+ME/CFS over 8 weeks; backstroke vs. freestyle at matched RPE → lower HR (no Valsalva, reduced cervical stress).
Treatment: Backstroke in thermoneutral pool as one of the safest aquatic modalities for POTS+ME/CFS patients. Pool noodle for cervical support. Walk-turns at wall; no flip turns. 5–10 min initial, progress cautiously.
Limitation: Zero published data on this adapted protocol in ME/CFS. NCT07454395 pending. Backstroke technically challenging for non-swimmers. Pool access is socioeconomic/geographical barrier. Chlorine may trigger MCAS symptoms. Requires swimming competence.

Speculation p=0.35Nutritional Anti-Catabolic Strategies Slow Muscle Wasting in Bedbound ME/CFS

Evidence: HMB (3 g/day) preserved lean body mass during complete bed rest in older adults (RCT: –2.05 vs. –0.17 kg placebo, p=0.02) and maintained mitochondrial OXPHOS content and dynamics during rehabilitation. Protein, creatine, vitamin D, and omega-3 strategies supported by sarcopenia/ICU deconditioning literature. All low-risk, no patient exertion required.
Citations: (Deutz et al. 2013) (Standley et al. 2017)
Mechanism: Protein ≥1.2 g/kg/day + leucine threshold (≥2.5 g/meal) → mTOR-mediated muscle protein synthesis activation. HMB → ubiquitin-proteasome pathway inhibition + mitochondrial dynamics preservation. Creatine → intramuscular phosphocreatine buffering. Omega-3 → anti-catabolic cytokine suppression.
Chapter ref: ch17: nutritional anti catabolic
Prediction: Bedbound ME/CFS receiving combined nutritional protocol (protein 1.5 g/kg/d + creatine 5 g/d + HMB 3 g/d) → slower mid-thigh CSA decline (ultrasound/DXA at 12 weeks) vs. bedbound controls; no increase in GI PEM triggers.
Treatment: Oral supplements — minimal invasiveness. Small frequent servings essential (gastric emptying slowed in severe patients). Monitor: renal function (creatine), serum calcium (vitamin D), GI tolerance. Aspiration risk assessment in severe dysphagia.
Limitation: No ME/CFS trial. All evidence from healthy older adults (bed rest), ICU, or sarcopenia populations. HMB absorption/metabolism unknown in ME/CFS. Creatine may cause GI upset. Compliance requires caregiver assistance.

Speculation p=0.35Severity-Stratified Muscle Preservation Protocol Minimizes PEM While Maintaining Muscle in Bedbound ME/CFS

Evidence: Energy envelope theory provides theoretical basis for matching intervention intensity to individual capacity. Tiered protocol: A (positioning + nutrition only), B (+ PROM + minimal nutrition), C (+ isometrics + full nutrition + NMES if tolerated). Progression and regression rules based on PEM monitoring.
Citations: Energy envelope theory (Jason 2008); existing intervention evidence from Phase 1.
Mechanism: Intervention intensity matched to PEM sensitivity via tiered protocol → each patient receives maximum muscle preservation benefit within their individual tolerance limit → lower PEM frequency vs. one-size-fits-all protocol.
Chapter ref: ch17: severity stratified preservation
Prediction: Bedbound ME/CFS patients on stratified protocol → lower PEM frequency + comparable muscle CSA decline rate vs. uniform protocol at 24 weeks.
Treatment: Individually calibrated intervention selection and progression rules for severe/bedbound patients. Autonomic monitoring (HR, BP) during passive interventions. PEM tracking at fixed intervals post-session.
Limitation: Tier definitions clinician-estimated, not empirically validated. PEM sensitivity variation may exceed tier granularity. Protocol complexity increases caregiver burden. Boundary between tiers subjective without objective biomarkers.

Speculation p=0.35ADL Capacity Stability as the Primary Fitness Outcome Metric in ME/CFS

Evidence: If fitness improvement cannot be achieved and maintenance is the ceiling, the natural outcome metric is ADL capacity stability measured over months to years rather than conventional fitness metrics (VO₂max, strength). FUNCAP-27 provides an 8-domain functional capacity assessment validated in ME/CFS. Serial assessments at 3-month intervals can track whether function is stable, declining, or improving.
Citations: (Sommerfelt et al. 2024) (Leonard A. Jason, Muldowney, and Torres-Harding 2008)
Mechanism: Stability IS success — a patient with stable FUNCAP scores over 6+ months is achieving the highest possible outcome. Declining scores → remediable causes of envelope shrinkage. Improving scores → verify sustained (≥2 consecutive 3-month assessments) vs. temporary fluctuation.
Chapter ref: ch17: adl stability metric
Prediction: Cohort study: serial FUNCAP-27 every 3 months over 24 months → fitness-maintenance-targeted counseling group shows equivalent or better trajectory vs. standard pacing, with lower boom-bust fluctuation rate. FUNCAP sensitivity to 3-month within-patient change not established — may require validation study first.
Treatment: Reframes flat trajectory as success, not “no progress.” Identifies declining patients earlier. Reduces pressure to “improve” that paradoxically drives overexertion. Integrates with existing FUNCAP clinical use.
Limitation: FUNCAP-27 sensitivity to 3-month within-patient change not established. Stability may reflect measure insensitivity, not true functional stability. Requires conceptual shift resisted by patients, clinicians, researchers. No trial data for this reframing.

Speculation p=0.32Space Medicine and ICU Countermeasure Programs Offer Partially Translatable Frameworks for Bedbound ME/CFS

Evidence: NASA astronaut countermeasures (nutritional, vibration, resistance), ICU early mobility (PROM safety/feasibility), sarcopenia guidelines (protein, HMB, vitamin D), SCI NMES (atrophy prevention without voluntary movement), and ALS positioning protocols all translate to ME/CFS once active components are removed.
Citations: (P. E. Morris et al. 2008) (Deutz et al. 2013) (Dirks et al. 2015) (Wollersheim et al. 2017)
Mechanism: Cross-disease analogy: extreme immobilization countermeasures → remove high-exertion components → adapt remaining nutritional, positioning, PROM elements to ME/CFS energy envelope → partial muscle/bone preservation without PEM risk from active components.
Chapter ref: ch17: cross disease bridges
Prediction: Adapted countermeasure protocol (nutritional + PROM + positioning, no active components) → muscle CSA decline –0.3 to –0.5%/week vs. untreated –7 to –10%/week; PEM frequency unchanged.
Treatment: Nutritional protocol (HMB + creatine + vitamin D3 + omega-3) adapted from NASA/sarcopenia without exercise. PROM + positioning adapted from ICU without active mobility. NMES titrated to PEM tolerance.
Limitation: All analogies extrapolated from populations with fundamentally different pathophysiology. Removing active components may render countermeasures ineffective — efficacy data exist only for protocols including active components. No ME/CFS adaptation study.

Speculation p=0.30Water Rowing as POTS/ME/CFS-Tolerable Modality

Evidence: Water rowing combines three protective mechanisms: seated constant body position, hydrostatic pressure benefit from chest-deep immersion, and compound upper+lower body movement distribution. Rowing’s rhythmic reciprocal pattern may entrain breathing and HRV. Face stays above water, unlike swimming. Zero ME/CFS trial data.
Citations: (Schmid et al. 2007) (Oka et al. 2014)
Mechanism: Constant seated position + hydrostatic preload + compound movement (load distributed) → low orthostatic demand + parasympathetic shift + reduced local metabolic demand.
Chapter ref: ch17: water rowing
Prediction: Water rowing (≤10 strokes/min, RPE ≤10, HR ≤85% AT) → lower HR per watt vs. land rowing; lower PEM (OR below 0.7) vs. matched-intensity land cycling; improved orthostatic tolerance post-rowing.
Treatment: Water rowing as a potential novel modality for mild-to-moderate ME/CFS POTS-comorbid patients with pool access. Ultra-conservative progression: 2 min/session start, +1 min every 2–3 weeks only if zero PEM.
Limitation: Zero ME/CFS water rowing data. Equipment access barrier (specialized pool ergometers). Pool transport may trigger PEM. Rowing is a learned motor skill. Compound demand may exceed capacity. Completely untested in ME/CFS.

Speculation p=0.25Multi-Variable ODE Extension Models Atrophy Rate as Function of Disuse, Nutrition, and PEM Frequency

Evidence: Mathematical induction from atrophy kinetics × nutritional intervention data. Model: dM/dt = –αD – β(1 – S) + γP where M=CSA, D=disuse, S=nutritional status, P=PEM frequency, and α,β,γ are patient-specific. No ME/CFS validation. Deutz 2013 provides potential α estimate.
Citations: Theory only; (Deutz et al. 2013) provides possible α parameter.
Mechanism: Muscle mass decline ≠ pure disuse in ME/CFS. Nutritional status (S) and PEM frequency (P) modulate atrophy slope. Addition of nutrition and PEM terms improves predictive accuracy over disuse-only model.
Chapter ref: ch17: atrophy ode
Prediction: Multi-variable model predicts CSA decline more accurately (R² improvement ≥0.10) than disuse-only model when tested against longitudinal ultrasound data from bedbound ME/CFS (n≥15) over 12–24 weeks.
Treatment: No clinical application until model validated. If validated: objective guidance for intervention intensity (is nutrition adequate? do we need better PEM prevention?).
Limitation: No ME/CFS validation. Parameters unknown for ME/CFS — Deutz α from healthy older adults, not chronically ill. Model assumes linear additivity — likely interacting and nonlinear. γ (PEM) hypothetical. May require additional terms (inflammation, subtype, age) for acceptable accuracy.

Speculation p=0.20Explicit Fitness-Maintenance Goal-Setting Reduces Exercise-Related Psychological Distress

Evidence: ME/CFS patients exist in a rehabilitation culture that equates progress with improvement. When the achievable ceiling is stability, the mismatch between expectation and reality generates frustration and may drive envelope overshoot. Explicitly naming fitness maintenance as the goal — with stability-as-success reframing — removes this conflict. ACT frameworks for living meaningfully within limitation are directly applicable.
Citations: ACT literature for chronic illness; no ME/CFS-specific trial.
Mechanism: Goal-behavior alignment psychology: when achievable goals match prescribed behavior, distress is lower than when unachievable goals are pursued. Substituting “maintenance” for “improvement” as the stated treatment goal aligns patient expectations with physiological reality.
Chapter ref: ch17: fitness acceptance
Prediction: Patients randomized to fitness-maintenance goal-setting vs. standard pacing → lower exercise-related distress at 12 weeks (validated exercise-avoidance/anxiety scale), equivalent or better PEM frequency.
Treatment: Protocol: expectation-setting at treatment initiation (“this movement program maintains function — it cannot build fitness”), outcome reframing (“stability is success”), monitoring for goal-behavior mismatch, ACT integration.
Limitation: Untested psychological intervention frame. Some patients find acceptance of limitation more distressing than pursuit of improvement, even if pursuit is futile. Cultural context matters — improvement narrative dominance varies across healthcare systems. No ME/CFS-specific trial.

Speculation p=0.15PEM Frequency May Accelerate Muscle Atrophy in ME/CFS Independently of Disuse

Evidence: Hypothetical: PEM episodes involve inflammatory activation, oxidative stress, and metabolic crisis — all catabolic stimuli. Repeated PEM may accelerate protein breakdown beyond disuse rate. dM/dt = f(disuse, PEM frequency, PEM severity, nutrition). If validated, PEM prevention becomes a de facto muscle preservation intervention.
Citations: Theoretical — no direct evidence for PEM-specific atrophy acceleration. Inflammatory catabolism in chronic illness is established; PEM-specific component purely speculative.
Mechanism: PEM episode → systemic inflammatory activation + oxidative stress + metabolic crisis → muscle protein breakdown spike → recovery-period catabolism → cumulative atrophy exceeds pure disuse rate.
Chapter ref: ch17: pem atrophy acceleration
Prediction: Bedbound ME/CFS matched for immobility: high-PEM (≥2/month) → faster CSA decline vs. low-PEM (≤0.5/month), independent of nutrition and positioning.
Treatment: PEM prevention (pacing, HR monitoring, energy envelope) may be a muscle preservation strategy — speculative pending evidence. Aggressive PEM prevention is already clinically indicated; this model provides additional rationale.
Limitation: Purely theoretical. No data correlating PEM frequency with muscle mass. Disuse duration and PEM frequency confounded (more severe → more PEM + longer immobility). PEM-specific atrophy beyond standard inflammatory catabolism not established.

Speculation p=n/aNMES/EMS as Muscle Preservation Strategy in Bedbound ME/CFS — Unknown PEM Risk

Evidence: NMES prevents muscle atrophy completely in fully sedated ICU patients (within-subject: control leg type I –16%, type II –24%; stimulated leg no atrophy, mTOR +19%). RCT shows NMES + PROM attenuates atrophy better than PROM alone. Bypasses volitional/CNS motor coordination. Unknown whether electrically-induced contractions trigger PEM identically to voluntary contractions.
Citations: (Dirks et al. 2015) (W. Bao et al. 2022)
Mechanism: NMES → direct motor unit activation via electrical stimulation → muscle contraction without CNS coordination or patient effort → mTOR pathway activation → muscle protein synthesis maintenance. Metabolic cost of electrically-induced vs. voluntary contractions unknown in ME/CFS.
Chapter ref: ch17: bedbound nmes and ch14a: nmes severe
Prediction: Pilot: bedbound ME/CFS receiving minimal NMES (5 min, lowest visible contraction, single muscle group) → PEM incidence not higher than sham stimulation; if unable to separate stimulation from PEM → NMES remains contraindicated pending further study.
Treatment: No clinical recommendation until safety established. Research priority: does NMES trigger PEM? If future research identifies sub-PEM-threshold NMES parameters → potentially valuable atrophy countermeasure for most vulnerable patients.
Limitation: No ME/CFS NMES trial exists. Safety question is prerequisite to efficacy question. Autonomic and metabolic effects of NMES uncharacterized in ME/CFS. Twice-daily ICU protocol likely too intensive. Contraindicated in active PEM until safety established.

19 Post-Exercise Recovery and PEM Resolution

Speculation p=0.45Resolution Failure as Primary PEM Defect

Evidence: PEM reflects failure of active resolution mechanisms (SPM biosynthesis, mitophagy, HSP clearance, vagal reactivation) rather than severity of exercise-induced damage. Damage magnitude may be normal; resolution machinery is defective. Convergent with SPM deficiency (cert 0.45) and autophagy failure (cert 0.45) hypotheses.
Citations: Ch.26 synthesis; resolution failure framework from SPM, autophagy, HSP literatures.
Mechanism: Exercise → normal damage signals → resolution pathways fail → damage persists → prolonged recovery. In healthy: robust SPM surge + mitophagy activation + HSP clearance → 2-4h recovery. In ME/CFS: blunted resolution → 24-72h+ recovery.
Chapter ref: ch27: resolution failure pem
Prediction: Post-exercise lipidomic time-course (0, 1, 4, 8, 24, 48h) in ME/CFS shows blunted RvD1/RvE1 surge at 1-4h vs controls (fold-change less than 1.5 vs greater than 3.0). PBMC mitophagy markers (PINK1, Parkin) peak delayed past 8h. Falsified if resolution time-course matches controls.
Treatment: Resolution-enhancing interventions (SPM precursors, autophagy inducers, vagal stimulation) prioritized over damage-suppression strategies.
Limitation: No post-exercise resolution time-course data in ME/CFS; damage-normal assumption untested — damage may also be supranormal.

Speculation p=0.40Recovery Failure as Network Collapse

Evidence: PEM recovery failure reflects collapse of multi-system coordination (autonomic, metabolic, immune, neuroendocrine) below a critical coupling threshold. Single-system deficits insufficient to explain prolonged recovery times. Analogous to power grid blackout: individual component failures cascade when compensatory reserve exhausted.
Citations: Ch.26 synthesis; network failure models from complex systems theory.
Mechanism: Physiological stress (exercise) → multi-system response → coupling between systems degrades beyond critical threshold → systems decouple → recovery processes fail → prolonged recovery. Below threshold: normal recovery. Above threshold: catastrophic recovery failure.
Chapter ref: ch27: recovery network collapse
Prediction: Continuous multi-system monitoring (HRV, glucose, actigraphy, temperature) during exercise recovery in ME/CFS will show rapid decline in cross-system coupling coherence preceding prolonged PEM, vs stable coupling in recovered controls. Falsified if coupling does not distinguish PEM from normal recovery.
Treatment: Multi-system monitoring for PEM prediction; threshold-based activity pacing to prevent crossing critical coupling threshold.
Limitation: Network collapse model is conceptual; critical threshold not empirically identified for any physiological variable pair.

Speculation p=0.40Antihistamine Pre-Treatment as PEM Blocker

Evidence: Histamine release during exercise from mast cells and basophils amplifies vasodilation, neuroinflammation, and cytokine cascades in ME/CFS. H1/H2 antihistamine pre-treatment (1h before activity) may block the histamine amplification step, preventing the inflammatory cascade that drives PEM. Supported by MCAS overlap (cert 0.45) and mast cell-MMP axis (cert 0.50).
Citations: Ch.26 synthesis; MCAS literature; mast cell degranulation during exercise documented.
Mechanism: Exercise → mast cell degranulation → histamine release → H1R/H2R activation → vasodilation + neuroinflammation + cytokine amplification → inflammatory cascade → PEM. Antihistamine pre-treatment blocks H1/H2 receptors → vasodilation/neuroinflammation reduced → inflammatory cascade truncated → PEM prevented or attenuated.
Chapter ref: ch27: antihistamine pem blockade
Prediction: Crossover trial (n=20): cetirizine 10mg + famotidine 20mg 1h before standardized CPET reduces PEM severity (DSQ-PEM at 24h, AUC) by ≥40% vs placebo pre-treatment. Falsified if PEM difference less than 20% or not significant.
Treatment: If validated: pre-exercise antihistamine protocol (H1+H2 blockade) as PEM prophylaxis. Low-risk, OTC, immediately accessible.
Limitation: No ME/CFS antihistamine pre-treatment trial. Mast cell degranulation triggered by exercise in ME/CFS unconfirmed. Antihistamines may not address non-histamine mast cell mediators.

Speculation p=0.35Thermal HSP70/PGC-1α Bypass as Exercise Mimetic

Evidence: Controlled heat exposure (sauna, hot pack) induces HSP70 and PGC-1α without contractile activity or cardiorespiratory demand. Passive heat elevates HSP70 in skeletal muscle, stimulates mitochondrial biogenesis via PGC-1α, and improves insulin sensitivity. Provides cellular exercise-mimetic benefits without PEM trigger of physical exertion.
Citations: Ch.26 synthesis; HSP70 thermal induction literature; PGC-1α heat response data.
Mechanism: Heat stress → HSP70 upregulation + PGC-1α activation → mitochondrial biogenesis + stress protein expression + metabolic adaptation → cellular training effect without muscle contraction → preserves conditioning without PEM.
Chapter ref: ch27: thermal exercise mimetic
Prediction: 4-week controlled heat therapy (sauna 45°C, 15 min, 3x/week) in ME/CFS increases PBMC HSP70 by ≥30% and muscle PGC-1α mRNA (biopsy) by ≥50% without PEM induction in >70% of participants. Falsified if PEM rate exceeds 50% or protein targets unchanged.
Treatment: Passive heat as non-exercise conditioning strategy for patients unable to tolerate any active movement.
Limitation: No ME/CFS heat therapy trial with HSP70/PGC-1α endpoints; heat intolerance may limit tolerability; sauna access barrier.

Hypothesis p=0.55Directional Heart-Rate Signal Separates Deconditioning from ME/CFS

Evidence: Davenport et al. 2025 argued that deconditioning and PEM are not mutually exclusive and that the lower (rather than elevated) exercise heart rate in post-infectious ME/CFS vs healthy volunteers is inconsistent with deconditioning and consistent with chronotropic incompetence and impaired oxidative metabolism (Davenport et al. 2025). Supported by (Davenport et al. 2019) (chronotropic intolerance as overlooked determinant), (Cook et al. 2022) (n=403 fitness-matched, CI + elevated RPE), C. (Linda). M. C. van Campen et al. (2023) (n=414), (Miwa 2023) (n=101). Deconditioning elevates submaximal HR (low stroke volume compensated by tachycardia); chronotropic incompetence reduces it. Origin: /integrate-topic davenport2025-effort-deconditioning.
Citations: (Davenport et al. 2025) (Davenport et al. 2019) (Cook et al. 2022) C. (Linda). M. C. van Campen et al. (2023; Miwa 2023)
Mechanism: In deconditioning, reduced stroke volume is compensated by elevated submaximal heart rate. In ME/CFS with chronotropic incompetence, the heart fails to raise heart rate at fixed workload despite low stroke volume and impaired oxidative metabolism — a failed-compensation signature. The direction of submaximal HR change (elevated in deconditioning vs reduced in ME/CFS) is the falsifiable separating signal.
Chapter ref: ch47: deconditioned-matched CPET separation; ch38 + ch42 effort-preference controversy; ch17 Novel Hypotheses from Two-Day CPET Findings
Prediction: In a three-arm 2-day CPET (ME/CFS; objectively activity-matched deconditioned controls; trained healthy controls), ME/CFS shows submaximal HR at fixed workload below deconditioned-matched controls, a Day-1→Day-2 decline in workload at ventilatory threshold (which deconditioned controls do not show), and a chronotropic index below 0.80 and below that of deconditioned-matched controls. Falsified if deconditioned controls reproduce the ME/CFS pattern (blunted HR + Day-2 decline).
Treatment: If validated, distinguishes energy-envelope/pacing management (ME/CFS) from reconditioning (deconditioning), preventing GET harm.
Limitation: The “lower HR” argument only survives if measured at fixed submaximal workload (deconditioning also lowers peak HR), if β-blockers/ivabradine and the POTS/hyperadrenergic subset are excluded, and if early termination is ruled out. Chronic inactivity can itself blunt β-adrenergic responsiveness.

20 Skeletal Muscle Regeneration

ID / Label	Details	Phase / Cert
Satellite Cell Depletion as a Mechanism of Progressive Muscle Damage in ME/CFS	Charlton 2026 AMS abstract: first direct measurement of satellite cells in ME/CFS/LC muscle — reduced Pax7⁺ SCs (P$<$ 0.001), trending reduced PDGFRα⁺ FAPs (P=0.061), SC-OXPHOS correlation ($r = 0.43$). If replicated, SC depletion provides mechanism for progressive muscle damage: each exertion causes micro-damage that cannot be repaired due to stem cell exhaustion. Single biobank, conference abstract only, unreplicated. (Braeden T. Charlton et al. 2026b) (Bhattacharya and Scimè 2024) (Dumont et al. 2015)	Phase 3 / 0.37
Glycolytic Fibre Shift as Both Consequence and Cause of Regeneration Failure	Bidirectional loop: OXPHOS failure → glycolytic fibre remodelling → SC niche degradation → impaired repair → further loss of oxidative fibres. SCs require OXPHOS for differentiation; the glycolytic shift documented in ME/CFS muscle may be both cause and consequence of regeneration failure. Untested mechanistic inference.	Phase 3 / 0.30
Is Satellite Cell Depletion in ME/CFS Primary or Secondary?	Four non-mutually-exclusive mechanisms: (1) primary autoimmune/viral niche attack, (2) secondary to mitochondrial failure, (3) secondary to chronic inflammation, (4) secondary to disuse. Different mechanisms → different interventions. Resolution requires independent replication, functional SC assays, longitudinal data, confounder adjustment.	Phase 3 / n/a
Satellite Cell Depletion as a Convergent Tissue Repair Mechanism	SC depletion converges with autonomic macrophage polarization and NK repair dysfunction into a multi-layered tissue repair crisis. No single intervention likely sufficient — combination strategies targeting multiple layers simultaneously may be necessary. Hypothesis-level convergence only.	Phase 3 / 0.37
Is the Shared Pathology Between ME/CFS and Long COVID Evidence of a Post-Infectious Satellite Cell Niche Vulnerability?	Near-identical SC depletion in ME/CFS and LC suggests convergent post-infectious mechanism. Key question: is SC depletion reversible? In aging, SC decline is permanent. If irreversible in ME/CFS, priority shifts from restoration to protection of remaining SCs — fundamentally different strategy.	Phase 3 / n/a

21 Weight Management in ME/CFS

Prediction p=0.65DXA as Standard ME/CFS Body Composition Assessment

Evidence: BMI misclassifies body composition in immobile populations (SCI, Liusuwan 2004). DXA provides fat mass, lean mass, bone density, visceral fat in 10-minute scan.
Citations: (Liusuwan et al. 2004)
Mechanism: Sarcopenic obesity invisible to BMI. DXA distinguishes fat gain from lean loss masking as stable weight.
Chapter ref: ch27: dxa standard assessment
Prediction: DXA reclassifies >20% of ME/CFS patients’ body composition status vs BMI-based classification.
Treatment: Without DXA, a patient losing 5 kg muscle and gaining 5 kg fat has “stable weight” — no one intervenes.
Limitation: DXA not available in most clinics; cost barrier; requires patient transport to facility.

Hypothesis p=0.55Overfeeding Paradox: Positive Energy Balance Worsens Sarcopenic Obesity in ME/CFS

Evidence: Biolo 2008: positive energy balance during 5-week bed rest accelerated muscle atrophy via oxidative stress. Energy balance maintenance was protective. ME/CFS-specific replication absent.
Citations: (Biolo et al. 2008)
Mechanism: In immobilized ME/CFS, excess calories increase oxidative stress and alter protein metabolism, accelerating muscle loss while promoting fat deposition. Well-intentioned overfeeding worsens the sarcopenic obesity it intends to prevent.
Chapter ref: ch27: overfeeding paradox
Prediction: Controlled overfeeding (+500 kcal/day × 4 weeks) in bedbound ME/CFS produces measurable decrease in lean mass (BIA/POCUS) and increase in urinary 8-isoprostane vs energy balance maintenance.
Treatment: Energy balance maintenance (not surplus) with protein prioritization within the caloric envelope. Stop encouraging bedbound patients to eat more to keep weight up.
Limitation: Biolo 2008 used healthy volunteers, not chronic illness. ME/CFS-specific overfeeding study needed.

Hypothesis p=0.55Metabolic Adaptation Amplifies Weight Regain in ME/CFS

Evidence: Weight loss triggers metabolic adaptation (REE falls more than predicted) persisting ≥1 year (Maclean 2011). ME/CFS baseline REE likely blunted.
Citations: (Maclean et al. 2011) (Alazzam et al. 2023)
Mechanism: ME/CFS blunted baseline REE + further diet-induced reduction = energy needs below survivable intake → regain exceeds pre-diet weight. Cycle worsens with each attempt.
Chapter ref: ch27: metabolic adaptation amplification
Prediction: Weight-cycling ME/CFS patients show greater metabolic adaptation than non-cycling matched for BMI and severity.
Treatment: “Calories in fewer than calories out” is not just ineffective but potentially harmful in ME/CFS.
Limitation: Metabolic adaptation well-established in general population; ME/CFS-specific amplification unstudied.

Prediction p=0.55Hypometabolic Index as Clinical Biomarker

Evidence: Ratio of measured REE to predicted REE defines hypometabolic index; values less than 0.80 indicate clinically significant hypometabolism. Analogous to Metabolic Reserve Score (ch30) but simpler.
Citations: (Alazzam et al. 2023) (Buchholz, McGillivray, and Pencharz 2003)
Mechanism: Measured REE / predicted REE ratio stratifies patients into high/low metabolic reserve phenotypes and guides caloric prescription.
Chapter ref: ch27: hypometabolic index
Prediction: Hypometabolic index correlates with weight trajectory over 6 months (r > 0.3) in ME/CFS consuming standardized diets.
Treatment: Single actionable clinical test — as essential as thyroid labs for metabolic assessment.
Limitation: Indirect calorimetry requires patient cooperation; difficult in very severe patients.

Speculation p=0.50POCUS and MUAC as Bedside Body Composition Surrogates

Evidence: MUAC and calf circumference predict sarcopenia in elderly. POCUS quadriceps thickness correlates with DXA lean mass. Bedbound-appropriate.
Citations: (Liusuwan et al. 2004)
Mechanism: 2-minute POCUS scan or MUAC measurement tracks muscle status without moving patient.
Chapter ref: ch27: pocus bedside composition
Prediction: POCUS quadriceps changes correlate with DXA lean mass changes (r above 0.7) over 6 months.
Treatment: A 2-minute bedside ultrasound feasible in any clinic; no special equipment beyond probe.
Limitation: Direct ME/CFS validation needed; operator-dependent measurement variability.

Prediction p=0.50ME/CFS-Calibrated REE Predictive Equation

Evidence: SCI literature shows 5–32% overestimation by standard equations. ME/CFS-adjusted correction factor (REE_Mifflin × 0.75–0.95) derived from PAL 1.2–1.4. Needs prospective validation.
Citations: (Alazzam et al. 2023) (Buchholz, McGillivray, and Pencharz 2003)
Mechanism: ME/CFS-specific correction factor based on SCI-derived overestimation range and severity-dependent activity multipliers.
Chapter ref: ch27: ree equation mecfs
Prediction: ME/CFS-adjusted equation improves prediction accuracy (lower bias, narrower LoA) vs unadjusted Mifflin-St Jeor against indirect calorimetry.
Treatment: Democratizes precision caloric prescription — any clinician with scale and formula can estimate needs.
Limitation: Equation needs validation; SCI analogy imperfect (intact sympathetic tone in ME/CFS may offset expected REE reduction).

Prediction p=0.50Respiratory Quotient as Substrate Inflexibility Marker

Evidence: RQ reflects fuel mix oxidized; impaired CPT/ACAD predicts elevated fasting RQ >0.85 in ME/CFS. No ME/CFS RQ data exist.
Citations: —
Mechanism: Elevated fasting RQ (>0.85) quantifies metabolic inflexibility to fat oxidation; tracks response to MCT oil, carnitine interventions.
Chapter ref: ch27: rq substrate inflexibility
Prediction: Fasting RQ in ME/CFS differs from BMI-matched sedentary controls by >0.05.
Treatment: Non-invasive 15-minute measurement; actionable data for fat-bypass strategy selection.
Limitation: No ME/CFS RQ data exist; RQ confounded by hyperventilation (common in ME/CFS).

Prediction p=0.50Positional Feeding Protocol for Bedbound Patients

Evidence: Supine feeding alters gastric emptying, esophageal motility, aspiration risk. Left lateral decubitus position improves gastric emptying.
Citations: (Craft et al. 2015)
Mechanism: Positional feeding strategies (semi-recumbent 30–45°, left lateral, small-volume frequent feeds) address mechanical barrier to adequate nutrition.
Chapter ref: ch27: positional feeding
Prediction: Modified feeding position improves protein intake (g/kg/d) by ≥20% in bedbound ME/CFS.
Treatment: Addresses fundamental access-to-nutrition barrier, not just metabolic one.
Limitation: Position effect size unknown in ME/CFS; aspiration risk must be individually assessed.

Speculation p=0.45Metformin XR Timing for Metabolic Support

Evidence: Metformin proposed for ME/CFS (Fineberg 2025). XR has better GI tolerability than IR. AMPK activation may improve fat oxidation.
Citations: (Fineberg, Moreau, and Schneider-Futschik 2025)
Mechanism: Metformin XR timed with meals improves fat oxidation via AMPK activation, reduces inflammation, may reduce leptin resistance.
Chapter ref: ch27: metformin metabolic platform
Prediction: Metformin XR improves fasting RQ (toward fat oxidation) and reduces CRP vs placebo over 12 weeks.
Treatment: Already available, inexpensive, weight-neutral. Off-label prescription possible.
Limitation: Complex I inhibition risk in population with pre-existing Complex I impairment.

Speculation p=0.40Severity-Tiered Weight Management Protocol

Evidence: No single approach fits all ME/CFS severity levels. Tiered protocol based on mobility/energy status ensures safety.
Citations: (Craft et al. 2015)
Mechanism: Four tiers: bedbound (liquid PSMF + stack), chairbound (+ TRF), housebound (+ standing tolerance), improved (+ exercise ladder). Explicit calorie targets and escalation criteria.
Chapter ref: ch27: severity tiered protocol
Prediction: Tiered protocol superior to ad-hoc management (DXA body composition) over 12 months.
Treatment: Prevents common error of prescribing housebound-level interventions to bedbound patients.
Limitation: No protocol tested; tier boundaries arbitrary; individual variability within severity strata.

Speculation p=0.40Creatine for Muscle and Cognitive Metabolic Support

Evidence: Creatine well-established for muscle preservation; cognitive evidence growing; no ME/CFS-specific trials.
Citations: (Scheibenbogen and Wirth 2025)
Mechanism: Creatine (5–10 g/d) increases muscle phosphocreatine stores, preserves mass during inactivity, reduces cognitive fatigue, improves glucose tolerance.
Chapter ref: ch27: creatine metabolic
Prediction: Creatine improves 31P-MRS recovery kinetics in ME/CFS vs activity-matched controls.
Treatment: Cheap, safe, available; targets both muscle preservation and cognition.
Limitation: GI upset possible; no ME/CFS-specific dosing data; water retention may confound weight monitoring.

Speculation p=0.40Pacing-Based Meal Timing Aligned with Energy Windows

Evidence: ME/CFS patients experience diurnal energy variability; standard meal timing fights this rhythm. Clinically observed strategy.
Citations: (Craft et al. 2015)
Mechanism: Eat when energy is available — one large protein-rich meal during daily energy window, liquid supplements when energy too low.
Chapter ref: ch27: pacing meal timing
Prediction: Energy-aligned timing improves daily protein intake and reduces meal-skipping vs fixed schedule (crossover).
Treatment: Respects patient’s actual capacity rather than imposing external structure that fails repeatedly.
Limitation: No formal study; energy window timing varies individually and day-to-day.

Speculation p=0.35ME/CFS Hypometabolic State Requires Recalibrated Caloric Targets

Evidence: SCI literature shows predictive equations overestimate RMR by 5-32%. No ME/CFS-specific REE study exists. Reduced mitochondrial substrate utilization and altered fuel preference suggest lower caloric needs than standard equations predict.
Citations: (Alazzam et al. 2023) (Buchholz, McGillivray, and Pencharz 2003)
Mechanism: Standard caloric equations overestimate ME/CFS energy needs by 15-30% in moderate-to-severe disease. Overestimation combined with appetite dysregulation drives positive energy balance and weight gain.
Chapter ref: ch27: hypometabolic caloric recalibration
Prediction: Indirect calorimetry in ≥30 ME/CFS patients across severity levels shows measured REE >5% below Harris-Benedict or Mifflin-St Jeor predicted values.
Treatment: Severity-stratified caloric targets using SCI-derived activity multipliers (1.1-1.3 for bedbound) instead of standard equations.
Limitation: No direct ME/CFS REE measurements exist. SCI involves neurogenic denervation absent in ME/CFS.

Speculation p=0.35MCT + Leucine + HMB Anti-Catabolic Stack

Evidence: MCT provides ketogenic fuel bypassing CPT1; leucine activates mTOR; HMB inhibits ubiquitin-proteasome. Each validated independently.
Citations: (Weijs and Wolfe 2025) (Scheibenbogen and Wirth 2025)
Mechanism: Three independent anti-catabolic nodes: energy substrate (MCT ketones), anabolic signal (leucine), catabolic brake (HMB). All powder/liquid, caregiver-implementable.
Chapter ref: ch27: mct fat oxidation bypass
Prediction: 8-week stack reduces urinary nitrogen excretion and preserves quadriceps thickness (POCUS) vs isocaloric control.
Treatment: Accessible without prescription; stable at room temperature; requires only ability to swallow.
Limitation: Combination unstudied; HMB absorption/metabolism in ME/CFS unknown.

Speculation p=0.35Metformin as Metabolic Platform for Weight Stabilization

Evidence: Metformin improves insulin sensitivity, activates AMPK, reduces inflammation (Fineberg 2025). May blunt metabolic adaptation (Maclean 2011).
Citations: (Fineberg, Moreau, and Schneider-Futschik 2025) (Maclean et al. 2011)
Mechanism: In hypometabolic ME/CFS, metformin may raise (normalize) metabolic rate rather than suppress it — bidirectional effect.
Chapter ref: ch27: metformin metabolic platform
Prediction: Metformin increases (or maintains) REE in hypometabolic ME/CFS while decreasing REE in matched controls.
Treatment: Repurposes metformin from “weight loss adjunct” to “metabolic normalizer.”
Limitation: Bidirectional effect speculative; no ME/CFS-specific metabolic rate data.

Speculation p=0.35L-Carnitine for CPT Bypass

Evidence: Carnitine is obligate carrier for long-chain fatty acid entry via CPT1/CPT2. Impaired CPT in ME/CFS may be partially correctable with 2–4 g/d.
Citations: —
Mechanism: Supraphysiological carnitine loading may increase fat oxidation rates and reduce glucose dependency driving hunger.
Chapter ref: ch27: carnitine cpt bypass
Prediction: High-dose L-carnitine reduces fasting RQ (increased fat oxidation) or increases ketones in ME/CFS.
Treatment: Available, cheap, safe, mechanistically targeted — low-hanging fruit nutraceutical.
Limitation: CPT bypass effect assumes functional but submaximal CPT, not structural deficiency; GI side effects at high doses.

Speculation p=0.35Omega-3 EPA/DHA for Inflammation and Anabolic Sensitivity

Evidence: Omega-3s reduce NF-κB, TNF-α, IL-6; improve muscle anabolic sensitivity; improve lean mass preservation during weight loss.
Citations: —
Mechanism: Omega-3s (2–4 g/d EPA/DHA) address inflammation-driven leptin resistance and inflammation-induced anabolic resistance simultaneously.
Chapter ref: ch27: omega3 anabolic sensitivity
Prediction: High-dose omega-3 (4 g/d) improves nitrogen balance and lean mass preservation during caloric restriction in ME/CFS vs placebo.
Treatment: Safe, available, easy to take; independent cardiovascular benefits.
Limitation: Fishy aftertaste/burping limits adherence; high-dose may prolong bleeding time; no ME/CFS-specific trials.

Speculation p=0.35Leptin-AMPK Double Lesion as Appetite Driver

Evidence: AMPK dysregulation confirmed in ME/CFS (ch09). Leptin resistance likely given elevated obesity prevalence and inflammation-leptin connection.
Citations: (Norris et al. 2017)
Mechanism: Leptin resistance + AMPK dysregulation = double lesion in energy sensing: brain receives “starving” signals and insufficient satiety, creating relentless hunger.
Chapter ref: ch27: leptin ampk driver
Prediction: ME/CFS patients with obesity show impaired POMC activation in response to exogenous leptin.
Treatment: Leptin sensitizers (not appetite suppressants) as correct therapeutic class.
Limitation: Leptin sensitivity not directly measured in ME/CFS; AMPK dysregulation documented but tissue-specific.

Speculation p=0.35Alternate-Day Modified Fasting for Muscle Preservation

Evidence: Dunn 2024: ADMF preserved FFM better than continuous restriction in cirrhosis+obesity. Mechanism via preserved autophagy, lower cortisol.
Citations: (Maclean et al. 2011)
Mechanism: Intermittent approach avoids sustained caloric restriction that may trigger PEM and HPA axis exacerbation. 12h window can expand to 14–16h.
Chapter ref: ch27: admf muscle preservation
Prediction: ADMF in ME/CFS shows non-inferior or superior muscle preservation vs isocaloric continuous feeding (matched protein).
Treatment: Avoids restriction-related PEM; may be better tolerated than continuous restriction.
Limitation: Single positive study in cirrhosis; null meta-analysis in general population; no ME/CFS data.

Speculation p=0.35GPCR Autoantibody Receptor-Level Blockade as taVNS Inertia Mechanism

Evidence: GPCR autoantibodies (particularly $\beta_2$-AR AAb) may block the splenic T-cell $\beta_2$-AR — a critical step in the cholinergic anti-inflammatory pathway — rendering increased vagal efferent firing inert for downstream anti-inflammatory and clinical benefit even when HRV engagement (cardiac vagal efferent) is confirmed. Origin: brainstorm.
Citations: (N. Azcue et al. 2026b) (Blitshteyn, Doherty, and Steinman 2026) (Percin et al. 2025)
Mechanism: taVNS → vagal efferents → splenic NE release → $\beta_2$-AR (blocked by AAb) → no ACh → no $\alpha_7$-nAChR → no TNF-$\alpha$ suppression → clinical benefit absent. HRV preserved because cardiac vagal efferents do not depend on $\beta_2$-AR.
Chapter ref: ch28: tvns dissociation mechanisms
Prediction: AAb-low patients respond to active taVNS with SPM elevation and clinical benefit vs sham; AAb-high patients show HRV increase but no SPM or clinical change. Falsified if AAb-high patients respond equivalently.
Treatment: Stratify tVNS trials by GPCR AAb status — AAb-high patients should not be included in trials designed to test taVNS efficacy, as their CAP is likely blocked at receptor level.
Limitation: No direct evidence that $\beta_2$-AR AAb block splenic CAP in humans. The pathway chain is long and each step is individually established but not demonstrated as a causal cascade in ME/CFS or PCC.

Speculation p=0.30Microbiome-Metabolite Profiling for Weight Trajectory

Evidence: Gut microbiome predicts weight gain in general population. ME/CFS dysbiosis well-documented.
Citations: —
Mechanism: Baseline microbiome composition predicts 12-month weight change, enabling preemptive dietary intervention. Bile acids and TMAO as energy harvest markers.
Chapter ref: ch27: microbiome weight trajectory
Prediction: Baseline microbiome predicts 12-month weight change (AUC > 0.65).
Treatment: Identifies dysbiosis-driven weight gain subset treatable with prebiotics/probiotics.
Limitation: ME/CFS-specific microbiome-weight correlation absent; confounded by diet, medications.

Speculation p=0.30PSMF for Severe Obesity in ME/CFS

Evidence: PSMF (800–1000 kcal, high protein) forces fat utilization while preserving muscle. Sukkar 2013 demonstrated safety via NG tube; Bakhach 2016 oral.
Citations: —
Mechanism: Very low calories + high protein (1.5–2.0 g/kg IBW) forces fat utilization; continuous amino acid supply preserves muscle.
Chapter ref: ch27: psmf severe obesity
Prediction: 4-week PSMF: less than 25% of weight loss from fat-free mass (DXA).
Treatment: Most aggressive viable option for severely obese patients where weight drives disability.
Limitation: Requires medical supervision (electrolyte monitoring, refeeding risk); zero ME/CFS data.

Speculation p=0.30Liquid PSMF for Severe Bedbound Patients

Evidence: Sukkar 2013 NG PSMF safe in morbid obesity. Liquid form eliminates meal prep barrier for severe patients.
Citations: (Craft et al. 2015)
Mechanism: Liquid PSMF (protein powder + micronutrients, 800–1000 kcal, 100–150 g protein) separates nutrition delivery from meal behavior.
Chapter ref: ch27: psmf severe obesity
Prediction: 8-week PSMF improves lean-to-fat ratio (DXA) vs ad-hoc intake.
Treatment: Eliminates all meal-related barriers for patients who cannot prepare food or chew.
Limitation: Most extreme intervention; requires medical supervision; zero ME/CFS data.

Speculation p=0.30Butyrate + Berberine + Protein as GLP-1 Pathway Stack

Evidence: All three components documented as GLP-1 modulators (ch27). Combination may produce synergistic endogenous GLP-1 stimulation.
Citations: —
Mechanism: Berberine activates AMPK; butyrate stimulates colonic L-cells; protein (leucine) stimulates GLP-1/PYY. Pulsatile rather than continuous receptor activation.
Chapter ref: ch27: glp1 pathway stack
Prediction: Stack increases post-prandial GLP-1 AUC ≥30% vs protein alone.
Treatment: “DIY GLP-1” approach — all components available, safe, no prescription required.
Limitation: Combination unstudied; GLP-1 AUC effect unknown; requires responsible framing.

Speculation p=0.30Berberine Dose-Timing for AMPK Synergy

Evidence: Berberine activates AMPK (same target affected in ME/CFS). Timing before largest meal may maximize effect (ch27).
Citations: —
Mechanism: 500 mg berberine 30 min before largest meal maximizes AMPK activation, improves fat oxidation, potentiates GLP-1 secretion.
Chapter ref: ch27: berberine dose timing
Prediction: Pre-meal berberine reduces post-prandial glucose AUC vs with-meal dosing.
Treatment: Accessible, cheap; timing optimization costs nothing.
Limitation: No ME/CFS timing data; berberine bioavailability varies by formulation; potential GI side effects.

Speculation p=0.30Cachexia-Like PEM Muscle Loss as Distinct Phenotype

Evidence: Some ME/CFS patients lose muscle rapidly during PEM, resembling cancer cachexia. TNF-α, IL-6, activin/myostatin drive proteolysis.
Citations: (Scheibenbogen and Wirth 2025)
Mechanism: PEM-associated inflammatory signaling drives active catabolic muscle loss via ubiquitin-proteasome and autophagy-lysosome pathways, not just disuse.
Chapter ref: ch27: cachexia pem phenotype
Prediction: PEM episodes elevate urinary activin/myostatin and 3-methylhistidine vs baseline.
Treatment: Shifts from “eat more protein” to “block catabolic signal” — pharmacological approach.
Limitation: Inflammatory signaling during PEM not fully characterized; cachexia analogy untested.

Speculation p=0.30ME/CFS as Chronic Low-Grade Catabolic Syndrome

Evidence: Cancer cachexia = rapid inflammatory muscle wasting. ME/CFS = slow PEM-driven wasting. Difference may be cytokine amplitude, not pathway.
Citations: (Scheibenbogen and Wirth 2025)
Mechanism: Same catabolic pathways at lower intensity; same anti-catabolic treatments at lower doses may be effective.
Chapter ref: ch27: slow cachexia phenotype
Prediction: Serum activin A or myostatin elevated in ME/CFS vs sedentary BMI-matched controls.
Treatment: Reframes ME/CFS from “functional fatigue syndrome” to “chronic low-grade catabolic syndrome.”
Limitation: No direct biomarker data; cytokine amplitude difference hypothesis untested.

Speculation p=0.25GLP-1 RA + ActRII Blockade Combination

Evidence: GLP-1 RAs produce 10–15% weight loss with 25–60% from lean mass. ActRII blockade preserves muscle during GLP-1 RA in preclinical models.
Citations: (Wilding et al. 2021) (Neeland, Linge, and Birkenfeld 2024) (Stefanakis et al. 2024)
Mechanism: Microdose GLP-1 RA for appetite + ActRII blockade (bimagrumab) for muscle preservation → fat-predominant weight loss with improved muscle mass.
Chapter ref: ch27: glp1 actriib combo
Prediction: Combination reduces proportion of weight loss from lean mass below 25% in human trial.
Treatment: For severe obesity + bedbound patients where substantial fat loss outweighs lean mass risk.
Limitation: Preclinical only; no human combination data; bimagrumab not approved for this indication.

Speculation p=0.25Urolithin A for Mitophagy-Directed Muscle Preservation

Evidence: Urolithin A induces mitophagy; clinical trials in sarcopenia show muscle strength benefits. ME/CFS mitochondrial damage central (Scheibenbogen 2025).
Citations: (Scheibenbogen and Wirth 2025)
Mechanism: Urolithin A removes dysfunctional mitochondria producing ROS instead of ATP; improves muscle mitochondrial quality.
Chapter ref: ch27: urolithin mitophagy
Prediction: 12-week Urolithin A improves 31P-MRS recovery kinetics vs placebo.
Treatment: Targets root mitochondrial pathology rather than downstream weight changes.
Limitation: No ME/CFS data; conversion from ellagitannins depends on gut microbiome composition.

Speculation p=0.25Cancer Cachexia Drugs Repurposed for ME/CFS

Evidence: Cancer cachexia shares elevated myostatin/activin, ubiquitin-proteasome activation, mitochondrial dysfunction with ME/CFS.
Citations: (Scheibenbogen and Wirth 2025)
Mechanism: Cachexia drugs (ActRIIB-Fc, anamorelin, SARMs, beta-blockers) directly applicable to preserving muscle in catabolic state where exercise is impossible.
Chapter ref: ch27: cachexia drugs repurposed
Prediction: Anamorelin increases lean mass (DXA) in ME/CFS over 12 weeks.
Treatment: Drug repurposing accelerates access — safety data already available from cancer trials.
Limitation: Bridge to ME/CFS speculative; cachexia drug doses may not translate; side effect profiles in ME/CFS unknown.

Speculation p=0.25taVNS for Post-COVID-19 Condition — Systematic Review and Null Controlled Trial Evidence

Evidence: Balan et al. 2026 systematic review (5 studies, n=154): all controlled trials null for clinical efficacy despite confirmed HRV engagement. Best-powered RCT (Percin et al., n~50): sham > active for fatigue. COVIVA sham-controlled RCT (n=45): no between-group differences. Positive signals from uncontrolled single-arm studies only. GRADE: efficacy “very low,” safety “low.” This evidence constrains the therapeutic inference from shared vagal dysfunction across PCC, ME/CFS, and POTS.
Citations: (Balan et al. 2026) (Percin et al. 2025) (Gierthmuehlen et al. 2026)
Mechanism: taVNS → confirmed HRV modulation → no clinical superiority over sham → HRV engagement does not translate to symptomatic benefit in post-infectious fatigue.
Chapter ref: ch28: tvns pcc systematic review; ch14d: tvns sham superior paradox; ch27: tvns pcc null evidence
Prediction: Sham-controlled ME/CFS taVNS trial will reproduce PCC pattern: HRV increase confirmed, no between-group clinical difference. Falsified if active taVNS shows clinically meaningful between-group effect on FUNCAP or PROMIS Fatigue at 12 weeks.
Treatment: Temper enthusiasm for tVNS as near-term ME/CFS treatment. Resolve mechanism before large trial: understand why HRV engagement fails to translate into clinical benefit.
Limitation: No ME/CFS-specific trial. PCC is the closest population — 5 studies provide indirect constraint. Sham-superior paradox unresolved. Evidence from PCC may not fully generalise to ME/CFS given different chronicity and severity.

Speculation p=0.20Vagal Tone Modulation for Appetite Regulation

Evidence: taVNS well-studied in depression/epilepsy; appetite effects preliminary. Vagal dysfunction hypothesized in ME/CFS (ch13).
Citations: —
Mechanism: taVNS improves vagal tone, enhances satiety signaling, increases parasympathetic drive to reduce stress-induced overeating. No exercise, 20 min/day lying down.
Chapter ref: ch27: vagal tone appetite
Prediction: 4 weeks taVNS reduces hunger scores (VAS) or increases post-prandial GLP-1 in ME/CFS vs sham.
Treatment: Addresses autonomic dysfunction other interventions don’t touch.
Limitation: No ME/CFS data; taVNS device cost; optimal parameters unknown in this population.

Speculation p=0.15TRH/T3 Augmentation for Hypometabolic State

Evidence: ME/CFS resembles non-thyroidal illness syndrome (low T3, normal TSH, elevated rT3). Low-dose T3 could increase metabolic rate.
Citations: —
Mechanism: Low-dose T3 or TRH increases metabolic rate without full thyroid suppression risk; target is functional hypometabolism, not hormone deficiency.
Chapter ref: ch27: trh t3 augmentation
Prediction: Low-dose T3 increases REE in ME/CFS with low T3/rT3 ratio vs placebo.
Treatment: Only for severe hypometabolic cases where other measures have failed.
Limitation: High risk — increased metabolic demand may worsen PEM; cardiac risk; requires extremely careful monitoring.

Speculation p=0.15UCP1 Thermogenesis via Mild Cold Exposure

Evidence: BAT activation via mild cold (16–19°C, 2–4 h/d) increases EE by 100–300 kcal/d in healthy. ME/CFS cold intolerance and autonomic dysfunction common.
Citations: (Buchholz, McGillivray, and Pencharz 2003)
Mechanism: Cold-induced thermogenesis provides non-exercise metabolic boost; but cold stress may trigger PEM, sympathetic overactivation, Raynaud’s exacerbation.
Chapter ref: ch27: cold thermogenesis
Prediction: Mild cold exposure (18°C, 2 h/d, 4 weeks) increases REE ≥5% without triggering PEM.
Treatment: Potential non-exercise metabolic boost for bedbound patients.
Limitation: More likely harmful than helpful; contraindicated in cold intolerance, Raynaud’s, autonomic dysfunction.

Question: Why does sham stimulation outperform active taVNS in the best-controlled PCC trials? Candidate explanations: (a) non-monotonic dose-response — standard parameters overshoot therapeutic window in autonomically compromised patients; (b) sham auricular input is non-specifically therapeutic, and active parameters counteract these benefits; (c) PCC natural history recovery obscures small between-group differences; (d) GPCR autoantibody receptor-level blockade makes increased vagal firing inert. p=(Balan et al. 2026) (Percin et al. 2025)n/a

Evidence: 3-arm sham-controlled trial (sham vs standard-dose tVNS vs low-dose tVNS) with GPCR AAb stratification to distinguish between candidate explanations.
Citations: ch14d:If POTS, ME/CFS, and Long COVID Share Vagal Dysfunction, Why Does Sham tVNS Outperform Active tVNS in Long COVID RCTs?
Mechanism: Falsified as a whole if no active arm separates from sham in any AAb-stratified subgroup at n >= 30 per arm, indicating the treatment premise itself is unsupported. Candidate (a) refuted if both active doses equivalent to sham; (b) refuted if sham does not outperform both active arms by >= 5 PROMIS points; (d) refuted if AAb-high patients respond equivalently to AAb-low.
Chapter ref: Periacetabular Brown Fat Activation in Immobility
Prediction: S
Treatment: 0.10
Limitation: BAT inactive in ME/CFS due to low sympathetic tone, warm environment, inflammation. Pharmacological activation (mirabegron) risky.

BAT activation could provide 100–300 kcal/d extra expenditure; but beta3-agonists activate same dysregulated sympathetic system. p=ch27:Periacetabular Brown Fat Activation During Immobility(Buchholz, McGillivray, and Pencharz 2003)

Evidence: Mirabegron increases supraclavicular BAT glucose uptake (18F-FDG PET) without orthostatic intolerance.
Citations: Potential metabolic boost for bedbound patients if safe activation achievable.
Mechanism: Highly speculative; more likely harmful than helpful; cardiovascular effects of beta3-agonists in ME/CFS unknown.
Chapter ref: ME/CFS as Functional Narcolepsy Type 2: Cytokine Mediated Orexin Suppression
Prediction: S
Treatment: 0.30
Limitation: ME/CFS involves chronic neuroinflammation that functionally suppresses orexin neuron activity, producing an acquired NT2-like state without autoimmune orexin neuron destruction. Animal models show IL-1$\beta$/TNF-$\alpha$ suppress orexin neurons; chemogenetic reactivation reverses lethargy. Plasma orexin-A reduced in post-COVID fatigue. However, CSF orexin-A not reduced in MS fatigue (null) and no anti-orexin autoantibodies in ME/CFS (null).

Post-viral infection $arrow$ chronic cytokine elevation $arrow$ IL-1$\beta$/TNF-$\alpha$ suppress orexin neuron firing in lateral hypothalamus $arrow$ functional orexin deficiency (reversible) $arrow$ fatigue + sleep fragmentation + autonomic instability. Distinct from NT1 autoimmune destruction (irreversible). p=ch14d:ME/CFS as Functional Narcolepsy Type 2: Cytokine-Mediated Orexin Suppression Without Autoimmune Destruction(Grossberg et al. 2011) (Gaykema and Goehler 2009) Ruhrländer et al. (2025; Constantinescu et al. 2011) (Germain et al. 2025)

Evidence: CSF orexin-A in ME/CFS falls in NT2 gray zone (110–200 pg/mL) in $\geq$ 30% of patients vs $\leq$ 5% controls; correlates inversely with fatigue severity ($r \geq 0.3$) and with CSF IL-6/TNF-$\alpha$. OX2R agonist improves fatigue $\geq$ 20% in 4-week trial. Falsified if CSF orexin-A indistinguishable from controls in $\geq$ 90% of patients.
Citations: If confirmed, OX2R agonists (danavorexton, oveporexton) could be repurposed for ME/CFS fatigue/sleep; anti-inflammatory treatment may restore orexin function.
Mechanism: No CSF orexin-A data in ME/CFS; plasma is poor proxy; MS null suggests pathway may be disease-specific; autoantibody null weakens but does not refute functional suppression hypothesis.
Chapter ref: Orexin Neurons as Metabolic Canaries: Preferential Failure Under Bioenergetic Stress
Prediction: S
Treatment: 0.20
Limitation: Orexin neurons are among the most metabolically demanding neurons (unmyelinated axons, massive arborization, autonomous pacemaking). Under systemic mitochondrial stress they may fail preferentially, analogous to substantia nigra dopaminergic neurons in Parkinson’s. CPT1B/carnitine link supports metabolic vulnerability.

Systemic mitochondrial dysfunction $arrow$ reduced ATP supply $arrow$ high-demand orexin neurons fail first $arrow$ fatigue + sleep disruption as early indicator of metabolic reserve depletion. CPT1B polymorphism impairs fatty acid $\beta$-oxidation $arrow$ orexin neuron vulnerability. p=ch14d:Orexin Neurons as Metabolic Canaries: Preferential Failure Under Systemic Bioenergetic Stress(Horiuchi et al. 2015) (Grossberg et al. 2011) (R. Rauf et al. 2025)

Evidence: CSF orexin-A correlates with PBMC spare respiratory capacity and serum lactate:pyruvate ratio ($r \geq 0.3$); ME/CFS patients with lowest orexin show most severe PEM. Carnitine supplementation increases CSF orexin-A $\geq$ 10% in carnitine-deficient ME/CFS. Falsified if orexin does not correlate with any mitochondrial function measure.
Citations: Positions orexin-A as early biomarker for metabolic reserve depletion; motivates carnitine supplementation trials with orexin as outcome.
Mechanism: Metabolic canary concept is by analogy with Parkinson’s; no direct evidence for preferential orexin vulnerability in ME/CFS. CPT1B data from single low-quality study.
Chapter ref: Orexin Tone as Metabolic Thermostat for R_headroom
Prediction: S
Treatment: 0.25
Limitation: Orexin neurons among most metabolically demanding CNS cells. Architecture C systemic metabolic deficit may express as orexin neuron dysfunction — orexin tone as central R_headroom readout.

Low systemic R_headroom $arrow$ orexin failure $arrow$ reduced CNS reserve. p=ch14d:Orexin Tone as a Metabolic Thermostat for R_headroom(Grossberg et al. 2011) (Horiuchi et al. 2015)

Evidence: Lowest PBMC spare respiratory capacity $arrow$ lowest CSF orexin-A (stronger than cytokine-orexin).
Citations: Orexin-A as CNS metabolic reserve biomarker.
Mechanism: No direct R_headroom-orexin study.
Chapter ref: Subclinical SOREMs as PEM Triggers
Prediction: S
Treatment: 0.20
Limitation: Ito 2023: orexin deficiency causes REM fragmentation. Partial deficiency may produce subclinical REM intrusions fragmenting NREM, preventing glymphatic clearance.

Sub-threshold REM intrusions $arrow$ fragmented NREM $arrow$ impaired glymphatic $arrow$ lower PEM threshold. p=ch14d:Subclinical SOREMs as PEM Triggers(Ito et al. 2023)

Evidence: 2-5x more REM intrusions in ME/CFS vs controls; count predicts next-day PEM (r > 0.4).
Citations: Automated sleep EEG scoring; OX2R agonists.
Mechanism: Requires automated EEG not validated in ME/CFS.
Chapter ref: Dual Hit Orexin Pathology
Prediction: S
Treatment: 0.30
Limitation: Functional suppression + T-cell destruction coexist: chronic neuroinflammation suppresses orexin AND gradually primes immune attack causing 10-30% loss over years.

Chronic neuroinflammation $arrow$ functional suppression + T-cell priming $arrow$ partial structural loss $arrow$ reversible+irreversible components. p=ch14d:Dual-Hit Orexin Pathology: Functional Suppression + Incomplete Autoimmune Destruction(Grossberg et al. 2011) (Lopez, Barateau, and Dauvilliers 2023) (Germain et al. 2025)

Evidence: CD8+ T-cell reactivity to orexin peptides; negative correlation with CSF orexin (r < -0.4); 20-40% postmortem HCRT reduction.
Citations: Anti-inflammatory + immunosuppression may be needed.
Mechanism: No CSF orexin T-cell or postmortem data in ME/CFS.
Chapter ref: Sex Specific Orexin Neuron Vulnerability
Prediction: S
Treatment: 0.25
Limitation: Estrogen increases orexin neuron metabolic demand, making female neurons more vulnerable. Explains 3-4x female predominance and perimenopausal onset.

Estrogen $arrow$ increased metabolic demand $arrow$ greater cytokine vulnerability $arrow$ female predominance. p=ch14d:Sex-Specific Orexin Neuron Vulnerability via Estrogen Modulation(Grossberg et al. 2011)

Evidence: Estradiol-treated LPS rodents: greater orexin suppression. Human: CSF orexin lowest in perimenopausal-onset women.
Citations: HRT/SERM modulation.
Mechanism: No sex-disaggregated orexin data.
Chapter ref: OX2R Downregulation from Chronic Low Orexin
Prediction: S
Treatment: 0.20
Limitation: Chronic low orexin produces OX2R downregulation in targets (LC, TMN). Even if orexin restored, receptors unresponsive — pharmacological tolerance.

Chronic low agonist $arrow$ GPCR desensitization $arrow$ reduced OX2R $arrow$ blunted orexin response. p=ch14d:OX2R Downregulation as Consequence of Chronic Low-Orexin Tone(R. Rauf et al. 2025)

Evidence: 4-week LPS reduces OX2R mRNA in LC/TMN; blunted acute danavorexton response.
Citations: OX2R agonist dose-escalation needed in trials.
Mechanism: No OX2R chronic suppression studies.
Chapter ref: Orexin Suppression as Epiphenomenon
Prediction: S
Treatment: 0.15
Limitation: Null findings in MS + no anti-orexin antibodies + acute-LPS limitation suggest orexin suppression is downstream of deeper metabolic failure.

Upstream mitochondrial failure $arrow$ suppresses orexin among others $arrow$ orexin treatments target downstream readout $arrow$ fail. p=ch14d:Orexin Suppression as Epiphenomenon, Not Mechanism(Constantinescu et al. 2011) (Germain et al. 2025)

Evidence: OX2R agonist RCT no significant fatigue/PEM improvement despite sleep consolidation.
Citations: Redirect to mitochondrial/IMM research.
Mechanism: No OX2R agonist trials in ME/CFS.
Chapter ref: NT2 and ME/CFS as Same Disease
Prediction: S
Treatment: 0.10
Limitation: NT2: EDS+MSLT without cataplexy, intermediate orexin (110-200). ME/CFS also meets EDS criteria. Diagnostic boundary may be artifact of which specialty seen.

Diagnostic artifact: sleep clinic $arrow$ NT2; ME/CFS clinic $arrow$ ME/CFS. Same intermediate orexin. p=ch14d:NT2 and ME/CFS as the Same Disease at Different Stages(R. Rauf et al. 2025) (López-Amador 2025)

Evidence: CSF orexin overlaps between NT2 and ME/CFS; continuous not bimodal symptom profiles.
Citations: Collapses two disease categories.
Mechanism: No simultaneous CSF orexin in both.
Chapter ref: Shared Orexin Dopamine in ADHD and ME/CFS
Prediction: S
Treatment: 0.25
Limitation: Orexin projects to VTA regulating DA firing. Deficiency reduces prefrontal DA (brain fog) and mesolimbic reward (anhedonia). 8.1% lower glucose in ADHD may be same hypothalamic orexin deficit.

Orexin deficiency $arrow$ reduced VTA DA $arrow$ prefrontal DA reduction + anhedonia. p=ch14d:Shared Orexin-Dopamine Dysregulation in ADHD and ME/CFS(Sakurai et al. 1998)

Evidence: Lowest CSF orexin-A: lowest CSF HVA, worst CPT-3, higher ADHD scores.
Citations: OX2R agonists may have dual fatigue+cognitive benefit.
Mechanism: No ME/CFS DA-orexin-attention study.
Chapter ref: Bidirectional Orexin Mast Cell Loop
Prediction: S
Treatment: 0.20
Limitation: Mast cells express OX1R/OX2R. Orexin activates mast cells; mast cell mediators suppress orexin. Orexin tightens BBB via OX1R — deficiency increases permeability.

Orexin-B deficiency $arrow$ reduced OX2R brainstem $arrow$ baroreflex blunted $arrow$ POTS. p=ch14d:Orexin-Baroreflex Failure as the POTS MechanismRuhrländer et al. (2025)

Evidence: CSF orexin-B inversely correlates with POTS; OX2R agonist pre-tilt reduces HR >15 bpm.
Citations: Orexin-B biomarker; OX2R agonist for ME/CFS+POTS.
Mechanism: No CSF orexin-B in POTS.
Chapter ref: Orexin Collagen Crosstalk in hEDS
Prediction: S
Treatment: 0.10
Limitation: hEDS involves altered TGF-beta. Orexin-A inhibits TGF-beta1 via OX1R. Deficiency reduces inhibition, increasing TGF-beta signaling.

SARS-CoV-2 $arrow$ orexin destruction (narcolepsy) or partial suppression (ME/CFS) $arrow$ gray-zone orexin $arrow$ ME/CFS risk. p=ch14d:Post-COVID Narcolepsy as Sentinel for Orexin-Targeted ME/CFS Prevention(Lopez, Barateau, and Dauvilliers 2023) Ruhrländer et al. (2025)

Evidence: 2-5% COVID develop new EDS; 30-50% gray-zone orexin; gray-zone predicts >50% ME/CFS at 12 months.
Citations: Early OX2R agonist in sentinel population.
Mechanism: COVID-narcolepsy link emerging.
Chapter ref: Danavorexton for ME/CFS PEM
Prediction: S
Treatment: 0.20
Limitation: OX2R agonist bypassing endogenous orexin. Increased MWT +11.1 in NT1. Could improve fatigue, cognition, PEM regardless of orexin neuron status.

OX2R agonism $arrow$ direct activation $arrow$ bypasses endogenous orexin $arrow$ improves fatigue/cognition/PEM. p=ch14d:Danavorexton as Targeted Oxidative Stress Therapy for ME/CFS PEM(R. Rauf et al. 2025) (Grossberg et al. 2011)

Evidence: During 2-day CPET: post-exertional FAS >40% reduction in orexin-low subgroup.
Citations: First mechanistically rational PEM drug.
Mechanism: No ME/CFS trial.
Chapter ref: Almorexant Short DORA
Prediction: S
Treatment: 0.15
Limitation: ~3h half-life may produce narrow orexin antagonism — enough NREM initiation without impairing later glymphatic processes.

Short half-life $arrow$ narrow orexin suppression $arrow$ NREM initiation without later impairment. p=ch14d:Almorexant as Short-Half-Life DORA for Sleep Architecture(Ito et al. 2023)

Evidence: Increases SWS >20% first cycle, improves DTI-ALPS, reduces unrefreshing sleep > longer DORAs.
Citations: Repurposing abandoned drug.
Mechanism: Withdrawn for CNS safety.
Chapter ref: Sulforaphane as Orexin Protective
Prediction: S
Treatment: 0.15
Limitation: Nrf2 activator upregulating antioxidant genes. Orexin neurons vulnerable to oxidative stress. Nrf2 in hypothalamus protects from cytokine damage.

Sulforaphane $arrow$ Nrf2 $arrow$ antioxidant genes $arrow$ protects orexin from cytokine/oxidative damage. p=ch14d:Sulforaphane as Orexin-Protective Nrf2 Activator(Horiuchi et al. 2015)

Evidence: 8 weeks: plasma orexin-A >15%, fatigue >20% improvement vs placebo.
Citations: Low-risk OTC orexin-protective supplement.
Mechanism: No direct orexin-Nrf2 studies.
Chapter ref: PGE2/EP3 Antagonists Disinhibit Orexin
Prediction: S
Treatment: 0.20
Limitation: PGE2 at EP3 at BBB transmits inflammatory signal to orexin. EP3 antagonists block gateway without systemic immunosuppression.

Cytokines $arrow$ PGE2 $arrow$ EP3 $arrow$ orexin suppression. EP3 antagonist $arrow$ blocks gateway. p=ch14d:PGE2/EP3 Antagonists to Disinhibit Orexin Neurons(Grossberg et al. 2011)

Evidence: EP3 antagonist in LPS model prevents orexin suppression; attenuates lethargy >50%.
Citations: Rescues orexin without immunosuppression.
Mechanism: EP3 antagonists research compounds only.
Chapter ref: LDN as Orexin Disinhibiting Agent
Prediction: S
Treatment: 0.25
Limitation: LDN microglial TLR4 antagonism reduces hypothalamic PGE2/TNF-alpha, disinhibiting orexin. Novel mechanism for established ME/CFS drug.

LDN $arrow$ TLR4 $arrow$ reduced microglial PGE2/TNF-alpha $arrow$ orexin disinhibition. p=ch14d:LDN as Orexin-Disinhibiting Agent via Microglial Suppression(Grossberg et al. 2011)

Evidence: LDN responders: plasma orexin-A increases vs non-responders; correlates with fatigue improvement (r > 0.5).
Citations: Reclassifies LDN from empirical to mechanistically rational.
Mechanism: No orexin measured in LDN-treated ME/CFS.
Chapter ref: L Carnitine + CoQ10 for Orexin Support
Prediction: S
Treatment: 0.20
Limitation: Orexin neurons depend on FAO. Horiuchi: carnitine deficiency causes orexin dysfunction. CoQ10 supports ETC. Combination supports orexin firing.

Carnitine $arrow$ FAO + CoQ10 $arrow$ ETC = orexin firing maintained under energy deficit. p=ch14d:L-Carnitine + CoQ10 for Orexin Neuron Bioenergetic Support(Horiuchi et al. 2015)

Evidence: 12 weeks: plasma orexin-A >20%, 6MWT >30 m; orexin correlates with function.
Citations: Low-risk low-cost CNS-validated intervention.
Mechanism: No combination orexin study.
Chapter ref: Glycine as Orexin Sparing Sleep Aid
Prediction: S
Treatment: 0.20
Limitation: Promotes sleep via SCN NMDA + glycinergic inhibition of orexin. Unlike Z-drugs, mechanism orexin-sparing — only during sleep initiation.

Apigenin $arrow$ GABAA + NF-kB $arrow$ reduced hypothalamic cytokines $arrow$ protects orexin. p=ch14d:Apigenin as Orexin-Protective Flavonoid(Grossberg et al. 2011)

Evidence: LPS mouse: attenuates orexin suppression >30% (Fos), lethargy >25%.
Citations: Safe food-derived sleep cocktail component.
Mechanism: No orexin-specific studies.
Chapter ref: PQQ as Orexin Mitochondrial Enhancer
Prediction: S
Treatment: 0.10
Limitation: Stimulates mitochondrial biogenesis via PGC-1alpha. Orexin high mitochondrial demand makes them dependent on turnover.

Morning light $arrow$ SCN $arrow$ SCN-orexin entrainment $arrow$ normalized rhythm amplitude. p=ch14d:Morning Bright Light for Orexin Entrainment(Sakurai et al. 1998)

Evidence: 4 weeks: circadian orexin-A amplitude >30%, fatigue >20% vs dim-red placebo.
Citations: Low-cost timing-critical refinement.
Mechanism: No orexin measured before/after light therapy.
Chapter ref: Cold Exposure for Orexin Activation
Prediction: S
Treatment: 0.15
Limitation: Dive reflex activates trigeminal-parasympathetic arc to LH. Orexin activated by cold stress. Brief exposure transiently activates.

Cold face $arrow$ trigeminal-parasympathetic reflex $arrow$ LH orexin $arrow$ transient release. p=ch14d:Timed Cold Exposure for Orexin Activation(Dauvilliers et al. 2011)

Evidence: 30-sec 10 degrees C: plasma orexin-A >15%, PVT >10%, pain VAS >20%.
Citations: Zero-cost no-equipment intervention.
Mechanism: Patient tolerance unknown.
Chapter ref: Slow Breathing for Orexin Vagal Coupling
Prediction: S
Treatment: 0.15
Limitation: Vagal afferent mediates inflammation-to-orexin suppression. Slow breathing enhances vagal tone, reducing inflammation signaling and modulating orexin via NTS.

Slow breathing $arrow$ vagal tone $arrow$ reduced inflammation signaling + orexin modulation. p=ch14d:Slow Breathing + Binaural Beats for Orexin-Vagal Coupling(Gaykema and Goehler 2009)

Evidence: 8 weeks: serum orexin-A >10%, fatigue >30%; HRV predicts orexin (R^2 > 0.5).
Citations: Free home-based first-line intervention.
Mechanism: No combined slow breathing + orexin measurement.
Chapter ref: Eliminating Orexin Suppressing Meds
Prediction: S
Treatment: 0.20
Limitation: DORAs, clonidine, BZDs, Z-drugs, beta-blockers suppress orexin. In low-orexin ME/CFS, these may exacerbate deficiency.

Non-invasive screen $arrow$ stepped escalation $arrow$ orexin-directed care for excluded. p=ch14d:Triage-Based Orexin Protocol for Severe PatientsRuhrländer et al. (2025)

Evidence: n=30 severe: >50% receive orexin-directed intervention; >20% show >30% fatigue reduction.
Citations: Addresses severe patient access gap.
Mechanism: No orexin-specific severe protocol.
Chapter ref: Orexin Responsive Subtype Algorithm
Prediction: S
Treatment: 0.20
Limitation: Algorithm: plasma orexin, actigraphy, ESS/FAS, MSLT, CPT1B defines orexin-responsive subtype.

Algorithm $arrow$ orexin-responsive subtype $arrow$ enriched OX2R response. p=ch14d:Orexin-Responsive ME/CFS Subtype Classification Algorithm(R. Rauf et al. 2025) (Horiuchi et al. 2015)

Evidence: 50% OX2R response in algorithm-defined subtype vs $<$ 10% non-orexin.
Citations: Stratification for efficient trials.
Mechanism: Algorithm requires validation.
Chapter ref: R_headroom + Orexin CNS Reserve Model
Prediction: S
Treatment: 0.20
Limitation: Add orexin variable O_t to Architecture C ODE. Orexin neurons priority consumers. Below threshold, orexin drops, reducing whole-brain reserve.

R_headroom below threshold $arrow$ orexin drops $arrow$ reduced CNS reserve $arrow$ PEM at higher systemic R_headroom. p=ch14d:R_headroom Extended with Orexin Tone as CNS-Specific Reserve(Grossberg et al. 2011)

Evidence: Model predicts PEM at higher systemic R_headroom when CNS orexin impaired; OX2R agonist shifts threshold left.
Citations: More complete Architecture C.
Mechanism: No ODE incorporated orexin.
Chapter ref: DAG Orexin Glymphatic Microglia Bifurcation
Prediction: S
Treatment: 0.25
Limitation: Extend DAG: orexin $arrow$ LC-NE $arrow$ glymphatic $arrow$ microglia $arrow$ cytokine $arrow$ orexin. Bifurcation analysis for bistability.

Positive feedback: orexin $arrow$ LC-NE $arrow$ glymphatic $arrow$ microglia $arrow$ cytokine $arrow$ orexin. Bifurcation determines stable states. p=ch14d:DAG Extension: Orexin-Glymphatic-Microglia Feedback Loop with Bifurcation(Grossberg et al. 2011)

Evidence: Bifurcation parameter: sudden onset crossed rapidly; gradual near threshold cross slowly.
Citations: Unifies sudden vs gradual onset.
Mechanism: Bifurcation novel for ME/CFS.
Chapter ref: ODE Orexin Boom Bust Dynamics
Prediction: S
Treatment: 0.15
Limitation: Boom-bust as relaxation oscillator: boom = orexin max; bust = crash below baseline. Pacing stabilizes mid-range.

Relaxation oscillator: boom $arrow$ max $arrow$ exhaustion $arrow$ bust $arrow$ slow recovery. Pacing $arrow$ stabilization. p=ch14d:ODE Model of Orexin Dynamics Under Boom-Bust Cycle(Grossberg et al. 2011)

Evidence: Optimal rest:activity 2:1 in orexin-deficient vs 1:1 controls.
Citations: Quantitative pacing prescription.
Mechanism: No orexin PEM model.
Chapter ref: CSF Orexin A Case Control Study (Research Question)
Prediction: OQ
Treatment: n/a
Limitation: No study has measured CSF orexin-A in ME/CFS. Animal models and post-COVID plasma data support dysfunction; MS null shows disease specificity.

CSF orexin-A resolves whether ME/CFS involves orexin dysfunction. Positive $arrow$ OX2R agonist trials. Null $arrow$ redirects to circadian or metabolic hypotheses. p=ch14d:Does ME/CFS Produce Acquired Orexinergic Dysfunction Detectable by CSF Orexin-A Measurement?(Grossberg et al. 2011) (Gaykema and Goehler 2009) Ruhrländer et al. (2025; Constantinescu et al. 2011)

Evidence: CSF orexin-A falls in NT2 gray zone (110–200 pg/mL) in $\geq$ 30% of ME/CFS vs $\leq$ 5% controls.
Citations: Foundational measurement determining orexin hypothesis viability.
Mechanism: LP requirement limits feasibility.
Chapter ref: Definitive CSF Orexin A LP Study (Protocol Design)
Prediction: OQ
Treatment: n/a
Limitation: Specific study protocol: CSF orexin-A in ME/CFS vs healthy, NT1, NT2 with standardized circadian-controlled sampling. Extends the research question Does ME/CFS Produce Acquired Orexinergic Dysfunction Detectable by CSF Orexin-A Measurement? with 4-group comparison and correlation endpoints.

Direct CSF orexin resolves fundamental question with disease-comparator design. p=ch14d:CSF Orexin-A as Definitive Case-Control LP Study(R. Rauf et al. 2025)

Evidence: 30-50% of ME/CFS in NT2 gray zone; orexin correlates with sleep (r > 0.4) and PEM (r > 0.3).
Citations: Determines orexin hypothesis viability.
Mechanism: LP barrier.
Chapter ref: OX2R PET Ligand for Neuron Integrity
Prediction: OQ
Treatment: n/a
Limitation: CSF measures output not distinguishing functional vs structural. OX2R PET provides in vivo density.

OX2R PET $arrow$ neuron density $arrow$ resolves functional vs structural. p=ch14d:OX2R PET Ligand for Orexin Neuron Integrity(R. Rauf et al. 2025)

Evidence: PET reduction: NT2 >30%, NT1 >60%, ME/CFS 10-30%. Predicts OX2R response.
Citations: Resolves functional vs structural.
Mechanism: No OX2R PET ligand exists.
Chapter ref: Orexin A Challenge Test for Subtyping
Prediction: OQ
Treatment: n/a
Limitation: Single OX2R agonist dose: serial autonomic, fatigue VAS, PVT identifies orexin-responsive patients.

Acute challenge $arrow$ responders define orexin-responsive subtype. p=ch14d:Orexin-A Challenge Test for ME/CFS Subtyping(Grossberg et al. 2011) (Weymann et al. 2014)

Evidence: 40-60% respond (>20% VAS + >15% PVT in 60 min).
Citations: Practical fast subtyping.
Mechanism: No human challenge data.
Chapter ref: HLA DQB1*02 in ME/CFS
Prediction: OQ
Treatment: n/a
Limitation: 98% NT1 carry vs 25% general. If ME/CFS shares autoimmune mechanism, elevated frequency. Null strengthens functional hypothesis.

Elevated frequency $arrow$ autoimmune; normal $arrow$ functional suppression. p=ch14d:HLA-DQB1*06:02 Frequency in ME/CFS(Lopez, Barateau, and Dauvilliers 2023)

Evidence: 30-40% in ME/CFS with lowest CSF orexin vs 25% in normal-orexin.
Citations: Low-cost genetic test.
Mechanism: No ME/CFS study.
Chapter ref: Preclinical Orexin PEM Model
Prediction: OQ
Treatment: n/a
Limitation: Exercise + immune challenge with orexin calcium imaging tests whether exercise inflammation suppresses orexin firing.

Exercise + immune challenge $arrow$ orexin imaging $arrow$ firing drops in primed group. p=ch14d:Orexin Neuron Activity During PEM in a Preclinical Model(Grossberg et al. 2011)

Evidence: Firing drops 40-60% in primed vs 10-20% exercise-only; recovery correlates with activity.
Citations: Validated PEM-orexin model for drug screening.
Mechanism: No chronic exercise+immune paradigm.
Chapter ref: CSF Orexin B/A Ratio Biomarker
Prediction: OQ
Treatment: n/a
Limitation: Orexin-A and -B differentially processed. Ratio distinguishes global loss from processing disruption.

Ratio: normal = global loss; altered = processing-deficit. p=ch14d:CSF Orexin-B/A Ratio as ME/CFS Subtype Biomarker(López-Amador 2025)

Evidence: Ratio differs between subtypes; predicts OX2R response.
Citations: Novel biomarker.
Mechanism: Orexin-B rarely measured.
Chapter ref: Salivary Orexin A Home Biomarker
Prediction: OQ
Treatment: n/a
Limitation: Salivary orexin circadian pattern. If correlates with CSF, timed overnight collection = home CNS orexin proxy.

Salivary rhythm $arrow$ correlates with CSF $arrow$ non-invasive orexin proxy. p=ch14d:Nighttime Salivary Orexin-A as Home-Assessable BiomarkerRuhrländer et al. (2025)

Evidence: Blunted in ME/CFS; correlates with actigraphy (r > 0.4) and unrefreshing sleep (r < -0.3).
Citations: Orexin assessment without LP.
Mechanism: No validated salivary orexin assay.
Chapter ref: Pupillographic Sleepiness as Orexin Surrogate
Prediction: OQ
Treatment: n/a
Limitation: Pupil controlled by sympathetic/parasympathetic modulated by orexin. PST instability in NT1 may reflect orexin deficiency.

Orexin deficiency $arrow$ reduced pupil sympathetic tone $arrow$ elevated PUI. p=ch14d:Pupillographic Sleepiness Test as Orexin Tone Surrogate(Nardone et al. 2011)

Evidence: PUI negatively correlates with CSF orexin (r > 0.5); predicts orexin $<$ 200 $>$ 80% sensitivity.
Citations: Cheap non-invasive office screening.
Mechanism: No orexin-PST correlation studied.
Chapter ref: CPT1B Genotyping as Orexin Risk Marker
Prediction: OQ
Treatment: n/a
Limitation: CPT1B rate-limiting for FAO. Horiuchi: rs2267384 associated with narcolepsy. Orexin neurons prefer FAO.

Risk allele $arrow$ reduced FAO $arrow$ impaired orexin energy supply. p=ch14d:CPT1B Genotyping as Genetic Risk Marker for Orexin Dysfunction(Horiuchi et al. 2015)

Evidence: rs2267384 enriched in ME/CFS with CSF orexin $<$ 200.
Citations: 5-minute PCR for predisposition.
Mechanism: Horiuchi low-certainty. No ME/CFS study.
Chapter ref: CSF Orexin A Phase Shift Artifact
Prediction: S
Treatment: 0.25
Limitation: CSF orexin varies 2x diurnally. NT1 threshold under standardized conditions. No ME/CFS study controlled circadian phase.

Speculation p=n/aCandidate Mechanisms for tVNS Sham-Superior Paradox and Resolution Trial Design

Evidence: Four candidate mechanisms: (1) GPCR AAb receptor-level CAP blockade (cert 0.35), (2) inadequate target engagement readout — HRV misses CAP engagement (cert 0.45), (3) non-monotonic dose-response (cert 0.15), (4) sham non-specific somatosensory benefit with active unblinding (cert 0.25). Proposed resolution: three-arm, AAb-stratified, multi-biomarker trial with brainstem fMRI substudy. Origin: brainstorm.
Citations: (Balan et al. 2026) (N. Azcue et al. 2026b) (T. Nelson et al. 2021)
Mechanism: Multivariate biomarker panel (HRV + plasma SPMs + TNF-$\alpha$ + NTS fMRI) + GPCR AAb stratification → resolves which mechanism(s) explain the dissociation → informs whether and how to proceed with ME/CFS tVNS development.
Chapter ref: ch28: tvns dissociation mechanisms; ch14d: tvns sham superior paradox
Prediction: At least one active arm separates from sham in AAb-low subgroup with correlated SPM/cytokine improvement; AAb-high patients show no clinical benefit despite any active dose. NTS fMRI distinguishes from peripheral-only engagement. Falsified if no arm separates in any subgroup or no biomarker correlation pattern emerges.
Treatment: Sham-Dose Paradox in tVNS for Post-Infectious Fatigue
Limitation: O

Open Question p=n/aREE Measurement Gap: Single Most Important Missing Data Point for ME/CFS Weight Management

Evidence: Zero published studies measuring REE by indirect calorimetry in ME/CFS. Current caloric recommendations based entirely on healthy-population equations.
Citations: —
Mechanism: Without REE data, all weight management guidance in ME/CFS is extrapolated. Multi-site study needed: indirect calorimetry, DXA/BIA, accelerometry across severity levels.
Chapter ref: ch27: ree mecfs severity
Prediction: —
Treatment: Establishes evidence base for severity-stratified caloric guidance.
Limitation: Indirect calorimetry requires patient cooperation and may be difficult in very severe patients.

Open Question p=n/aWeight Loss May Improve ME/CFS Symptoms in Obese Patients

Evidence: FM meta-analysis (D’Onghia 2021, 58 studies): weight loss by any modality improves pain, fatigue, function. No equivalent ME/CFS study. Shared pathophysiology (central sensitization, mitochondrial dysfunction) suggests analogous benefit.
Citations: (D’Onghia et al. 2021) (Caumo et al. 2025)
Mechanism: If obesity compounds functional impairment (Flores 2013) and disrupts pain inhibition (Caumo 2025), weight loss may reduce central sensitization and improve ME/CFS symptom burden.
Chapter ref: ch27: weight loss symptom improvement
Prediction: —
Treatment: Carefully designed ME/CFS-adapted weight loss trial: high-protein, non-exercise, body-composition-monitored. Primary endpoint: DSQ-PEM, secondary: pain, function, fatigue.
Limitation: PEM risk from caloric restriction. No ME/CFS-specific weight loss trial exists.

22 TRPM3, MMP-9, IL-11 and Inflammaging

Speculation p=0.50mTOR Tone Index: pSer258-ATG13/Total ATG13 Ratio as mTORC1 Activity Biomarker

Evidence: pSer258-ATG13 is directly phosphorylated by mTORC1 at the autophagy initiation complex (ULK1/ATG13/FIP200). The phospho/total ATG13 ratio reflects the fraction of the autophagy gate actively held closed — a direct mTORC1 “tone” readout. Normalizes inter-individual ATG13 expression differences. Preliminary signal from Ruan 2025 rapamycin pilot: reduced pSer258-ATG13 after treatment (Ruan et al. 2025). Suitable as pharmacodynamic biomarker for mTORC1-targeted interventions. (Mannick and Lamming 2023) (Ruan et al. 2025) (Rachakatla and Kalashikam 2022)
Citations: (Mannick and Lamming 2023) (Ruan et al. 2025) (Rachakatla and Kalashikam 2022)
Mechanism: mTORC1 activity→ATG13 Ser258 phosphorylation→pSer258-ATG13/total ATG13 ratio quantifies mTORC1 “tone” at the autophagy gate. A tone index >0.5 (>50% of ATG13 phosphorylated) predicts non-functional autophagy initiation. Post-24-hour-fasted ratio provides “autophagy reserve” score. Proximal, dynamic, mechanistically specific.
Chapter ref: ch06: mTOR tone index
Prediction: Fed/fasted pSer258-ATG13 ratio discriminates ME/CFS from healthy (AUC >0.75, n=50/group). Patients with tone index >2.0 show ≥2× higher response rate to rapamycin/metformin vs tone index ≤1.5. Test-retest ICC >0.7 over 4 weeks. Falsified if ratio does not discriminate groups or predict treatment response.
Treatment: Tone index as companion biomarker for mTOR-targeted therapy selection in clinical trials. PBMC immunoblot (USD 200–300 per sample) — research-accessible, not yet standardized for clinical use.
Limitation: Only one study (Ruan 2025) has measured pSer258-ATG13 in ME/CFS — uncontrolled pilot. No formal validation in healthy ME/CFS cohorts. Dynamic range, circadian variation, meal influence, and inter-laboratory reproducibility unknown.

Speculation p=0.45Nocturnal Autophagy Failure as the Cellular Basis of Unrefreshing Sleep

Evidence: Autophagy peaks during the overnight fasted period when mTORC1 is naturally suppressed. In ME/CFS, constitutive mTORC1 hyperactivation (Section The Biogenesis Trap: ME/CFS Cells Waste Energy on Dysfunctional Mitochondrial Production in Chapter Energy Metabolism and Mitochondrial Function) may blunt the nocturnal autophagy surge, preventing clearance of cellular waste accumulated during the day. The patient wakes with the same cellular burden, producing subjective unrefreshing sleep despite objectively adequate sleep architecture. Distinct from sleep architecture theories — explains failure of cellular restoration, not sleep quality. (Drosen et al. 2025) (Rachakatla and Kalashikam 2022)
Citations: (Drosen et al. 2025) (Rachakatla and Kalashikam 2022)
Mechanism: SNS→PKA→AMPK suppression→mTORC1 constitutively active→nocturnal autophagy fails→damaged proteins/mitochondria accumulate overnight→unrefreshing sleep. Interventions restoring circadian autophagy (TRE, metformin, rapamycin) should improve sleep recovery scores independently of sleep time/architecture.
Chapter ref: ch06: nocturnal autophagy sleep
Prediction: PBMC pSer258-ATG13 shows flattened nighttime rhythm (nocturnal decline < 20%) in ME/CFS vs healthy (> 40% decline) during 24-hour inpatient sampling. Rapamycin (morning dosing) restores the trough and improves subjective unrefreshing sleep by week 4. Falsified if nocturnal pSer258-ATG13 rhythm is normal in ME/CFS.
Treatment: TRE, metformin, or rapamycin as autophagy restoration strategies for unrefreshing sleep. No clinical recommendation — rapamycin is research-stage. TRE is safest but requires trial in ME/CFS sleep context.
Limitation: Mechanism inferred from general circadian autophagy biology. No serial pSer258-ATG13 measurements performed in ME/CFS. Unrefreshing sleep may have multiple causes — mTORC1-driven autophagy failure is one candidate mechanism, not the sole explanation.

Speculation p=0.40mTORC1→IMPDH→Purine Metabolism→Mitochondrial Dysfunction Axis

Evidence: Gile et al. (2026) Phase II observational study (n=86 enrolled; 70 day 36, 40 day 90 — 53% attrition): LCMS purine metabolomics showed rapamycin modulates IMP→XMP conversion via IMP dehydrogenase (IMPDH) inhibition. Flow cytometry confirmed reduced IMPDH activity. Purine supplementation induced mitochondrial oxidative stress in PBMCs; rapamycin partially mitigated. Seahorse OCR: improved mitochondrial respiration (basal, ATP-linked, maximal, spare capacity) in responder PBMCs after 90 days. Microglial inflammation reduced. Same Simmaron/Bateman Horne/Mayo consortium as prior rapamycin/ATG13 studies. Uncontrolled (no placebo). NCT06257420. 0.50→0.40: trial design limits (no control group, responder-biased molecular data, single consortium) constrain certainty to lower bound of medium range. (Gile et al. 2026)
Citations: (Gile et al. 2026)
Mechanism: mTORC1 hyperactivation → IMPDH upregulation (via ATF4-mediated transcriptional control of one-carbon pathway) → elevated IMP→XMP flux → purine intermediate accumulation → purine-driven mitochondrial oxidative stress → impaired mitochondrial respiration (basal, ATP-linked, maximal OCR) → extracellular purine release → microglial P2X7 receptor activation → NLRP3 inflammasome → IL-1β → neuroinflammation. Distinct from mTORC1→ATG13→autophagy block — parallel downstream pathology contributing to mitochondrial dysfunction via a different biochemical route.
Chapter ref: ch07: mTOR/AMPK autophagy balance, ch08: mTOR→SASP endothelial senescence
Prediction: IMPDH activity elevated in ME/CFS PBMCs vs controls (≥1.5-fold) and correlates with mTORC1 activity (pS6K, p4E-BP1). Rapamycin reduces IMPDH activity and normalizes the IMP/XMP ratio in a dose-dependent manner. Purine supplementation at ME/CFS plasma-relevant concentrations impairs mitochondrial OCR in control PBMCs. The P2X7→NLRP3 link is falsified if rapamycin’s microglial anti-inflammatory effect is independent of purine concentration changes (i.e., IMPDH inhibition and microglial markers do not correlate within patients).
Treatment: IMPDH as drug target downstream of mTORC1 — could be modulated without direct mTORC1 inhibition (avoiding immunosuppression from mTORC2 co-inhibition). Mycophenolate mofetil (IMPDH inhibitor) is FDA-approved for transplant immunosuppression but carries its own risk profile. No clinical recommendation — both rapamycin and IMPDH inhibitors are research-stage for ME/CFS.
Limitation: Uncontrolled study (no placebo). 53% attrition at 90 days. Molecular results biased to responders — purine/metabolic improvement may reflect responder biology, not rapamycin effect per se. Single consortium (Simmaron) — needs independent replication. IMPDH→P2X7→NLRP3 cascade in ME/CFS microglia is entirely inferred from separate biochemical data. IMPDH inhibitor alternative (mycophenolate) has different risk profile not evaluated in ME/CFS.

Hypothesis p=0.30mTOR Hyperactivation → BBB Compromise → Pediatric Neuroinflammation in Post-Infectious Syndromes

Evidence: Fronticelli Baldelli and Buonsenso (2025) narrative review: proposes mTOR as mechanistic link between peripheral infection-driven inflammation and CNS dysfunction in pediatric post-infectious syndromes. Stepwise cascade: sustained mTOR activation→T-cell/macrophage pro-inflammatory skew→BBB compromise (endothelial mTOR weakens tight junctions, increases vesicular transport)→microglial mTOR→neuroinflammation, impaired synaptic plasticity. Framework spans Long COVID, ME/CFS, PANS/PANDAS in children. pS6 as candidate mTOR pathway biomarker. (Fronticelli Baldelli and Buonsenso 2025)
Citations: (Fronticelli Baldelli and Buonsenso 2025)
Mechanism: Inferred cascade (review-level; no single experiment has demonstrated consecutive steps in pediatric post-infectious patients): Infection→sustained mTORC1 activation in immune cells→pro-inflammatory T-cell/macrophage polarization (proposed, not measured in pediatric post-infectious cohorts)→endothelial mTOR signaling proposed to weaken BBB tight junctions and increase vesicular transport (review inference; no pediatric BBB permeability data post-infection)→cytokines and autoreactive cells may enter CNS→engagement of mTOR in microglia and neurons proposed to drive neuroinflammation, impaired synaptic maintenance, and neurotransmitter disruption→fatigue, cognitive dysfunction, neuropsychiatric symptoms. The endothelial mTOR→BBB link is structurally unfalsifiable at current resolution (no method to isolate endothelial mTOR signaling from systemic mTOR activity in pediatric BBB in vivo); only the coarse pS6⊗BBB-marker correlation is testable.
Chapter ref: ch08: mTOR→SASP endothelial senescence
Prediction: Pediatric post-infectious patients (Long COVID, ME/CFS) show elevated pS6 in PBMCs vs healthy controls. pS6 levels correlate with BBB permeability markers (S100B, CSF/serum albumin ratio). Rapamycin reduces pS6 and BBB permeability markers in a pediatric trial. Falsified if pS6 is normal in pediatric post-infectious patients or if mTOR inhibition does not reduce BBB permeability.
Treatment: mTORC1 inhibitors (rapamycin) as potential intervention for pediatric post-infectious neuroinflammation. Entirely preclinical for pediatrics — no human pediatric mTOR inhibitor trial for post-infectious syndromes exists. Safety concerns: rapamycin is an immunosuppressant with growth and developmental risks in children.
Limitation: Review only — no primary human data. Pediatric focus with adult ME/CFS inference. Many steps lack pediatric human evidence. Endothelial mTOR→BBB tight-junction/vesicular-transport steps are structurally unfalsifiable at current technical resolution. Single-proponent model. mTOR→psychiatric symptoms link is plausible but untested in children with post-infectious syndromes. Journal: MDPI Children (IF ~2.5). Proceed with extreme caution: pediatric rapamycin use carries additional developmental risks beyond adult safety concerns.

Speculation p=0.35Serum IL-11 Elevation Reflects Accelerated Inflammaging in ME/CFS

Evidence: First report of elevated serum IL-11 in ME/CFS (n=40 vs 38, p < 0.001) (Chinnappan et al. 2026). IL-11 is a master regulator of inflammaging — IL-11 KO mice live ~25% longer with reduced aging pathology (Widjaja et al. 2024). 0.30→0.35: convergence with HMGB1 DAMP — both feed into NLRP3 inflammasome endpoint via distinct pathways.
Citations: (Chinnappan et al. 2026) (Widjaja et al. 2024)
Mechanism: IL-11 elevation → JAK/STAT and NF-κB signaling → NLRP3 inflammasome activation, ERK/AMPK/mTORC1 dysregulation → chronic sterile inflammation mimicking accelerated aging → fatigue, cognitive dysfunction, metabolic impairment.
Chapter ref: ch07: il 11 inflammaging
Prediction: Plasma IL-11 (citrate plasma) elevated in independent ME/CFS cohort; correlates with p16INK4a and SASP proteins. Falsified if plasma IL-11 is normal in independent cohort.
Treatment: Anti-IL-11 therapy is preclinical (mouse only). Zero clinical recommendation at present.
Limitation: Single unreplicated study. Serum (not plasma) used — same pre-analytical caveat as MMP-9. Age mismatch (51 vs 43, p < 0.05) confounds age-dependent IL-11 expression. Samples stored >10 years at -80°C. Mouse data only for inflammaging model.

Speculation p=0.35EBV-Directed Mast Cell Degranulation as MMP-9 Source in ME/CFS

Evidence: rEBV protein (100 ng/ml) activates human cord blood-derived mast cells to release MMP-9 in vitro (2,464 vs 433 pg/ml, p < 0.001, n=3) (Chinnappan et al. 2026). 0.30→0.35: convergence with GPCR AAb→Mast Cell Sensitization Loop (cert 0.35) — different mast cell activation inputs, independent mechanisms converging on shared effector.
Citations: (Chinnappan et al. 2026) (Kempuraj et al. 2024) (Bonetto et al. 2022)
Mechanism: EBV reactivation → viral proteins activate tissue mast cells → MMP-9 release → ECM degradation, BBB disruption → peripheral inflammatory mediators access CNS → neuroinflammation, cognitive dysfunction. Convergent pathway with spike protein → microglia MMP-9 in Long COVID.
Chapter ref: ch07: ebv mast cell mmp9
Prediction: Plasma MMP-9 higher in EBV-reactive ME/CFS (EA-IgG, VCA-IgM positive) vs EBV-latent. Mast cell stabilizers (cromolyn, ketotifen) reduce plasma MMP-9 in EBV-reactive patients. Falsified if plasma MMP-9 does not differ by EBV reactivation status or mast cell stabilizers do not reduce it.
Treatment: Mast cell stabilizers would be low-risk intervention targeting upstream MMP-9 release. No clinical recommendation without plasma-based replication.
Limitation: Entirely in vitro (cord blood mast cells, not ME/CFS patient cells). n=3 due to 12-week culture requirement. Serum MMP-9 used for human data — must be replicated in plasma (see ch20:Critical Pre-Analytical Caveat: Serum vs Plasma for MMP-9). Unreplicated.

Speculation p=0.35MMP-9 BBB Neuroinflammatory Trap as Self-Amplifying Loop

Evidence: EBV → mast cell → MMP-9 (Chinnappan et al. 2026). MMP-9 correlates with BBB disruption (S100B) (Bonetto et al. 2022). Spike protein → microglia → MMP-9 (Kempuraj et al. 2024) (Tsilioni and Theoharides 2023). 0.30→0.35: convergence with HMGB1 DAMP (cert 0.55) — both propose self-amplifying neuroinflammatory loops via different amplification axes (MMP-9/BBB vs TLR4/RAGE).
Citations: (Chinnappan et al. 2026) (Bonetto et al. 2022) (Kempuraj et al. 2024) (Tsilioni and Theoharides 2023)
Mechanism: Initiation: viral proteins → mast cell MMP-9 → BBB tight junction degradation. Amplification: peripheral IL-11 entry → microglial MMP-9 → further BBB damage → more peripheral entry. Persistence: loop becomes self-sustaining even after trigger resolution. TRPM3 dysfunction impairs calcium-dependent BBB repair.
Chapter ref: ch14h: mmp9 bbb neuroinflammatory trap
Prediction: Serial plasma/CSF S100B + MMP-9 + IL-11 show progressive increase over 12 months. S100B predicts subsequent MMP-9/IL-11 increases (Granger causality). Mast cell stabilizers reduce plasma MMP-9. Falsified if MMP-9 normalizes during remission periods or if CSF MMP-9 is normal in ME/CFS.
Treatment: Mast cell stabilizers + MMP-9 inhibitors could break the loop if administered early. No clinical recommendation without longitudinal data confirming loop dynamics.
Limitation: No single study has measured all loop components simultaneously in ME/CFS. Loop inferred from separate populations (ME/CFS, COVID-19). BBB data from COVID-19, not ME/CFS. All MMP-9 studies to date used serum — magnitudes unreliable.

Speculation p=0.35Serum/Plasma MMP-9 Ratio as Platelet Activation Biomarker

Evidence: Serum MMP-9 is 3-4× higher than plasma due to platelet/leukocyte degranulation during clotting (Jung et al. 2008) (Olson et al. 2008). ME/CFS may involve platelet hyperactivation (limited evidence). Ratio = serum MMP-9 / plasma MMP-9 from paired samples provides functional platelet activation readout. Precedent in chronic spontaneous urticaria. Low-cost, ELISA-based, clinically accessible.
Citations: (Jung et al. 2008) (Olson et al. 2008) (Garvin et al. 2015)
Mechanism: If ME/CFS platelets are hyperactive → greater MMP-9 release during clotting → higher serum/plasma MMP-9 ratio than controls. Ratio captures platelet biology otherwise invisible to standard platelet count. Validated ratio provides functional platelet assay without flow cytometry.
Chapter ref: ch20: mmp9 ratio platelet biomarker
Prediction: In paired samples (n=50 ME/CFS, n=50 controls), ratio differentiates groups (AUC >0.70) and correlates with PF4, beta-thromboglobulin, P-selectin. Falsified if ratio does not differ between ME/CFS and controls or does not correlate with established platelet activation markers.
Treatment: Ratio provides platelet function information to refine antiplatelet or mast-cell-stabilizing treatment stratification. Not a clinical recommendation.
Limitation: Ratio concept is novel — never formally validated. Sampling protocol must be rigorously standardized (tube type, centrifugation, time-to-freeze). Confounded by medications (aspirin, NSAIDs), platelet count, recent exercise. Not validated in ME/CFS.

Speculation p=0.30IL-11 → mTORC1 → PIP2 Depletion → TRPM3 Dysfunction

Evidence: IL-11 elevation in ME/CFS (Chinnappan et al. 2026). IL-11 drives ERK/AMPK/mTORC1 (Widjaja et al. 2024). TRPM3 gating requires PIP2; reduced TRPM3/PIP2 co-localization in ME/CFS (Eaton-Fitch et al. 2021). 0.25→0.30: convergence with PIP2/GPCR Convergence (cert 0.45) — independent upstream mechanisms (mTORC1 vs PLC) converging on same PIP2 depletion endpoint.
Citations: (Chinnappan et al. 2026) (Widjaja et al. 2024) (Eaton-Fitch et al. 2021)
Mechanism: IL-11 → mTORC1 hyperactivity → PIP2 depletion in NK cell membranes → reduced TRPM3 gating → impaired Ca2+ flux → reduced NK cytotoxicity. Links two independent ME/CFS findings into a unified causal cascade.
Chapter ref: ch14h: il11 trpm3 inflammaging
Prediction: ME/CFS NK cells exposed to IL-11 at patient serum concentrations show reduced TRPM3-mediated Ca2+ flux within 24-48h. Anti-IL-11 antibody pre-treatment prevents this effect. Rapamycin partially restores TRPM3 function. Falsified if IL-11 does not affect TRPM3 function or mTORC1 inhibition does not restore it.
Treatment: If validated, anti-IL-11 or mTORC1 modulation (rapamycin) could restore TRPM3 function. Both are preclinical for ME/CFS. No clinical recommendation.
Limitation: IL-11→TRPM3 link entirely inferred. No two consecutive steps demonstrated in same experiment. IL-11 data from unreplicated Chinnappan 2026. mTORC1-PIP2 link in immune cell membranes not directly demonstrated. mTORC1 can increase, not deplete, PIP2.

Speculation p=0.25Bimodal Lithium Dose-Response: Multiple Mechanism-Specific Optima

Evidence: Lithium engages multiple targets with different concentration optima: NCS-1/InsP3R1 modulation (IC50 ~350 µM), IMPase inhibition (IC50 ~0.8 mM), GSK-3β inhibition (IC50 ~2 mM). Toricelli 2021 demonstrates a preclinical bimodal dose-response in hippocampal cultures: neuroprotection and anti-inflammatory effects (reduced IL-1α, IL-6, NF-κB; increased IL-10) at 2-20 µM Li₂CO₃ vs toxicity at 200 µM. Clinical evidence consists of three data points at three doses from non-comparable systems (Sikorav 2mg positive, Guttuso 10-15mg null, Guttuso 40-45mg positive). This is a post-hoc observation, not an emergent pattern — the available points are consistent with biphasic, monotonic, or flat dose-response given measurement variance. (Toricelli et al. 2021) (Guttuso, Zhu, and Zahra 2024) (Sikorav 2026)
Citations: (Toricelli et al. 2021) (Guttuso, Zhu, and Zahra 2024)
Mechanism: Different Li⁺ mechanisms engage at different concentrations. NCS-1/IP3R modulation (nM-µM) may dominate at microdoses; IMPase/GSK-3β (µM-mM) at low-therapeutic doses. Different clinical endpoints (sensory hypersensitivity, fatigue, cognition, suicidal ideation) may have different dose-response curves. Formal demonstration requires prospective dose-ranging study — current data are insufficient to claim a validated pattern.
Chapter ref: ch08: low dose lithium
Prediction: A dose-ranging study (2, 10, 20, 40 mg Li⁺) in ME/CFS should show non-monotonic efficacy curves across endpoints. Falsified if all endpoints improve or fail along the same monotonic dose-response curve. Falsified with stronger evidence if dose-ranging in a relevant cellular model (GPCR-stimulated PBMCs) shows graded, not multiphasic, Li⁺ effects on IP3-mediated Ca²⁺ transients.
Treatment: If validated, lithium dose selection would be mechanism-specific: 1-5 mg for sensory/suicidal endpoints, 40-45 mg for cognitive/fatigue endpoints. No clinical recommendation without prospective confirmation.
Limitation: Post-hoc observation from three non-comparable systems. No controlled dose-ranging study. Toricelli bimodal curve is in-vitro mouse data — human translation unknown. Between-subject lithium pharmacokinetic variability (renal clearance, tissue distribution) may produce overlapping serum concentrations across dose zones.

Speculation p=0.25Sensory Hypersensitivity as PIP₂ Gating Instability in TRP Channels

Evidence: Sikorav 2026 case report: sensory hypersensitivity (sound, screens, crowds, eye contact) occurred exclusively during depressive episodes and resolved completely on lithium citrate 2 mg/day. The episode-specific, state-dependent pattern suggests a threshold mechanism — when PIP₂ drops below a critical level, TRP channel gating becomes unstable (“noisy” channels, spontaneous opening, hyper-response to subthreshold stimuli). Lithium may stabilize the system by modestly reducing PI cycle flux (even at nM-µM concentrations) and smoothing PIP₂ supply-demand balance. This is distinct from treating depression — lithium stabilizes the sensory gating system directly, and mood improvement follows reduced sensory assault. (Sikorav 2026) (Eaton-Fitch et al. 2021) (S. Saha, Krishnan, and Raghu 2023)
Citations: (Sikorav 2026) (Eaton-Fitch et al. 2021) (S. Saha, Krishnan, and Raghu 2023)
Mechanism: PIP₂ depletion→TRPM3/TRPV1/Piezo channel gating instability→sensory hypersensitivity during low-PIP₂ states (episodes). Lithium→reduced PI cycle flux→stabilized PIP₂ supply-demand balance→reduced channel noise→sensory hypersensitivity resolution. Mood improvement is downstream of sensory stabilization, not the primary mechanism.
Chapter ref: ch08: ultralow dose lithium case
Prediction: ME/CFS patients with sensory hypersensitivity should show TRPM3/PIP₂ co-localization deficit inversely correlated with sensory gating scores. Lithium (2-5 mg/day) should increase TRPM3/PIP₂ co-localization and reduce sensory gating deficits in parallel at 8 weeks. Falsified if TRPM3/PIP₂ co-localization does not correlate with sensory scores (r < 0.2) or if lithium does not affect co-localization.
Treatment: If validated, lithium microdose (1-5 mg/day) could be investigated as a sensory hypersensitivity intervention in ME/CFS — entirely research-stage. No clinical recommendation. TRPM3/PIP₂ co-localization assays are research tools, not clinical labs.
Limitation: Based on n=1 self-report in a non-ME/CFS patient. No direct evidence of lithium effects on TRP channel gating at microdoses. PIP₂ measurement in human immune cells is a research technique with limited standardization. Sensory gating deficit in ME/CFS has face validity but no quantitative TRPM3/PIP₂ correlation data.

Speculation p=0.25Lithium as Trigger-Specific Stress Resilience Modifier

Evidence: The Sikorav 2026 case identifies a specific trigger profile: sleep deprivation, alcohol, altitude change, seasonal summer fatigue — all increase cerebral metabolic demand or reduce cerebral oxygen delivery. The key behavioral observation: “ability to feel fatigue without depressive cascade” — stress resilience improvement, not constant symptom suppression. This suggests lithium at ultralow doses may raise the threshold for trigger-induced decompensation (PEM-like phenomenon) rather than acting as a constant mood stabilizer. Mechanism: if lithium slightly reduces futile ER Ca²⁺ cycling via NCS-1/IP3R modulation (see NCS-1 in ME/CFS: Elevated, Normal, or Reduced?), the metabolic cost of maintaining cellular homeostasis decreases, leaving more reserve capacity for trigger-related demands. (Sikorav 2026) (Schlecker et al. 2006)
Citations: (Sikorav 2026) (Schlecker et al. 2006)
Mechanism: Chronic IP3 signaling→futile ER Ca²⁺ cycling→elevated ATP demand for SERCA→reduced metabolic reserve→triggers (sleep deprivation, altitude, alcohol) push system past compensation threshold→symptom cascade. Lithium (nM-µM)→NCS-1/IP3R modulation→reduced Ca²⁺ leak→increased metabolic reserve→higher trigger tolerance→ability to experience fatigue without cascade.
Chapter ref: ch08: ultralow dose lithium case
Prediction: Within-subject trial of 2 mg lithium citrate vs placebo during controlled stress challenge (sleep restriction, hypoxic challenge): lithium should reduce symptom escalation. ER calcium store content (thapsigargin-releasable pool) should increase after 4 weeks of lithium, reflecting reduced IP3R-mediated leak. Falsified if lithium does not increase stress tolerance or ER Ca²⁺ stores.
Treatment: If validated, lithium microdose would serve as a PEM prevention/prophylaxis strategy — taken before known triggers (travel, sleep disruption) rather than daily for symptom suppression. Entirely speculative — no human data on prophylactic lithium for stress resilience.
Limitation: n=1 self-report in non-ME/CFS patient (no PEM). “Stress resilience” is a subjective construct with no validated quantitative measure in this context. ER Ca²⁺ store content measurement in ME/CFS has not been performed. The mechanism (NCS-1/IP3R at nM Li⁺) is biochemically plausible but unmeasured — the IC50 gap (350 µM vs nM serum) remains a significant uncertainty.

Open Question p=0.20NCS-1/InsP3R1 Amplification of Mast Cell Degranulation and Lithium as Functional Mast Cell Stabilizer

Evidence: Mast cells express NCS-1, which regulates IgE-triggered exocytosis via PI4Kβ (Kappel 2003, cert 0.70). NCS-1 amplifies InsP3R1 channel open probability ~5-fold (Schlecker 2006). Lithium disrupts NCS-1/InsP3R1 at IC50 ~350 µM. MRGPRX2, C3aR, C5aR on mast cells signal through Gαq→PLC→IP3→Ca²⁺→degranulation (Roy 2021 review, cert 0.85). The mechanistic chain (Li→NCS-1 disruption→reduced IP3-mediated Ca²⁺→raised degranulation threshold) is assembled from separate literatures and has no direct experimental support — no study has tested lithium’s effect on mast cell degranulation at any concentration. (Kappel et al. 2003) (Kappel et al. 2006) (Kappel et al. 2007) (Schlecker et al. 2006) (Roy et al. 2021) (Chaki et al. 2022)
Citations: (Kappel et al. 2003) (Schlecker et al. 2006) (Roy et al. 2021)
Mechanism: GPCR autoantibodies (anti-M3, anti-β2AR)→chronic Gαq activation on mast cells→PLC→PIP2→IP3→Ca²⁺→lowered degranulation threshold. NCS-1 amplifies this ~5-fold via InsP3R1. Lithium→NCS-1/InsP3R1 disruption→dampened IP3-mediated Ca²⁺→raised degranulation threshold — functional mast cell stabilizer distinct from cromolyn/ketotifen/omalizumab because it targets the GPCR→PLC→IP3 arm, not the FcεRI pathway.
Chapter ref: ch07: lithium mast cell ncs1
Prediction: Lithium (1-10 µM) pre-incubation should reduce β-hexosaminidase release ≥30% from patient-derived mast cells stimulated with MRGPRX2 agonists (compound 48/80, substance P). Falsified if lithium has no effect or increases degranulation. IgE-mediated degranulation should be unaffected — confirming pathway specificity (Gαq-IP3 vs ITAM-Syk-PLCγ). Plasma tryptase should decrease after 4 weeks of lithium 2 mg/day in MCAS-positive ME/CFS patients.
Treatment: If validated, lithium microdose could be investigated as adjunct mast cell stabilizer for MCAS-dominant ME/CFS — entirely research-stage. Distinct mechanism from cromolyn/ketotifen → possible synergy testing.
Limitation: No study tests Li⁺ effect on mast cell degranulation at any concentration. NCS-1/InsP3R1 interaction never studied in mast cells. NCS-1 expression never measured in ME/CFS tissue. Lithium tissue concentrations at 2 mg/day are unknown; may not reach mast cells at sufficient levels. Mechanism inoperative for IgE-mediated degranulation (FcεRI uses ITAM→Syk→PLCγ, not Gαq).

Open Question p=0.15Lithium as Specialized Pro-Resolving Mediator (SPM) Biosynthesis Enhancer

Evidence: Basselin 2010 demonstrated chronic lithium increases brain 17-HDHA 1.9-fold in rats — 17-HDHA is the committed intermediate for D-series resolvins (RvD1-6) and protectins (PD1), generated by 15-lipoxygenase from DHA. Toricelli 2021 showed microdose lithium (2-20 µM) shifts cytokine profile toward pro-resolution (IL-10↑, IL-6↓, IL-1α↓, NF-κB↓), a profile consistent with resolvin activity though SPMs were not measured. Lithium also inhibits COX-2 and PGE₂ in activated microglia, potentially favoring substrate switch toward SPM biosynthesis. The complete chain (Li⁺→15-LOX→17-HDHA→RvD→GPCR→M2 shift) is assembled from separate literatures; no study has directly measured SPMs after lithium treatment. (Basselin et al. 2010) (Toricelli et al. 2021) (Stachowicz 2023)
Citations: (Basselin et al. 2010) (Toricelli et al. 2021)
Mechanism: Lithium→15-LOX upregulation→DHA conversion to 17-HDHA→resolvin D1-6 and protectin D1 biosynthesis→SPM receptor activation (ChemR23/GPR32/ALX)→active inflammatory resolution→M2/pro-resolving phenotype shift. Provides a mechanistic bridge between Toricelli’s cytokine profile and lithium’s ultralow-dose effects, independent of NCS-1/IMPase/GSK-3β.
Chapter ref: Ch. 17 — SPM family evidence status section
Prediction: LC-MS/MS measurement of resolvin D1, protectin D1, maresin 1 in culture supernatant from lithium-treated (1-10 µM) LPS-stimulated microglia or PBMCs should show ≥50% increase vs vehicle at 24h. Falsified if lithium does not increase SPM levels or if the increase is ≤20%. In vivo: plasma SPM levels should increase after 4 weeks of lithium 2 mg/day in ME/CFS patients. Lithium+EPA/DHA combination should show greater SPM increase than either alone.
Treatment: If validated, lithium+omega-3 combination therapy could target inflammatory resolution in ME/CFS through a novel mechanism (SPM biosynthesis enhancement) — entirely research-stage. No clinical recommendation.
Limitation: No study has measured SPMs after lithium at any dose. Basselin 1.9-fold 17-HDHA increase is in rats at chronic lithium doses — translation to human microdose unknown. 15-LOX expression in human immune cells may differ from rat brain. SPM measurement by LC-MS/MS is specialized and not clinically available. Lithium’s COX-2 inhibition could reduce (not enhance) SPM precursor availability via the COX-2 pathway for aspirin-triggered resolvins.

23 Microvascular and Endothelial Dysfunction

ID / Label	Details	Phase / Cert
spec endothelial-hypertrophy-heterogeneous-perfusion	EM evidence of endothelial hypertrophy in ME/CFS skeletal muscle capillaries (Braeden T. Charlton et al. 2025) may narrow capillary lumens, creating heterogeneous perfusion — perfused and excluded capillaries interleaved — that NIRS averages cannot detect. Combined with RBC stiffness, narrowed capillaries become impassable. Functional capillary dropout without anatomical rarefaction. Origin: brainstorm.	Phase 5 / 0.40
spec capillary-bm-diagnostic-biomarker	Near-complete separation of HC and patients by %BM coverage (max HC 62.7% vs min ME/CFS 63.2%) (Braeden T. Charlton et al. 2025) exceeds discriminative power of any existing blood biomarker. If validated by ROC in pooled multi-country dataset (n > 70), EM-measured %BM coverage could serve as a histological gold-standard diagnostic biomarker — analogous to duodenal biopsy for coeliac disease. Invasive → confirmatory role in equivocal cases; needs non-invasive surrogate (serum HA/TSG-6 or NIRS) for routine use. Origin: brainstorm.	Phase 5 / 0.45
spec systemic-bm-microvascular	Capillary BM thickening documented in 3 limb muscles may be systemic — affecting cardiac, brain, GI, and skin capillaries — explaining multi-system ME/CFS symptoms via a single structural lesion. No multi-organ BM data exist. Testable by skin punch biopsy dermal capillary BM vs vastus lateralis BM correlation. Origin: brainstorm.	Phase 5 / 0.30
oq capillary-bm-alternatives	Five alternative explanations for capillary BM thickening: (1) epiphenomenon of mitochondrial dysfunction, (2) immune-mediated endothelial injury as primary scar, (3) neurovascular dysregulation → hypoxic BM remodeling, (4) long-term deconditioning incompletely excluded by 60d bed rest model, (5) all-of-the-above convergent final common pathway. Not mutually exclusive; treatment strategy depends on which mechanism is dominant in individual patients. Origin: brainstorm critical categories.	Phase 5 / n/a
lim muscle-specific-microvascular	Capillary BM thickening data limited to limb skeletal muscle. No data for diaphragm, cardiac, smooth muscle, or skin capillaries. If muscle-specific → explains exertional symptoms only. If systemic → explains multi-system ME/CFS. Distinction requires same-patient multi-site biopsy. Origin: brainstorm critical categories.	Phase 5 / n/a

24 Iron Redox Polarity

ID / Label	Details	Phase / Cert
hyp iron-redox-polarity-diagnostic-bifurcation	ME/CFS and Long COVID show divergent iron handling: ME/CFS = functional iron deficiency (high ferritin, low TSAT, low hepcidin) vs LC = multi-compartment iron dysregulation (monocyte loading, lymphocyte starvation, stress erythropoiesis). The hepcidin paradox: Kavyani2023 found hepcidin decreased ~50% in ME/CFS — opposite to the IL-6→hepcidin→ferroportin model prediction. Therapeutic bifurcation: iron supplementation may harm ME/CFS functional iron deficiency patients; LC patients need phenotyping (24% have genuine iron deficiency). Evidence: Hanson2024 Nat Immunol (n=214, PASC prediction 72%), Kavor2022 Nat Commun (42 LC+19 ME/CFS comparator), Kavyani2023 Mol Neurobiol, Swiatczak2022 Diagnostics, Baklund2021 J Clin Med, Sonnweber2022, Gietl2024. Falsifiable: head-to-head iron panel comparison must show ferritin/TSAT/hepcidin polarity. Origin: cynaera-gaps investigation + literature synthesis.	Phase 3 / 0.55
hyp erythrocyte-dysfunction-lc-specific	Long COVID shows a distinct erythrocyte-level O2 transport defect (impaired O2-Hb binding, increased CO-Hb, decreased TSAT, elevated MCH) (Kronstein-Wiedemann et al. 2024) — not yet described in ME/CFS. If LC-specific, this provides a second axis of divergence: ME/CFS fatigue is mitochondrial (ATP production failure), LC fatigue additionally involves impaired O2 delivery at RBC level. Falsified if ME/CFS patients also show RBC dysfunction. Testable: co-oximetry + O2 dissociation curves in matched cohorts. Origin: literature integration.	Phase 3 / 0.45
spec iron-ferroptosis-divergent-triggers	Ferroptosis (iron-dependent lipid peroxidation) is a candidate shared mechanism in both conditions with divergent triggers: inflammatory iron overload + GPX4 depletion in LC (Sousa, Yehia, and Abulseoud 2023) vs chronic oxidative stress + impaired antioxidant capacity in ME/CFS in context of functional iron deficiency. The functional-iron-deficiency→ferroptosis link is mechanistically paradoxical (trapped iron should reduce ferroptosis risk) and requires NTBI redistribution hypothesis for coherence. Falsified if lipid peroxidation markers are not elevated in ME/CFS. Indirect evidence only; no tissue-level ferroptosis measurement in either condition. Origin: literature synthesis + brainstorm.	Phase 3 / 0.35
oq iron-chelation-vs-supplementation	When to iron-chelate vs iron-supplement in post-viral fatigue — entirely mechanistic model with zero interventional data. Questions: Does oral iron help/harm ME/CFS stratified by ferritin/TSAT? Does iron chelation improve ME/CFS functional iron deficiency? Does the ~24% of LC with genuine iron deficiency benefit from repletion? Does hepcidin predict response? Until trials exist: measure full iron panel before prescribing; treat genuine ID regardless of diagnosis; do NOT supplement iron in functional ID pattern. Origin: cynaera-gaps investigation.	Phase 3 / n/a

ID / Label	Details	Phase / Cert
spec hepcidin-independent-ferroportin-blockade	Four hepcidin-independent mechanisms may explain the paradox of low hepcidin (Kavyani et al. 2024) yet persistent functional iron deficiency: (a) ferroportin trafficking defect via IRP/IRE dysregulation, (b) ceruloplasmin ferroxidase deficiency preventing iron loading onto transferrin, (c) NCOA4 ferritinophagy blockade trapping iron in ferritin, (d) LCN2/NGAL futile iron cycling. Under this model, low hepcidin is not a paradox — it is a compensatory response to downstream iron export machinery failure. All four mechanisms untested in ME/CFS. Falsified if all four candidates normal. Origin: brainstorm.	Phase 5 / 0.40
spec temporal-phase-shift-iron	The ME/CFS vs LC iron polarity may be temporal, not diagnostic: LC studies sample Phases 0–I (1–6 months: stress erythropoiesis, variable hepcidin) while ME/CFS studies sample Phases II–III (>2 years: low hepcidin, functional iron deficiency). Both may traverse same trajectory at different timepoints. Predicts hepcidin declines progressively over 2+ years in prolonged LC. Falsified if hepcidin remains elevated in long-duration LC >2 years. Origin: brainstorm.	Phase 5 / 0.35
spec monocyte-ferroptosis-amplifier	Iron-loaded monocytes (Hanson2024) may deliver concentrated iron to tissues on macrophage differentiation, sensitizing resident cells to ferroptosis. Creates a monocyte-mediated ferroptosis amplification loop: iron loading → tissue deposition → ferroptosis → DAMP release → monocyte recruitment → more iron delivery. Falsified if ME/CFS monocytes have normal labile iron pool or tissue biopsies show no iron/ferroptosis co-localization. Origin: brainstorm.	Phase 5 / 0.30
pred ferritin-tsat-ratio-diagnostic	Ferritin:TSAT ratio (FTR) as computationally tractable diagnostic tool: FTR over 10 = functional iron deficiency (ferritin ≥150 µg/L, TSAT ≤15%), FTR under 5 = genuine iron deficiency, FTR 5–10 = indeterminate. Predicted AUC ≥0.75 for ME/CFS vs post-COVID-without-ME/CFS discrimination. Requires iron panel only ($20–50), deployable in any primary care setting. Not validated — no study has computed FTR in any post-viral fatigue population. Origin: brainstorm.	Phase 5 / 0.40
spec deferiprone-functional-iron-deficiency	Deferiprone (oral iron chelator, black box: agranulocytosis/neutropenia) as rational intervention if hepcidin-independent ferroportin blockade is the mechanism: membrane-permeable, enters cells without ferroportin, chelates trapped labile iron directly. Danazol (hepcidin antagonist, Danazol/Hepcidin Antagonism for Iron Redistribution) may be misdirected if hepcidin already low. Hypothetical safety pilot: n=10–15, ferritin >150 µg/L + TSAT < 20%, 4 weeks, weekly ANC. NOT a clinical recommendation — black-box warning, fatal infection risk, zero ME/CFS data. Origin: brainstorm.	Phase 5 / 0.30
lim iron-redox-null-hypotheses	Six null hypotheses constraining the iron redox polarity model: N1 measurement artifact (hepcidin single-measurement, cert 0.55 — most testable), N2 patient-selection bias (severe ME/CFS unstudied, cert 0.25), N3 confounding-by-comorbidity (undiagnosed autoimmune/infection driving ferritin, cert 0.30), N4 transient-state (iron normalizes on recovery, cert 0.20), N5 therapeutic-indifference (iron-modifying interventions don’t change outcomes, cert 0.40), N6 common-pathway (iron phenotype is downstream biomarker of upstream pathology, cert 0.50). N1 is highest-priority: independent hepcidin replication would cost $50,000 and take <6 months. Origin: brainstorm — critical categories 11 and 12.	Phase 5 / n/a

25 T-Cell Mitochondrial Exhaustion

ID / Label	Details	Phase / Cert
CD8+ T-Cell Mitochondrial Fragmentation Underlies Acquired Immune Exhaustion	CD8+ T-cell mitochondrial fragmentation (DRP1-mediated fission) as the mechanism underlying acquired immune exhaustion: post-infectious triggers $\rightarrow$ DRP1 activation $\rightarrow$ mitochondrial fission $\rightarrow$ failed metabolic reprogramming $\rightarrow$ epigenetic exhaustion in CD8+ TEM cells. Acquired (not inherited — DecodeME GWAS neuronal enrichment, no immune-cell signal). Consistent with Schreiner 2020 (HHV-6/DRP1 in PBMCs), Missailidis 2020 (Complex V defect in lymphocytes), Mandarano 2020 (metabolic dysfunction), Iu 2024 (exhaustion reprogramming). 3 independent reinforcement domains (ch06 selective-energy, ch07 immune-energy-starvation niche, ch14d HIV/cancer parallels). Falsified if CD8+ TEM mitochondrial morphology is normal on TEM. Origin: brainstorm — literature synthesis.	Phase 7 / 0.60
cd8 fatty acid oxidation shift	Maya 2023: CD4+ and CD8+ T cells + NK cells shift to fatty acid oxidation (away from glycolysis) in ME/CFS (Maya et al. 2023). This may represent a fuel-economy mode preserving survival at the cost of effector function. Origin: literature synthesis.	Phase 3 / 0.50
me cfs immune suppression	Petrov 2026 (n=207): ME/CFS shows immune suppression (reduced costimulatory molecules, impaired CCR7 trafficking), not the activation/exhaustion pattern of Long COVID (Petrov et al. 2026). Eaton-Fitch 2024 confirms at gene expression level: ME/CFS = downregulated IFN/Ig genes (suppression), LC = dysregulated antigen presentation (activation). Origin: literature synthesis.	Phase 3 / 0.65
severity stratified tcell senescence	Lee 2025 (n=96, UK Biobank): severe ME/CFS distinguished from mild/moderate by increased cytotoxic effector molecules + early immunosenescence (CD28−) markers (Lee et al. 2025). Immune dysfunction progresses with severity. Origin: literature synthesis.	Phase 3 / 0.65

ID / Label	Details	Phase / Cert
Systematic Evidence Gaps in the CD8+ T-Cell Mitochondrial Exhaustion Literature	Systematic evidence gaps in CD8+ mitochondrial exhaustion literature: cohort non-independence (Hanson trio = single patient group), activity confounding (no study controls for step count), missing mechanistic intermediate (DRP1 not measured in primary CD8+ TEM cells), functional validation absent (no antigen-specific recall assay), small sample winner’s curse (largest study n=53). Cumulative probability CD8+ mito exhaustion is primary causal mechanism: ~17%. Three highest-priority experiments: TEM imaging, DRP1 quantification in CD8+ TEM, antigen-specific recall assay. Origin: brainstorm — evidence quality assessment.	Phase 5 / 0.75
Null Hypotheses for T-Cell Mitochondrial Exhaustion	Five nested null hypotheses for CD8+ mitochondrial exhaustion: N1 activity confound (P~0.45), N2 no clinical consequence (P~0.35), N3 CNS-primary — downstream of neuroendocrine/autonomic dysfunction (P~0.30), N4 protective exhaustion — adaptive brake limiting immunopathology (P~0.20), N5 measurement artifact (P~0.15). Cumulative probability all five are false: ~17%. Nulls are testable with experiments of feasible scope (6–18 months). Origin: brainstorm — null hypothesis assessment.	Phase 5 / n/a
DRP1-ROS-pERK Positive Feedback Loop May Make CD8+ Mitochondrial Fragmentation Self-Sustaining	DRP1-ROS-pERK positive feedback loop: DRP1 activation → mito fragmentation → ETC disruption → ROS → ERK1/2 phosphorylation → DRP1 Ser616 phosphorylation → sustained fission. Documented in cancer/neurodegeneration but untested in ME/CFS T cells. Schreiner 2020 (DRP1 in PBMCs) + Shankar 2025 (lymphocyte ROS + SOD2 depletion) provide two nodes; pERK is the missing third. Predicts reversibility: breaking loop at any node should restore mito fusion. Distinguished from irreversible damage model. Falsified if p-DRP1(Ser616) and p-ERK are normal in CD8+ TEM cells. Origin: brainstorm.	Phase 5 / 0.40
Research Priorities for Validating the CD8+ T-Cell Mitochondrial Exhaustion Hypothesis	Three highest-impact experiments for CD8+ mitochondrial exhaustion: (1) TEM imaging of sorted CD8+ TEM cells — confirm/refute fragmentation prediction, (2) DRP1/fission-fusion protein quantification in primary CD8+ TEM cells — the missing mechanistic link, (3) antigen-specific recall response with concurrent metabolic readout — test whether metabolically exhausted cells actually fail to respond. Origin: brainstorm — research gap synthesis.	Phase 5 / n/a
HIV-Associated CD8+ T-Cell Mitochondrial Dysfunction as a 30-Year Natural Experiment for ME/CFS	HIV (virally suppressed on ART) produces CD8+ phenotype strikingly similar to ME/CFS: elevated PD-1/TIM-3, reduced mito respiration, FAO shift, CD28− senescence, impaired recall. Persists without detectable virus — strongest clinical precedent for post-viral CD8+ exhaustion without chronic replication. HIV field has developed dual-phenotyping panel (PD-1/TIM-3 for exhaustion + CD28/CD57 for senescence) distinguishing reversible from irreversible dysfunction. NAC trials in HIV partially restored CD4+/CD8+ counts — clinical precedent for antioxidant CD8+ restoration. mtDNA depletion documented in HIV+ CD8+ cells (Morse 2019) — technical roadmap. No direct HIV-ME/CFS comparison exists. Origin: brainstorm — cross-disease.	Phase 5 / 0.40
ME/CFS CD8+ Exhaustion vs Cancer Immunotherapy Exhaustion: Shared Transcriptional Machinery, Different Triggers	ME/CFS CD8+ TEM cells express same exhaustion TFs (TOX, EOMES, TCF7) as tumor-infiltrating lymphocytes (David S. Iu et al. 2024). Key difference: trigger is likely mitochondrial metabolic failure, not chronic antigen (Cliff 2019 found no HHV seroprevalence differences n=251 (Cliff et al. 2019); Petrov 2026 found immune suppression not activation (Petrov et al. 2026)). Checkpoint inhibitors (PD-1 blockade) contraindicated pending ex vivo safety data — risk of triggering autoimmunity in autoimmune-prone population (GPCR autoantibodies). TCF7 expression may identify “early” (reversible) exhaustion subset responsive to metabolic interventions. TCR clonality distinguishes polyclonal (mitochondrial) vs oligoclonal (antigen-driven) exhaustion. Origin: brainstorm — cross-disease.	Phase 5 / 0.35

26 Hypothalamic CRH-Neuron Depletion

Speculation p=0.30Selective Depletion of Hypothalamic CRH Neurons in Severe ME/CFS

Evidence: Preliminary brain-autopsy series presented at IACFS/ME 2025 (Da Silva et al., University of Amsterdam / Netherlands Brain Bank): dramatically reduced PVN CRH-producing neurons in 7 severe deceased ME/CFS patients vs controls, with AVP/OXT neurons spared and downstream pituitary receptor/POMC downregulation (Da Silva 2025). Not peer-reviewed; no primary publication. Swaab-group PVN CRH quantification methodology is well established (A. M. Bao and Swaab 2010) (A. M. Bao, Meynen, and Swaab 2008). Prior ME/CFS autopsy literature sparse (Ferrero et al. 2017). Origin: literature synthesis.
Citations: (Da Silva 2025) (A. M. Bao and Swaab 2010) (A. M. Bao, Meynen, and Swaab 2008) (Tak et al. 2011) (Ferrero et al. 2017)
Mechanism: Loss of PVN CRH neurons removes the initiating signal of the HPA cascade, relocating documented ME/CFS hypocortisolism from adrenal/feedback level to a central manufacturing deficit. Low morning cortisol becomes the readout of absent CRH drive rather than adrenal or feedback pathology.
Chapter ref: ch09: central crh loss
Prediction: A peer-reviewed, severity-stratified replication will confirm reduced PVN CRH-neuron counts in severe ME/CFS relative to age/sex/agonal-state-matched controls, with preserved AVP/OXT counts. Falsified if independent PVN CRH quantification finds normal or increased CRH-neuron numbers in ME/CFS, or if the deficit disappears after controlling for agonal state and medication.
Treatment: If central CRH machinery is structurally depleted, cortisol replacement addresses the symptom (low cortisol) not the cause and may be counterproductive; no clinical action warranted at current evidence.
Limitation: Single unpublished conference source; n=7; severe/very-severe only; end-of-life tissue cannot separate cause, consequence, or artefact; no other brain regions quantified; no replication.

Speculation p=0.25Cell-Type-Specific CRH Vulnerability Distinguishes ME/CFS from Depression and MS

Evidence: In depression (Raadsheer et al. 1994) and MS (Purba et al. 1995) (same Netherlands Brain Bank methodology (A. M. Bao, Meynen, and Swaab 2008)), PVN CRH neurons are increased; the reported ME/CFS finding is the opposite (reduced) (Da Silva 2025). Selective GnRH-neuron death in Long COVID hypothalamus (Sauve et al. 2023) provides a post-infectious cell-type-specific precedent (cross-disease, not yet shown in ME/CFS). Origin: literature synthesis.
Citations: (Da Silva 2025) (Raadsheer et al. 1994) (Purba et al. 1995) (Sauve et al. 2023) (A. M. Bao, Meynen, and Swaab 2008)
Mechanism: A process that selectively removes/silences CRH neurons while sparing AVP and OXT populations, opposite in direction to the CRH-neuron increase seen in stress-driven hyperactive-HPA conditions — arguing ME/CFS hypocortisolism is not stress-system burnout but a distinct cell-type-specific vulnerability.
Chapter ref: ch09: crh cell type specificity
Prediction: Head-to-head PVN histology will show ME/CFS CRH-neuron counts below controls while depression/MS counts remain above, with AVP/OXT preserved across all groups. Falsified if ME/CFS CRH-neuron direction matches depression/MS, or if AVP/OXT are also depleted (indicating global rather than selective loss).
Treatment: None. Mechanistic distinction only.
Limitation: Indirect ME/CFS-vs-depression contrast (different cohorts, not head-to-head); rests on the same unpublished finding.

Speculation p=0.18Downstream Symptom Predictions of CRH-Neuron Loss: Pain Amplification and Exertional Autonomic Failure

Evidence: Contingent on Selective Depletion of Hypothalamic CRH Neurons in Severe ME/CFS. CRH/urocortins mediate central stress-induced analgesia; parvocellular PVN CRH neurons shape exertion-evoked sympathetic output. ME/CFS shows hypocortisolism (Tak et al. 2011), widespread pain/fibromyalgia overlap, and exertional/orthostatic intolerance. No ME/CFS study links CRH-neuron number to pain or autonomic reserve. Origin: brainstorm.
Citations: (Tak et al. 2011) (Da Silva 2025)
Mechanism: Loss of central CRH removes tonic analgesic inhibition (→ raised pain sensitivity, reduced stress-induced analgesia) and impairs acute stress-evoked sympathetic reserve while sparing baseline tone (→ exertional/orthostatic/thermoregulatory failure with normal resting measures).
Chapter ref: ch09: crh loss downstream symptoms
Prediction: ME/CFS will show reduced conditioned pain modulation correlating with cortisol output, and blunted sympathetic responses (MSNA/plasma NE) to laboratory stress with preserved resting tone. Falsified if pain modulation and stress-evoked sympathetic responses are normal, or fail to correlate with HPA measures.
Treatment: None. Mechanistic prediction only.
Limitation: Doubly contingent (on the unconfirmed depletion finding and on untested ME/CFS-specific circuit links); indirect.

Speculation p=0.10Trigger-Specific and Autoimmune-Mediated CRH Loss

Evidence

Two low-certainty extensions retained for future cycles. Trigger-specificity by analogy to selective GnRH-neuron death after SARS-CoV-2 (Sauve et al. 2023); two-hit autoimmune targeting via anti-hypothalamus autoantibodies (De Bellis et al. 2021) supplying specificity with complement/microglia as effectors. Origin: brainstorm.

Citations

(Sauve et al. 2023) (De Bellis et al. 2021) (Da Silva 2025)

Mechanism

Neurotropic-pathogen-specific vulnerability making CRH loss a subtype marker; (b) autoantibody targeting + complement/microglial phagocytosis explaining CRH-vs-AVP/OXT selectivity.

Chapter ref

ch09: crh loss trigger autoimmune

Prediction

Trigger-stratified autopsy series will show CRH counts differing by infectious trigger; PVN co-staining will show IgG on CRH but not AVP/OXT neurons with adjacent microglia. Falsified if CRH loss is trigger-independent or shows no IgG colocalisation.

Treatment

None now; if the two-hit model were supported, early immunomodulation could theoretically halt (not reverse) damage — untested.

Limitation

Very low certainty; extensions of an already-preliminary finding; deferred pending replication and pilot colocalisation data.

Open Question p=n/aWhat Drives CRH-Neuron Loss — Neuroinflammation, Autoimmunity, or Excitotoxicity?

Evidence: Candidate drivers make competing predictions. Immune-inflammatory central HPA hypofunction model (G. Morris, Anderson, and Maes 2017) vs a null: TSPO-PET has not consistently shown neuroinflammation in ME/CFS (TSPO sensitivity/attribution caveats apply). Anti-pituitary/anti-hypothalamus autoantibodies in a CFS subset (De Bellis et al. 2021) support an autoimmune alternative. Post-infectious neuronal death precedent (Sauve et al. 2023). Origin: literature synthesis.
Citations: (G. Morris, Anderson, and Maes 2017) (De Bellis et al. 2021) (Sauve et al. 2023) (Da Silva 2025)
Mechanism: Neuroinflammatory/excitotoxic damage, autoimmune targeting of CRH-producing cells or their pituitary targets, or direct post-infectious neuronal death — not mutually exclusive; current evidence cannot adjudicate.
Chapter ref: ch09: crh loss driver
Prediction: Simultaneous histology + autoantibody + neuroinflammation markers in the same brains will distinguish drivers: inflammatory signature (activated microglia near depleted PVN), autoantibody deposition, or neither. No such combined dataset exists.
Treatment: Driver identity dictates rational therapy class (anti-inflammatory vs immunomodulatory); none justified until the driver is established.
Limitation: No combined dataset; TSPO-PET null constrains but does not exclude the neuroinflammatory model; all drivers inferred.

Open Question p=n/aWhich Experiments Would Confirm or Refute Central CRH-Neuron Loss?

Evidence: The finding’s value lies in feasible experiments on existing NBB tissue: multiplexed CRH+microglia+T-cell+IgG staining (driver), blinded three-group stereology (depression contrast (Raadsheer et al. 1994) (Purba et al. 1995)), CRH-count vs disease-duration regression (cause vs consequence), and hypothalamic snRNA-seq (beyond-CRH discovery). Origin: brainstorm.
Citations: (Raadsheer et al. 1994) (Purba et al. 1995) (Sauve et al. 2023) (A. M. Bao, Meynen, and Swaab 2008)
Mechanism: Each experiment maps to one interpretive fork: colocalisation → driver; head-to-head stereology → real vs artefactual direction reversal; duration regression → progressive vs fixed; snRNA-seq → cell-type breadth + glial signature.
Chapter ref: ch09: crh loss experiments
Prediction: Multiplexed staining will localise (or fail to localise) immune markers to CRH-depleted zones; blinded stereology will confirm (or not) ME/CFS < controls < depression; duration regression slope sign will discriminate progressive from fixed loss. Any outcome is informative.
Treatment: N/A — research directions only.
Limitation: Some experiments limited by existing cohort size (n=7); snRNA-seq depends on tissue RNA integrity.

27 Ocular Sjögren / ME/CFS Overlap

Speculation p=0.28Functional Lacrimal Denervation as a Candidate Non-Autoimmune Route to Sicca in ME/CFS

Evidence: ME/CFS parasympathetic dysfunction is documented (Néstor Azcue et al. 2023); the lacrimal functional unit is parasympathetically innervated (CN VII, pterygopalatine ganglion). Sjögren’s sicca is destruction-driven (Wu et al. 2024); the M3-autoantibody account posits antibody-mediated blockade (Shared M3 Muscarinic Autoantibodies Link Sjögren’s Syndrome Sicca and ME/CFS Autonomic Dysfunction). This entry proposes a third, non-autoimmune route: functional denervation from autonomic withdrawal, distinguishable by a pilocarpine challenge test (denervation → preserved/supersensitive response; destruction → blunted). No direct ME/CFS data. Origin: brainstorm.
Citations: (Néstor Azcue et al. 2023) (Wu et al. 2024) (Lépine, Robert, and Sleno 2024)
Mechanism: Parasympathetic withdrawal → reduced cholinergic drive to lacrimal/salivary glands → aqueous-deficient sicca with preserved gland architecture. Contrasts with Sjögren’s lymphocytic destruction and with M3-antibody blockade. Denervation supersensitivity predicts preserved or exaggerated response to exogenous cholinergic agonist.
Chapter ref: ch14d: mecfs lacrimal denervation, ch14d: me cfs sicca m3 antibodies
Prediction: Standardised pilocarpine challenge (oral M3 agonist; Schirmer’s at 0/30/60/90 min): $\geq 5$ mm tear increase in the majority of ME/CFS sicca patients vs a minority of primary Sjögren’s sicca controls; pilocarpine responsiveness correlates with resting HRV. Salivary-gland ultrasound normal in ME/CFS sicca. Falsified if ME/CFS sicca shows SGUS abnormalities matching Sjögren’s or an equally blunted pilocarpine response. The test distinguishes functional impairment from gland destruction but NOT denervation from M3-antibody blockade; discriminating the specific non-autoimmune claim requires stratifying pilocarpine response by M3-autoantibody titre (preserved response in the antibody-negative subset). Interpret blunted responses against anticholinergic burden (chronic use causes glandular atrophy).
Treatment: If denervation-driven: cholinergic agonists (pilocarpine, cevimeline). Research hypothesis only, not a recommendation. The pilocarpine challenge is a provocation test, not bloodwork-free simplicity — it requires cardiac monitoring in a population with prevalent orthostatic intolerance. Contraindicated in uncontrolled asthma, narrow-angle glaucoma, acute iritis, GI/biliary obstruction, sick sinus syndrome, concurrent beta-blockers. Side effects (sweating, nausea, diarrhoea, bradycardia) may limit tolerability.
Limitation: No direct ME/CFS data; inferred from documented dysautonomia + lacrimal neuroanatomy. Overlaps with M3-autoantibody account — the pilocarpine challenge distinguishes functional impairment from gland destruction but NOT denervation from M3-antibody blockade (both predict preserved response). Sicca in ME/CFS is multifactorial (anticholinergic medications, dehydration); chronic anticholinergic use can itself cause glandular atrophy, confounding the challenge. Cholinergic agonists unlicensed for ME/CFS; use requires supervised cardiac monitoring.

Speculation p=0.25The Ocular Surface as a Shared Neuro-Immune Window Across Sjögren’s and ME/CFS

Evidence: Sjögren’s tear proteomics discriminates autoimmune from non-autoimmune sicca (Lépine, Robert, and Sleno 2024) (George, Kurien, and Scofield 2023); tear IL-6/IL-17/MMP-9/BAFF track systemic disease activity (Wu et al. 2024). Corneal confocal microscopy (CCM) of the subbasal nerve plexus detects small-fiber loss in Sjögren’s (Luzu et al. 2022), predicts serological activity (Y. Wang et al. 2025), and shows corneal nerve abnormalities in fibromyalgia dry eye (Vergés et al. 2025). CCM already detects SFN in ME/CFS and post-COVID cohorts (Néstor Azcue et al. 2025) (Néstor Azcue et al. 2023) Cañadas et al. (2023). Distinct from the T-cell tear entry (Tear-Fluid T-Cell Dysregulation as an Accessible Readout of Systemic Immune Reprogramming) — this entry centres the Sjögren’s inflammatory-cytokine + corneal C-fiber axis. Origin: literature synthesis.
Citations: (Lépine, Robert, and Sleno 2024) (George, Kurien, and Scofield 2023) (Wu et al. 2024) (Luzu et al. 2022) (Y. Wang et al. 2025) (Vergés et al. 2025) (Néstor Azcue et al. 2025) (Néstor Azcue et al. 2023) Cañadas et al. (2023)
Mechanism: Ocular surface may integrate two dysregulated signals: (a) tear inflammatory mediators reflecting systemic immune activity, and (b) corneal subbasal C-fiber density reflecting small-fiber integrity. The lacrimal functional unit is parasympathetically innervated (CN VII), so ME/CFS dysautonomia could reduce tear secretion downstream of the same autonomic pathology implicated elsewhere. Convergence would make the eye a mostly non-invasive site (tear sampling low-burden; CCM a specialist procedure, not bedside) reflecting the neuro-immune and small-fiber arms of ME/CFS.
Chapter ref: ch14d: ocular surface neuroimmune window, ch14d: mecfs tear proteome
Prediction: In an ME/CFS cohort vs matched controls, CCM shows reduced corneal nerve fiber density (lower CNFD in cases, matching Sjögren’s/fibromyalgia direction) AND tear IL-6/MMP-9 is elevated in the objective-dry-eye subset. Falsified if CCM shows no group difference in corneal nerve density OR tear inflammatory markers do not differ between ME/CFS cases with sicca and controls (failure of either conjunct refutes the joint window claim).
Treatment: No treatment proposed. If validated, tear sampling (low-burden) plus corneal confocal microscopy (a specialist procedure requiring a fixed device and operator, NOT a bedside test) could largely non-invasively detect small-fiber and inflammatory features of ME/CFS — of particular value where skin-biopsy nerve testing is impractical, though CCM’s equipment requirement limits true bedside/bedbound accessibility.
Limitation: No ME/CFS study has measured the tear proteome or performed CCM as a primary endpoint; every ME/CFS-specific claim is analogical (Sjögren’s, fibromyalgia, post-COVID). Sicca in ME/CFS is multifactorial (anticholinergic medications, dehydration, dysautonomia) and need not reflect autoimmune glandular pathology. Corneal nerve changes are non-specific across systemic conditions.

Speculation p=0.20Corneal Nerve Tortuosity as Separate ODE State Variable from Fiber Density

Evidence: Azcue et al. (2025) found corneal nerve tortuosity (AUC=0.720) is a better discriminator of ME/CFS from controls than CNFD (AUC=0.63), suggesting tortuosity and density are driven by different processes. Phase 4 brainstorm (idea 7.1) proposes a two-variable SFN ODE extension separating tortuosity T (ECM/glycocalyx degradation → fiber kinking) from density F (axonal die-back). ECM/glycocalyx disruption documented in ME/CFS vascular endothelium (Wust 2024, ch06). Origin: brainstorm.
Citations: (Néstor Azcue et al. 2025)
Mechanism: ROS + autoantibody-mediated ECM/glycocalyx degradation → perineurial support loss → nerve fiber buckling (tortuosity increase) independent of axonal die-back (density decrease). Two separable pathological processes with different rate constants: tortuosity (rapid ECM, reversible), density (slow axonal, less reversible).
Chapter ref: ch4: 1 — see SFN ODE discussion following cnfd sfn observable
Prediction: Longitudinal ME/CFS CCM data: tortuosity T increases early (constant gamma_ECM > 0) while density F declines later (slower k_degen). T and F trajectories are statistically distinguishable (no significant cross-correlation at lag=0) and T/F ratio is a monotonic disease progression marker. Falsified if T and F change synchronously or tortuosity changes only when density is already reduced.
Treatment: If tortuosity is ECM-driven: glycocalyx-stabilizing interventions (sulodexide, doxycycline) vs if density loss is axonal: regenerative interventions (NGF, growth factors). Different treatment targets for different SFN phenotypes.
Limitation: Two-variable model entirely theoretical; no longitudinal ME/CFS CCM data; ECM degradation in trigeminal ganglion unstudied; tortuosity may reflect mechanical deformation from dry eye / blinking artifact rather than glycocalyx pathology.

Open Question p=n/aDoes the ME/CFS Tear Proteome Resemble the Sjögren’s Signature?

Evidence: The ME/CFS tear proteome is entirely uncharacterized. Sjögren’s tear proteomics has matured to validated discriminant panels (Lépine, Robert, and Sleno 2024); fibromyalgia shows ocular-surface and corneal-nerve abnormalities (Vergés et al. 2025). No study has applied the same LC-MRM tear panel to an ME/CFS cohort. Bears on the long-standing seronegative-Sjögren’s hypothesis for an ME/CFS subset (see ch14d Sjögren’s block). Origin: literature synthesis.
Citations: (Lépine, Robert, and Sleno 2024) (George, Kurien, and Scofield 2023) (Vergés et al. 2025)
Mechanism: If a subset of ME/CFS patients harbour subclinical autoimmune sicca, their tears could carry a Sjögren’s-like inflammatory-proteomic signature (IL-6, IL-17, MMP-9, BAFF, β2-microglobulin); alternatively the signature may be distinct or absent, arguing against the shared-autoimmune-subgroup model.
Chapter ref: ch14d: mecfs tear proteome, ch14d: ocular surface neuroimmune window
Prediction: Applying the validated Sjögren’s tear LC-MRM panel to an ME/CFS cohort will either separate a sicca-positive subset from controls (supporting shared subclinical autoimmunity) or fail to (arguing against it). Falsified as a shared-signature claim if no ME/CFS subset shows Sjögren’s-like tear proteomic clustering.
Treatment: N/A — research direction only. A non-invasive tear test could, if positive, help identify an ME/CFS subset overlapping biologically with a treatable autoimmune disease.
Limitation: Untested in ME/CFS. Tear composition confounded by ocular surface disease, diet, environment, sleep. A negative result would not exclude autoimmunity confined to compartments not reflected in tears.

Open Question p=n/aOcular-Surface Signal in ME/CFS May Be Artefact (Medication / Dry-Eye / Spurious-Overlap Confounds)

Evidence: Critical self-audit of the ocular-surface hypotheses (The Ocular Surface as a Shared Neuro-Immune Window Across Sjögren’s and ME/CFS, Does the ME/CFS tear proteome resemble the Sjögren’s signature?, Functional Lacrimal Denervation — a Candidate Non-Autoimmune Route to Sicca in ME/CFS). Zero direct ME/CFS tear/CCM primary-endpoint studies exist (~0.95 certainty of gap). Alternative explanations: anticholinergic-medication-induced sicca (~0.50), dry-eye-driven cytokine/nerve changes (~0.45), spurious tear-proteomic overlap as shared DED endotype (~0.40). The one fatigue-spectrum ocular study (Vergés et al. 2025) did not control for anticholinergic medication; Sjögren’s tear panels (Lépine, Robert, and Sleno 2024) may misclassify autonomic dry eye; tear cytokine assays vary by time/method; referral-clinic selection bias inflates apparent overlap; no multimodal (CCM+tear+IENFD+autonomic) study exists in any disease. Origin: brainstorm critical categories 10–12.
Citations: (Vergés et al. 2025) (Lépine, Robert, and Sleno 2024) (Wu et al. 2024)
Mechanism: Confounds that could produce ocular findings without implicating ME/CFS systemic biology: (1) anticholinergic drugs reduce secretion; (2) local dry-eye inflammation elevates tear cytokines and remodels corneal nerves; (3) common final inflammatory pathway of dry eye mimics disease-mechanism overlap.
Chapter ref: ch14d: ocular surface mecfs confounds
Prediction: Any positive ME/CFS ocular-surface finding must survive adjustment for anticholinergic burden and dry-eye severity, and be replicated with standardised tear-collection methods, before it can be attributed to ME/CFS systemic biology. Falsified as a confound-only account if tear-serum cytokine correlation persists after dry-eye adjustment and in medication-free patients.
Treatment: N/A — methodological caveat. Guards against premature clinical use of unvalidated ocular biomarkers.
Limitation: The confounds themselves are inferred; some (e.g. medication burden) are directly testable and should be measured in any future ME/CFS ocular study.

28 LDN Hormetic Dose-Response

ID / Label	Details	Phase / Cert
ldn hormetic window	LDN shows non-monotonic dose-response within the clinical 0.5 to 4.5 mg range because TLR4 partial antagonism triggers Nrf2-mediated compensatory anti-inflammatory priming at lower doses; higher doses within the LDN range remove the basal TLR4 tone needed to sustain this compensatory response. Four distinct mechanisms have non-overlapping dose optima. No within-range dose-response trial in any condition. Falsifiable prediction: prospective four-arm crossover trial must show non-monotonic individual response curves. Falsified if all individual curves are monotonic within the tested range.	Phase 3 / 0.30
multi target dose optimum divergence	LDN’s four mechanisms have distinct concentration-response curves with potentially non-overlapping optima. A patient’s optimal dose reveals which mechanism is dominant. Prediction: patients with TRPM3 dysfunction should respond to higher LDN doses while patients with inflammation-driven symptoms should respond to lower doses. Falsified if there is no correlation between baseline TRPM3 function, inflammatory markers, and individual optimal LDN dose.	Phase 3 / 0.25
hormesis multi drug principle	Non-monotonic dose-response is a recurring pattern across ME/CFS pharmacotherapy spanning 17+ medications (LDN, LDA, lithium, melatonin, sulforaphane, corticosteroids, DORAs, duloxetine, beta-blockers, modafinil, H1 antihistamines, rapamycin, allopregnanolone, NAC, ketotifen, quercetin, taVNS). The hormesis framework unifies these observations via Nrf2-mediated compensatory upregulation (Calabrese corpus), catecholamine inverted-U at prefrontal D1/α2A receptors (Arnsten, Cools), mTORC1/mTORC2 dose selectivity (Sarbassov, Lamming), and biphasic concentration-response at GABA-A (Andreen). Falsifiable prediction: individual inversion-point position (standardised dose at which symptom improvement turns to worsening) should correlate across drugs within each patient if a hormetic reserve trait exists; mean pairwise r ≥ 0.4 expected, with ≥60% of all 136 pairwise comparisons reaching r ≥ 0.3. Falsified if mean pairwise r < 0.2 and fewer than 20% of pairs reach r ≥ 0.3. Indeterminate if mean r falls in 0.2–0.4 range or 20–60% of pairs are above threshold — then hormetic reserve signal is too weak/noisy for a single-trait model and would require mechanistic-clustering decomposition. (Calabrese 2002) (Calabrese and Baldwin 2003) (Calabrese 2010) (H. Sun et al. 2020) (Arnsten 2011) (Cools and D’Esposito 2011) (Sarbassov et al. 2006) (Lamming et al. 2012) (Andréen et al. 2009)	Phase 3 / 0.35
ldn dose response research gap	No within-range LDN dose-response trial exists for ME-CFS. The upcoming LIFT trial uses a single fixed dose and cannot address this gap.	Phase 3 / n/a
hormetic mechanistic clustering	Non-monotonic dose-response drugs group into five mechanistic categories (Nrf2, catecholamine, D2 partial-agonist, mTOR/autophagy, GABAergic/neurosteroid). Inversion-point positions should correlate within categories (r ≥ 0.4) but not across (r < 0.2). Cluster 3 (D2 partial-agonist: aripiprazole/LDA, single-member) is an occupancy-dependent inverted-U, pharmacologically distinct from both Nrf2 hormesis and PFC catecholamine inverted-U — the curve is identical in any population with dopamine deficit, not ME/CFS-specific. Lithium and corticosteroids are bridge drugs spanning multiple categories. Falsifiable prediction: within-patient intra-class r ≥ 0.4 in ≥4 of 5 categories; cross-category max pairwise r < 0.2. Falsified if all pairwise r < 0.2 including within-category. Indeterminate: 0.2 ≤ r < 0.4 across all (requires expanded N). (Calabrese 2010) (Arnsten 2011) (Cools and D’Esposito 2011) (Sarbassov et al. 2006) (Andréen et al. 2009) (Crosby, Kalantar, and DeRisi 2021) (H. Sun et al. 2020)	Phase 4 / 0.25
hormetic inversion point battery hip b	A 6-drug within-patient crossover pilot trial (LDN, sulforaphane, duloxetine, modafinil, rapamycin, allopregnanolone — each at 4 dose levels) to estimate cross-drug inversion-point correlation effect size. With n=20, the 95% CI on pairwise r spans approximately -0.05 to 0.71 — the 0.2-to-0.4 transition zone is within the CI, preventing decisive classification for most outcomes. The pilot therefore estimates effect size for a definitive trial requiring n ≥ 80 to distinguish confirmed (r ≥ 0.4) from falsified (r < 0.2). If 30–50% show inversions, effect size is too small to reject confounding at n=20; requires n ≥ 80 replication. Due to high PEM burden, a staged design is proposed: Phase 1 = 2-drug crossover (LDN + duloxetine, ~14–18 weeks); Phase 2 = expand to 6 drugs only conditional on Phase 1 r ≥ 0.3. Estimated cost: $ 1.2M–$ 1.7M (Phase 1 + Phase 2 combined). No pharmaceutical company will fund (all 6 drugs generic). (Samuel et al. 2019) (Samuel et al. 2023)	Phase 4 / n/a
hormetic reserve heritability	If inversion-point correlation r ≥ 0.4 is confirmed in HIP-B, hormetic quotient (HQ) is measurable and predicted to be ~40–60% heritable — a quantitative endophenotype for ME/CFS susceptibility analogous to P50 sensory gating in schizophrenia. Predictions: MZ twin pairs discordant for ME/CFS should show correlated HQ values (r ≥ 0.5); unaffected first-degree relatives should show intermediate HQ; GWAS on HQ (n ≥ 500) should identify loci in NFE2L2, KEAP1, COMT, TLR4, ADRB1/2, NR3C1, FKBP5, MTOR. Falsified if HQ shows no family concordance (r < 0.2 in MZ pairs).	Phase 4 / 0.20
hormesis cross disease generality	If hormetic reserve is heritable and measurable in ME/CFS, the same battery may reveal narrowed hormetic windows in other post-infectious diseases (Long COVID, PTLDS, fibromyalgia, POTS) and in elderly populations with decreased stress-response adaptivity. Null hypothesis: hormetic windows narrow with age in all populations, not disease-specifically. Testable with HIP-B in age-matched healthy controls vs ME/CFS vs Long COVID cohorts. Falsifiable prediction: if HIP-B is administered across all three groups, the HOIP model predicts disease-specific inversion-point narrowing (ME/CFS r < Long COVID r < PTLDS r < healthy r). Falsified if all groups show identical mean pairwise r — hormetic narrowing is age-driven, not disease-specific. Indeterminate if some disease pairs differ and others do not (mixed signal).	Phase 4 / n/a

29 Interoceptive Dose-Finding

ID / Label	Details	Phase / Cert
Deliberate Intermittent Dosing as Interoceptive N-of-1 Experimentation	Deliberate intermittent dosing in ME/CFS — patients skipping doses, taking drug holidays, pulsing medications — may represent rational interoceptive N-of-1 experimentation rather than non-adherence. The allostatic-interoceptive network computes allostatic significance from interoceptive afferent signals and updates predictive models of bodily state. Repeated perturbation-and-sensing cycles (dose → symptom change → dose adjustment) allow the network to approximate the dose-response curve without biomarkers. The hormetic dose-response framework establishes the therapeutic window as a 3D volume (dose × time × response) with time-dependent features; the interoceptive framework proposes that patients are probing this volume through deliberate pulse-and-assess cycles. Falsifiable: qualitative interview data from ME/CFS patients who pulse medications should reveal deliberate interoceptive experimentation in ≥10% of patients. Falsified if fewer than 10% report interoceptive dose-finding as a reason for pulsing. Individual mechanistic components range from cert 0.30 (time-dependent hormesis) to cert 0.70 (allostatic-interoceptive network mapping); the conceptual link between them is untested, cert 0.20 for the integrated claim. (J. Zhang et al. 2025) (H. Sun et al. 2018) (Mushak 2016)	Phase 1 / 0.20

30 Skeletal Asymmetry and Postural Mechanics

ID / Label	Details	Phase / Cert
spec skeletal-asymmetry-cascade	Skeletal asymmetry (rotoscoliosis, DAMI, ILMI) as primary mechanical driver of ME/CFS via four pathways: compensatory muscle overuse, sympathetic chain irritation, mechanical nerve compression, cervical aging spiral. Origin: Gerlier 2026-07-21, personal communication.	Phase 1 / 0.10
spec ch08-thoracolumbar-sympathetic-irritation	Thoracolumbar sympathetic chain irritation from rotoscoliosis producing multi-organ dysautonomia without requiring CCI. Anatomical precedent: Schulte2010 (sympathetic chain vulnerable to thoracic spine surgery).	Phase 1 / 0.10
spec mechanical-postural-subgroup	Skeletal asymmetry defines a distinct ME/CFS subgroup: non-hypermobile, positionally modulated, gradual-onset, age-worsening. Distinct from hypermobility/hEDS subgroup.	Phase 1 / 0.10
lim skeletal-asymmetry-evidence-gap	The Gerlier hypothesis has near-zero direct ME/CFS evidence at any link. 10 indirect papers; all supporting evidence comes from surgical complication reports, genetic disease models, and clinical reasoning. DAMI/ILMI yield zero PubMed results.	Phase 2 / n/a
spec skeletal-asymmetry-cascade, ch15 Fascial and Connective Tissue Innervation	Skeletal asymmetry produces chronic low-grade mechanical nerve compression (lateral femoral cutaneous, sciatic, pudendal) distinct from SFN — a compression neuropathy amplified by central sensitization. Improvement predicted with postural correction.	Phase 2 / 0.10
spec skeletal-asymmetry-cascade, “How does the asymmetry originate?”	Competing hypotheses for skeletal asymmetry origin: developmental/traumatic (Gerlier: neonatal cervical subluxation → spiralization), congenital/genetic, acquired postural/deconditioning, or idiopathic. Cascade downstream is agnostic to origin.	Phase 2 / n/a — competing origins

31 Hidradenitis Suppurativa as Autoinflammatory Comparator

L p=0.70Autoinflammatory Disease Category Absent from ME/CFS Literature

Evidence: PubMed search for “autoinflammatory disease” AND (“chronic fatigue syndrome” OR ME/CFS) returned zero results (July 2026). Autoinflammatory diseases (FMF, CAPS, TRAPS, HS, AOSD, SAPHO, Behçet’s) are innate-immune-driven, IL-1beta/IL-18/NLRP3-mediated conditions with fatigue as a major symptom — yet the entire category has never been compared to or studied alongside ME/CFS. This is a categorical research gap (absence of investigation), not a null result.
Mechanism: Not a mechanistic claim — an evidence-gap observation. Autoinflammatory diseases share the NLRP3/IL-1beta effector arm with ME/CFS PEM models, produce fluctuating fatigue, are treated with mechanistically-targeted therapies (anakinra, canakinumab, colchicine), but are distinguishable by elevated systemic inflammatory markers (CRP, SAA, ESR) that are typically normal/minimally elevated in ME/CFS. The gap may reflect a real biological distinction or a field artefact.
Chapter ref: ch14d: autoinflammatory category absent
Prediction: Not applicable — this is a categorical evidence gap, not a testable hypothesis. Adding ME/CFS screening instruments to autoinflammatory disease registries would directly address the gap.
Treatment: No treatment implication. Research implication: add DSQ-PEM and CCC/IOM criteria to autoinflammatory registries (Eurofever, HS ALLIANCE) at minimal cost — a one-year timeline to establish or refute autoinflammatory-ME/CFS comorbidity.
Limitation: Litigation search limitation: zero results may reflect PubMed indexing gaps (autoinflammatory disease is a relatively recent category, unified ~1999; many constituent diseases were historically indexed under “rheumatology” or “dermatology”). Google Scholar and EMBASE search may yield additional results. The gap is documented, not guaranteed — a positive finding could emerge from databases or registries not yet searched.

Speculation p=0.35HS-NLRP3-IL-1beta Pathway as Mechanistic Bridge to ME/CFS Fatigue

Evidence: NLRP3 is a firmly established driver of HS inflammation (scRNA-seq explant (Moran et al. 2023) cert 0.75; PCR overexpression (Krajewski, Szukała, and Szepietowski 2024) cert 0.50; metformin AMPK-NLRP3 (Petrasca et al. 2023) cert 0.65). NLRP3 mediates fatigue in mouse models: KO mice show markedly reduced LPS-fatigue and swim-fatigue with decreased brain IL-1beta (ZT Zhang et al. 2016) cert 0.70 (Z. Zhang et al. 2017) cert 0.65. PEM model in CFS/Long COVID includes NLRP3→IL-1beta→neuroinflammation (Jin et al. 2026) cert 0.65. Single epidemiological association HS–ME/CFS OR 1.72 (Prens et al. 2022) cert 0.70. Zero direct HS–ME/CFS mechanistic studies exist. Kilgour 2026: NLRP3 inhibition alone (AZD9056) insufficient for clinical HS response despite restoring PBMC cytokines — suggests redundant pathways.
Citations: (Moran et al. 2023) (Krajewski, Szukała, and Szepietowski 2024) (Petrasca et al. 2023) (ZT Zhang et al. 2016) (Z. Zhang et al. 2017) (Jin et al. 2026) (Prens et al. 2022)
Mechanism: HS systemic inflammation → NLRP3/IL-1beta/IL-17 → systemic cytokine spillover → neuroinflammation → fatigue. Both HS and ME/CFS share NLRP3/IL-1beta as a plausibly common fatigue mediator; HS provides a human autoinflammatory model where the NLRP3 axis is causal and therapeutic targets are FDA-approved, making it a tractable platform for studying cytokine→fatigue mechanisms that cannot be directly studied in ME/CFS. Distinct from classical autoimmunity (adaptive-T/B-cell-driven) — HS is an innate-immune-driven autoinflammatory disease of the IL-1beta/IL-18/NLRP3 axis.
Chapter ref: ch14d: hs nlrp3 mechanistic bridge
Prediction: Observational study of HS patients initiating biologics: anti-IL-1beta therapy (anakinra/canakinumab) will show the largest FSS/PROMIS-Fatigue reduction by Week 16 among cytokine-targeting agents, exceeding anti-TNF and anti-IL-17. Falsified if no anti-cytokine therapy reduces fatigue beyond placebo despite clinical HS response (HiSCR≥50).
Treatment: No direct ME/CFS treatment implication. HS biologics are not indicated for ME/CFS. The hypothesis is mechanistic: HS as model system for cytokine→fatigue biology. Kilgour 2026 (NLRP3 inhibition alone ineffective for HS) already constrains any single-agent NLRP3 strategy.
Limitation: Entire bridge is inferential — zero direct NLRP3 measurements in ME/CFS patients, zero HS biologic trials with fatigue endpoints. Prens 2022 is cross-sectional and self-reported (single study). HS has its own pathogenic drivers (follicular occlusion, keratinocyte dysfunction, pilosebaceous microbiome) unrelated to ME/CFS. Fatigue phenotype in HS never characterised for PEM — unknown whether Type 1 (post-exertional) or Type 2 (constant cytokine-driven).

Speculation p=0.35Kinesiophobia as Shared Behavioral Phenotype Across HS, FM, and ME/CFS

Evidence: HS patients have significantly higher kinesiophobia and lower physical activity vs controls; pain intensity, fatigue severity, and depressive symptoms are independent predictors in multivariable regression (Meral Ketenci, Meral, and Meral Obholzer 2026) cert 0.60. Convergent with documented activity-avoidance patterns in FM and ME/CFS. No cross-condition TSK comparison has been performed.
Citations: (Meral Ketenci, Meral, and Meral Obholzer 2026)
Mechanism: Repeated symptom exacerbation after physical activity → learned avoidance (kinesiophobia) → deconditioning → reduced activity tolerance → further avoidance — a unified behavioural phenotype of chronic inflammatory conditions. Mediated by a shared neurobiological substrate (possibly IL-1beta/IL-6 sickness behaviour acting on anterior insula/ACC) rather than condition-specific psychology. Distinct physical triggers (skin friction in HS, diffuse pain in FM, metabolic/PEM in ME/CFS) converge on the same behavioural output.
Chapter ref: ch14d: hs kinesiophobia shared phenotype
Prediction: TSK across HS/FM/ME/CFS cohorts: structural equation model shows configural invariance (CFI>0.95, RMSEA $<$ 0.06) for a latent “movement-avoidance” factor driven equally by pain and fatigue. Falsified if configural invariance is rejected across conditions.
Treatment: Graded-activity and pain-neuroscience-education interventions developed for FM could be adapted to HS and ME/CFS with minimal modification if kinesiophobia is a shared phenotype. Critical caveat: for ME/CFS patients with metabolic PEM, kinesiophobia reduction without addressing the metabolic limit could be harmful — distinguishing perceptual from metabolic avoidance is the clinical priority.
Limitation: Single HS study (Meral Ketenci 2026). No cross-condition TSK data. Correlation ≠ causation — fatigue-pain-depression-kinesiophobia cluster could be confounded by sleep, socioeconomic status, or diagnostic odyssey. TSK was validated in musculoskeletal pain, not inflammatory skin disease — psychometric properties in HS unknown. IL-1beta/insula→kinesiophobia link is itself inferential, never tested in any condition.

Speculation p=0.30Prodromal HS Fatigue as PEM Latency Model

Evidence: 83.3% of HS patients experience prodromal symptoms 12–24+ h before visible lesions; 32% report fatigue prodrome, alongside malaise (23%), headache (11%), nausea (2%) (Ring et al. 2017) cert 0.65. Temporal pattern parallels delayed PEM onset (12–48 h). NLRP3/IL-1beta activation in incipient follicular inflammation → systemic cytokine spillover → sickness behaviour is the proposed mechanism. Zero studies have directly compared HS prodrome time-course to ME/CFS PEM time-course.
Citations: (Ring et al. 2017)
Mechanism: Local NLRP3/IL-1beta activation in incipient HS lesion → systemic IL-1beta/IL-6/TNF-alpha spillover → sickness behaviour (fatigue, malaise, hyperalgesia) 12–24 h before clinical lesion — temporally analogous to PEM onset latency post-exertion. If both share a common effector (cytokine→sickness-behaviour), HS provides a tractable model where the trigger is visible/accessible (skin) and serial sampling is feasible — impractical in ME/CFS where the trigger (exertion) is not localisable.
Chapter ref: ch14d: hs prodrome pem latency
Prediction: Serial serum IL-6/TNF-alpha/IL-1beta Q4h through HS flare prodrome-to-resolution: cytokine peak temporally precedes fatigue-severity peak by ≥4 h in N-of-1 responder analyses. PEM-like symptom latency correlates with cytokine-to-fatigue lag (r>0.5). Falsified if fatigue rises simultaneously with or before systemic cytokines.
Treatment: Research-stage model only. If validated, HS becomes a “fast-track” platform for testing anti-IL-1beta pre-treatment for aborting cytokine-induced fatigue — relevant to both HS and ME/CFS but with an accessible spontaneous trigger rather than requiring controlled exertion.
Limitation: Ring 2017 is a questionnaire study (n=72) with no serum cytokines — prodrome entirely patient-reported, no validated fatigue instrument. PEM comparison is structural analogy, not empirical. HS biopsies cannot ethically confirm incipient inflammation during prodrome — cytokine source is inferred. Intrafollicular anaerobic microbiome may drive inflammation in ways with no ME/CFS parallel.

32 Clinical Trial Methodology

Hypothesis p=0.55Inadequate Treatment Duration and Spectrum as a Systematic Confound in Negative Chronic Disease Trials

Evidence: Lyme retreatment RCTs (Klempner 2001) found “no benefit” to 90-day antibiotics, but enrolled pre-treated patients (mean 4.7yr, 3+ prior courses) and did not cover co-infections (Klempner et al. 2001). DeLong’s independent biostatistical review found all 4 retreatment RCTs underpowered; Krupp 2003 and Fallon 2008 showed significant benefit (DeLong et al. 2012) (Krupp et al. 2003) (Fallon et al. 2008). Borrelia forms persister/biofilm variants requiring combination therapy (Feng et al. 2019). Standard regimens miss Babesia, Bartonella co-infections (Popov, Bashchobanov, and Andonova 2026). In ME/CFS: Watt (2012) found longer valganciclovir→better response (p=0.0002) (Watt et al. 2012); Fluge (2015) 23-week mean response lag (Ø. Fluge et al. 2015); Strayer (2020) treatment window at 2–8yr (Strayer, Young, and Mitchell 2020).
Citations: (Klempner et al. 2001) (DeLong et al. 2012) (Krupp et al. 2003) (Fallon et al. 2008) (Feng et al. 2019) (Popov, Bashchobanov, and Andonova 2026) (Watt et al. 2012) (Ø. Fluge et al. 2015) (Strayer, Young, and Mitchell 2020) (Ø. Fluge et al. 2019) (Cameron 2006)
Mechanism: Three-part framework for interrogating negative trials: (1) duration — was treatment long enough for chronic pathway normalization (not just acute intervention)? (2) spectrum — did coverage include co-morbid mechanisms (co-pathogens, co-morbid pathways)? (3) window — were patients treated within the disease-duration treatment window (before irreversible pathology)? The Lyme paradigm shows that all three factors can conspire to produce false-negative trial conclusions. Does NOT assert that all negative trials are false negatives — the definitive RituxME Phase III (Fluge 2019) was genuinely negative despite 12-month duration.
Chapter ref: ch32: lyme paradigm
Prediction: An ME/CFS antiviral trial testing 12+ months of ganciclovir derivatives in HHV-6/EBV co-infected patients within 2–8 years illness duration will show higher response rates than trials testing shorter courses in unstratified populations. Falsified if extended-duration combination antiviral trials in virus-selected ME/CFS patients show no benefit over placebo.
Treatment: Not a treatment recommendation — a methodological framework for trial design. Implies that negative trial results should not be cited as evidence that a mechanism is irrelevant without first checking whether duration, spectrum, and treatment window confounded the outcome.
Limitation: No prospective ME/CFS trial has tested extended-duration vs standard-duration head-to-head. Framework derived from cross-disease evidence (Lyme). Rituximab Phase III counterexample shows duration is not a universal explanation. High-certainty for Lyme; hypothesis-generating for ME/CFS.

Open Question p=n/aCaveats to the Duration Critique: Selection Bias, Placebo Response, and Natural Recovery as Alternative Confounds

Evidence: The duration critique has significant limitations (Cameron 2006) (Ø. Fluge et al. 2019) @[“Smith2015ME/CFSTxSysRev”] (Watt et al. 2012) (Horowitz and Freeman 2020). Selection bias toward pre-treated refractory patients may explain Klempner’s negative result better than treatment duration. Placebo response rates exceed 30% in blinded ME/CFS trials. Natural recovery (5–10%/year) can contaminate extended-duration trial results. Watt 2012’s duration-response finding is retrospective (confounding by indication). The three-part framework (duration × spectrum × window) may be unfalsifiable in practice because factors cannot be independently tested. Origin: brainstorm.
Citations: (Cameron 2006) (Ø. Fluge et al. 2019) @[“Smith2015ME/CFSTxSysRev”] (Watt et al. 2012) (Horowitz and Freeman 2020)
Mechanism: Five independent confounds that could produce positive signals in extended-duration trials without genuine treatment efficacy: (1) selection-bias enrollment of refractory patients → ‘negative’ trial is really a population effect not a treatment effect; (2) placebo-response maintenance in blinded trials; (3) natural recovery contamination; (4) retrospective confounding by indication (responders kept on drug longer); (5) unfalsifiability of the multi-factor framework.
Chapter ref: ch32: duration caveats
Prediction: Head-to-head duration-randomized RCT (6mo vs 12mo valganciclovir) will show the duration effect is present (treatment × time interaction p < 0.05) but its magnitude is ≤30% of what retrospective studies suggest, after controlling for placebo, natural recovery, and selection bias.
Treatment: N/A — methodological critique. Affects interpretation of existing trial results, not clinical recommendations.
Limitation: Synthesizes evidence from multiple studies at different certainty levels. No prospective data directly tests the alternative confounds in ME/CFS. The caveats similarly rest on indirect evidence and may themselves overestimate the importance of alternative explanations.

Open Question p=n/aPriority Research Directions to Test the Duration Critique in ME/CFS

Evidence: Four research programs derived from the duration criticism framework and the Lyme→ME/CFS analogy. (1) DeLong-style biostatistical reanalysis of all 35 ME/CFS treatment trials @[“Smith2015ME/CFSTxSysRev”] (DeLong et al. 2012). (2) Head-to-head 6mo vs 12mo valganciclovir RCT (Montoya et al. 2013) (Watt et al. 2012). (3) Prospective illness-duration-stratified trial testing the 2–8yr treatment window (Strayer, Young, and Mitchell 2020). (4) Adaptive platform trial with duration escalation based on interim response. Origin: brainstorm.
Citations: @[“Smith2015ME/CFSTxSysRev”] (DeLong et al. 2012) (Montoya et al. 2013) (Watt et al. 2012) (Strayer, Young, and Mitchell 2020)
Mechanism: Each direction directly tests one component of the duration critique without relying on the Lyme analogy. The DeLong-style reanalysis quantifies how many ME/CFS “negative” trials were structurally underpowered. The head-to-head duration RCT isolates the duration variable. The stratified trial prospectively tests the treatment-window hypothesis. The adaptive platform maps the dose-duration-response curve.
Chapter ref: ch32: duration critique research
Prediction: The DeLong-style reanalysis will find $>=$ 60% of ME/CFS treatment trials lacked adequate power for clinically meaningful effects. The 12-month valganciclovir arm will outperform the 6-month arm with a moderate effect size (Cohen’s d 0.3–0.5). The 3–8 year stratum will show the highest response rate, statistically distinguishable from less than 3 and more than 8 year strata.
Treatment: Indirectly: positive results would support longer treatment durations in clinical practice for virus-selected patients within the treatment window. Currently, all four research programs are hypothetical — no prospective duration-randomized data exist.
Limitation: None of the proposed studies have been conducted. The DeLong-style reanalysis relies on published (potentially selectively reported) data. The RCT designs are hypothetical and may prove infeasible due to cost, recruitment, or toxicity concerns with extended valganciclovir (myelotoxicity). Origin: brainstorm.

33 Pharmacodiagnostic Matrix

ID / Label	Details	Phase / Cert
sec pharmacodiagnostic-matrix	Pharmacodiagnostic matrix: formal multi-drug diagnostic inference — every medication cross-indexed against every mechanistic hypothesis, using constraint-satisfaction scoring to localize bottlenecks from multi-drug response patterns. Extends the extended diagnostic algorithm (Synthesis: Differential Diagnostic Algorithm (Extended)) from sequential probing to formal matrix-based inference. Methodological precedents: diagnosis ex juvantibus (Laragh 1988), N-of-1 Bayesian inference (Samuel 2019/2023), response-based stratified treatment (Zhang 2022), computational phenotyping (Strauss 2021), active learning diagnostic decision trees (Ravichandran 2024). Origin: methodology proposal.	Phase 1 / 0.30
sec pharmacodiagnostic-matrix, parameter stability	Test-retest reliability of drug-response-derived pharmacodiagnostic scores is unknown. Computational phenotyping literature (Schaaf 2024) demonstrates ICC 0.01–0.71 for RL model parameters. Within-patient variability (placebo, fluctuation, regression to mean) may similarly degrade pharmacodiagnostic parameter stability. Research needed before clinical deployment. Origin: methodology integration.	Phase 2 / n/a
sec pharmacodiagnostic-matrix, labeling bias	Matrix cell assignment (expected response direction) requires clinician judgment. Ravichandran 2024 demonstrated that clinician heuristics degrade diagnostic inference below random. Independent double-labeling + inter-rater reliability measurement needed before clinical deployment. Origin: methodology integration.	Phase 2 / n/a
sec pharmacodiagnostic-matrix, validation cohort	Validation: apply matrix retrospectively to patients with known mechanism (GPCR AAb confirmed, TRPM3 validated). Verify matrix places highest probability on correct mechanism. Validate against Scheibenbogen’s IA cohort, Stanford/System’s iCPET cohort, NIH ME/CFS study medication histories. Feasible within 6 months — no new trials required. Origin: methodology proposal.	Phase 2 / n/a

34 Stigmatisation and Nomenclature

Hypothesis p=0.50Perceived Stigma Mediates Worse Functional Outcomes in ME/CFS via Causal Attribution Pathway

Evidence: Froehlich 2022 (n=499 self-diagnosed ME/CFS): perceived stigma mediates relationship between negative causal attributions (controllable/unstable causes) and lower satisfaction with social roles + functional status. Looper 2004 (n=203): perceived stigma in FSS independently associated with worse health outcomes vs medically explained conditions, with ME/CFS among the most affected. Ko 2022 systematic review: stigma in FSS consistently associated with worse health outcomes — depression, lower QOL, higher symptom burden. (Froehlich et al. 2022) (Looper and Kirmayer 2004) (Ko et al. 2022)
Citations: (Froehlich et al. 2022) (Looper and Kirmayer 2004) (Ko et al. 2022)
Mechanism: Negative causal attributions (psychosomatic framing, controllable/unstable cause beliefs) → perceived stigma → reduced social role satisfaction + lower functional status + diminished health-related QOL. Stigma is not merely a psychosocial burden — it is an independent mediator of worse disease trajectories. Causal attributions by clinicians, family, and the public shape patient outcomes through stigma pathway.
Chapter ref: ch01: psychosocial
Prediction: Longitudinal study demonstrating that reduction in perceived stigma (via clinician validation or biomedical diagnosis) predicts improvement in functional status and social role satisfaction at 12-month follow-up. Falsified if changes in perceived stigma are not associated with changes in functional outcomes over time.
Treatment: Clinician validation + biomedical education may serve as therapeutic interventions by reducing perceived stigma. No clinical recommendation for formal stigma-targeted therapy without controlled trial data.
Limitation: Cross-sectional design — mediation pathway inferred, not demonstrated longitudinally. Self-diagnosed samples may overrepresent high-stigma patients. FSS stigma review primarily cross-sectional studies.

Hypothesis p=0.45Illness Name (“Chronic Fatigue Syndrome”) Is an Independent Vector of Stigma

Evidence: Jason 2002 (n=143): experimental vignette study — “chronic fatigue syndrome” label generated significantly more negative attributions (lazy, less responsible, less likely to recover) than “myalgic encephalopathy.” IOM 2015 report proposed renaming to SEID specifically to reduce stigmatising effects. (Leonard A. Jason et al. 2002) (Committee on the Diagnostic Criteria for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome 2015)
Citations: (Leonard A. Jason et al. 2002) (Committee on the Diagnostic Criteria for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome 2015)
Mechanism: The illness name “chronic fatigue syndrome” trivialises the condition — it emphasises a universal human experience (fatigue) while omitting PEM, the hallmark symptom. The name activates stereotypes of laziness/malingering, reducing clinician seriousness, social support, and patient self-perception. Name-based stigma is a modifiable structural determinant of healthcare interactions.
Chapter ref: ch34: nomenclature controversy
Prediction: Randomised experiment: clinicians presented with identical clinical vignettes but different diagnostic labels show measurable differences in treatment recommendations (biomedical investigation vs psychosocial referral), seriousness ratings, and empathy scores. “Myalgic encephalomyelitis” should elicit more biomedical investigation and higher seriousness ratings than “CFS.” Falsified if diagnostic label has no effect on clinician behaviour.
Treatment: Adopting less stigmatising nomenclature (ME, myalgic encephalomyelitis, SEID) may reduce clinical dismissal and improve diagnostic legitimacy. No clinical recommendation — this is a policy/advocacy issue.
Limitation: Single experimental vignette study (n=143) — partial replication only. Vignette studies may not fully capture real-world clinical behaviour. Name change alone cannot overcome decades of ingrained attitudes.

Hypothesis p=0.45ME/CFS Stigma Constitutes Comparable or Higher Burden than Other Functional Somatic Syndromes

Evidence: Looper 2004 (n=203): ME/CFS perceived stigma comparable to or higher than other FSS, substantially higher than medically explained conditions. Ko 2022 systematic review: stigma in FSS systematically associated with worse health outcomes; ME/CFS among most affected conditions in the FSS category. (Looper and Kirmayer 2004) (Ko et al. 2022)
Citations: (Looper and Kirmayer 2004) (Ko et al. 2022)
Mechanism: Conditions without visible signs or validated biomarkers attract greater delegitimisation irrespective of biological basis. ME/CFS sits at the extreme of this spectrum: contested nosology + psychiatric framing + invisible symptoms + fatigue-focused name → maximal delegitimisation. The pattern is structural — it tracks illness legitimacy perception, not disease severity.
Chapter ref: ch01: psychosocial
Prediction: Head-to-head comparison of perceived stigma, healthcare dismissal experiences, and public attitudes across ME/CFS, IBS, fibromyalgia, and medically explained conditions (RA, MS) should show ME/CFS at the extreme of the delegitimisation spectrum. Falsified if ME/CFS shows comparable stigma to RA or MS.
Treatment: De-stigmatisation strategies developed for other contested illnesses (MS historical trajectory, peptic ulcer/H. pylori paradigm shift) may be applicable to ME/CFS. Policy/advocacy implications.
Limitation: Only one head-to-head comparison study (Looper 2004). Systematic review aggregates across heterogeneous stigma measures. Public attitudes may have evolved since 2004.

Prediction p=0.35Biomedical Validation as Anti-Stigma Intervention with Measurable Clinical Benefit

Evidence: Qualitative evidence consistently shows that receiving a biomedical diagnosis and validation from a knowledgeable clinician is the most powerful anti-stigma intervention reported by patients (Guise 2010, Melby 2024, Asbring 2002). Terman 2020 validated stigma scale has not been tested as a clinical outcome measure. (Guise, McVittie, and McKinlay 2010) (Melby and Nair 2024) (Asbring and Närvänen 2002) (Terman et al. 2020)
Citations: (Guise, McVittie, and McKinlay 2010) (Melby and Nair 2024) (Terman et al. 2020)
Mechanism: Biomedical diagnosis + clinician validation → reduced perceived stigma → improved treatment engagement, reduced distress, potential biological benefit via stress pathway attenuation. Stigma reduction may be a measurable clinical outcome rather than merely a process variable.
Chapter ref: ch01: psychosocial
Prediction: Pre/post study: administer Terman 2020 ME/CFS Stigma Scale at first specialist ME/CFS clinic appointment and at 3-month follow-up after biomedical diagnosis and education. Stigma scores should decrease ≥1 SD. Reduction should correlate with improved treatment adherence and QOL. Concurrent biomarker measurements (CRP, IL-6, morning cortisol) should show improvement trajectory paralleling stigma reduction. Falsified if stigma scores do not change after biomedical diagnosis and education.
Treatment: ME/CFS-specialised clinical services with biomedical emphasis may provide measurable clinical benefit beyond diagnosis alone through stigma reduction. No specific anti-stigma intervention protocol validated.
Limitation: Qualitative evidence only — no pre/post stigma measurement study exists. Stigma scale not validated as outcome measure. Service context effects — specialist clinic patients may differ from community patients. Regression to the mean possible.

Speculation p=0.30Healthcare Dismissal as Chronic Stressor Accelerating Disease Progression

Evidence: Qualitative evidence spanning 25 years (1999–2024): healthcare dismissal — being disbelieved, trivialised, or labelled as psychiatric — is the most consistent finding across qualitative ME/CFS research. Stigma operates as a chronic psychosocial stressor; chronic stress is a known accelerator of inflammatory, metabolic, and neurodegenerative processes. McManimen 2018: unsupportive social interactions independently predict suicidal ideation after controlling for depression (n=495). (Asbring and Närvänen 2002) (Guise, McVittie, and McKinlay 2010) (Melby and Nair 2024) (Deale and Wessely 2001) (McManimen et al. 2018)
Citations: (McManimen et al. 2018) (Guise, McVittie, and McKinlay 2010) (Melby and Nair 2024)
Mechanism: Healthcare dismissal → chronic psychosocial stress → HPA axis dysregulation, sympathetic overactivity, increased inflammatory signalling → worsened disease trajectory. Stress-induced glucocorticoid resistance in immune cells → unresolved inflammation → amplification of existing ME/CFS pathophysiology (mitochondrial, autonomic, immune). Stigma → stress → biological amplification — not merely psychological suffering.
Chapter ref: ch01: psychosocial
Prediction: ME/CFS patients who report high healthcare dismissal should show elevated inflammatory markers (CRP, IL-6) and flattened cortisol diurnal slope vs those reporting low dismissal, after controlling for disease severity. Reduction in experienced dismissal (following change to validating clinician) should be associated with reduction in inflammatory markers at 6-month follow-up. Falsified if no association exists between dismissal and inflammatory markers.
Treatment: Clinician training in validation and trauma-informed care may have biological as well as psychological benefits — not merely “improving patient satisfaction.” No clinical recommendation beyond standard trauma-informed and validation approaches.
Limitation: Entirely inferred — no study has directly measured the biological (neuroendocrine/immune) effects of healthcare dismissal in ME/CFS patients. Qualitative evidence establishes prevalence and distress; biological mechanism remains hypothetical. Confounding by disease severity is possible (more severe patients both elicit more dismissal AND have worse inflammatory profiles).

Speculation p=0.30Media Framing Amplifies ME/CFS Stigma in Healthcare Encounters

Evidence: Knudsen 2011 (n=280 UK newspaper articles): 70% emphasised psychological/behavioural characterisations. Media psychiatric framing reinforces public perception of the disease as non-serious or self-inflicted. Patients report media coverage directly harming their social and healthcare interactions. (Knudsen et al. 2011)
Citations: (Knudsen et al. 2011)
Mechanism: Media coverage→public perception of ME/CFS as psychological/behavioural→social disbelief + clinician scepticism→patient experiences dismissal in medical encounters→amplified perceived stigma→worse health outcomes. Media is an upstream structural determinant of stigmatising healthcare interactions.
Chapter ref: ch01: psychosocial
Prediction: Temporal analysis: periods of increased psychiatric framing in media should be followed (within 3-6 months) by measurable increases in perceived stigma in clinical cohorts and online patient communities. Positive shift: after major biomedical discovery coverage, patient-reported dismissal should transiently decrease. Falsified if no temporal association between media framing and patient stigma reports.
Treatment: Strategic science communication — active media engagement by biomedical researchers to counter psychiatric framing narratives. Policy/media recommendation, not clinical intervention.
Limitation: Single content analysis (2011 UK only) — media landscape has changed substantially. Causal direction unclear — media may reflect rather than shape public attitudes. Social media, not just traditional press, now dominates information environment.

Speculation p=0.25Psychiatric Embedding in CFS Services Generates Structural Stigma

Evidence: Terman 2019 (n=336): mandatory or structurally embedded psychiatric referral in CFS services perceived by patients as delegitimising. This effect is pronounced in health systems where psychiatry gatekeeps CFS services (historically UK NICE pre-2021 model). Hussein 2024 scoping review (14 sources): lack of diagnostic pathways, contested nosology, insufficient clinician education, and absence of specialised services create structural stigma beyond individual clinician bias. (Terman, Cotler, and Jason 2019) (Hussein et al. 2024)
Citations: (Terman, Cotler, and Jason 2019) (Hussein et al. 2024) (Bayliss et al. 2014)
Mechanism: When psychiatry gatekeeps access to CFS services, the system structurally communicates that the condition is psychological — regardless of individual clinician intentions. Structural stigma operates through service design (psychiatric intake, CBT/GET as default treatments, absence of biomedical workup) rather than individual attitudes. Patients internalise this framing, reducing treatment engagement and hope.
Chapter ref: ch34: nomenclature section
Prediction: Comparison of patient outcomes (diagnostic confidence, treatment engagement, satisfaction, perceived stigma) in health systems with psychiatry-gatekept CFS services vs biomedically-led services (e.g., Norway biomedical clinics, post-2021 UK NICE). Psychiatry-gatekept systems should show higher perceived stigma and lower treatment engagement. Falsified if no difference in perceived stigma between service models.
Treatment: Separation of ME/CFS from mental health services — biomedical clinical pathways with psychiatry as optional consultation, not gatekeeping. Policy recommendation, not clinical guideline.
Limitation: Single cross-sectional study (n=336). Causal direction unclear — patients with higher pre-existing stigma may be more likely to perceive structural delegitimisation. System comparison observational only — no randomised service model studies exist.

Open Question p=n/aChild and Adolescent ME/CFS Stigma Understudied and Potentially Amplified by Educational Settings

Evidence: Parslow 2017: systematic review of qualitative child ME/CFS studies finds stigma as recurring theme — from teachers, peers, and healthcare providers. Children face unique stigmatisation risks: educational consequences (school refusal accusations, grade loss), dependency on adults for care access, limited agency in healthcare encounters. No dedicated child/adolescent ME/CFS stigma study exists. Parslow et al., 2017 qualitative systematic review identifies stigma as recurring theme in child ME/CFS studies — teachers, peers, healthcare providers.
Citations: —
Mechanism: Children with ME/CFS are triply vulnerable: invisible illness + developmental stage (perceived as malingering/coping avoidance) + dependency on adults who may disbelieve them. Stigma in educational settings — teachers and school administrators dismissing illness as avoidance — may compound health-related stigma, causing educational harm independent of physical illness burden.
Chapter ref: ch01: psychosocial
Prediction: Adapt the Terman 2020 stigma scale for paediatric populations and administer to adolescent ME/CFS patients + age-matched controls with T1DM (visible/manageable chronic illness) and juvenile arthritis (medically legitimised). ME/CFS adolescents should show highest stigma scores. Educational outcomes (grades, attendance, attainment) should correlate inversely with stigma in ME/CFS but not in comparison groups. Falsified if ME/CFS adolescents show stigma levels comparable to T1DM controls.
Treatment: Paediatric-specific anti-stigma interventions: school-based education, teacher training, formal educational support plans that acknowledge illness legitimacy. No clinical recommendation — research gap first.
Limitation: No direct paediatric stigma data. Paediatric stigma scale not developed. Parslow 2017 focuses on experiences broadly, not stigma specifically.

35 Economic Impact

ID / Label	Details	Phase / Cert
The IOM 2015 Economic Benchmark	IOM 2015 established baseline: 836,000–2.5M Americans affected; USD 17–24B annual economic cost; USD 18,000–29,000 per patient per year; indirect costs ~2/3 of total. Modeled extrapolation from prevalence surveys, not direct cost measurement. IOM + Clayton 2015 share same evidence base — treated as one source.	Phase 3 / 0.77
Australian Cost-of-Illness Confirmation	Two independent Australian cost-of-illness studies converge on AU$14.5B annual (Zhao 2023 n=128, AU$28,800/patient) and AU$14,523/patient mean annual cost (Close 2020 n=485, 73% indirect costs, 16.6% employed). Cross-national replication of IOM magnitude.	Phase 3 / 0.70
KCE Belgium Population-Level Confirmation	KCE Belgian HTA needs assessment (Cornelis 2026, n=749): mean 8.6yr work invalidity; 73.2% ≥1 comorbidity; 50% >2yr diagnostic delay. Government HTA body formally evaluating ME/CFS signals institutional recognition.	Phase 3 / 0.68
The Employment Gap	Employment rates 16.6–27% across studies vs 60–84% general population. >75% unable to work (Podell 2020). NZ administrative data (Bowden 2026, n=1,902): 18.3% employed vs 83.8% general population. Spanish cohort (Castro-Marrero 2019): 52.3% unemployed, 45.3% on sick leave. Multiple countries, consistent direction.	Phase 3 / 0.75
Employment Retention Interventions	No study has tested workplace accommodations, flexible scheduling, remote work, or phased return-to-work programs for ME/CFS. Intervention question well-defined and testable; no funding body has prioritized it.	Phase 3 / 0.55
Family Economic Impact	Brittain 2021 (n=68 patients + 118 family members, FROM-16 tool): 87% family moderate/severe quality-of-life impact; 50.2% family-income reduction. No standalone monetary caregiver valuation exists. Informal care included in Australian cost-of-illness indirect-cost estimates.	Phase 3 / 0.55
The Burden-to-Funding Ratio	Mirin 2020: ME/CFS burden:funding ratio ~1,000:1 (USD 17–24B cost vs USD 15M NIH funding). MS comparator ~30:1 (USD 39,000–68,000/patient vs USD 115M); RA comparator ~32:1 (USD 12,000–21,000/patient vs USD 86M). Three-order-of-magnitude gap. Funding figures public NIH data and verifiable.	Phase 3 / 0.65
No Formal Return-on-Investment Analysis	No formal return-on-investment analysis for ME/CFS research funding. Burden:funding ratio is descriptive, not causal. Cochrane 2021 systematic review confirmed zero cost-effectiveness studies for any ME/CFS intervention. This limitation is itself a consequence of the underfunding it critiques.	Phase 3 / n/a
Zero Cost-Effectiveness Studies	Cochrane 2021: six pre-2021 economic evaluations, all CBT/GET-based, none based on modern non-GET care models. After NICE 2021 GET reversal, pre-2021 CEA evidence is not just thin — its clinical basis is obsolete. Wan 2024 bibliometric analysis confirms tiny, fragmented field.	Phase 3 / n/a
Comparative Neglect as a Structural Phenomenon	ME/CFS comparable to MS/RA on severity, prevalence, and economic burden but receives 7–13% of their per-DALY research funding. Gap too large to be explained by any single factor — likely self-reinforcing cycle: low funding → few researchers → slow progress → perceived intractable → continued low funding. Testable: dedicated research program with evaluation component.	Phase 3 / 0.35
The Missing Economic Evidence	Five identified gaps: (1) no US claims-data cost study; (2) no longitudinal lifetime-cost study; (3) no cost-effectiveness of diagnostic pathway; (4) no caregiver monetary valuation; (5) no developing-country data. All feasibly addressable with existing methods; gaps confirmed by systematic review (Cochrane 2021, Wan 2024).	Phase 3 / 0.60
syn:economic-impact-model	Cross-country synthesis: USD 18,000–29,000/patient/year; employment ~20% vs ~80% general; caregiver 50% income reduction; 1,000:1 burden:funding ratio; 30–40x worse than MS/RA. Strongest supported conclusion: current funding level unjustifiable on any cost-effectiveness principle. Policy change requires demonstrating current funding is indefensible, not computing optimal level.	Phase 3 / 0.65

36 Global Perspectives on ME/CFS

ID / Label	Details	Phase / Cert
Post-Infectious Fatigue Follows Infectious Disease Burden Geographically	Post-infectious fatigue follows infectious disease burden geographically. Dengue (endemic in 100+ countries, predominantly LMICs) produces chronic fatigue comparable to post-EBV CFS (Condé 2026, first SR). Chikungunya: 38% chronic fatigue at 30mo (Duvignaud 2018). Post-epidemic sequelae documented across history (Miller 2026). The countries with the most triggering infections have the least ME/CFS diagnostic infrastructure. Global ME/CFS research studies only the fraction of post-infectious fatigue cases occurring in places where ME/CFS is diagnosed — a geographic selection bias of unknown magnitude.	Phase 3 / 0.55
The LMIC Fatigue Blind Spot	Hypothesis: If post-infectious ME/CFS occurs at comparable rates across all triggering infections, LMICs with highest infectious-disease burden should have highest ME/CFS prevalence — but they report the lowest because they have least diagnostic infrastructure. Single data point: Iran post-COVID CFS 17.5% (Simani 2021). No replication from other LMICs.	Phase 3 / 0.35
Neurasthenia: The Cultural Precursor to Global ME/CFS	Cross-cultural evidence (Ware & Kleinman 1992, Lee 1998, Starcevic 1999): neurasthenia in China and CFS in the US are different cultural idioms for overlapping fatigue syndromes. Shenjing shuairuo persists as culturally acceptable idiom in Chinese society. ME/CFS prevalence estimates using Western diagnostic criteria may produce artefactually low prevalence in non-Western settings — core finding conceptually replicated; inference untested.	Phase 3 / 0.40
Cultural Idioms Beyond East Asia	Neurasthenia/CFS literature covers China and East Asia. No empirical cross-cultural ME/CFS studies from South Asia (kamzori, vata imbalance), Sub-Saharan Africa (post-malaria fatigue, “thinking too much”), or Latin America. Culturally validated ME/CFS screening tools do not exist for non-Western settings.	Phase 3 / n/a
Clinical Diagnosis Without Exclusionary Testing Is the Global Default	IOM/CCC criteria require exclusion of alternative diagnoses via laboratory testing. In LMICs without reliable TSH, CBC, ferritin, CRP, or ANA testing, the diagnostic algorithm cannot be executed as written. Bangladesh RCT protocol (Sarker 2024) applies Fukuda criteria pragmatically. ICD codes exist globally; the diagnostic pathway that justifies assigning them does not.	Phase 3 / 0.50
ICD Coding Exists; Disability Recognition Does Not	ME/CFS coded as G93.3 (ICD-10), 8E49 (ICD-11). ICD coding exists globally, but disability recognition requires national systems that operationalise the code. In LMICs where disability insurance is weak or absent, ICD coding confers no practical benefit. Policy wins at the global level do not translate to protection at the local level without national adoption.	Phase 3 / 0.50
TCM Herbal Formulations: Signal Without Strength	TCM herbal formulations show signal for fatigue reduction in 23 RCTs (n=1,776), but all low quality — small samples, high risk of bias, heterogeneous interventions (Wang 2014). Evidence insufficient for specific formulation recommendation.	Phase 3 / 0.50
TCM Mind-Body Exercises: Moderate Effect, Low Risk	Tai Chi, Qigong, Baduanjin show moderate effect on fatigue with no SAEs (Kong 2023 SR/MA). Accessible in LMIC settings where these practices are culturally embedded and low-cost. Generalisability to non-Chinese populations uncertain. PEM risk unstudied in these protocols — severe/very severe patients unlikely to tolerate.	Phase 3 / 0.50
Acupuncture and Moxibustion: Widely Available, Moderately Supported	Acupuncture/moxibustion show small-to-moderate effect in 31 RCTs (Wang 2017 NMA). Widely available across East Asia and Indian AYUSH integration. Low-risk symptom-management option; not disease-modifying. Blinding limitations inherent to acupuncture RCTs.	Phase 3 / 0.50
Traditional Medicine Evidence is Fractional and Culturally Bounded	Traditional medicine evidence base for ME/CFS is almost entirely TCM. Systematic reviews of Ayurveda, Siddha, Unani, and African traditional medicine for chronic fatigue are absent from PubMed. Cannot generalise from TCM to other traditional medicine systems.	Phase 3 / n/a
ME/CFS Meets the Definition of a Neglected Disease in Global Health	ME/CFS satisfies criteria for a neglected disease (Arron 2024): severe morbidity (EQ-5D ~0.40–0.55, worse than MS/stroke), mechanisms understudied, research concentrated in high-income countries. No WHO global ME/CFS initiative exists. No ME/CFS disability weight in GBD. National Academies IACI workshop (2024) identified cross-disease mechanisms but lacked LMIC representation.	Phase 3 / 0.55
What Would a Global ME/CFS Surveillance System Look Like?	No international surveillance system tracks post-infectious fatigue following dengue/chikungunya/COVID-19 outbreaks in LMICs. Bangladesh RCT protocol (Sarker 2024) provides small-scale model. Until a surveillance system exists, every assertion about global ME/CFS prevalence is an extrapolation.	Phase 3 / n/a
The Unfalsifiability Trap	The hidden-burden thesis has unrestricted auxiliary hypotheses to absorb falsification — any null finding can be attributed to cultural inappropriateness of criteria, unavailable exclusionary workup, or wrong triggering infection. A non-falsifiable claim should carry lower certainty than structural plausibility alone warrants. The chapter must specify what evidence would change its mind. Origin: brainstorm Phase 4, categories 10 and 12.	Phase 5 / n/a
What Evidence Would Falsify the Hidden-Burden Thesis?	Three categories of evidence would weaken/refute the hidden-burden thesis: (1) differential pathogen profiles — if post-infectious ME/CFS conversion rates vary by order of magnitude across triggering infections; (2) protective factors — helminth immune modulation, early-life immune training, younger population structure; (3) competing mortality — susceptible patients die of acute infection in LMICs. All counterarguments and the thesis they challenge rest on inference from the same absence of data. Origin: brainstorm Phase 4, categories 10 and 11.	Phase 5 / 0.20
The ICD-11 Empty-Vessel Hypothesis	ICD-11 8E49 is globally available — but the implementation pathway (national HIT adoption, physician training, diagnostic algorithms, disability systems, clinical guidelines) requires conditions absent from most LMICs. The code may produce zero measurable change in diagnosis rates where none of the 5 implementation conditions hold. Origin: brainstorm Phase 4, category 1.	Phase 5 / 0.40
Sentinel PEM Surveillance in Post-Arbovirus Cohorts	Lowest-cost highest-value research action: add PEM-screening module (DSQ-PEM, 1-min sit-to-stand) to existing post-dengue/chikungunya/Zika cohort follow-ups in Brazil, India, Vietnam, Thailand. USD 150–300K, 5 sentinel sites, no lab infrastructure needed. Would generate first post-arboviral ME/CFS prevalence estimates. Origin: brainstorm Phase 4, category 2.	Phase 5 / 0.40
Culturally Adapted PEM Screening Tools	PEM screening translated into Hindi, Bengali, Swahili cannot just translate “do you feel worse after exertion?” — must culturally calibrate exertion concepts, rest/work boundaries, and fatigue idioms. Cognitive interview methodology standard; gold-standard circularity problem: need culturally adapted criteria to identify patients to validate the tool. Origin: brainstorm Phase 4, category 2.	Phase 5 / 0.35

37 History of ME/CFS

ID / Label	Details	Phase / Cert
fhyp:psychosomatic-lag	When an illness cluster appears with consistent clinical phenotype, negative standard laboratory tests, female predominance, and absence of mortality, the default medical response is psychosomatic attribution. Documented across >5 diseases: ME/CFS (45 years McEvedy→IOM), MS (>100 years Charcot→MRI), fibromyalgia (~20 years), Gulf War Illness (19 years), Long COVID (~18 months). Compression trend observable. Mechanism: medicine’s evidentiary hierarchy privileges positive lab findings over clinical phenomenology. Predicts next unexplained cluster will follow same trajectory within 10 years. Origin: brainstorm.	Phase 5 / 0.65
institutional incentives over evidence	McEvedy 1970 mass hysteria hypothesis was empirically weak but dominated clinical teaching for 40 years — was this driven by evidence quality or institutional incentives (reduced disability claims, psychiatric department jurisdictional expansion, confirmation bias under McEvedy’s logic)? Falsifiable via analysis of disability claim denial rates, psychiatric department funding, and guideline change timing across diseases. If evidence quality is primary driver, the hypothesis is disproven. Origin: brainstorm — null hypothesis assessment.	Phase 5 / 0.70
retrospective outbreak diagnosis	Pre-1988 outbreak reports (Gilliam 1938, Royal Free 1957, Acheson 1959) cannot be validated against modern diagnostic criteria — no archival samples exist. Retrospective diagnostic assignment is inductive. Alternative: multiple distinct post-infectious syndromes with similar clinical description. Origin: brainstorm — evidence quality.	Phase 5 / 0.55
evidence quality outbreak sources	Foundational ME/CFS documents are non-peer-reviewed field investigation reports and case series, not modern peer-reviewed studies. DecodeME 2025 is a preprint. Core institutional events (IOM 2015, NICE 2021) are higher-certainty. Origin: brainstorm — evidence quality.	Phase 5 / n/a
narrative arc confirmation bias	Chapter’s psychosomatic-to-biological arc is one defensible reading, not the only reading. A skeptic could organize the same events differently: provisional psychiatric explanation → continued negative biological investigation → patient advocacy pressured institutions → guidelines reversed → tentative biological signals. Transparency about interpretive choice. Origin: brainstorm — evidence quality.	Phase 5 / n/a
asymmetrical methodological scrutiny	Chapter applies detailed criticism to PACE trial (n=641, Lancet) but less scrutiny to biological evidence: Walitt 2024 (n=17, small), DecodeME 2025 (preprint). Asymmetry defensible because PACE shaped clinical guidelines affecting hundreds of thousands, but should be acknowledged. Origin: brainstorm — evidence quality.	Phase 5 / n/a
history not therapeutic	Historical knowledge does not reduce PEM, improve sleep, or restore function. Chapter value is epistemic (understanding how medicine arrived here) and strategic (recognizing patterns), not therapeutic. Inclusion justified by document scope, not immediate patient benefit. Origin: brainstorm — self-critique.	Phase 5 / n/a

38 Subjective-Measurable Discrepancy Index

ID / Label	Details	Phase / Cert
The Subjective-Measurable Discrepancy is Not an Isolated Befuddlement — It Patterns Across Domains	The subjective-measurable discrepancy — patients report severe symptoms that standard clinical tests fail to capture or contradict — is a replicated, multi-domain, diagnosis-independent finding documented across sleep (Watson2003, Watson2004, Armitage2009 — MZ twin-controlled), autonomic (Novak2024 — n=2627, zero subjective-objective correlation), physical activity (Vergauwen2021), cognition (Teodoro2018 — 186-study review), and systemic biomarkers (Byrnes2009 — zero peripheral blood transcriptomic signal in 44 twin pairs). Seven independent research cohorts, convergent designs, zero contradictory findings. Not explained by psychiatric comorbidity, poor effort, deconditioning, or instrument invalidity. Origin: /integrate-topic subjective-measurable-discrepancy-index.	Phase 3 / 0.75
syn:subjective-measurable-discrepancy-index	Synthesis of three non-exclusive explanations for the discrepancy: (1) provocation-dependence — abnormalities emerge only under stress, standard resting labs miss them; (2) CNS confinement — primary pathology is brainstem/hypothalamic/microglial, not reflected in peripheral blood; (3) interoceptive amplification — patients perceive real physiological signals that healthy brains filter out. Together they reframe the discrepancy from “patients report what tests can’t confirm” to “patients report what standard tests can’t measure.” Origin: /integrate-topic subjective-measurable-discrepancy-index.	Phase 3 / 0.75 (inherited from constituent evidence)
The Discrepancy Index as a Subtyping Tool: High Discrepancy → Dysautonomia-Dominant	A formal discrepancy index — subjective autonomic symptom score (COMPASS-31) ÷ objective autonomic deficit (QASAT) — may subtype patients: high discrepancy → dysautonomia-dominant (normal resting, abnormal only on provocation, autonomic-responsive); low discrepancy → immune-inflammatory (abnormal resting biomarkers, immunomodulation-responsive). Predicts treatment stratification: high-discrepancy patients respond better to midodrine/pyridostigmine; low-discrepancy patients respond better to IVIG/corticosteroids. Untested. Origin: /integrate-topic subjective-measurable-discrepancy-index.	Phase 3 / 0.45
The Discrepancy Index as an Interoceptive Accuracy Measure	Alternative framing: the discrepancy index is a readout of interoceptive processing gain — how precisely the brain weights ascending interoceptive signals. High-discrepancy patients have high-gain interoceptive systems perceiving signals that healthy brains filter out. Reframes discrepancy as neurobiological trait, not disease classification. Predictive processing framework, testable via heartbeat detection and respiratory resistance discrimination tasks. Origin: /integrate-topic subjective-measurable-discrepancy-index.	Phase 3 / 0.30
The Discrepancy Index is a Measurement Framework, Not a Validated Diagnostic Tool	The discrepancy index is a conceptual framework, not a validated clinical instrument. No standardised formula exists; no test-retest reliability, sensitivity/specificity, or clinical utility data exist. Structural issues: domain selection/weighting, provocation standardisation, severity dependency (may invert in severe patients), threshold calibration, and domain-specific convergence (HGS correlates — Paffrath2024). Should be treated as hypothesis-generating, not a clinical decision tool. Origin: /integrate-topic subjective-measurable-discrepancy-index.	Phase 3 / n/a
What Measurement Paradigm Can Bridge the Discrepancy Gap?	Is there any instrument that can bridge the COMPASS-31/QASAT orthogonality? Candidates: provocation-based patient-report, wearable + ecological momentary assessment, microstructural objective measures, challenge-test protocols. Null result (no instrument bridges the gap) would support CNS confinement — constructs are ontologically distinct, patient’s experience integrates CNS-level information inaccessible to any peripheral instrument. Origin: /integrate-topic subjective-measurable-discrepancy-index.	Phase 3 / n/a
Why Do Some Domains Show Convergence?	Why do some domains show subjective-objective convergence (HGS, HRV, CBF during tilt) while others show complete divergence (PSG, MSLT, QEEG, COMPASS-31/QASAT, peripheral blood transcriptomics)? Hypotheses: provocation intensity, measurement specificity, temporal coupling. Identifying systematic patterns guides instrument design — invest in high-provocation, high-specificity, temporally-coupled measures. Origin: /integrate-topic subjective-measurable-discrepancy-index.	Phase 3 / 0.30
Discrepancy Magnitude as Illness-Trajectory Predictor	Extrapolation from Friedberg2022 (lower HRV → nonimprovement, but patient-reported activity patterns did not discriminate): high-discrepancy patients (severe report, mild objective dysfunction) may have better prognosis than low-discrepancy patients (severe report, severe objective dysfunction). Alternatively: high discrepancy = early-stage (subjective distress precedes measurable pathology), low discrepancy = late-stage (measurable damage accumulated). If discrepancy predicts trajectory, index becomes treatment-allocation decision tool. Origin: /integrate-topic subjective-measurable-discrepancy-index.	Phase 3 / 0.25
The Energy-Conservation Signal: The Brain Detects Metabolic Flux Failure That Blood Tests Miss	The brain’s hypothalamic AMPK/mTOR metabolic sensors detect ATP flux failure (rate insufficiency) even when metabolite pool sizes (blood glucose, lactate) are normal. Standard blood tests measure pools; the brain measures flux. Subjective fatigue reflects correct detection of flux insufficiency — no perceptual amplification needed. The discrepancy is a measurement domain mismatch (pools vs. flux), not a patient error. Impaired phosphocreatine recovery on 31P-MRS supports this; the hypothalamic link to fatigue perception is untested in ME/CFS. Origin: brainstorm — Phase 5, category 1.	Phase 5 / 0.30
Temporal Decoupling: Subjective Integration Across Weeks vs. Objective Snapshots at One Moment	Subjective symptom reports integrate across weeks (recall period of validated instruments), objective measures capture a single timepoint. If ME/CFS fluctuates, subjective report captures worst moments (peak-end rule); objective measure randomly samples from the distribution’s body. Discrepancy = distribution tail vs. random draw — would occur with perfect interoception. Vergauwen2021 (matched 12-day windows) still found rs=0.35-0.38 — temporal decoupling is partial only. Origin: brainstorm — Phase 5, category 1.	Phase 5 / 0.40
The Discrepancy Evidence Base Has a Systematic Instrument-Mismatch Confound	Every study in the discrepancy evidence base uses multi-week-recall subjective instruments vs. single-timepoint objectives. The discrepancy is partly designed into the protocol — a consequence of retrospective-integrative vs. instantaneous-sampling instruments, not solely a discovery about the disease. Vergauwen2021 with matched 12-day windows still shows weak correlation — instrument bias is partial. Origin: brainstorm — Phase 5, category 12 (evidence quality).	Phase 5 / 0.60
Byrnes2009’s Null Result May Reflect Tissue-Mismatch, Not CNS Confinement	Byrnes2009’s null (zero PBMC transcriptomic signal) is cited as strongest evidence for CNS confinement. Alternative: tissue-mismatch — peripheral blood leukocytes are the wrong cell type for muscle/endothelial/brainstem/enterochromaffin pathology. The null is strong evidence against systemic transcriptomic signal in blood leukocytes; weak evidence for CNS confinement specifically. Muscle biopsy, endothelial isolation, or CSF proteomics might reveal the signal. Origin: brainstorm — Phase 5, category 12.	Phase 5 / 0.50
The Discrepancy Index’s Severity Dependency May Be Fatal for Subtyping	The discrepancy index may measure severity, not subtype — mild (low objective, high subjective → high discrepancy), severe (high objective, high subjective → low discrepancy). The subtyping hypothesis survives only if discrepancy predicts treatment response WITHIN severity tiers. Ambiguity admitted but magnitude/direction unknown — without severity-stratified validation, subtyping is unfalsifiable. Origin: brainstorm — Phase 5, category 12.	Phase 5 / 0.45
The Achievement’s Certainty (0.75) Overestimates the Independence of the Evidence Base	The achievement’s cert 0.75 treats 5 domains as 5 independent replications. Reality: sleep uses one twin cohort twice (Watson2003, Armitage2009); autonomic is 1 study (Novak2024); activity found weak positive, not zero (Vergauwen2021 rs=0.35–0.38); cognition is a review, not primary data (Teodoro2018); biomarker is a tissue-specific null (Byrnes2009). Five legs, shared wood. More appropriate cert: 0.55–0.60. Origin: brainstorm — Phase 5, category 12.	Phase 5 / 0.55
Null Hypothesis: Does the Discrepancy Index Add Clinical Value Beyond Severity and Duration?	The default null for any novel clinical instrument: does the discrepancy index add diagnostic, prognostic, or therapeutic value beyond existing assessment (symptom severity + duration)? If all three arms fail the null, the index is scientifically interesting but clinically useless — an academic construct. Burden of proof is on demonstrating added value, not assuming it. Origin: brainstorm — Phase 5, category 11 (null hypothesis).	Phase 5 / n/a
Is the Discrepancy an ME/CFS-Specific Signal or Fully Explained by Known Confounds?	After controlling for severity, symptom fluctuation variance, psychiatric comorbidity (HADS), medication count/class, age, and gender — the ME/CFS-specific residual discrepancy may be zero. If so, the discrepancy is a quantitative amplification of normal interoceptive noise driven by severity, not an ME/CFS-specific mechanism. The framework collapses to “severe illness → large subjective-objective mismatch — any disease.” A surviving disease-specific residual confirms the discrepancy as an ME/CFS property. Origin: brainstorm — Phase 5, category 11.	Phase 5 / 0.40

References

Acanfora, Domenico, Maria Nolano, Chiara Acanfora, Camillo Colella, Vincenzo Provitera, Giuseppe Caporaso, Giuseppe Rengo, Raffaele Antonelli Incalzi, and Gerardo Casucci. 2026. “Vagal Cholinergic Denervation of the Gastric Mucosa in Long-COVID-19: In Vivo Evidence of Structural Autonomic Dysfunction.” International Journal of Infectious Diseases 152: 108973. https://doi.org/10.1016/j.ijid.2026.108973.

Adam, Lucas. 2024. “PoCoVIT Trial: Methylprednisolone in Long COVID.”

Akinlusi, Idris, Brian Kan, Ted Shi, Jose Barragan, Carlos Bouchot, and Jorge Cervantes. 2025. “Human Microglia Polarization Following Infection with the Lyme Disease Spirochete.” Journal of Investigative Medicine 73 (1): 172–78. https://doi.org/10.1177/10815589241290206.

Akowuah, P. K., E. Botchway, E. Owusu, D. Ohene, T. Abonambugre, Y. Saeed Adam, A. Asherow, and E. Deletsu. 2025. “Are Corneal Nerve and Dendritic Cell Parameters Assessed via Corneal Confocal Microscopy Good Markers for Multiple Sclerosis? – A Systematic Review and Meta-Analysis.” Journal of Neuroimmunology 407: 578697. https://doi.org/10.1016/j.jneuroim.2025.578697.

Alazzam, A. M., M. W. Alrubaye, J. A. Goldsmith, and A. S. Gorgey. 2023. “Trends in Measuring BMR and RMR After Spinal Cord Injury: A Comprehensive Review.” British Journal of Nutrition 130 (10): 1684–98. https://doi.org/10.1017/S0007114523000831.

Al-Hakeim, Hussein Kadhem, Haneen Tahseen Al-Rubaye, Dhurgham Shihab Al-Hadrawi, Abbas F Almulla, and Michael Maes. 2023. “Long-COVID Post-Viral Chronic Fatigue and Affective Symptoms Are Associated with Oxidative Damage, Lowered Antioxidant Defenses and Inflammation: A Proof of Concept and Mechanism Study.” Molecular Psychiatry 28 (2): 564–78. https://doi.org/10.1038/s41380-022-01836-9.

Almutairi, Mohammed M, Abdulrahman Althekair, Fahad Almutairi, Mohammed Alatabani, and Abdulaziz Alsaikhan. 2024. “Mitochondrial Dysfunction and Mitophagy in ADHD: Cellular and Molecular Mechanisms.” Saudi Pharmaceutical Journal 32 (12): 102212. https://doi.org/10.1016/j.jsps.2024.102212.

Amanna, Ian J., Nichole E. Carlson, and Mark K. Slifka. 2007. “Duration of Humoral Immunity to Common Viral and Vaccine Antigens.” New England Journal of Medicine 357 (19): 1903–15. https://doi.org/10.1056/NEJMoa066092.

Anderson, G. M., E. H. Cook, R. D. Blakely, J. S. Sutcliffe, and J. Veenstra-VanderWeele. 2024. “Long COVID-19 and Peripheral Serotonin: A Commentary and Reconsideration.” Journal of Inflammation Research 17: 2169–72. https://doi.org/10.2147/JIR.S456000.

Anderson, R. H., C. Lettieri, R. Baker, P. A. Low, and E. E. Benarroch. 2021. “Autonomic Nervous System Activation in Iliac Vein Compression Syndrome.” Clinical Autonomic Research 31 (3): 215–24. https://doi.org/10.1007/s10286-021-00723-4.

Andréen, Lotta, Sigrid Nyberg, Sahruh Turkmen, Guido van Wingen, Guillén Fernández, and Torbjörn Bäckström. 2009. “Sex Steroid Induced Negative Mood May Be Explained by the Paradoxical Effect Mediated by GABA-A Modulators.” Psychoneuroendocrinology 34 (8): 1121–32. https://doi.org/10.1016/j.psyneuen.2009.02.003.

Apostolou, E., M. Rizwan, P. Moustardas, P. Sjögren, B. C. Bertilson, B. Bragée, O. Polo, and A. Rosén. 2022. “Saliva Antibody-Fingerprint of Reactivated Latent Viruses After Mild/Asymptomatic COVID-19 Is Unique in Patients with Myalgic-Encephalomyelitis/Chronic Fatigue Syndrome.” Frontiers in Immunology 13: 949787. https://doi.org/10.3389/fimmu.2022.949787.

Arcani, Robin, Elisabeth Jouve, Laurent Chiche, and Noémie Jourde-Chiche. 2023. “Categorization of Patients with Systemic Lupus Erythematosus Using Disease Activity, Patient-Reported Outcomes, and Transcriptomic Signatures.” Clinical Rheumatology 42: 2061–70. https://doi.org/10.1007/s10067-023-06525-8.

Aregawi, Mesfin, Brian Walitt, Peter Sullivan, Gustavo Norato, J. David Benjamin, and David Goldstein. 2026. “Central Noradrenergic Deficiency in Post-Infectious Chronic Fatigue: Neurobehavioral Correlates.” Brain Communications. https://doi.org/10.1093/braincomms/fcag173.

Arnold, Lesley M., Yili Lu, Leslie J. Crofford, Madelaine Wohlreich, Michael J. Detke, Smriti Iyengar, and David J. Goldstein. 2004. “A Double-Blind, Multicenter Trial Comparing Duloxetine with Placebo in the Treatment of Fibromyalgia Patients with or Without Major Depressive Disorder.” Arthritis and Rheumatism 50 (9): 2974–84.

Arnsten, Amy F T. 2011. “Catecholamine Influences on Dorsolateral Prefrontal Cortical Networks.” Biological Psychiatry 69 (12): e89–99. https://doi.org/10.1016/j.biopsych.2011.01.027.

Asbring, Pia, and Anna-Liisa Närvänen. 2002. “Women’s Experiences of Stigma in Relation to Chronic Fatigue Syndrome and Fibromyalgia.” Qualitative Health Research 12 (2): 148–60. https://doi.org/10.1177/104973230201200202.

Asch, Ruth H., Chadi G. Abdallah, Richard E. Carson, and Irina Esterlis. 2024. “Challenges and Rewards of in Vivo Synaptic Density Imaging, and Its Application to the Study of Depression.” Neuropsychopharmacology 50 (1): 153–63. https://doi.org/10.1038/s41386-024-01913-3.

Azcue, Néstor et al. 2025. “Small Fiber Neuropathy in the Post-COVID Condition and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Clinical Significance and Diagnostic Challenges.” European Journal of Neurology 32 (2): e70016. https://doi.org/10.1111/ene.70016.

Azcue, Néstor, Rocio Del Pino, Miriam Acera, Teresa Fernández-Valle, Mayte Ayo-Gonzalez, Juan Carlos Gómez-Esteban, Beatriz Ibañez, David Otaegui, María Sanchez-Rodriguez, and Iñigo Gabilondo. 2023. “Dysautonomia and Small Fiber Neuropathy in Post-COVID Condition and Chronic Fatigue Syndrome.” Journal of Translational Medicine 21 (1): 814. https://doi.org/10.1186/s12967-023-04678-3.

Azcue, N., A. Prada, R. Del Pino, M. Acera, T. Fernández-Valle, N. Ayo-Mentxakatorre, T. Pérez-Concha, et al. 2026b. “Involvement of Autoantibodies Against G Protein-Coupled Receptors in Post-COVID Condition and Chronic Fatigue Syndrome.” Scientific Reports 16. https://doi.org/10.1038/s41598-026-49131-9.

———, et al. 2026a. “Involvement of Autoantibodies Against G Protein-Coupled Receptors in Post-COVID Condition and Chronic Fatigue Syndrome.” Scientific Reports 16 (1): 11837. https://doi.org/10.1038/s41598-026-49131-9.

Badhwar, S., T. J. Pereira, K. Kerr, R. Bray, F. Tabassum, L. Sergio, and H. Edgell. 2025. “Autonomic Phenotyping, Brain Blood Flow Control, and Cognitive-Motor-Integration in Long COVID and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A Pilot Study.” Autonomic Neuroscience 262: 103358. https://doi.org/10.1016/j.autneu.2025.103358.

Baghdasaryan, N., H. Hettlich, M. Katz, V. Navasardyan, J. Borggrefe, and W. Fan. 2026. “In Vivo Confocal Microscopy of Corneal Subbasal Nerve Plexus Detects Early Chemotherapy-Induced Polyneuropathy.” Cornea 45 (5). https://doi.org/10.1097/ICO.0000000000003948.

Balan, Adrian, Giles Graham, Sorin Herban, Marius Marcu, Nini Gheorghe, Gabriela Mara, Florin Claudiu Rasinar, et al. 2026. “Transcutaneous Auricular Vagus Nerve Stimulation for Post-COVID-19 Condition: A Systematic Review and Critical Appraisal of Clinical Evidence.” Journal of Clinical Medicine 15 (11): 4247. https://doi.org/10.3390/jcm15114247.

Bantle, C. M., A. T. Phillips, R. J. Smeyne, S. M. Rocha, K. E. Olson, and R. B. Tjalkens. 2019. “Infection with Mosquito-Borne Alphavirus Induces Selective Loss of Dopaminergic Neurons, Neuroinflammation and Widespread Protein Aggregation.” NPJ Parkinson’s Disease 5: 20. https://doi.org/10.1038/s41531-019-0090-8.

Bao, A. M., G. Meynen, and D. F. Swaab. 2008. “The Stress System in Depression and Neurodegeneration: Focus on the Human Hypothalamus.” Brain Research Reviews 57 (2): 531–53. https://doi.org/10.1016/j.brainresrev.2007.04.005.

Bao, A. M., and D. F. Swaab. 2010. “Corticotropin-Releasing Hormone and Arginine Vasopressin in Depression: Focus on the Human Postmortem Hypothalamus.” Vitamins and Hormones 82: 339–65. https://doi.org/10.1016/S0083-6729(10)82018-7.

Bao, W., J. Yang, M. Li, K. Chen, Z. Ma, Y. Bai, and Y. Xu. 2022. “Prevention of Muscle Atrophy in ICU Patients Without Nerve Injury by Neuromuscular Electrical Stimulation: A Randomized Controlled Study.” BMC Musculoskeletal Disorders 23 (1): 780. https://doi.org/10.1186/s12891-022-05739-2.

Barriales, Diego, Itziar Martı́n-Ruiz, Ana Carreras-González, Marta Montesinos-Robledo, Mikel Azkargorta, Ibon Iloro, Iraide Escobés, et al. 2021. “Borrelia Burgdorferi Infection Induces Long-Term Memory-Like Responses in Macrophages with Tissue-Wide Consequences in the Heart.” PLoS Biology 19 (1): e3001062. https://doi.org/10.1371/journal.pbio.3001062.

Bartley, Christopher M, and David A Ross. 2020. “Schizophrenia: A Homecoming.” Biological Psychiatry 88 (4): e15–17. https://doi.org/10.1016/j.biopsych.2020.06.013.

Basselin, M., H. W. Kim, M. Chen, K. Ma, S. I. Rapoport, R. C. Murphy, and S. E. Farias. 2010. “Lithium Modifies Brain Arachidonic and Docosahexaenoic Metabolism in Rat Lipopolysaccharide Model of Neuroinflammation.” Journal of Lipid Research 51 (5): 1049–56. https://doi.org/10.1194/jlr.M002469.

Bayliss, Kirstie, Mark Goodall, Anna Chisholm, Beth Fordham, Carolyn Chew-Graham, Lisa Riste, Louise Fisher, Karina Lovell, Sarah Peters, and Alison Wearden. 2014. “Overcoming the Barriers to the Diagnosis and Management of Chronic Fatigue Syndrome/ME in Primary Care: A Meta-Synthesis of Qualitative Studies.” BMC Family Practice 15: 44. https://doi.org/10.1186/1471-2296-15-44.

Berende, Anneleen, Hadewych JM ter Hofstede, Fidel J Vos, Henriët van Middendorp, Michiel L Vogelaar, Mirjam Tromp, Frank H van den Hoogen, A Rogier T Donders, Andrea WM Evers, and Bart Jan Kullberg. 2016. “Randomized Trial of Longer-Term Therapy for Symptoms Attributed to Lyme Disease.” New England Journal of Medicine 374 (13): 1209–20. https://doi.org/10.1056/NEJMoa1505425.

Bernard, Quentin, and Linden T Hu. 2020. “Innate Immune Memory to Repeated Borrelia Burgdorferi Exposure.” Journal of Immunology 205 (12): 3383–89. https://doi.org/10.4049/jimmunol.2000686.

Berthier, J, Francky Teddy Endomba, Michel Lecendreux, et al. 2025. “Cerebral Blood Flow in Attention Deficit Hyperactivity Disorder: A Systematic Review.” Neuroscience 567: 67–76. https://doi.org/10.1016/j.neuroscience.2024.11.075.

Bhattacharya, Debashish, and Anthony Scimè. 2024. “Metabolic Reprogramming in Skeletal Muscle Stem Cells During Activation and Differentiation.” Skeletal Muscle 14: 18. https://doi.org/10.1186/s13395-024-00352-2.

Biolo, G., F. Agostini, B. Simunic, M. Sturma, L. Torelli, J. C. Preiser, T. Debevec, I. B. Mekjavic, R. Pisot, and M. V. Narici. 2008. “Positive Energy Balance Is Associated with Accelerated Muscle Atrophy and Increased Erythrocyte Glutathione Turnover During 5 Wk of Bed Rest.” American Journal of Clinical Nutrition 88 (4): 950–58. https://doi.org/10.1093/ajcn/88.4.950.

Blaes, Franz, Gerd Wallukat, et al. 2011. “Autoimmunity Against the β2 Adrenergic Receptor and Muscarinic-2 Receptor in Complex Regional Pain Syndrome.” PAIN 152 (12): 2690–700. https://doi.org/10.1016/j.pain.2011.06.012.

Blitshteyn, Svetlana. 2025. “Neuroinflammation at the Dorsolateral Inferior Medulla.” Biomedicines 13 (1): 166. https://doi.org/10.3390/biomedicines13010166.

Blitshteyn, Svetlana, Taylor Doherty, and Lawrence Steinman. 2026. “Postural Orthostatic Tachycardia Syndrome, Myalgic Encephalomyelitis/Chronic Fatigue Syndrome and Long COVID as Neuroimmune Disorders.” ImmunoTargets and Therapy 15: 1–10. https://doi.org/10.2147/ITT.S581262.

Blomberg, J., M. Rizwan, A. Böhlin-Wiener, A. Elfaitouri, P. Julin, O. Zachrisson, A. Rosén, and C. G. Gottfries. 2019. “Antibodies to Human Herpesviruses in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Patients.” Frontiers in Immunology 10: 1946. https://doi.org/10.3389/fimmu.2019.01946.

Bonaz, Bruno, Thomas Bazin, and Sonia Pellissier. 2018. “The Vagus Nerve at the Interface of the Microbiota-Gut-Brain Axis.” Frontiers in Neuroscience 12: 49. https://doi.org/10.3389/fnins.2018.00049.

Bonetto, Valentina, Silvia Brossa, Chiara Marrocu, Rosanna Vaschetto, Elisa Zavattaro, Luca Tonda, Vincenzo Cantaluppi, et al. 2022. “MMP-9 Correlates with BBB Damage Markers S100B and NSE in COVID-19 Neurological Patients.” Journal of Clinical Medicine 11 (12): 3456. https://doi.org/10.3390/jcm11123456.

Braga, Joeffre, Elad J. Y. Kuik, Mariel Lepra, Pablo M. Rusjan, Stephen J. Kish, and Jeffrey H. Meyer. 2025. “Astrogliosis Marker [11C]SL25.1188 After COVID-19 with Ongoing Depressive and Cognitive Symptoms.” Biological Psychiatry 97 (8): 816–24. https://doi.org/10.1016/j.biopsych.2024.09.027.

Braga, Joeffre, Mariel Lepra, Stephen J. Kish, Pablo M. Rusjan, Zahra Nasser, Nicolaas Verhoeff, Neil Vasdev, et al. 2023. “Neuroinflammation After COVID-19 with Persistent Depressive and Cognitive Symptoms.” JAMA Psychiatry 80 (8): 787–95. https://doi.org/10.1001/jamapsychiatry.2023.1321.

Breitschwerdt, Edward B, Ricardo G Maggi, Janice C Bush, and Emily Kingston. 2025. “Babesia and Bartonella Species DNA in Blood and Enrichment Blood Cultures from People with Chronic Fatigue and Concurrent Neurological Symptoms.” Pathogens 15 (1): 2. https://doi.org/10.3390/pathogens15010002.

Buchholz, A. C., C. F. McGillivray, and P. B. Pencharz. 2003. “Physical Activity Levels Are Low in Free-Living Adults with Chronic Paraplegia.” Obesity Research 11 (4): 563–70. https://doi.org/10.1038/oby.2003.79.

Buchwald, Dedra, Rhoda L Ashley, Terry Pearlman, Phalla Kith, and Anthony L Komaroff. 1996. “Viral Serologies in Patients with Chronic Fatigue and Chronic Fatigue Syndrome.” Journal of Medical Virology 50 (1): 25–30. https://doi.org/10.1002/(SICI)1096-9071(199609)50:1<25::AID-JMV6>3.0.CO;2-V.

Buchwald, Dedra, Richard Herrell, Suzanne Ashton, Michael Belcourt, Karen Schmaling, Patrick Sullivan, Michael Neale, and Jack Goldberg. 2001. “A Twin Study of Chronic Fatigue.” Psychosomatic Medicine 63 (6): 936–43. https://doi.org/10.1097/00006842-200111000-00012.

Bush, JC, C Robveille, RG Maggi, and EB Breitschwerdt. 2024. “Neurobartonelloses: Emerging from Obscurity.” Parasites & Vectors 17 (1): 416. https://doi.org/10.1186/s13071-024-06491-3.

Cabezas-Cruz, Alejandro, Adnan Hodžić, Lourdes Mateos-Hernández, Marinela Contreras, and José de la Fuente. 2021. “Tick-Human Interactions: From Allergic Klendusity to the $\alpha$-Gal Syndrome.” Biochemical Journal 478 (9): 1783–94. https://doi.org/10.1042/BCJ20200915.

Calabrese, Edward J. 2002. “Hormesis: Changing View of the Dose-Response, a Personal Account of the History and Current Status.” Mutation Research 511 (3): 181–89. https://doi.org/10.1016/S1383-5742(02)00013-3.

———. 2010. “Hormesis Is Central to Toxicology, Pharmacology and Risk Assessment.” Human & Experimental Toxicology 29 (4): 249–61. https://doi.org/10.1177/0960327109363973.

Calabrese, Edward J, and Linda A Baldwin. 2003. “Toxicology Rethinks Its Central Belief.” Nature 421 (6924): 691–92. https://doi.org/10.1038/421691a.

Cambras, Trinitat, Jesús Castro-Marrero, María Carmen Zaragoza, Antoni Díez-Noguera, and José Alegre. 2023. “Skin Temperature Circadian Rhythms and Dysautonomia in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: The Role of Endothelin-1 in the Vascular Tone Dysregulation.” International Journal of Molecular Sciences 24 (5): 4835. https://doi.org/10.3390/ijms24054835.

Cameron, D. J. 2006. “Generalizability in Two Clinical Trials of Lyme Disease.” Epidemiologic Perspectives and Innovations 3: 12. https://doi.org/10.1186/1742-5573-3-12.

Campen, C Linda M C van, Freek W A Verheugt, Peter C Rowe, and Frans C Visser. 2020. “Cerebral Blood Flow Is Reduced in ME/CFS During Head-up Tilt Testing Even in the Absence of Hypotension or Tachycardia: A Quantitative, Controlled Study Using Doppler Echography.” Clinical Neurophysiology Practice 5: 50–58. https://doi.org/10.1016/j.cnp.2020.01.003.

Campen, C. (Linda) M. C. van, Freek W. A. Verheugt, Peter C. Rowe, and Frans C. Visser. 2023. “Orthostatic Chronotropic Incompetence in Patients with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS).” IBRO Neuroscience Reports 15: 1–10. https://doi.org/10.1016/j.ibneur.2023.04.005.

Cañadas, P., L. Gonzalez-Vides, M. Alberquilla García-Velasco, P. Arriola, N. Guemes-Villahoz, J. A. Gegúndez-Fernández, C. D. Méndez-Hernández, et al. 2023. “Neuroinflammatory Findings of Corneal Confocal Microscopy in Long COVID-19 Patients, 2 Years After Acute SARS-CoV-2 Infection.” Diagnostics 13 (22): 3469. https://doi.org/10.3390/diagnostics13223469.

Cantrell, S., J. Rilinger, C. Stallkamp Tidd, and R. Wilson. 2025. “Corneal Confocal Microscopy in Postural Orthostatic Tachycardia Syndrome (POTS) as a Diagnostic Tool for Small Fiber Neuropathy.” Cureus.

Cao, J., J. Qu, B. Odilov, B. Lu, Y. Zhang, L. Li, Q. Zhang, and J. Xiong. 2022. “Corneal Nerve Parameter Reference Values for Chinese Adults Assessed by Corneal Confocal Microscopy.” Journal of Diabetes Research 2022: 4913031. https://doi.org/10.1155/2022/4913031.

Capuron, Lucile, Giuseppe Pagnoni, Daniel F. Drake, Bobbi J. Woolwine, James R. Spivey, Robert J. Crowe, John R. Votaw, and Andrew H. Miller. 2012. “Dopaminergic Mechanisms of Reduced Basal Ganglia Responses to Hedonic Reward During Interferon Alfa Administration.” Archives of General Psychiatry 69 (10): 1044–53. https://doi.org/10.1001/archgenpsychiatry.2011.2094.

Cassiani-Ingoni, Riccardo, Erik S Cabral, Jan D Lünemann, Zoila Garza, Tim Magnus, Harald Gelderblom, Peter J Munson, Adriana Marques, and Roland Martin. 2006. “Borrelia burgdorferi Induces TLR1 and TLR2 in Human Microglia and Peripheral Blood Monocytes but Differentially Regulates HLA-Class II Expression.” Journal of Neuropathology and Experimental Neurology 65 (6): 540–48. https://doi.org/10.1097/00005072-200606000-00002.

Caumo, W., A. Deitos, F. Carvalho, D. C. Kraychete, L. C. Antunes, J. A. Bragatti, and I. L. S. Torres. 2025. “Obesity as a Disruptor of the Pain Inhibition Response in Fibromyalgia: A Pooled Multi-Trial Analysis of 521 Patients.” European Journal of Pain 29 (5): e70145. https://doi.org/10.1002/ejp.70145.

Chackerian, Bryce, and David S. Peabody. 2020. “Factors That Govern the Induction of Long-Lived Antibody Responses.” Viruses 12 (1): 74. https://doi.org/10.3390/v12010074.

Chaki, Shaswati, Ibrahim Alkanfari, Saptarshi Roy, Aetas Amponnawarat, Yvonne Hui, Carole A Oskeritzian, and Hydar Ali. 2022. “Inhibition of Orai Channel Function Regulates Mas-Related G Protein-Coupled Receptor-Mediated Responses in Mast Cells.” Frontiers in Immunology 12: 803335. https://doi.org/10.3389/fimmu.2021.803335.

Chang, Xiao, Yichuan Liu, Frank Mentch, Joseph Glessner, Huiqi Qu, Kenny Nguyen, Patrick M A Sleiman, and Hakon Hakonarson. 2020. “Mitochondrial DNA Haplogroups and Risk of Attention Deficit and Hyperactivity Disorder in European Americans.” Translational Psychiatry 10: 370. https://doi.org/10.1038/s41398-020-01064-1.

Charlton, Braeden T, Kasper Janssen, David M Systrom, David Putrino, and Rob C I Wüst. 2026a. “Post-Exertional Malaise and the Myth of Cardiac Deconditioning: Rethinking the Pathophysiology of Long COVID.” British Journal of Sports Medicine. https://doi.org/10.1136/bjsports-2025-111387.

Charlton, Braeden T., Anouk Slaghekke, Brent Appelman, Morne Eggelbusch, Jelle Y. Huijts, Wendy Noort, Paul W. Hendrickse, et al. 2025. “Skeletal Muscle Properties in Long COVID and ME/CFS Differ from Those Induced by Bed Rest.” medRxiv. https://doi.org/10.1101/2025.06.23.25330153.

Charlton, Braeden T., Anouk Slaghekke, Jelle Y. Huijts, Brent Appelman, P. L. Chen, Richie P. Goulding, Frank W. Bloemers, et al. 2026b. “An Inability to Recover: Reduced Regenerative Markers and Altered Metabolism in Patients with ME/CFS and Long COVID.” AMS 2026 Conference, Abstract C14.

Chayama, Yuki, Narsimha R. Rao, Dheeraj Perla, Ian Bowers, Seung Eon Cho, Malabika Das, Shabnam Etemadi, et al. 2026. “Physiological Brain Clearance Architecture Revealed by Neuronal Protein Tracing.” Cell 189: 1–19. https://doi.org/10.1016/j.cell.2026.04.048.

Che, X., A. Ranjan, C. Guo, K. Zhang, R. Goldsmith, S. Levine, K. J. Moneghetti, et al. 2025. “Heightened Innate Immunity May Trigger Chronic Inflammation, Fatigue and Post-Exertional Malaise in ME/CFS.” NPJ Metabolic Health and Disease 3 (1): 34. https://doi.org/10.1038/s44324-025-00079-w.

Chen, H-J, B Appelman, HLDM Willemen, J den Dunnen, N Eijkelkamp, et al. 2026. “Transfer of IgG from Long COVID Patients Induces Symptomatology in Mice.” Cell Reports Medicine 7 (4): 102693. https://doi.org/10.1016/j.xcrm.2026.102693.

Chen, R., K. Wang, J. Yu, D. Howard, L. French, Z. Chen, C. Wen, and Z. Xu. 2020. “The Spatial and Cell-Type Distribution of SARS-CoV-2 Receptor ACE2 in the Human and Mouse Brains.” Frontiers in Neurology 11: 573095. https://doi.org/10.3389/fneur.2020.573095.

Chen, W., J. Li, X. Qiang, L. Lou, C. S. Zhu, and M. Deng. 2026. “Pharmacological Intervention of the HMGB1-pCTS-L Axis to Ameliorate Inflammatory Diseases.” Frontiers in Immunology 17: 1843251. https://doi.org/10.3389/fimmu.2026.1843251.

Chida, Yoichi, and Xiaoling Mao. 2009. “Does Psychosocial Stress Predict Symptomatic Herpes Simplex Virus Recurrence? A Meta-Analytic Investigation on Prospective Studies.” Brain, Behavior, and Immunity 23 (7): 917–25. https://doi.org/10.1016/j.bbi.2009.04.009.

Chinnappan, Bhuvaneswari, Duraisamy Kempuraj, Ramasamy Thangavel, Mary E Ahmed, Smita Zaheer, Gopal Selvakumar, Shankar S Iyer, Sudhir P Raikwar, and Theoharis C Theoharides. 2026. “Elevated Serum Levels of Interleukin-11 and Matrix Metalloproteinase-9 in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.” Frontiers in Immunology 17: 1827700. https://doi.org/10.3389/fimmu.2026.1827700.

Chopra, P. 2026. “Postural Orthostatic Tachycardia Syndrome: When Dysautonomia Misleads – a Mechanistic Argument for Compensatory Orthostatic Tachycardia.” Frontiers in Neurology 17: 1806502. https://doi.org/10.3389/fneur.2026.1806502.

Ciregia, Federica, Laxmikanth Kollipara, Laura Giusti, René P Zahedi, et al. 2016. “Bottom-up Proteomics Suggests an Association Between Differential Expression of Mitochondrial Proteins and Chronic Fatigue Syndrome.” Translational Psychiatry 6: e904. https://doi.org/10.1038/tp.2016.184.

Clarion, Jessica, Zella Berill, Apryl Susi, Edward Mitre, David Schwartz, and Cade M Nylund. 2026. “Post-COVID-19 Onset of Allergic Conditions in a Propensity-Matched Cohort of Children and Adults.” Annals of Allergy, Asthma and Immunology. https://doi.org/10.1016/j.anai.2026.05.022.

Cliff, J. M., E. C. King, J. S. Lee, N. Sepúlveda, A. S. Wolf, C. Kingdon, E. Bowman, et al. 2019. “Cellular Immune Function in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS).” Frontiers in Immunology 10: 796. https://doi.org/10.3389/fimmu.2019.00796.

Committee on the Diagnostic Criteria for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. 2015. Beyond Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Redefining an Illness. Washington, DC: National Academies Press. https://doi.org/10.17226/19012.

Constantinescu, Cris S., Gerlinde Niepel, Miranda Patterson, Dhruvit K. Bhatt, and Gavin Giovannoni. 2011. “Orexin A (hypocretin-1) Levels Are Not Reduced While Cocaine/Amphetamine Regulated Transcript (CART) Levels Are Increased in Patients with Multiple Sclerosis.” Journal of the Neurological Sciences 307 (1–2): 127–31. https://doi.org/10.1016/j.jns.2011.04.024.

Cook, Dane B., Stephanie VanRiper, Ryan J. Dougherty, Jacob B. Lindheimer, Michael J. Falvo, Yang Chen, Jin-Mann S. Lin, Elizabeth R. Unger, and The MCAM Study Group. 2022. “Cardiopulmonary, Metabolic, and Perceptual Responses During Exercise in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS): A Multi-Site Clinical Assessment of ME/CFS (MCAM) Sub-Study.” PLOS ONE 17 (3): e0265315. https://doi.org/10.1371/journal.pone.0265315.

Cools, Roshan, and Mark D’Esposito. 2011. “Inverted-U-Shaped Dopamine Actions on Human Working Memory and Cognitive Control.” Biological Psychiatry 69 (12): e113–25. https://doi.org/10.1016/j.biopsych.2011.03.028.

Coughlin, Jennifer M, Ting Yang, Alison W Rebman, Kathleen T Bechtold, Yong Du, William B Mathews, Wojciech G Lesniak, et al. 2018. “Imaging Glial Activation in Patients with Post-Treatment Lyme Disease Symptoms: A Pilot Study Using [11C]DPA-713 PET.” Journal of Neuroinflammation 15 (1): 346. https://doi.org/10.1186/s12974-018-1381-4.

Couteaudier, M., M. Nivard, J. Cochard, F. Mammano, P. Roingeard, H. de Rocquigny, and P. Chouteau. 2025. “Hypoxia-Inducible Factor 2 Triggers the Production of Highly Infectious Native-Like Hepatitis C Virus Particles.” Cellular and Molecular Life Sciences 82 (1): 241. https://doi.org/10.1007/s00018-025-05739-0.

Craft, J. M., B. M. Wipfli, C. J. Hough, A. Gifford, and C. D’Lauro. 2015. “Unique Barriers and Needs in Weight Management for Obese Women with Fibromyalgia.” Explore 11 (1): 51–58. https://doi.org/10.1016/j.explore.2014.10.005.

Crosby, Lauren D., Kara L. Kalantar, and Joseph L. DeRisi. 2021. “Pilot Study of Low-Dose Aripiprazole for the Treatment of ME/CFS.” BMC Neurology 21 (1): 52. https://doi.org/10.1186/s12883-021-02078-4.

D’Onghia, M., J. Ciaffi, L. Lisi, D. Giunchi, N. Malavolta, and F. Ursini. 2021. “Fibromyalgia and Obesity: A Comprehensive Systematic Review and Meta-Analysis.” Seminars in Arthritis and Rheumatism 51 (3): 608–14. https://doi.org/10.1016/j.semarthrit.2021.02.007.

Da Silva, José Philipe. 2025. “Hypothalamic CRH Neuron Depletion in Severe ME/CFS: Autopsy Findings from the Netherlands Brain Bank ME/CFS Donation Programme.” Conference presentation at IACFS/ME 2025 (not peer-reviewed; reported via Health Rising blog). https://www.healthrising.org/blog/2025/12/04/chronic-fatigue-hpa-axis-autopsy/.

Dalmau, Josep, Amy J Gleichman, Ethan G Hughes, Jeffrey E Rossi, Xiaoyu Peng, Meizan Lai, Scott K Dessain, Myrna R Rosenfeld, Rita Balice-Gordon, and David R Lynch. 2008. “Anti-NMDA-Receptor Encephalitis: Case Series and Analysis of the Effects of Antibodies.” The Lancet Neurology 7 (12): 1091–98. https://doi.org/10.1016/S1474-4422(08)70224-2.

Das, S., K. Taylor, J. Kozubek, J. Sardell, and A. Gardner. 2022. “Genetic Risk Factors for ME/CFS Identified Using Combinatorial Analysis.” Journal of Translational Medicine 20: 598. https://doi.org/10.1186/s12967-022-03815-8.

Dattwyler, Raymond J, David J Volkman, Benjamin J Luft, John J Halperin, John Thomas, and Marc G Golightly. 1988. “Seronegative Lyme Disease: Dissociation of Specific t- and b-Lymphocyte Responses to Borrelia Burgdorferi.” New England Journal of Medicine 319 (22): 1441–46. https://doi.org/10.1056/NEJM198812013192203.

Dauvilliers, Yves, Sophie Bayard, John M. Shneerson, Giuseppe Plazzi, Allen J. Myers, and Diego Garcia-Borreguero. 2011. “High Pain Frequency in Narcolepsy with Cataplexy.” Sleep Medicine 12 (6): 572–77. https://doi.org/10.1016/j.sleep.2011.01.010.

Davenport, Todd E., Mary Lehnen, Staci R. Stevens, J. Mark VanNess, Jared Stevens, and Christopher R. Snell. 2019. “Chronotropic Intolerance: An Overlooked Determinant of Symptoms and Activity Limitation in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome?” Frontiers in Pediatrics 7: 82. https://doi.org/10.3389/fped.2019.00082.

Davenport, Todd E., Carmen Scheibenbogen, Mark A. Zinn, Mary Dimmock, Janet Stone, Karl J. Tronstad, Øystein Fluge, et al. 2025. “Altered Effort and Deconditioning Are Not Valid Explanations of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.” Nature Communications 16: 9176. https://doi.org/10.1038/s41467-025-64538-0.

Davis, J. T., J. E. Elliott, J. W. Duke, A. Cristobal, and A. T. Lovering. 2023. “Hyperoxia-Induced Stepwise Reduction in Blood Flow Through Intrapulmonary, but Not Intracardiac, Shunt During Exercise.” American Journal of Physiology: Regulatory, Integrative and Comparative Physiology 324 (5): R689–700. https://doi.org/10.1152/ajpregu.00014.2023.

De Becker, P. et al. 1998. “Cold Pressor Test Reveals Sympathetic Overactivity in Chronic Fatigue Syndrome.” Clinical Autonomic Research 8 (6): 347–52. https://doi.org/10.1007/BF02309571.

De Bellis, A., G. Bellastella, V. Pernice, P. Cirillo, M. Longo, M. I. Maiorino, K. Esposito, and A. Bellastella. 2021. “Hypothalamic-Pituitary Autoimmunity and Related Impairment of Hormone Secretions in Chronic Fatigue Syndrome.” Journal of Clinical Endocrinology and Metabolism 106 (12): e5147–55. https://doi.org/10.1210/clinem/dgab429.

Deale, Alicia, and Simon Wessely. 2001. “Patients’ Perceptions of Medical Care in Chronic Fatigue Syndrome.” Social Science & Medicine 52 (12): 1859–64. https://doi.org/10.1016/S0277-9536(00)00302-6.

DecodeME Consortium, Chris P Ponting, et al. 2025. “Initial Findings from the DecodeME Genome-Wide Association Study of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.” medRxiv. https://doi.org/10.1101/2025.08.06.25333109v1.

DeLong, A. K., B. Blossom, E. L. Maloney, and S. E. Phillips. 2012. “Antibiotic Retreatment of Lyme Disease in Patients with Persistent Symptoms: A Biostatistical Review of Randomized, Placebo-Controlled, Clinical Trials.” Contemporary Clinical Trials 33 (6): 1132–42. https://doi.org/10.1016/j.cct.2012.08.009.

Deng, H., S. Jia, C. Zhu, J. Hua, Z. Wang, X. Sun, W. Liu, et al. 2026. “IRF3 Attenuates Hypoxia Signaling by Retaining HIF-α in the Cytoplasm.” Cell Reports 45 (1): 116815. https://doi.org/10.1016/j.celrep.2025.116815.

Deutz, N. E. P., S. L. Pereira, N. P. Hays, J. S. Oliver, N. K. Edens, C. M. Evans, and R. R. Wolfe. 2013. “Effect of ${\beta}$-Hydroxy-${\beta}$-Methylbutyrate (HMB) on Lean Body Mass During 10 Days of Bed Rest in Older Adults.” Clinical Nutrition 32 (5): 704–12. https://doi.org/10.1016/j.clnu.2013.02.011.

Dirks, M. L., D. Hansen, A. Van Assche, P. Dendale, and L. J. C. Van Loon. 2015. “Neuromuscular Electrical Stimulation Prevents Muscle Wasting in Critically Ill Comatose Patients.” Clinical Science 128 (6): 357–65. https://doi.org/10.1042/CS20140447.

Dong, Yan, Yantong Chen, Yanshuang Luo, Meng Liu, Chao Song, Xuesong Chen, Fusong Yang, Qingyi Luo, and Guozhong Zhou. 2026. “Glycolytic Reprogramming in Host Response to Borrelia burgdorferi.” Experimental and Therapeutic Medicine 32 (1): 187. https://doi.org/10.3892/etm.2026.13182.

Drosen, ME, S Bulbule, G Gottschalk, D Peterson, LA Allen, L Arnold, and A Roy. 2025. “Inactivation of ATG13 Stimulates Chronic Demyelinating Pathologies in Muscle-Serving Nerves and Spinal Cord.” Immunologic Research 73 (1): 27. https://doi.org/10.1007/s12026-024-09557-7.

Drummond, P. D., and P. M. Finch. 2022. “Pupillary Reflexes in Complex Regional Pain Syndrome: Asymmetry to Arousal Stimuli Suggests an Ipsilateral Locus Coeruleus Deficit.” Journal of Pain 23 (1): 131–40. https://doi.org/10.1016/j.jpain.2021.07.003.

Dumont, Nicolas A., C. Florian Bentzinger, Marie-Claude Sincennes, and Michael A. Rudnicki. 2015. “Satellite Cells and Skeletal Muscle Regeneration.” Comprehensive Physiology 5 (3): 1027–59. https://doi.org/10.1002/cphy.c140068.

Eaton-Fitch, N, H Cabanas, S du Preez, D Staines, and S Marshall-Gradisnik. 2021. “The Effect of IL-2 Stimulation and Treatment of TRPM3 on Channel Co-Localisation with PIP2 and NK Cell Function in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Patients.” Journal of Translational Medicine 19: 306. https://doi.org/10.1186/s12967-021-02974-4.

Eckey, Macy, Peng Li, Brett Morrison, Jonas Bergquist, Ronald W. Davis, and Wenzhong Xiao. 2025. “Patient-Reported Treatment Outcomes in ME/CFS and Long COVID.” Proceedings of the National Academy of Sciences 122 (28): e2426874122. https://doi.org/10.1073/pnas.2426874122.

Egg, R., B. Högl, S. Glatzl, R. Beer, and T. Berger. 2002. “Autonomic Instability, as Measured by Pupillary Unrest, Is Not Associated with Multiple Sclerosis Fatigue Severity.” Multiple Sclerosis 8 (3): 256–60. https://doi.org/10.1191/1352458502ms793oa.

Ekman, L., H. Tufvesson, E. Englund, L. B. Dahlin, and B. Ohlsson. 2025. “Symptoms and Objective Signs of Peripheral Sensory Neuropathy in POTS and Correlations to Gastrointestinal Symptoms.” PLoS One 20 (7): e0327549. https://doi.org/10.1371/journal.pone.0327549.

El-Rhermoul, Fatema-Zahra et al. 2023. “Autoimmunity in Long COVID and POTS.” Oxford Open Immunology 4 (1): iqad002. https://doi.org/10.1093/oxfimm/iqad002.

Engert, L. C., R. Dang, S. Daniel, S. M. Bertisch, J. H. Maley, T. G. Fong, C. N. Serhan, J. M. Mullington, and M. Haack. 2026. “Sleep Disturbance Affects Inflammatory Resolution in Long COVID.” Prostaglandins Leukotrienes and Essential Fatty Acids 204: 102728. https://doi.org/10.1016/j.plefa.2026.102728.

Fallon, B. A., J. G. Keilp, K. M. Corbera, E. Petkova, C. B. Britton, E. Dwyer, I. Slavov, et al. 2008. “A Randomized, Placebo-Controlled Trial of Repeated IV Antibiotic Therapy for Lyme Encephalopathy.” Neurology 70 (13): 992–1003. https://doi.org/10.1212/01.WNL.0000284604.61160.2d.

Fanet, Haïl, Lucile Capuron, Nathalie Castanon, Frédéric Calon, and Sylvie Vancassel. 2021. “Tetrahydrobiopterin (BH4) Pathway: From Metabolism to Neuropsychiatry.” Current Neuropharmacology 19 (5): 591–609. https://doi.org/10.2174/1570159X18666200729103529.

Farrow, C. E., R. A. Robles, G. K. Prisk, P. Harbut, A. Malhotra, T. C. Amis, and P. D. Wagner. 2023. “Increased Intrapulmonary Shunt and Alveolar Dead Space Post-COVID-19.” Journal of Applied Physiology 135 (5): 1012–22. https://doi.org/10.1152/japplphysiol.00267.2023.

Feder, Henry M, Barbara JB Johnson, Susan O’Connell, Eugene D Shapiro, Allen C Steere, Gary P Wormser, and Ad Hoc International Lyme Disease Group. 2007. “A Critical Appraisal of "Chronic Lyme Disease".” New England Journal of Medicine 357 (14): 1422–30. https://doi.org/10.1056/NEJMra072023.

Fedorowski, Artur et al. 2017. “Antiadrenergic Autoimmunity in Postural Tachycardia Syndrome.” Europace 19 (7): 1211–19. https://doi.org/10.1093/europace/euw154.

Feng, J., T. Li, R. Yee, Y. Yuan, C. Bai, M. Cai, W. Shi, et al. 2019. “Stationary Phase Persister/Biofilm Microcolony of Borrelia Burgdorferi Causes More Severe Disease in a Mouse Model of Lyme Arthritis.” Discovery Medicine 27 (148): 125–38.

Ferreira, M. T., J. Gambetta, E. Wainstein, and N. Labropoulos. 2023. “Venous Compression Syndromes: A Systematic Review of Clinical Presentation and Management.” Phlebology 38 (7): 532–48. https://doi.org/10.1177/02683555221144738.

Ferrero, K., M. Silver, A. Cocchetto, E. Masliah, and D. Langford. 2017. “CNS Findings in Chronic Fatigue Syndrome and a Neuropathological Case Report.” Journal of Investigative Medicine 65 (5): 974–83. https://doi.org/10.1136/jim-2016-000390.

Filippatos, Filippos, Dimitra-Ifigeneia Matara, Athanasios Michos, and Konstantinos Kakleas. 2025. “Immunological Mechanisms Underlying Allergy Predisposition After SARS-CoV-2 Infection in Children.” Cells 14 (19): 1511. https://doi.org/10.3390/cells14191511.

Fineberg, D, A Moreau, and EK Schneider-Futschik. 2025. “A Perspective on the Role of Metformin in Treating Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) and Long COVID.” ACS Pharmacology and Translational Science. https://doi.org/10.1021/acsptsci.5c00229.

Fitzgerald, Bryna L, Barbara Graham, Mark J Delorey, Adoracion Pegalajar-Jurado, M Nurul Islam, Gary P Wormser, John N Aucott, et al. 2021. “Metabolic Response in Patients with Post-Treatment Lyme Disease Symptoms/Syndrome.” Clinical Infectious Diseases 73 (7): e2342–49. https://doi.org/10.1093/cid/ciaa1455.

Flaskamp, Lena, Clemens Roubal, Shahab Uddin, Franziska Sotzny, Claudia Kedor, Sandra Bauer, Carmen Scheibenbogen, and Martin Seifert. 2022. “Serum of Post-COVID-19 Syndrome Patients with or Without ME/CFS Differentially Affects Endothelial Cell Function In Vitro.” Cells 11 (15): 2376. https://doi.org/10.3390/cells11152376.

Fluder, Natalia, Morgane Humbel, Emeline Recazens, Alexis A Jourdain, Camillo Ribi, et al. 2026. “Mitochondrial Dysfunction Drives Natural Killer Cell Dysfunction in Systemic Lupus Erythematosus.” JCI Insight. https://doi.org/10.1172/jci.insight.195170.

Fluge, Ø., I. G. Rekeland, K. Lien, H. Thürmer, P. C. Borchgrevink, C. Schäfer, K. Sørland, et al. 2019. “B-Lymphocyte Depletion in Patients with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial.” Annals of Internal Medicine 170 (9): 585–93. https://doi.org/10.7326/M18-1451.

Fluge, Ø., K. Risa, S. Lunde, K. Alme, I. G. Rekeland, D. Sapkota, E. K. Kristoffersen, et al. 2015. “B-Lymphocyte Depletion in Myalgic Encephalopathy/Chronic Fatigue Syndrome. An Open-Label Phase II Study with Rituximab Maintenance Treatment.” PLoS ONE 10 (7): e0129898. https://doi.org/10.1371/journal.pone.0129898.

Fluge, Øystein, Olav Bruland, Kristin Risa, Anette Storstein, and Olav Mella. 2011. “Benefit from B-Lymphocyte Depletion Using the Anti-CD20 Antibody Rituximab in Chronic Fatigue Syndrome: A Double-Blind and Placebo-Controlled Study.” PLOS ONE 6 (10): e26838. https://doi.org/10.1371/journal.pone.0026838.

Freitag, Helma, Milena Szklarski, Sibylle Lorenz, Franziska Sotzny, Stephan Bauer, Anke Philippe, Claudia Kedor, et al. 2021. “Autoantibodies to Vasoregulative G-Protein-Coupled Receptors Correlate with Symptom Severity, Autonomic Dysfunction and Disability in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.” Journal of Clinical Medicine 10 (16): 3675. https://doi.org/10.3390/jcm10163675.

Froehlich, Laura, Daniel B R Hattesohl, Joseph Cotler, Leonard A Jason, Carmen Scheibenbogen, and Uta Behrends. 2022. “Causal Attributions and Perceived Stigma for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.” Journal of Health Psychology 27 (10): 2291–2304. https://doi.org/10.1177/13591053211027631.

Fronticelli Baldelli, Giovanni, and Danilo Buonsenso. 2025. “Proposed Mechanistic Axis of Infections and mTOR Hyperactivation: A Multidisciplinary Review of Immune, Rheumatologic, and Psychiatric Links.” Children 12 (12): 1603. https://doi.org/10.3390/children12121603.

Fu, Qi, and Benjamin D Levine. 2018. “Exercise and Non-Pharmacological Treatment of POTS.” Autonomic Neuroscience 215: 20–27. https://doi.org/10.1016/j.autneu.2018.07.001.

Fu, Qi, Tiffany B VanGundy, M Galbreath, Shigeki Shibata, Manish Jain, Jeffrey L Hastings, Paul S Bhella, and Benjamin D Levine. 2010. “Cardiac Origins of the Postural Orthostatic Tachycardia Syndrome.” Journal of the American College of Cardiology 55 (25): 2858–68. https://doi.org/10.1016/j.jacc.2010.02.043.

Gangwar, A., Pooja, M. Sharma, K. Singh, A. Patyal, G. Bhaumik, K. Bhargava, and N. K. Sethy. 2019. “Intermittent Normobaric Hypoxia Facilitates High Altitude Acclimatization by Curtailing Hypoxia-Induced Inflammation and Dyslipidemia.” Pflügers Archiv - European Journal of Physiology 471 (7): 949–59. https://doi.org/10.1007/s00424-019-02273-4.

Garvin, P, L Nilsson, L Jonasson, M Kristenson, S Jonmarker, and E Theodorsson. 2015. “Circulating Matrix Metalloproteinase-9 Is Associated with Cardiovascular Disease: The Influence of Pre-Analytical Factors.” Scandinavian Journal of Clinical and Laboratory Investigation 75 (5): 394–401.

Gaykema, Ronald P. A., and Lisa E. Goehler. 2009. “Lipopolysaccharide Challenge-Induced Suppression of Fos in Hypothalamic Orexin Neurons: Their Potential Role in Sickness Behavior.” Brain, Behavior, and Immunity 23 (7): 926–30. https://doi.org/10.1016/j.bbi.2009.03.005.

George, Chelsea T., Biji T. Kurien, and R. Hal Scofield. 2023. “The Potential Utility of Salivary and Tear Proteomics to Discriminate Sjögren’s Disease from Non-Sjögren’s Sicca.” International Journal of Molecular Sciences 24 (24): 17497. https://doi.org/10.3390/ijms242417497.

Georgopoulos, Apostolos P, Lisa M James, and Philip K Peterson. 2025. “HLA and Pathogens in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) and Other Post-Infection Conditions.” Scientific Reports 15: 37303. https://doi.org/10.1038/s41598-025-21230-z.

Germain, Arnaud, Jillian R Jaycox, Christopher J Emig, Aaron M Ring, and Maureen R Hanson. 2025. “An in-Depth Exploration of the Autoantibody Immune Profile in ME/CFS Using Novel Antigen Profiling Techniques.” International Journal of Molecular Sciences 26 (6): 2799. https://doi.org/10.3390/ijms26062799.

Ghadban, R., M. Bay-Smidt, T. Bjørnkær, D. Gaist, J. V. Holbech, T. A. Gaist, M. Wirenfeldt, and S. H. Sindrup. 2025. “The Correlation Between Functional and Morphometric Small Fiber Assessment in Mixed Etiology Polyneuropathy.” Journal of the Peripheral Nervous System 30 (2): e70005.

Gharib, M., G. Ponirakis, M. Dafaalla, H. Gad, M. Elgassim, et al. 2025. “Corneal Confocal Microscopy: A Novel Biomarker of Small Fibre Neuropathy in SLE.” Lupus Science & Medicine.

Gierthmuehlen, Mortimer, Kirsten Schmieder, Niklas Thon, and Petra C. Gierthmuehlen. 2026. “Transcutaneous Auricular Vagal Nerve Stimulation Against Fatigue Syndrome in Patients with Long COVID: Results of the Randomized, Placebo-Controlled Clinical Pilot Trial COVIVA.” Neurology and Therapy 15 (3): 1327–43. https://doi.org/10.1007/s40120-026-00928-w.

Gile, Brooke, Sarojini Bulbule, Mubaraq A. Toriola, Brian T. Ruan, Shabnam Marium, Anna Benko, Stephanie Grach, et al. 2026. “Association of Rapamycin Treatment with the Modulation of Purine Metabolism, Reduced Microglial Inflammatory Responses, Improved Mitochondrial Energy Metabolism, and Alleviation of Fatigue Symptoms in ME/CFS Subjects: Pilot Findings from Phase-II Observational Study.” Journal of Translational Medicine 24 (1): 921. https://doi.org/10.1186/s12967-026-08575-3.

Giloteaux, Ludovic, Maureen R. Hanson, and Betsy A. Keller. 2016. “A Pair of Identical Twins Discordant for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Differ in Physiological Parameters and Gut Microbiome Composition.” American Journal of Case Reports 17: 720–29. https://doi.org/10.12659/ajcr.900314.

Giménez-Orenga, Karen, Justine Pierquin, Joanna Brunel, Benjamin Charvet, Eva Martín-Martínez, Margot Lemarinier, Steven Fried, Alexandre Lucas, Hervé Perron, and Elisa Oltra. 2025. “Blood Parameters Differentiate Post COVID-19 Condition from Myalgic Encephalomyelitis/Chronic Fatigue Syndrome and Fibromyalgia.” Brain, Behavior, and Immunity – Health 48: 101058. https://doi.org/10.1016/j.bbih.2025.101058.

Girgis, Alexander A, Raffaello Cimbro, Ting Yang, Alison W Rebman, Thelio Sewell, Daniela Villegas de Flores, Aarti Vadalia, et al. 2025. “Aberrant t-Cell Phenotypes in a Cohort of Patients with Post-Treatment Lyme Disease.” Frontiers in Immunology 16: 1607619. https://doi.org/10.3389/fimmu.2025.1607619.

Goebel, A., K. Busch, R. Riedl, and C. Sommer. 2021. “Passive Transfer of Fibromyalgia IgG Induces Pain and Fatigue in Mice.” Pain 162 (4): 893–904. https://doi.org/10.1097/j.pain.0000000000002134.

Gopinath, Divya, Ken Huei Koe, Manoj Kumar Maharajan, and Sujata Panda. 2023. “A Comprehensive Overview of Epidemiology, Pathogenesis and the Management of Herpes Labialis.” Viruses 15 (1): 225. https://doi.org/10.3390/v15010225.

Gracia Aznar, A., F. Moreno Egea, R. Gracia Banzo, R. Gutierrez, J. M. Rizo, and P. Rodriguez-Ledo. 2024. “Pro-Resolving Inflammatory Effects of a Marine Oil Enriched in Specialized Pro-Resolving Mediators (SPMs) Supplement and Its Implication in Patients with Post-COVID Syndrome (PCS).” Biomedicines 12 (10): 2221. https://doi.org/10.3390/biomedicines12102221.

Grist, J. T., G. J. Collier, H. Walters, M. Kim, M. Chen, G. Abu Eid, A. Laws, et al. 2022. “Lung Abnormalities Detected with Hyperpolarized 129Xe MRI in Patients with Long COVID.” Radiology 305 (3): 709–17. https://doi.org/10.1148/radiol.220069.

Grossberg, Aaron J., XinXia Zhu, Gina M. Leinninger, Peter R. Levasseur, Theodore P. Braun, Martin G. Jr. Myers, and Daniel L. Marks. 2011. “Inflammation-Induced Lethargy Is Mediated by Suppression of Orexin Neuron Activity.” Journal of Neuroscience 31 (31): 11376–86. https://doi.org/10.1523/JNEUROSCI.2311-11.2011.

Guise, Jennifer, Chris McVittie, and Andy McKinlay. 2010. “A Discourse Analytic Study of ME/CFS (Chronic Fatigue Syndrome) Sufferers’ Experiences of Interactions with Doctors.” Journal of Health Psychology 15 (3): 426–35. https://doi.org/10.1177/1359105309350515.

Gunning, W. T., B. L. Karabin, T. M. Blomquist, and B. P. Grubb. 2016. “Postural Orthostatic Tachycardia Syndrome Is Associated with Platelet Storage Pool Deficiency.” Medicine (Baltimore) 95 (37): e4849. https://doi.org/10.1097/MD.0000000000004849.

Guo, Yuanbin, Sitong Zhou, Shujie Ren, Xin Liu, Mohsen Nemat-Gorgani, Michael J. Gresser, Ronald W. Davis, and Jiandi Wan. 2025. “Microfluidic Assessment of PO2-Regulated RBC Capillary Velocity in ME/CFS.” Blood: Red Cells & Iron 1 (3): 100019. https://doi.org/10.1182/bloodrci.2024.100019.

Guo, Y., T. Wei, N. Hu, and X. Zhou. 2021. “Disrupted Homeostasis of Synovial Hyaluronic Acid and Its Associations with Synovial Mast Cell Proteases of Rheumatoid Arthritis Patients and Collagen-Induced Arthritis Rats.” Immunologic Research 69 (6): 584–93. https://doi.org/10.1007/s12026-021-09231-2.

Guttuso, Thomas, Rongbing Zhu, and Kara Zahra. 2024. “Lithium for Cognitive Impairment in Long COVID: A Randomized Clinical Trial.” JAMA Network Open 7 (8): e2427562. https://doi.org/10.1001/jamanetworkopen.2024.27562.

Hammarlund, Erika, A. Thomas, Ian J. Amanna, L. A. Holden, O. D. Slayden, B. Park, L. Gao, and Mark K. Slifka. 2017. “Plasma Cell Survival in the Absence of b Cell Memory.” Nature Communications 8 (1): 1781. https://doi.org/10.1038/s41467-017-01901-w.

Hanna, R. D., L. M. Sheldahl, and F. E. Tristani. 1993. “Effect of Enhanced Preload with Head-Out Water Immersion on Exercise Response in Men with Healed Myocardial Infarction.” American Journal of Cardiology 71 (12): 1041–44. https://doi.org/10.1016/0002-9149(93)90570-3.

Hartung, Olivier, Anderson Loundou, Fabrice Barlesi, Christian Ducerf, and Jean-Marc Pernes. 2019. “Impact of Iliac Vein Compression on Cerebral Venous Outflow: A Pilot Study Using Doppler Ultrasound.” Journal of Vascular Ultrasound 43 (2): 77–84. https://doi.org/10.1177/1544316719845718.

Hartwig, C. et al. 2020. “ME/CFS IgG Fails to Activate the Β2-Adrenergic Receptor.” Brain, Behavior, and Immunity Health.

Hauglund, Natalie L., Mie Andersen, Klaudia Tokarska, Tessa Radovanovic, Celia Kjaerby, Frederikke L. Sørensen, Zuzanna Bojarowska, et al. 2025. “Norepinephrine-Mediated Slow Vasomotion Drives Glymphatic Clearance During Sleep.” Cell 188 (3): 606–622.e17. https://doi.org/10.1016/j.cell.2024.11.027.

Hetland, Geir, Magne Kristoffer Fagerhol, Markus Karl Hermann Wiedmann, et al. 2022. “Elevated NETs and Calprotectin Levels After ChAdOx1 nCoV-19 Vaccination Correlate with the Severity of Side Effects.” Vaccines 10 (8): 1267. https://doi.org/10.3390/vaccines10081267.

Hochecker, Barbara, Katja Matt, Melanie Scherer, Alica Meßmer, Alexander von Ardenne, and Jörg Bergemann. 2025. “Heat Vs. Fatigue: Hyperthermia as a Possible Treatment Option for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS).” International Journal of Molecular Sciences 26 (11): 5339. https://doi.org/10.3390/ijms26115339.

Hoel, F., A. Hoel, I. K. N. Pettersen, I. G. Rekeland, K. Risa, K. Alme, K. Sørland, et al. 2021. “A Map of Metabolic Phenotypes in Patients with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.” JCI Insight 6 (16): e149217. https://doi.org/10.1172/jci.insight.149217.

Hoel, Filip, Anna Hoel, Ida K. Pettersen, Ingrid G. Rekeland, Kristin Risa, Kine Alme, Kari Sørland, et al. 2021. “A Map of Metabolic Phenotypes in Patients with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.” JCI Insight 6 (18): e149217. https://doi.org/10.1172/jci.insight.149217.

Horiuchi, Hiroko, Tetsuya Ogata, Tadao Morino, Junji Takeba, Haruo Okumura, and Seiji Miyamoto. 2015. “Carnitine Deficiency Disturbs Orexin Neuron Activity Under Metabolic Stress.” Neuroscience Letters 606: 7–11. https://doi.org/10.1016/j.neulet.2015.08.033.

Hornig, Mady, José G Montoya, Nancy G Klimas, Susan Levine, Donna Felsenstein, Lucinda Bateman, Daniel L Peterson, et al. 2015. “Distinct Plasma Immune Signatures in ME/CFS Are Present Early in the Course of Illness.” Science Advances 1 (1): e1400121. https://doi.org/10.1126/sciadv.1400121.

Horowitz, R. I., and P. R. Freeman. 2020. “Efficacy of Double-Dose Dapsone Combination Therapy in the Treatment of Chronic Lyme Disease/Post-Treatment Lyme Disease Syndrome (PTLDS) and Associated Co-Infections: A Report of Three Cases and Retrospective Chart Review.” Antibiotics 9 (11): 725. https://doi.org/10.3390/antibiotics9110725.

Hussein, Sabreena, Lindsay Eiriksson, Michelle MacQuarrie, Shanon Merriam, Marissa Dalton, Luis Nacul, and Eliana Lacerda. 2024. “Healthcare System Barriers Impacting the Care of Canadians with Myalgic Encephalomyelitis: A Scoping Review.” Journal of Evaluation in Clinical Practice 30 (7): 1337–60. https://doi.org/10.1111/jep.14047.

Ibrahim, K. N., R. Wasim, and E. Rahman. 2026. “HMGB1-Mediated Neuroinflammation: Molecular Mechanisms and Emerging Therapeutic Approaches.” Inflammopharmacology 34: 3085–3108. https://doi.org/10.1007/s10787-026-02211-8.

Imanaka, B. et al. 2026. “Splicing Alterations Associated with Multiple Homozygous TNXB Variants in a Patient with Suspected Classical-Like Ehlers-Danlos Syndrome.” Biochemical Genetics. https://doi.org/10.1007/s10528-026-11416-z.

Inderyas, Maira, Kiran Thapaliya, Sonya Marshall-Gradisnik, and Leighton Barnden. 2026. “Distinct Functional Connectivity Patterns in Myalgic Encephalomyelitis and Long COVID Patients During Cognitive Fatigue: A 7 Tesla Task-fMRI Study.” Journal of Translational Medicine 24 (1): 236. https://doi.org/10.1186/s12967-026-07708-y.

Ito, Hiroto, Noriaki Fukatsu, Sheikh Mizanur Rahaman, Yasutaka Mukai, Shuntaro Izawa, Daisuke Ono, Thomas S. Kilduff, and Akihiro Yamanaka. 2023. “Deficiency of Orexin Signaling During Sleep Is Involved in Abnormal REM Sleep Architecture in Narcolepsy.” Proceedings of the National Academy of Sciences U.S.A. 120 (41): e2301951120. https://doi.org/10.1073/pnas.2301951120.

Iu, David S., Jessica Maya, Luyen T. Vu, Elizabeth A. Fogarty, Adrian J. McNairn, Faraz Ahmed, Carl J. Franconi, et al. 2024. “Transcriptional Reprogramming Primes CD8+ t Cells Toward Exhaustion in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.” Proceedings of the National Academy of Sciences 121 (50): e2415119121. https://doi.org/10.1073/pnas.2415119121.

Iu, Derek S, Lauren E Klevorn, Sanjana Bhatt, Sunita Bhatt, et al. 2024. “Transcriptional Reprogramming Primes CD8+ T Cells Toward Exhaustion in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.” Proceedings of the National Academy of Sciences 121 (52): e2415119121. https://doi.org/10.1073/pnas.2415119121.

Janicki, J. S., G. L. Brower, J. D. Gardner, M. F. Forman, J. A. Jr. Stewart, D. B. Murray, and A. L. Chancey. 2006. “Cardiac Mast Cell Regulation of Matrix Metalloproteinase-Related Ventricular Remodeling in Chronic Pressure or Volume Overload.” Cardiovascular Research 69 (3): 657–65. https://doi.org/10.1016/j.cardiores.2005.10.020.

Janssen Daalen, J. M., M. J. Meinders, F. Giardina, S. Mathur, P. N. Ainslie, D. H. J. Thijssen, and B. R. Bloem. 2025. “Hypoxic Conditioning in Parkinson’s Disease: Randomized Controlled Multiple n-of-1 Trials.” Nature Communications 16: 8469. https://doi.org/10.1038/s41467-025-63324-2.

Jason, Leonard A., Kathleen Muldowney, and Susan Torres-Harding. 2008. “The Energy Envelope Theory and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.” AAOHN Journal 56 (5): 189–95. https://doi.org/10.3928/08910162-20080501-06.

Jason, Leonard A, Renee R Taylor, Sigita Plioplys, Zuzana Stepanek, and Jennifer Shlaes. 2002. “Evaluating Attributions for an Illness Based Upon the Name: Chronic Fatigue Syndrome, Myalgic Encephalopathy and Florence Nightingale Disease.” American Journal of Community Psychology 30 (1): 133–48. https://doi.org/10.1023/A:1014328319297.

Jin, H, Y An, J Huang, T Luo, and X Wu. 2026. “Pathophysiological Mechanisms of Post-Exertional Malaise: An Integrative Analysis Based on the Metabolism-Immune-Neuro Interaction Model.” Frontiers in Immunology 17: 1774310. https://doi.org/10.3389/fimmu.2026.1774310.

Johansson, Johanna, Richard Levi, Malin Jakobsson, Susanne Gunnarsson, and Kersti Samuelsson. 2022. “Multiprofessional Neurorehabilitation After COVID-19 Infection Should Include Assessment of Visual Function.” Archives of Rehabilitation Research and Clinical Translation 4 (2): 100184. https://doi.org/10.1016/j.arrct.2022.100184.

Joseph, Phillip, Carlo Arevalo, Rudolf K F Oliveira, Mariana Faria-Urbina, Donna Felsenstein, Anne Louise Oaklander, and David M Systrom. 2021. “Insights from Invasive Cardiopulmonary Exercise Testing of Patients with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.” Chest 160 (2): 642–51. https://doi.org/10.1016/j.chest.2021.01.082.

Jung, K, A Meisser, P Bischof, M Lein, K Miller, and D Schnorr. 2008. “Preanalytical Determinants of Total and Free Prostate-Specific Antigen and Their Ratio: A Systematic Review.” Clinical Chemistry 54 (10): 1626–37.

Kaczmarek, M. P. 2023. “Heterogenous Circulating miRNA Changes in ME/CFS Converge on a Unified Cluster of Target Genes: A Computational Analysis.” PLoS ONE 18 (12): e0296060. https://doi.org/10.1371/journal.pone.0296060.

Kang, Jae-Eun, Miranda M. Lim, Randall J. Bateman, James J. Lee, Liam P. Smyth, John R. Cirrito, Nobuhiro Fujiki, Seiji Nishino, and David M. Holtzman. 2009. “Amyloid-$\beta$ Dynamics Are Regulated by Orexin and the Sleep-Wake Cycle.” Science 326 (5955): 1005–7. https://doi.org/10.1126/science.1180962.

Kang, Zhenming, Guoshao Zhu, Changsheng Su, Xianmei Zhong, Jianchuan Lin, and Yiqin Lin. 2026. “Delivery of HSP70 mRNA via Exosomes Ameliorates Sleep Deprivation-Induced Cognitive Impairments in Mice.” Translational Psychiatry 16: 123. https://doi.org/10.1038/s41398-026-04044-z.

Kappel, S, D H Bhatt, C Letts, M Bissonnette, T W Abrams, A Helli, S Laporte, et al. 2003. “Neuronal Calcium Sensor-1 and Phosphatidylinositol 4-Kinase Beta Regulate IgE Receptor-Triggered Exocytosis in Cultured Mast Cells.” Journal of Cell Science 116 (Pt 20): 4151–62. https://doi.org/10.1242/jcs.00716.

———, et al. 2006. “Neuronal Calcium Sensor-1 and Phosphatidylinositol 4-Kinase Beta Stimulate Extracellular Signal-Regulated Kinase 1/2 Signaling by Accelerating Recycling Through the Endocytic Recycling Compartment.” Molecular Biology of the Cell 17 (8): 3579–91. https://doi.org/10.1091/mbc.e06-01-0040.

Kappel, S, R Bissonnette, A Helli, S A Laporte, and D H Bhatt. 2007. “The Mast Cell: Where Endocytosis and Regulated Exocytosis Meet.” In Molecular Mechanisms of Exocytosis, 237–50. Springer. https://doi.org/10.1007/978-0-387-69086-7_19.

Kavyani, Bahar, Seong Beom Ahn, Daniel Missailidis, Sarah J. Annesley, Paul R. Fisher, Richard Schloeffel, Gilles J. Guillemin, David B. Lovejoy, and Benjamin Heng. 2024. “Dysregulation of the Kynurenine Pathway, Cytokine Expression Pattern, and Proteomics Profile Link to Symptomology in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS).” Molecular Neurobiology 61 (7): 3771–87. https://doi.org/10.1007/s12035-023-03784-z.

Kawano, T., M. Kashiwagi, M. Kanuka, C. K. Chen, S. Yasugaki, S. Hatori, S. Miyazaki, et al. 2023. “ER Proteostasis Regulators Cell-Non-Autonomously Control Sleep.” Cell Reports 42 (3): 112267. https://doi.org/10.1016/j.celrep.2023.112267.

Kell, D. B., and E. Pretorius. 2022. “The Potential Role of Ischaemia-Reperfusion Injury in Chronic, Relapsing Diseases Such as Rheumatoid Arthritis, Long COVID, and ME/CFS: Evidence, Mechanisms, and Therapeutic Implications.” Biochemical Journal 479 (16): 1653–1708. https://doi.org/10.1042/BCJ20220154.

Keller, Betsy A, Candace N Receno, Carl J Franconi, Sebastian Harenberg, Jared Stevens, Xiangling Mao, Staci R Stevens, et al. 2024. “Cardiopulmonary and Metabolic Responses During a 2-Day CPET in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Translating Reduced Oxygen Consumption to Impairment Status to Treatment Considerations.” Journal of Translational Medicine 22 (1): 627. https://doi.org/10.1186/s12967-024-05410-5.

Kempf, Volkhard A J, Maria Lebiedziejewski, Kari Alitalo, Joo-Hee Wälzlein, Urs Ehehalt, Jeannette Fiebig, Stephan Huber, et al. 2005. “Activation of Hypoxia-Inducible Factor-1 in Bacillary Angiomatosis: Evidence for a Role of Hypoxia-Inducible Factor-1 in Bacterial Infections.” Circulation 111 (8): 1054–62. https://doi.org/10.1161/01.CIR.0000155608.07691.B7.

Kempuraj, Duraisamy, Irene Tsilioni, Kristina K Aenlle, Nancy G Klimas, and Theoharis C Theoharides. 2024. “Long COVID Elevated MMP-9 and Release from Microglia by SARS-CoV-2 Spike Protein.” Translational Neuroscience 15 (1): 20220352. https://doi.org/10.1515/tnsci-2022-0352.

Kerstholt, Mariska, Freek R van de Schoor, Marije Oosting, Simone J C F M Moorlag, Yang Li, Martin Jaeger, Wouter A van der Heijden, et al. 2022. “Identifying Platelet-Derived Factors as Amplifiers of B. Burgdorferi-Induced Cytokine Production.” Clinical and Experimental Immunology 210 (1): 53–67. https://doi.org/10.1093/cei/uxac073.

Kindlon, Tom. 2011. “Reporting of Harms Associated with Graded Exercise Therapy and Cognitive Behavioural Therapy in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.” Bulletin of the IACFS/ME 19 (2): 59–111.

Klempner, M. S., L. T. Hu, J. Evans, C. H. Schmid, G. M. Johnson, R. P. Trevino, D. Norton, et al. 2001. “Two Controlled Trials of Antibiotic Treatment in Patients with Persistent Symptoms and a History of Lyme Disease.” The New England Journal of Medicine 345 (2): 85–92. https://doi.org/10.1056/NEJM200107123450202.

Kleshnev, Valery. 2004. “Propulsive Efficiency of Rowing.” Rowing Biomechanics Newsletter 4 (7).

Knudsen, Ann Kristin, Anne-Nina Omenås, Samuel B Harvey, Camilla M Løvvik, Linn V Lervik, and Arnstein Mykletun. 2011. “Chronic Fatigue Syndrome in the Media: A Content Analysis of Newspaper Articles.” JRSM Short Reports 2 (5): 42. https://doi.org/10.1258/shorts.2011.011016.

Ko, C, P Lucassen, B van der Linden, A Ballering, and T Olde Hartman. 2022. “Stigma Perceived by Patients with Functional Somatic Syndromes and Its Effect on Health Outcomes — a Systematic Review.” Journal of Psychosomatic Research 154: 110715. https://doi.org/10.1016/j.jpsychores.2021.110715.

Koelle, David M, Serge Barcy, Meei-Li Huang, Rhoda L Ashley, Lawrence Corey, Judy Zeh, Suzanne Ashton, and Dedra Buchwald. 2002. “Markers of Viral Infection in Monozygotic Twins Discordant for Chronic Fatigue Syndrome.” Clinical Infectious Diseases 35 (5): 518–25. https://doi.org/10.1086/341774.

Koopmans, Frank, Pim van Nierop, Maria Andres-Alonso, Andrea Byrnes, Tony Cijsouw, Marcelo P. Coba, L. Niels Cornelisse, et al. 2019. “SynGO: An Evidence-Based, Expert-Curated Knowledge Base for the Synapse.” Neuron 103 (2): 217–234.e4. https://doi.org/10.1016/j.neuron.2019.05.002.

Kowal, C. et al. 2004. “Anti-NR2/NMDAR Antibodies Cross a Compromised BBB in Neuropsychiatric SLE.” Journal of Clinical Investigation.

Kowal, Krzysztof, Richard S Schacterele, Peter H Schur, Anthony L Komaroff, and Lawrence M DuBuske. 2002. “Prevalence of Allergen-Specific IgE Among Patients with Chronic Fatigue Syndrome.” Allergy and Asthma Proceedings 23 (1): 35–39.

Krajewski, PK, W Szukała, and JC Szepietowski. 2024. “The NLRP3 Inflammasome Gene Is Overexpressed in Hidradenitis Suppurativa Lesions: A Preliminary Study on the Role of Pyroptosis in Disease Pathogenesis.” Current Issues in Molecular Biology 46 (3): 2544–52. https://doi.org/10.3390/cimb46030161.

Kronstein-Wiedemann, Romy, Kristin Tausche, Martin Kolditz, Maria Teichert, Julia Thiel, Dirk Koschel, Torsten Tonn, and Stephan R. Künzel. 2024. “Long-COVID Is Associated with Impaired Red Blood Cell Function.” Hormone and Metabolic Research 56 (4): 318–23. https://doi.org/10.1055/a-2186-8108.

Krupp, L. B., L. G. Hyman, R. Grimson, P. K. Coyle, P. Melville, S. Ahnn, R. Dattwyler, and B. Chandler. 2003. “Study and Treatment of Post Lyme Disease (STOP-LD): A Randomized Double Masked Clinical Trial.” Neurology 60 (12): 1923–30. https://doi.org/10.1212/01.WNL.0000071227.23769.9e.

Kubat, B., G. Ozkan, C. Sanal Toprak, M. Demirci, and S. Akkaya Turhan. 2026. “Corneal Confocal Microscopy in Fibromyalgia Syndrome: Small Fiber Neuropathy, and Treatment Outcomes.” Eye 40 (2): 279–86. https://doi.org/10.1038/s41433-025-04132-2.

Kuhlow, Christopher J, Juan C Garcia-Monco, James L Coleman, and Jorge L Benach. 2005. “Murine Microglia Are Effective Phagocytes for Borrelia burgdorferi.” Journal of Neuroimmunology 168 (1-2): 183–87. https://doi.org/10.1016/j.jneuroim.2005.06.030.

Lakatos, Szandra, and Judit Rosta. 2025. “Bidirectional Interplay Between Microglia and Mast Cells.” International Journal of Molecular Sciences 26 (15): 7556. https://doi.org/10.3390/ijms26157556.

Lamming, Dudley W, Lan Ye, Pekka Katajisto, Marcus D Goncalves, Maki Saitoh, Deanna M Stevens, James G Davis, et al. 2012. “Rapamycin-Induced Insulin Resistance Is Mediated by mTORC2 Loss and Uncoupled from Longevity.” Science 335 (6076): 1638–43. https://doi.org/10.1126/science.1215135.

Lantos, Paul M. 2015. “Chronic Lyme Disease.” Infectious Disease Clinics of North America 29 (2): 325–40. https://doi.org/10.1016/j.idc.2015.02.006.

Lanz, Tobias V., R. C. Brewer, P. P. Ho, J. S. Moon, C. Merrill, D. A. Ryan, L. McQuillen, et al. 2022. “Clonally Expanded b Cells in Multiple Sclerosis Bind EBNA1 and GlialCAM.” Nature 603 (7900): 321–27. https://doi.org/10.1038/s41586-022-04432-7.

Laredj, Leila N, Floriana Licitra, and Hélène M Puccio. 2014. “The Molecular Genetics of Coenzyme Q Biosynthesis in Health and Disease.” Biochimie 100: 78–87. https://doi.org/10.1016/j.biochi.2013.12.006.

Lee, Ji-Sook, Eliana Lacerda, Caroline Kingdon, Erik Abken, Gaia Susannini, Hazel M. Dockrell, Luis Nacul, and Jacqueline M. Cliff. 2025. “Abnormal T-Cell Activation and Cytotoxic T-Cell Frequency Discriminate Symptom Severity in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.” Journal of Translational Medicine 23: 669. https://doi.org/10.1186/s12967-025-07507-x.

Lépine, Marylène, Marie-Claude Robert, and Lekha Sleno. 2024. “Discovery and Verification of Sjögren’s Syndrome Protein Biomarkers in Tears by Targeted LC-MRM.” Journal of Proteome Research 23 (6): 2219–29. https://doi.org/10.1021/acs.jproteome.4c00163.

Li, M., X. Duan, J. Zhang, and D. Yang. 2024. “Repercussions of SARS-CoV-2 Infection on Intrapulmonary Shunt in Patients Undergoing One-Lung Ventilation.” Journal of Cardiothoracic Surgery 19 (1): 522. https://doi.org/10.1186/s13019-024-03037-7.

Lind, T., F. R. Melo, A. M. Gustafson, A. Sundqvist, X. O. Zhao, A. Moustakas, H. Melhus, and G. Pejler. 2022. “Mast Cell Chymase Has a Negative Impact on Human Osteoblasts.” Matrix Biology 112: 1–19. https://doi.org/10.1016/j.matbio.2022.07.005.

Linden, Marisol van der et al. 2023. “Hyperactivated Platelets and Fibrinaloid Microclots in ME/CFS.” Pharmaceuticals. https://doi.org/10.3390/ph16030390.

Lisowski, Ł., J. Lisowska, A. Charytonowicz, Z. Mariak, I. Obuchowska, and J. Konopińska. 2025. “The Diagnostic Significance of Pupillary Reflex Pathways: Insights from Classical Examination and Advanced Pupillometry.” Frontiers in Neuroscience 19: 1677431. https://doi.org/10.3389/fnins.2025.1677431.

Little, A. J., P. M. Chen, M. D. Vesely, R. N. Khan, J. Fiedler, J. Garritano, F. I. Maisha, J. M. McNiff, and J. Craft. 2023. “HIF-1 Regulates Pathogenic Cytotoxic t Cells in Lupus Skin Disease.” JCI Insight 8 (16): e166076. https://doi.org/10.1172/jci.insight.166076.

Liu, Yuhan Karida, Devina Persaud, Erica L. Vieira, Joeffre Braga, Pablo Rusjan, Laura Miler, Jennifer S. Rabin, et al. 2026. “Loss of Vesicular Monoamine Transporter 2 in Striatum of Long COVID and Relationship to Neuropsychiatric Symptoms.” eBioMedicine. https://doi.org/10.1016/j.ebiom.2026.106339.

Liusuwan, R. A., L. M. Widman, R. T. Abresch, D. M. Styne, and C. M. McDonald. 2004. “Altered Body Composition Affects Resting Energy Expenditure and Interpretation of Body Mass Index in Children with Spinal Cord Injury.” Journal of Spinal Cord Medicine 27 (Suppl 1): S24–28. https://doi.org/10.1080/10790268.2004.11754900.

Lladós, Gemma, Marta Massanella, Roser Coll-Fernández, Raúl Rodríguez, Electra Hernández, Giuseppe Lucente, Cristina López, et al. 2024. “Vagus Nerve Dysfunction in the Post-COVID-19 Condition: A Pilot Cross-Sectional Study.” Clinical Microbiology and Infection 30 (4): 515–21. https://doi.org/10.1016/j.cmi.2023.11.007.

Loçasso, F. A., H. A. Filho, R. M. P. Alvarenga, S. L. Schimidt, F. K. Fiorelli, P. D. S. Ramos, S. C. L. Leidersnaider, et al. 2024. “Assessing the Impact of IL-6 and Serotonin on Pain and Symptomatology in Fibromyalgia: An Exploratory Clinical Study.” Journal of Personalized Medicine 14 (8): 886. https://doi.org/10.3390/jpm14080886.

Locke, Steven, Jane O’Brien, Adeel S Zubair, Mayanka Rethana, Ali S Moffarah, Peter J Krause, and Shelli F Farhadian. 2023. “Neurologic Complications of Babesiosis, United States, 2011–2021.” Emerging Infectious Diseases 29 (6): 1127–35. https://doi.org/10.3201/eid2906.221890.

Loebel, M., M. Eckey, F. Sotzny, E. Hahn, S. Bauer, P. Grabowski, J. Zerweck, et al. 2017. “Serological Profiling of the EBV Immune Response in Chronic Fatigue Syndrome Using a Peptide Microarray.” PLoS ONE 12 (6): e0179124. https://doi.org/10.1371/journal.pone.0179124.

Looper, Karl J, and Laurence J Kirmayer. 2004. “Perceived Stigma in Functional Somatic Syndromes and Comparable Medical Conditions.” Journal of Psychosomatic Research 57 (4): 373–78. https://doi.org/10.1016/j.jpsychores.2004.03.005.

Lopez, Raphael, Lucie Barateau, and Yves Dauvilliers. 2023. “T-Cell Mediated Autoimmunity in Narcolepsy Type 1.” Current Opinion in Pulmonary Medicine 29 (6): 543–50. https://doi.org/10.1097/MCP.0000000000001007.

López-Amador, Noé. 2025. “An Integrative Review on the Orexin System and Hypothalamic Dysfunction in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Implications for Precision Medicine.” Exploration of Neuroprotective Therapy 5: 1004112. https://doi.org/10.37349/ent.2025.1004112.

Lucey, Brendan P., Haiyan Liu, Cristina D. Toedebusch, David Freund, Tiara Redrick, Samir L. Chahin, Kwasi G. Mawuenyega, et al. 2023. “Suvorexant Acutely Decreases Tau Phosphorylation and a$\beta$ in the Human CNS.” Annals of Neurology 94 (1): 27–40. https://doi.org/10.1002/ana.26641.

Luo, Y et al. 2025. “Role of Nrf2/HO-1 Axis in Chronic Fatigue Associated with Fibromyalgia.” Journal of Inflammation Research 18: 1053–67. https://doi.org/10.2147/JIR.S478258.

Luzu, Justine, Antoine Labbé, Annabelle Réaux-Le Goazigo, Guillaume Rabut, Hong Liang, Bénédicte Dupas, and Christophe Baudouin. 2022. “In Vivo Confocal Microscopic Study of Corneal Innervation in Sjögren’s Syndrome with or Without Small Fiber Neuropathy.” The Ocular Surface 25: 155–62. https://doi.org/10.1016/j.jtos.2022.07.003.

Lynch, Adam, Patrick Pearson, Sergey N Savinov, Andrew Y Li, and Stephen M Rich. 2023. “Lactate Dehydrogenase Inhibitors Suppress Borrelia Burgdorferi Growth in Vitro.” Pathogens 12 (7): 962. https://doi.org/10.3390/pathogens12070962.

Lyne, T., L. Camporota, and H. Montgomery. 2024. “Contribution of Intrapulmonary Shunt to the Pathogenesis of Profound Hypoxaemia in Viral Infection: A Mechanistic Discussion with an Illustrative Case.” Journal of the Intensive Care Society 25 (4): 427–31. https://doi.org/10.1177/17511437241267745.

Maccallini, P. 2026. “Biological Insights from Genome-Wide Association Studies and Whole Genome Sequencing of Myalgic Encephalomyelitis/ Chronic Fatigue Syndrome.” Research Square [Preprint], June. https://doi.org/10.21203/rs.3.rs-9702020/v1.

MacDonald, Kristine L, Michael T Osterholm, Kathleen H LeDell, Karen E White, Charlotte H Schenck, Chun C Chao, David H Persing, James L Hadler, Homayoon Farzadegan, and Lyle R Petersen. 1996. “A Case-Control Study to Assess Possible Triggers and Cofactors in Chronic Fatigue Syndrome.” American Journal of Medicine 101 (6): 103–10. https://doi.org/10.1016/S0002-9343(96)00245-6.

Maclean, P. S., A. Bergouignan, M. A. Cornier, and M. R. Jackman. 2011. “Biology’s Response to Dieting: The Impetus for Weight Regain.” American Journal of Physiology. Regulatory, Integrative and Comparative Physiology 301 (3): R581–600. https://doi.org/10.1152/ajpregu.00755.2010.

Maes, Michael, Abbas F. Almulla, Aristo Vojdani, Elizabeta Dzhambazova, Drozdstoy Stoyanov, Yanchao Zhang, and Asmo Vojdani. 2025. “Chronic Fatigue Syndrome, Depression, and Anxiety Symptoms Due to Relapsing-Remitting Multiple Sclerosis Are Associated with Reactivation of Epstein-Barr Virus and Human Herpesvirus 6.” Neuro Endocrinology Letters 46 (1): 15–26.

Maes, Michael, Marta Kubera, Kristina Stoyanova, and Jean-Claude Leunis. 2021. “The Reification of the Clinical Diagnosis of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) as an Immune and Oxidative Stress Disorder: Construction of a Data-Driven Nomothetic Network and Exposure of ME/CFS Subgroups.” Current Topics in Medicinal Chemistry 21 (16): 1488–99. https://doi.org/10.2174/1568026621666210727170147.

Maes, Michael, and Jean-Claude Leunis. 2014. “Attenuation of Autoimmune Responses to Oxidative Specific Epitopes, but Not Nitroso-Adducts, Is Associated with a Better Clinical Outcome in Myalgic Encephalomyelitis/chronic fatigue syndrome.” Neuro Endocrinology Letters 35 (7): 577–85.

Maes, Michael, Ivana Mihaylova, Marta Kubera, Marc Uytterhoeven, Nico Vrydags, and Eugene Bosmans. 2009. “Coenzyme Q10 Deficiency in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) Is Related to Fatigue, Autonomic and Neurocognitive Symptoms.” Neuro Endocrinology Letters 30 (4): 470–76.

Magarinos, N. J., K. J. Bryant, A. J. Fosang, R. Adachi, R. L. Stevens, and H. P. McNeil. 2013. “Mast Cell-Restricted, Tetramer-Forming Tryptases Induce Aggrecanolysis in Articular Cartilage by Activating Matrix Metalloproteinase-3 and -13 Zymogens.” Journal of Immunology 191 (3): 1404–12. https://doi.org/10.4049/jimmunol.1300856.

Maksoud, Rebekah, Natalie Eaton-Fitch, Michael Matula, Hélène Cabanas, Donald Staines, and Sonya Marshall-Gradisnik. 2021. “Systematic Review of Sleep Characteristics in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.” Healthcare 9 (5): 568. https://doi.org/10.3390/healthcare9050568.

Malik, A., Z. Brown, A. Ryder, V. Balayan, L. Jameson, P. Vu, A. Al-Jumah, and J. Hasoon. 2025. “Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs) for Treatment of Fibromyalgia: A Comprehensive Clinical Review.” Psychopharmacology Bulletin 55 (2): 24–40. https://doi.org/10.64719/pb.4519.

Malik, V., B. Roy, A. Sarkar, K. Shivkumar, S. Khalsa, R. Kumar, and O. A. Ajijola. 2026. “Brain Tissue Changes, Network Dysfunction, and Cerebral Hemodynamic Deficits in Postural Orthostatic Tachycardia Syndrome.” Heart Rhythm. https://doi.org/10.1016/j.hrthm.2026.02.020.

Mancini, Donna M., Dane B. Cook, Danielle L. Brunjes, Tiffany Soto, Michelle Blate, Patrick Quan, Tadahiro Yamazaki, Anna Norweg, and Benjamin H. Natelson. 2026. “Cardiopulmonary Exercise Test Results Do Not Change over Two Sequential Days in Patients with Chronic Fatigue Syndrome.” Frontiers in Physiology 17: 1816082. https://doi.org/10.3389/fphys.2026.1816082.

Mandarano, Alexandra H., Jessica Maya, Ludovic Giloteaux, Daniel L. Peterson, Marco Maynard, C. Gunnar Gottschalk, and Maureen R. Hanson. 2020. “Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Patients Exhibit Altered t Cell Metabolism and Cytokine Associations.” Journal of Clinical Investigation 130 (3): 1491–1505. https://doi.org/10.1172/JCI132185.

Mannick, JB, and DW Lamming. 2023. “Targeting the Biology of Aging with mTOR Inhibitors.” Nature Aging 3 (6): 642–60. https://doi.org/10.1038/s43587-023-00416-y.

Mar, P. L., V. Raj, B. K. Black, I. Biaggioni, C. A. Shibao, S. Y. Paranjape, W. D. Dupont, D. Robertson, and S. R. Raj. 2014. “Acute Hemodynamic Effects of a Selective Serotonin Reuptake Inhibitor in Postural Tachycardia Syndrome: A Randomized, Crossover Trial.” Journal of Psychopharmacology 28 (2): 155–61. https://doi.org/10.1177/0269881113512911.

Marchetta, M., R. I. Lopez, A. C. Hogwood, G. Thomas, G. Abbate, R. Markley, J. M. Canada, and A. Abbate. 2025. “Heart Rate Lowering with Ivabradine and Burden of Symptoms in Patients with Postural Orthostatic Tachycardia Syndrome.” Journal of Cardiovascular Pharmacology 86 (1): 28–32. https://doi.org/10.1097/FJC.0000000000001705.

Marshall, R. S., M. Kim, T. Rundek, S. Wolpert, and J. L. Schindler. 2022. “Cerebral Venous Outflow Impairment and Orthostatic Intolerance: A Systematic Review.” Neurology 98 (14): e1432–44. https://doi.org/10.1212/WNL.0000000000200134.

Martin, A. 2019. “An Acquired or Heritable Connective Tissue Disorder? A Review of Hypermobile Ehlers Danlos Syndrome.” European Journal of Medical Genetics 62 (7): 103672. https://doi.org/10.1016/j.ejmg.2019.103672.

Marzec, Natalie S, Christina Nelson, Paul Ravi Waldron, Brian G Blackburn, Syed Hosain, Tara Greenhow, Gary M Green, Catherine Lomen-Hoerth, Marjorie Golden, and Paul S Mead. 2017. “Serious Bacterial Infections Acquired During Treatment of Patients Given a Diagnosis of Chronic Lyme Disease — United States.” MMWR Morbidity and Mortality Weekly Report 66 (23): 607–9. https://doi.org/10.15585/mmwr.mm6623a3.

Master, C. L., O. E. Podolak, K. J. Ciuffreda, K. B. Metzger, N. R. Joshi, C. C. McDonald, S. S. Margulies, M. F. Grady, and K. B. Arbogast. 2020. “Utility of Pupillary Light Reflex Metrics as a Physiologic Biomarker for Adolescent Sport-Related Concussion.” JAMA Ophthalmology 138 (11): 1135–41. https://doi.org/10.1001/jamaophthalmol.2020.3466.

Matheny, M. V., T. Craig, and T. Al-Shaikhly. 2025. “Systematic Review of Omalizumab for Refractory Clonal and Non-Clonal Mast Cell Activation Syndrome.” Allergy and Asthma Proceedings 46 (1): 11–18. https://doi.org/10.2500/aap.2025.46.240076.

Mathew, G. T., and P. Novak. 2026. “Prevalence of Central Sensitization in Postural Tachycardia Syndrome.” JAMA Network Open 9 (1): e2553694. https://doi.org/10.1001/jamanetworkopen.2025.53694.

Maya, Jessica, Seth M. Leddy, Christopher G. Gottschalk, Darrin L. Peterson, and Maureen R. Hanson. 2023. “Altered Fatty Acid Oxidation in Lymphocyte Populations of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.” International Journal of Molecular Sciences 24 (3): 2010. https://doi.org/10.3390/ijms24032010.

McManimen, Stephanie L, Damani McClellan, Jamie Stoothoff, and Leonard A Jason. 2018. “Effects of Unsupportive Social Interactions, Stigma, and Symptoms on Patients with Myalgic Encephalomyelitis and Chronic Fatigue Syndrome.” Journal of Community Psychology 46 (8): 959–71. https://doi.org/10.1002/jcop.21984.

Medow, M. S., and J. M. Stewart. 2024. “Phenylephrine Alters Phase Synchronization Between Cerebral Blood Velocity and Blood Pressure in ME/CFS with Orthostatic Intolerance.” American Journal of Physiology-Regulatory, Integrative and Comparative Physiology 326 (6): R599–608. https://doi.org/10.1152/ajpregu.00071.2024.

Melby, Line, and Roshan das Nair. 2024. “’We Have No Services for You…so You Have to Make the Best Out of It’: A Qualitative Study of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Patients’ Dissatisfaction with Healthcare Services.” Health Expectations 27 (1): e13900. https://doi.org/10.1111/hex.13900.

Meltendorf, Stefan, Katrin Vogel, Christoph Thurm, Florian Prätsch, Dirk Reinhold, Hans-Georg Heuft, Monika Stoll, Marino Venerito, Jens Geginat, and Michael Schindler. 2022. “IL-13 Determines Specific IgE Responses and SARS-CoV-2 Immunity After Mild COVID-19 and Novel mRNA Vaccination.” European Journal of Immunology 52 (12): 1990–2002. https://doi.org/10.1002/eji.202249951.

Meral Ketenci, B, HB Meral, and Z Meral Obholzer. 2026. “Determinants of Kinesiophobia in Patients with Hidradenitis Suppurativa: The Role of Pain, Fatigue, Physical Activity and Depression.” BMC Psychology. https://doi.org/10.1186/s40359-026-05165-2.

Mignolet, M., D. Van den Hove, C. Van Den Broeke, K. Tilleman, D. Elewaut, and S. Scheers. 2026. “Passive Transfer of IgG from Long COVID Patients Induces Pain in Mice via Dorsal Root Ganglion Sensitization.” Science Translational Medicine 18 (823): eabi1234. https://doi.org/10.1126/scitranslmed.abi1234.

Miranda-Hurtado, M., R. Hira, K. M. Bourne, S. Ranada, J. R. Baker, R. S. Sheldon, and S. R. Raj. 2026. “Stroke Volume Reduction Impairs Cerebrovascular Regulation Through ETCO2 in Postural Orthostatic Tachycardia Syndrome.” Clinical Autonomic Research 36 (2): 257–69. https://doi.org/10.1007/s10286-025-01181-1.

Miwa, Kunihisa. 2023. “Orthostatic Intolerance and Chronotropic Incompetence in Patients with Myalgic Encephalomyelitis or Chronic Fatigue Syndrome.” Circulation Reports 5 (2): 55–61. https://doi.org/10.1253/circrep.cr-22-0114.

Moen, Erika, and Akiko Iwasaki. 2025. “Neuroimmune Pathophysiology of Long COVID.” Psychiatry and Clinical Neurosciences 79 (9): 514–28. https://doi.org/10.1111/pcn.13855.

Moezzi, Adam, Anna Ushenkina, Anders Widgren, Jonas Bergquist, et al. 2025. “Haptoglobin Phenotypes and Structural Variants Associate with Post-Exertional Malaise and Cognitive Dysfunction in Myalgic Encephalomyelitis.” Journal of Translational Medicine 23 (1). https://doi.org/10.1186/s12967-025-07006-z.

Montoya, Jose G, Andreas M Kogelnik, Munveer Bhangoo, Mitchell R Lunn, Louis Flamand, Lindsey E Merrihew, Tessa Watt, Jessica T Kubo, Jane Paik, and Manisha Desai. 2013. “Randomized Clinical Trial to Evaluate the Efficacy and Safety of Valganciclovir in a Subset of Patients with Chronic Fatigue Syndrome.” Journal of Medical Virology 85 (12): 2101–9. https://doi.org/10.1002/jmv.23713.

Moran, B, CM Smith, A Zaborowski, M Ryan, J Karman, RW Dunstan, KM Smith, et al. 2023. “Targeting the NLRP3 Inflammasome Reduces Inflammation in Hidradenitis Suppurativa Skin.” British Journal of Dermatology 189 (4): 447–58. https://doi.org/10.1093/bjd/ljad184.

Morris, D., Y. Qu, A. Haas de Mello, Y. Jones-Hall, T. Liu, M. Weglarz, T. Ivanciuc, R. Garofalo, and A. Casola. 2025. “Role of Hypoxia-Inducible Factors in Respiratory Syncytial Virus Infection-Associated Lung Disease.” International Journal of Molecular Sciences 26 (7): 3182. https://doi.org/10.3390/ijms26073182.

Morris, G., G. Anderson, and M. Maes. 2017. “Hypothalamic-Pituitary-Adrenal Hypofunction in Myalgic Encephalomyelitis (ME)/Chronic Fatigue Syndrome (CFS) as a Consequence of Activated Immune-Inflammatory and Oxidative and Nitrosative Pathways.” Molecular Neurobiology 54 (9): 6806–19. https://doi.org/10.1007/s12035-016-0170-2.

Morris, Gerwyn, George Anderson, Michael Berk, and Michael Maes. 2013. “Coenzyme Q10 Depletion in Medical and Neuropsychiatric Disorders: Potential Repercussions and Therapeutic Implications.” Molecular Neurobiology 48 (3): 883–903. https://doi.org/10.1007/s12035-013-8477-8.

Morris, Gerwyn, and Michael Maes. 2014. “Mitochondrial Dysfunctions in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Explained by Activated Immuno-Inflammatory, Oxidative and Nitrosative Stress Pathways.” Metabolic Brain Disease 29 (1): 19–36. https://doi.org/10.1007/s11011-013-9435-x.

Morris, P. E., A. Goad, C. Thompson, K. Taylor, B. Harry, L. Passmore, A. Ross, et al. 2008. “Early Intensive Care Unit Mobility Therapy in the Treatment of Acute Respiratory Failure.” Critical Care Medicine 36 (8): 2238–43. https://doi.org/10.1097/CCM.0b013e318180b90e.

Moustardas, Petros, Helen Setterud, Helena Meijer, Gunnel Andersson, Jenny Roth, Ava Dashti, Björn Johansson, António Filipe Macedo, and Neil Lagali. 2026. “Long-Term Ocular Symptoms Following COVID-19 Linked to Immune Dysregulation, Dysautonomia and Peripheral Neuropathy.” Nature Communications 17 (1): 5624. https://doi.org/10.1038/s41467-026-74858-4.

Munana, K R, S M Vitek, B C Hegarty, D L Kordick, and E B Breitschwerdt. 2001. “Infection of Fetal Feline Brain Cells in Culture with Bartonella henselae.” Infection and Immunity 69 (1): 564–69. https://doi.org/10.1128/IAI.69.1.564-569.2001.

Mushak, Paul. 2016. “Temporal Stability of Chemical Hormesis (CH): Is CH Just a Temporary Stop on the Road to Thresholds and Toxic Responses?” Science of the Total Environment 569-570: 1446–56. https://doi.org/10.1016/j.scitotenv.2016.06.233.

Mwesigwa, N., P. Millar Vernetti, A. Kirabo, B. Black, T. Ding, J. Martinez, J. A. Palma, and I. Biaggioni. 2024. “Atomoxetine on Neurogenic Orthostatic Hypotension: A Randomized, Double-Blind, Placebo-Controlled Crossover Trial.” Clinical Autonomic Research 34 (6): 561–69. https://doi.org/10.1007/s10286-024-01051-2.

Myers, Tereance A, Deepak Kaushal, and Mario T Philipp. 2009. “Microglia Are Mediators of Borrelia burgdorferi-Induced Apoptosis in SH-SY5Y Neuronal Cells.” PLoS Pathogens 5 (11): e1000659. https://doi.org/10.1371/journal.ppat.1000659.

Nagy-Szakal, Dorottya, Brent L. Williams, Nischay Mishra, Xiaoyu Che, Bohyun Lee, Lucinda Bateman, Nancy G. Klimas, et al. 2017. “Fecal Metagenomic Profiles in Subgroups of Patients with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.” Microbiome 5: 44. https://doi.org/10.1186/s40168-017-0261-y.

Nardone, Raffaele, Juergen Bergmann, Alexander Kunz, Monica Christova, Francesco Brigo, Frediano Tezzon, Eugen Trinka, and Stefan Golaszewski. 2011. “Cortical Excitability Changes in Patients with Excessive Daytime Sleepiness.” Sleep Medicine 12 (7): 653–58. https://doi.org/10.1016/j.sleep.2011.01.016.

Naseri, A., M. A. Fard, M. Zarei, M. Jabbarvand, and F. Taheri. 2025. “Prevalence and Risk Factors of Dry Eye Disease After COVID-19: A Systematic Review and Meta-Analysis.” International Ophthalmology 45 (1): 134. https://doi.org/10.1007/s10792-025-03532-9.

Natelson, Benjamin H., Dana Vu, Xiangling Mao, Nora Weiduschat, Fumiharu Togo, Gudrun Lange, Mary Blate, and Guoxin Kang. 2015. “Effect of Milnacipran Treatment on Ventricular Lactate in Fibromyalgia: A Randomized, Double-Blind, Placebo-Controlled Trial.” Journal of Pain 16 (11): 1211–19. https://doi.org/10.1016/j.jpain.2015.08.004.

Naviaux, Robert K, Jane C Naviaux, Kefeng Li, A Taylor Bright, William A Alaynick, Lin Wang, Asha Baxter, Neil Nathan, Wayne Anderson, and Eric Gordon. 2016. “Metabolic Features of Chronic Fatigue Syndrome.” Proceedings of the National Academy of Sciences 113 (37): E5472–80. https://doi.org/10.1073/pnas.1607571113.

Nawrocki, Courtney C, Mark J Delorey, Austin R Earley, Sarah A Hook, Kiersten J Kugeler, Grace E Marx, Paul S Mead, and Alison F Hinckley. 2025. “Nonspecific Symptoms Attributable to Lyme Disease in High-Incidence Areas, United States, 2017-2021.” Emerging Infectious Diseases 31 (14): 30–37. https://doi.org/10.3201/eid3114.250459.

Neeland, I. J., J. Linge, and A. L. Birkenfeld. 2024. “Changes in Lean Body Mass with Glucagon-Like Peptide-1-Based Therapies and Mitigation Strategies.” Diabetes, Obesity and Metabolism 26 (Suppl 4): 3–15. https://doi.org/10.1111/dom.15728.

Neglén, Peter, and Seshadri Raju. 2008. “May Thurner Syndrome: Pathophysiology and Management.” Perspectives in Vascular Surgery and Endovascular Therapy 20 (1): 59–67. https://doi.org/10.1177/153100350802000108.

Nelson, M. J. et al. 2021. “Post-Exercise Heart Rate Recovery Is Discriminatory for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.” Journal of Translational Medicine 19: 416. https://doi.org/10.1186/s12967-021-03086-9.

Nelson, Todd, Lan-Xin Zhang, Hui Guo, Luis Nacul, and Xiaowei Song. 2021. “Brainstem Abnormalities in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A Scoping Review and Evaluation of Magnetic Resonance Imaging Findings.” Frontiers in Neurology 12: 769511. https://doi.org/10.3389/fneur.2021.769511.

Nemani, K, J R Jaycox, U Akcan, B M Schuman, S M Yeon, N Harano, K Qin, et al. 2026. “High Prevalence of CNS-Directed Autoantibodies in Patients with Schizophrenia.” bioRxiv [Preprint]. https://doi.org/10.64898/2026.05.04.722731.

Nirakis, Nikolaos, Sofia Dimothyra, Eleftheria Karadima, and Vasileia Ismini Alexaki. 2025. “Metabolic Regulation of Immune Memory and Function of Microglia.” eLife 14: e107552. https://doi.org/10.7554/eLife.107552.

Norris, T., K. Hawton, J. Hamilton-Shield, and E. Crawley. 2017. “Obesity in Adolescents with Chronic Fatigue Syndrome: An Observational Study.” Archives of Disease in Childhood 102 (1): 35–39. https://doi.org/10.1136/archdischild-2016-311293.

Nunen, Sheryl van. 2015. “Tick-Induced Allergies: Mammalian Meat Allergy, Tick Anaphylaxis and Their Significance.” Asia Pacific Allergy 5 (1): 3–16. https://doi.org/10.5415/apallergy.2015.5.1.3.

Nunes, M., M. Vlok, A. Proal, D. B. Kell, and E. Pretorius. 2024. “Data-Independent LC-MS/MS Analysis of ME/CFS Plasma Reveals a Dysregulated Coagulation System, Endothelial Dysfunction, Downregulation of Complement Machinery.” Cardiovascular Diabetology 23: 260. https://doi.org/10.1186/s12933-024-02315-x.

O’Sullivan, Gerard J., Charles P. Semba, Diler Bilecen, Nilgun Ozturk, and Oliver Hartung. 2018. “Lower Extremity Venous Outflow Obstruction and the Quality of Life After Stent Placement.” Cardiovascular and Interventional Radiology 41 (10): 1568–75. https://doi.org/10.1007/s00270-018-2042-8.

Oh, Jiyeon, Myeongcheol Lee, Minji Kim, Hyeon Jin Kim, Seung Won Lee, Sang Youl Rhee, Ai Koyanagi, et al. 2024. “Incident Allergic Diseases in Post-COVID-19 Condition: Multinational Cohort Studies from South Korea, Japan and the UK.” Nature Communications 15 (1): 2830. https://doi.org/10.1038/s41467-024-47176-w.

Ohmori, Takashi, Keishi Adachi, Yoshimitsu Fukuda, Satoshi Tamahara, Naoaki Matsuki, and Kenichiro Ono. 2004. “Glucose Uptake Activity in Murine Red Blood Cells Infected with Babesia Microti and Babesia Rodhaini.” Journal of Veterinary Medical Science 66 (8): 945–49. https://doi.org/10.1292/jvms.66.945.

Oishi, Katsutaka, Yuta Yoshida, Kosuke Kaida, Kozue Terai, Hiroyuki Yamamoto, and Atsushi Toyoda. 2025. “Potential Non-Invasive Biomarkers of Chronic Sleep Disorders Identified by Salivary Metabolomic Profiling Among Middle-Aged Japanese Men.” Sci Rep 15 (April): 10980. https://doi.org/10.1038/s41598-025-95403-1.

Oka, Takakazu, Tokusei Tanahashi, Toshiyuki Chijiwa, Batsaikhan Lkhagvasuren, Nobuyuki Sudo, and Kagari Oka. 2014. “Isometric Yoga Improves the Fatigue and Pain of Patients with Chronic Fatigue Syndrome Who Are Resistant to Conventional Therapy: A Randomized, Controlled Trial.” Biopsychosocial Medicine 8 (1): 27. https://doi.org/10.1186/s13030-014-0027-8.

Oka, Takakazu, Haruyoshi Wakita, and Kanae Kimura. 2017. “Development of a Recumbent Isometric Yoga Program for Patients with Severe Chronic Fatigue Syndrome/Myalgic Encephalomyelitis: A Pilot Study to Assess Feasibility and Efficacy.” Biopsychosocial Medicine 11: 5. https://doi.org/10.1186/s13030-017-0090-z.

Olson, D A, S A Fuhrman, M N Blumenthal, and I A Hashim. 2008. “Importance of Pre-Analytical Sample Preparation for Matrix Metalloproteinase-9 Measurement.” Clinical Chemistry and Laboratory Medicine 46 (3): 337–43. https://doi.org/10.1515/CCLM.2008.069.

Omdal, R et al. 2026. “Persistent Fatigue in Long-COVID Is Not Associated with Peripheral Inflammatory or Cellular Stress Biomarkers: A Cross-Sectional Controlled Study.” Brain, Behavior, & Immunity – Health.

Onwordi, Ellis C., Els F. Halff, Thomas Whitehurst, Ayla Mansur, Marie-Caroline Cotel, Lisa Wells, Hannah Creeney, et al. 2020. “Synaptic Density Marker SV2A Is Reduced in Schizophrenia Patients and Unaffected by Antipsychotics in Rats.” Nature Communications 11 (1): 246. https://doi.org/10.1038/s41467-019-14122-0.

Onwordi, Ellis C., Thomas Whitehurst, Ayla Mansur, Ben Statton, Alex Berry, Marina Quinlan, Declan P. O’Regan, et al. 2021. “The Relationship Between Synaptic Density Marker SV2A, Glutamate and n-Acetyl Aspartate Levels in Healthy Volunteers and Schizophrenia: A Multimodal PET and Magnetic Resonance Spectroscopy Brain Imaging Study.” Translational Psychiatry 11 (1): 393. https://doi.org/10.1038/s41398-021-01515-3.

Oreskovic, I., A. Petzold, I. N. Petropoulos, and S. Hau. 2026. “Corneal Confocal Microscopy as a Paraclinical Test in Neurodegenerative Disease: A Scoping Review.” British Journal of Ophthalmology.

Palomo, I. M., B. Cox, M. V. Williams, and M. E. Ariza. 2026. “Chronic Reactivation of Persistent Human Herpesviruses EBV, HHV-6 and VZV and Heightened Anti-dUTPase IgG Antibodies Are a Recurrent Hallmark in Post-Infectious ME/CFS and Is Associated with Fatigue.” Journal of Medical Virology 98 (1): e70769. https://doi.org/10.1002/jmv.70769.

Paredes, S., S. Cantillo, K. D. Candido, and N. N. Knezevic. 2019. “An Association of Serotonin with Pain Disorders and Its Modulation by Estrogens.” International Journal of Molecular Sciences 20 (22): 5729. https://doi.org/10.3390/ijms20225729.

Parhizkar, Samira, Xin Bao, Wei Chen, Nicholas Rensing, Yusi Chen, Maia Kipnis, Sophie Song, et al. 2025. “Lemborexant Ameliorates Tau-Mediated Sleep Loss and Neurodegeneration in Males in a Mouse Model of Tauopathy.” Nature Neuroscience 28 (7): 1460–72. https://doi.org/10.1038/s41593-025-01966-7.

Parmak Yener, N., Y. Fırat, M. Seferoğlu, A. M. Kargın, and Y. Kılıçaslan. 2026. “Exploratory Analysis of Pupillography-Based Machine Learning for Assessing Autonomic Dysfunction in Multiple Sclerosis.” Multiple Sclerosis and Related Disorders 112: 107326. https://doi.org/10.1016/j.msard.2026.107326.

Parodis, Ioannis, Julius Lindblom, Leonardo Palazzo, Alexander Tsoi, Nursen Cetrez, et al. 2025. “Poor Health-Related Quality of Life Despite Lupus Low Disease Activity State or Definitions of Remission in Systemic Lupus Erythematosus (SLE) Remission in Patients with SLE: Results from a Clinical Trial Setting.” RMD Open 11: e006061. https://doi.org/10.1136/rmdopen-2025-006061.

Parthasarathy, Geetha, and Shiva Kumar Goud Gadila. 2022. “Neuropathogenicity of Non-Viable Borrelia burgdorferi Ex Vivo.” Scientific Reports 12 (1): 688. https://doi.org/10.1038/s41598-021-03837-0.

Parthasarathy, Geetha, and Mario T Philipp. 2015. “Inflammatory Mediator Release from Primary Rhesus Microglia in Response to Borrelia burgdorferi Results from the Activation of Several Receptors and Pathways.” Journal of Neuroinflammation 12: 60. https://doi.org/10.1186/s12974-015-0274-z.

Patel, A., I. Chen, J. J. Iliff, M. Nedergaard, and A. Kastrup. 2024. “Venous Stasis and Glymphatic System Impairment: A Mechanistic Link to Chronic Fatigue Syndromes.” Fluids and Barriers of the CNS 21 (1): 89. https://doi.org/10.1186/s12987-024-00567-2.

Patrick, David M, Ruth R Miller, Jennifer L Gardy, SM Parker, Muhammad G Morshed, Theodore S Steiner, Joel Singer, Kaveh G Shojania, Patrick Tang, and Complex Chronic Disease Study Group. 2015. “Lyme Disease Diagnosed by Alternative Methods: A Phenotype Similar to That of Chronic Fatigue Syndrome.” Clinical Infectious Diseases 61 (7): 1084–91. https://doi.org/10.1093/cid/civ470.

Peacock, Brandon N, Teshome B Gherezghiher, Jennifer D Hilario, and Gottfried H Kellermann. 2015. “New Insights into Lyme Disease.” Redox Biology 5: 66–70. https://doi.org/10.1016/j.redox.2015.03.002.

Percin, Aysun, Ahmet Veli Ozden, Selma Yenisehir, et al. 2025. “Effects of Transcutaneous Auricular Vagus Nerve Stimulation on Fatigue in Post-COVID Syndrome: A Randomized, Single-Blind, Sham-Controlled Study.” International Journal of Clinical Practice 2025: 5641307. https://doi.org/10.1155/ijcp/5641307.

Petrasca, A, R Hambly, N Kearney, CM Smith, EK Pender, J Mac Mahon, AM O’Rourke, et al. 2023. “Metformin Has Anti-Inflammatory Effects and Induces Immunometabolic Reprogramming via Multiple Mechanisms in Hidradenitis Suppurativa.” British Journal of Dermatology 189 (6): 730–40. https://doi.org/10.1093/bjd/ljad305.

Petrov, S., M. Bozhkova, M. Ivanovska, T. Kalfova, D. Dudova, Y. Todorova, R. Dimitrova, and M. Murdjeva. 2026. “Comprehensive Immunophenotyping of Monocytes and Dendritic Cells Suggests Distinct Pathophysiology in Chronic Fatigue Syndrome and Long COVID.” International Journal of Molecular Sciences 27 (10): 4488. https://doi.org/10.3390/ijms27104488.

Platts-Mills, Thomas A E, Roopesh Singh Gangwar, Lisa Workman, and Jeffrey M Wilson. 2025. “The Immunology of Alpha-Gal Syndrome: History, Tick Bites, IgE, and Delayed Anaphylaxis to Mammalian Meat.” Immunological Reviews 332 (1): e70035. https://doi.org/10.1111/imr.70035.

Pollak, T A, R McCormack, M Peakman, T R Nicholson, and A S David. 2014. “Prevalence of Anti-N-Methyl-D-Aspartate (NMDA) Receptor Antibodies in Patients with Schizophrenia and Related Psychoses: A Systematic Review and Meta-Analysis.” Psychological Medicine 44 (12): 2475–87. https://doi.org/10.1017/S003329171300295X.

Popov, G., D. Bashchobanov, and R. Andonova. 2026. “Tick-Borne Co-Infection in Lyme Disease: Clinical Impact, Diagnostic Challenges, and Therapeutic Perspectives.” Microorganisms 14 (2): 325. https://doi.org/10.3390/microorganisms14020325.

Portilho, Amanda Izeli, Valéria Oliveira Silva, Hernan Hermes Monte Da Costa, Victor Hugo Silva, Ana Paula de Mattos Barbosa, Livia Melo Villar, and Elizabeth Natal De Gaspari. 2024. “An Unexpected IgE Anti-Receptor Binding Domain Response Following Natural Infection and Different Types of SARS-CoV-2 Vaccination.” Scientific Reports 14: 18950. https://doi.org/10.1038/s41598-024-71047-5.

Prens, LM, K Bouwman, LD Troelstra, EP Prens, BZ Alizadeh, and B Horváth. 2022. “New Insights in Hidradenitis Suppurativa from a Population-Based Dutch Cohort: Prevalence, Smoking Behaviour, Socioeconomic Status and Comorbidities.” British Journal of Dermatology 186 (5): 814–22. https://doi.org/10.1111/bjd.20954.

Purba, J. S., F. C. Raadsheer, M. A. Hofman, R. Ravid, C. H. Polman, W. Kamphorst, and D. F. Swaab. 1995. “Increased Number of Corticotropin-Releasing Hormone Expressing Neurons in the Hypothalamic Paraventricular Nucleus of Patients with Multiple Sclerosis.” Neuroendocrinology 62 (1): 62–70. https://doi.org/10.1159/000126989.

Quadt, Lisa, Jenny Csecs, Robert Bond, et al. 2024. “Childhood Neurodivergent Traits, Inflammation and Chronic Disabling Fatigue in Adolescence: A Longitudinal Case-Control Study.” BMJ Open 14 (7): e084203. https://doi.org/10.1136/bmjopen-2024-084203.

Raadsheer, F. C., W. J. Hoogendijk, F. C. Stam, F. J. Tilders, and D. F. Swaab. 1994. “Increased Numbers of Corticotropin-Releasing Hormone Expressing Neurons in the Hypothalamic Paraventricular Nucleus of Depressed Patients.” Neuroendocrinology 60 (4): 436–44. https://doi.org/10.1159/000126778.

Rachakatla, A, and RR Kalashikam. 2022. “Calorie Restriction-Regulated Molecular Pathways and Its Impact on Various Age Groups: An Overview.” DNA and Cell Biology 41 (5): 459–68. https://doi.org/10.1089/dna.2021.0922.

Raij, T., and K. Raij. 2024. “Association Between Fatigue, Peripheral Serotonin, and L-Carnitine in Hypothyroidism and in Chronic Fatigue Syndrome.” Frontiers in Endocrinology 15: 1358404. https://doi.org/10.3389/fendo.2024.1358404.

Ranathunga, N., M. Sterling, E. Sierra-Silvestre, J. Chen, A. B. Schmid, L. Bisset, M. W. Coppieters, and S. F. Farrell. 2026. “Small Nerve Fibre Pathology in Non-Neuropathic Chronic Pain Conditions: A Systematic Review and Meta-Analysis.” Pain 167 (3): 577–90. https://doi.org/10.1097/j.pain.0000000000003826.

Rauf, M., A. Naveed, and M. U. Asghar. 2026. “Post-Acute Sequelae of COVID-19: A Disorder of Impaired Innate Immune Resolution – A Narrative Review.” Clinical Immunology 277: 110701. https://doi.org/10.1016/j.clim.2026.110701.

Rauf, R., S. Asif, A. AlSaafeen, et al. 2025. “Orexin Deficiency in Narcolepsy: Molecular Mechanisms, Clinical Phenotypes, and Emerging Therapeutic Frontiers.” Brain and Behavior 15 (10): e70984. https://doi.org/10.1002/brb3.70984.

Repka-Ramirez, M S, K Naranch, Y J Park, A Velarde, D Clauw, and J N Baraniuk. 2001. “IgE Levels Are the Same in Chronic Fatigue Syndrome (CFS) and Control Subjects When Stratified for Atopic Status.” Annals of Allergy, Asthma and Immunology 86 (2): 175–80. https://doi.org/10.1016/S1081-1206(10)62229-6.

Ribeiro, A., T. Wallraven, M. Lech, K. Adorjan, H. C. Stubbe, M. Seifert, A. Wöhnl, V. Kesseler, J. Negele, and C. Schmaderer. 2026. “SARS-CoV-2 Spike S1-Mediated HIF-2α Activation in Retinal Endothelial Cells Suggests a Mechanism Contributing to Post-COVID Endothelial Dysfunction.” Frontiers in Immunology 17: 1770758. https://doi.org/10.3389/fimmu.2026.1770758.

Ring, HC, P Theut Riis, K Zarchi, IM Miller, DM Saunte, and GB Jemec. 2017. “Prodromal Symptoms in Hidradenitis Suppurativa.” Clinical and Experimental Dermatology 42 (3): 261–65. https://doi.org/10.1111/ced.13025.

Rizzuto, V., M. Laurino, R. Montanari, A. Gemignani, M. Figus, G. Covello, N. Candelise, D. Borroni, G. Laganovska, and L. Mesin. 2025. “Pupillary Hippus as a Biomarker: Spectral Signatures and Complexity Approaches in Autonomic and Clinical Contexts.” Bioengineering 12 (12): 1376. https://doi.org/10.3390/bioengineering12121376.

Robinson, M. J., M. R. Dowling, C. Pitt, K. O’Donnell, R. H. Webster, D. L. Hill, Z. Ding, et al. 2022. “Long-Lived Plasma Cells Accumulate in the Bone Marrow at a Constant Rate from Early in an Immune Response.” Science Immunology 7 (76): eabm8389. https://doi.org/10.1126/sciimmunol.abm8389.

Rocha, Sandra M, Tatiana Saraiva, Ana C Cristóvão, Raquel Ferreira, Tiago Santos, Marta Esteves, Cláudia Saraiva, et al. 2016. “Histamine Induces Microglia Activation and Dopaminergic Neuronal Toxicity via H1 Receptor Activation.” Journal of Neuroinflammation 13 (1): 137. https://doi.org/10.1186/s12974-016-0600-0.

Rodrigues, Tamara, Gabriel Salles Beltrão, Heloísa Girardi, and Aguinaldo R. Pinto. 2025. “Viral Reprogramming of Glial Metabolism as a Driver of Neuroinflammation.” Frontiers in Immunology 16: 1686774. https://doi.org/10.3389/fimmu.2025.1686774.

Roy, Saptarshi, Chalatip Chompunud Na Ayudhya, Manoj Thapaliya, Venkata Deepak, and Hydar Ali. 2021. “Multifaceted MRGPRX2: New Insight into the Role of Mast Cells in Health and Disease.” Journal of Allergy and Clinical Immunology 148 (2): 293–308. https://doi.org/10.1016/j.jaci.2021.03.049.

Ruan, BT, S Bulbule, B Gile, A Reyes, B Chheda, L Bateman, J Bell, et al. 2025. “Low-Dose Rapamycin Alleviates Clinical Symptoms of Fatigue and PEM in ME/CFS Patients via Improvement of Autophagy: A Pilot Study.” Journal of Translational Medicine 23: 1148. https://doi.org/10.1186/s12967-025-07213-8.

Rubio, Jose, and Vasileios C Kyttaris. 2023. “Undifferentiated Connective Tissue Disease: Comprehensive Review.” Current Rheumatology Reports 25: 98–106. https://doi.org/10.1007/s11926-023-01099-5.

Ruhrländer, Jana, Styliani Syntila, Elisabeth Schieffer, and Bernhard Schieffer. 2025. “The Orexin System and Its Impact on the Autonomic Nervous and Cardiometabolic System in Post-Acute Sequelae of COVID-19.” Biomedicines 13 (3): 545. https://doi.org/10.3390/biomedicines13030545.

Ruijgt, T. M. et al. 2026. “Wearable HRV Reveals Lower 24-Hour Post-Exercise Heart Rate Variability in Long COVID and Nighttime HRV Predicts PEM Above Ventilatory Threshold 1.” Journal of Translational Medicine 24: 487. https://doi.org/10.1186/s12967-026-05891-6.

Saarinen, J., N. Kalkkinen, H. G. Welgus, and P. T. Kovanen. 1994. “Activation of Human Interstitial Procollagenase Through Direct Cleavage of the Leu83-Thr84 Bond by Mast Cell Chymase.” Journal of Biological Chemistry 269 (27): 18134–40.

Sáez-Francàs, Naia, José Alegre, Neus Calvo, et al. 2012. “Attention-Deficit Hyperactivity Disorder in Chronic Fatigue Syndrome Patients.” Psychiatry Research 200 (2–3): 748–53. https://doi.org/10.1016/j.psychres.2012.04.041.

Saha, Arnab K. et al. 2025. “ME/CFS Red Blood Cell Deformability and Oxidative Stress.”

Saha, Sankhanil, Harini Krishnan, and Padinjat Raghu. 2023. “IMPA1 Dependent Regulation of Phosphatidylinositol 4,5-Bisphosphate and Calcium Signalling by Lithium.” Life Science Alliance 7 (2): e202302425. https://doi.org/10.26508/lsa.202302425.

Sakurai, T., A. Amemiya, M. Ishii, I. Matsuzaki, R. M. Chemelli, H. Tanaka, S. C. Williams, et al. 1998. “Orexins and Orexin Receptors: A Family of Hypothalamic Neuropeptides and G Protein-Coupled Receptors That Regulate Feeding Behavior.” Cell 92 (5): 573–85. https://doi.org/10.1016/S0092-8674(02)09256-5.

Sales, T., A. Daniel, L. Silva, A. Franco, H. Costa Filho, C. Monteiro, A. Ferreira, et al. 2026. “The Protease Inhibitor Darunavir Prevents Esophagitis and Impairments in Esophageal Barrier Function in a Mouse Model of GERD.” American Journal of Physiology — Gastrointestinal and Liver Physiology 330 (6): G718–26. https://doi.org/10.1152/ajpgi.00058.2025.

Samuel, Joyce P., Cynthia S. Bell, Joshua A. Samuels, Charanya Rajan, Ashley K. Walton, Charles Green, and Jon E. Tyson. 2023. “N-of-1 Trials Vs. Usual Care in Children with Hypertension: A Pilot Randomized Clinical Trial.” American Journal of Hypertension 36 (2): 126–32. https://doi.org/10.1093/ajh/hpac117.

Samuel, Joyce P., Jon E. Tyson, Charles Green, Cynthia S. Bell, Claudia Pedroza, Donald Molony, and Joshua Samuels. 2019. “Treating Hypertension in Children with n-of-1 Trials.” Pediatrics 143 (4): e20181818. https://doi.org/10.1542/peds.2018-1818.

Sander, L., G. Oommen, C. Brophy, S. Bohus-Roper, G. Chiaro, F. Bremner, and V. Iodice. 2025. “Validation of Monocular Pupillometry in Healthy Controls and Patients with Autonomic Dysfunction: Pupillary Biomarkers for Autonomic Failure.” European Journal of Neurology 32 (8): e70320. https://doi.org/10.1111/ene.70320.

Sandhu, D., S. Magor-Elliott, N. Petousi, N. Talbot, A. Bennett, and P. A. Robbins. 2026. “Alveolar Deadspace and Intrapulmonary Shunt in Healthy Individuals and in Individuals Who Have Recovered from COVID-19 Infection.” Experimental Physiology 111 (2): 556–67. https://doi.org/10.1113/EP092971.

Sandvik, M., K. Sørland, E. Leirgul, I. Rekeland, C. Stavland, O. Mella, and Ø. Fluge. 2023. “Endothelial Dysfunction in ME/CFS Patients.” PLoS One 18 (2): e0280942. https://doi.org/10.1371/journal.pone.0280942.

Santos Guedes de Sa, Silva, K. 2026. “A Causal Link Between Autoantibodies and Neurological Symptoms in Long COVID.” Cell 189 (11): 3214–3235.e37. https://doi.org/10.1016/j.cell.2026.04.044.

Sarbassov, Dos D, Siraj M Ali, Shomit Sengupta, Joon-Ho Sheen, Peggy P Hsu, Alex F Bagley, Andrew L Markhard, and David M Sabatini. 2006. “Prolonged Rapamycin Treatment Inhibits mTORC2 Assembly and Akt/PKB.” Molecular Cell 22 (2): 159–68. https://doi.org/10.1016/j.molcel.2006.03.029.

Sardell, Jessica M., S. Das, M. Pearson, J. Kozubek, K. Taylor, and A. Gardner. 2026. “Identification of Novel Reproducible Combinatorial Genetic Risk Factors for Myalgic Encephalomyelitis in the DecodeME Patient Cohort and Commonalities.” Journal of Translational Medicine 24: 420. https://doi.org/10.1186/s12967-026-08167-1.

Sauve, F., S. Nampoothiri, S. A. Clarke, D. Fernandois, C. F. F. Coelho, J. Dewisme, E. G. Mills, et al. 2023. “Long-COVID Cognitive Impairments and Reproductive Hormone Deficits in Men May Stem from GnRH Neuronal Death.” EBioMedicine 96: 104784. https://doi.org/10.1016/j.ebiom.2023.104784.

Scheibenbogen, Carmen, Madlen Loebel, Helma Freitag, Anne Krueger, Sandra Bauer, Michaela Antelmann, Wolfram Doehner, et al. 2018a. “Immunoadsorption to Remove Β2 Adrenergic Receptor Antibodies in Chronic Fatigue Syndrome.” PLoS One 13 (3): e0193672. https://doi.org/10.1371/journal.pone.0193672.

Scheibenbogen, Carmen, Madlen Loebel, Helma Freitag, Anne Krueger, Stephan Bauer, Madeleine Antelmann, Wolfram Doehner, et al. 2018b. “Immunoadsorption to Remove Beta2 Adrenergic Receptor Antibodies in Chronic Fatigue Syndrome CFS/ME.” PLOS ONE 13 (3): e0193672. https://doi.org/10.1371/journal.pone.0193672.

Scheibenbogen, Carmen, and Klaus J. Wirth. 2025. “Key Pathophysiological Role of Skeletal Muscle Disturbance in Post COVID and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS): Accumulated Evidence.” Journal of Cachexia, Sarcopenia and Muscle. https://doi.org/10.1002/jcsm.13669.

Schlecker, C., W. Boehmerle, A. Jeromin, B. DeGray, A. Varshney, Y. Sharma, K. Szigeti-Buck, and B. E. Ehrlich. 2006. “Neuronal Calcium Sensor-1 Enhancement of InsP3 Receptor Activity Is Inhibited by Therapeutic Levels of Lithium.” Journal of Clinical Investigation 116 (6): 1668–74. https://doi.org/10.1172/JCI22466.

Schmid, Jean-Paul, Markus Noveanu, Cyrill Morger, Raymond Gaillet, Mauro Capoferri, Matthias Anderegg, and Hugo Saner. 2007. “Influence of Water Immersion, Water Gymnastics and Swimming on Cardiac Output in Patients with Heart Failure.” Heart 93 (6): 722–27. https://doi.org/10.1136/hrt.2006.094870.

Scholz, Michael, Andrea E. Steuer, Akos Dobay, Hans-Peter Landolt, and Thomas Kraemer. 2026. “Leveraging the Metabolic Fingerprint of Sleep Deprivation and Sleep Restriction for Forensic Applications: A Machine Learning Study in Oral Fluid Metabolomics.” J Proteome Res, May. https://doi.org/10.1021/acs.jproteome.5c01064.

Schou, M, S G Sæther, K Borowski, B Teegen, D Kondziella, W Stoecker, A Vaaler, and S K Reitan. 2016. “Prevalence of Serum Anti-Neuronal Autoantibodies in Patients Admitted to Acute Psychiatric Care.” Psychological Medicine 46 (16): 3303–13. https://doi.org/10.1017/S0033291716002038.

Schreiner, Philipp, Thomas Harrer, Carmen Scheibenbogen, Stephanie Lamer, Andreas Schlosser, Robert K Naviaux, and Bhupesh K Prusty. 2020. “Human Herpesvirus-6 Reactivation, Mitochondrial Fragmentation, and the Coordination of Antiviral and Metabolic Phenotypes in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.” ImmunoHorizons 4 (4): 201–15. https://doi.org/10.4049/immunohorizons.2000006.

Schwarting, Andreas, Tamara Möckel, Freya Lütgendorf, Konstantinos Triantafyllias, Sophia Grella, et al. 2019. “Fatigue in SLE: Diagnostic and Pathogenic Impact of Anti-N-Methyl-D-Aspartate Receptor (NMDAR) Autoantibodies.” Annals of the Rheumatic Diseases 78: 1226–33. https://doi.org/10.1136/annrheumdis-2019-215098.

Seeley, M. C., H. O’Brien, G. Wilson, C. Coat, T. Smith, K. Hickson, R. Casse, A. J. Page, C. Gallagher, and D. H. Lau. 2025. “Novel Brain SPECT Imaging Unravels Abnormal Cerebral Perfusion in Patients with Postural Orthostatic Tachycardia Syndrome and Cognitive Dysfunction.” Scientific Reports 15 (1): 3487. https://doi.org/10.1038/s41598-025-87748-4.

Sendrowski, D. P., E. A. Buker, and S. S. Gee. 1997. “An Investigation of Sympathetic Hypersensitivity in Chronic Fatigue Syndrome.” Optometry and Vision Science 74 (8): 660–63. https://doi.org/10.1097/00006324-199708000-00027.

Sepúlveda, Nuno, Jorge Carneiro, Eliana Lacerda, and Luis Nacul. 2019. “Myalgic Encephalomyelitis/Chronic Fatigue Syndrome as a Hyper-Regulated Immune System Driven by an Interplay Between Regulatory t Cells and Chronic Human Herpesvirus Infections.” Frontiers in Immunology 10: 2684. https://doi.org/10.3389/fimmu.2019.02684.

Serhan, C. N., S. Libreros, and R. Nshimiyimana. 2022. “E-Series Resolvin Metabolome, Biosynthesis and Critical Role of Stereochemistry of Specialized Pro-Resolving Mediators (SPMs) in Inflammation-Resolution: Preparing SPMs for Long COVID-19, Human Clinical Trials, and Targeted Precision Nutrition.” Seminars in Immunology 59: 101597. https://doi.org/10.1016/j.smim.2022.101597.

Serrano, Maria-Eleni, Eugene Kim, Marija M. Petrinovic, Federico Turkheimer, and Diana Cash. 2022. “Imaging Synaptic Density: The Next Holy Grail of Neuroscience?” Frontiers in Neuroscience 16: 796129. https://doi.org/10.3389/fnins.2022.796129.

Shen, J., Y. Lai, Y. Lu, Y. Liu, J. Zhang, Y. Wu, Y. Pan, et al. 2024. “NRF2-HIF2α Signaling Attenuates Endothelial Cell Senescence and Maintains Intercellular Junctions in Diabetes.” International Journal of Biological Sciences 20 (10): 4055–73. https://doi.org/10.7150/ijbs.96719.

Shor, Samuel. 2011. “Seronegative Chronic Lyme Disease in a Large Proportion of Patients with Internationally-Defined Chronic Fatigue Syndrome.” San Francisco, CA: Presentation at IACFS/ME Biennial Conference.

Sikorav, Michael. 2026. “Ultra-Low-Dose Lithium Citrate for Recurrent Brief Depressive Episodes with Sensory Hypersensitivity: A Self-Experiment Case Report.” Psychiatrie Internationale (independent journal). June 2026.

Skowera, A, A Cleare, D Blair, L Bevis, S C Wessely, and M Peakman. 2004. “High Levels of Type 2 Cytokine-Producing Cells in Chronic Fatigue Syndrome.” Clinical and Experimental Immunology 135 (2): 294–302. https://doi.org/10.1111/j.1365-2249.2004.02354.x.

Slifka, Mark K., and Ian J. Amanna. 2019. “Role of Multivalency and Antigenic Threshold in Generating Protective Antibody Responses.” Frontiers in Immunology 10: 956. https://doi.org/10.3389/fimmu.2019.00956.

Smit, Alexander, Philipp Fleischmann, Thomas S Knauer, Christian Y Mardin, Georg Michelson, Julia Zott, Moritz Güttes, et al. 2026. “Task-Evoked Pupillary Dynamics Are Altered in Post-COVID Syndrome.” Medical Sciences 14 (2): 269. https://doi.org/10.3390/medsci14020269.

Soejima, Yuji, Takao Munemoto, Akinori Masuda, Yuuki Uwatoko, Masaaki Miyata, and Chuwa Tei. 2015. “Effects of Waon Therapy on Chronic Fatigue Syndrome: A Pilot Study.” Internal Medicine 54 (3): 333–38. https://doi.org/10.2169/internalmedicine.54.3042.

Sommer, C., and N. Üçeyler. 2025. “Small Fiber Pathology in Fibromyalgia Syndrome.” Pain Reports 10 (1): e1223.

Sommerfelt, Knut, Trude Schei, Kathleen A. Seton, and Simon R. Carding. 2024. “Assessing Functional Capacity in Myalgic Encephalopathy/Chronic Fatigue Syndrome: A Patient-Informed Questionnaire.” Journal of Clinical Medicine 13 (12): 3486. https://doi.org/10.3390/jcm13123486.

Sousa, Ricardo Augusto Leoni, Amr Yehia, and Osama A. Abulseoud. 2023. “Attenuation of Ferroptosis as a Potential Therapeutic Target for Neuropsychiatric Manifestations of Post-COVID Syndrome.” Frontiers in Neuroscience 17: 1237153. https://doi.org/10.3389/fnins.2023.1237153.

Stachowicz, K. 2023. “Regulation of COX-2 Expression by Selected Trace Elements and Heavy Metals: Health Implications, and Changes in Neuronal Plasticity. A Review.” Journal of Trace Elements in Medicine and Biology 79: 127226. https://doi.org/10.1016/j.jtemb.2023.127226.

Stanculescu, Dominic, Nuno Sepúlveda, Chin Leong Lim, and Jonas Bergquist. 2021. “Lessons from Heat Stroke for Understanding Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.” Frontiers in Neurology 12: 789784. https://doi.org/10.3389/fneur.2021.789784.

Standley, R. A., G. Distefano, S. L. Pereira, M. Tian, O. J. Kelly, P. M. Coen, N. E. P. Deutz, R. R. Wolfe, and B. H. Goodpaster. 2017. “Effects of ${\beta}$-Hydroxy-${\beta}$-Methylbutyrate on Skeletal Muscle Mitochondrial Content and Dynamics, and Lipids After 10 Days of Bed Rest in Older Adults.” Journal of Applied Physiology 123 (5): 1092–1100. https://doi.org/10.1152/japplphysiol.00192.2017.

Stefanakis, K., T. Karagiannis, A. I. Hatzitolios, and D. Baltzis. 2024. “The Impact of Weight Loss on Fat-Free Mass, Muscle, Bone and Hematopoiesis Health.” Metabolism 158: 156057. https://doi.org/10.1016/j.metabol.2024.156057.

Stein, E., C. Heindrich, K. Wittke, C. Kedor, R. Rust, H. Freitag, F. Sotzny, et al. 2025. “Efficacy of Repeated Immunoadsorption in Patients with Post-COVID Myalgic Encephalomyelitis/Chronic Fatigue Syndrome and Elevated Β2-Adrenergic Receptor Autoantibodies: A Prospective Cohort Study.” The Lancet Regional Health — Europe 49: 101161. https://doi.org/10.1016/j.lanepe.2024.101161.

Stein, Elisa, Cornelia Heindrich, Kirsten Wittke, Claudia Kedor, Rebekka Rust, Helma Freitag, Franziska Sotzny, et al. 2025. “Efficacy of Repeated Immunoadsorption in Patients with Post-COVID Myalgic Encephalomyelitis/Chronic Fatigue Syndrome and Elevated Beta2-Adrenergic Receptor Autoantibodies: A Prospective Cohort Study.” The Lancet Regional Health - Europe 48: 101161. https://doi.org/10.1016/j.lanepe.2024.101161.

Strayer, D. R., D. Young, and W. M. Mitchell. 2020. “Effect of Disease Duration in a Randomized Phase III Trial of Rintatolimod, an Immune Modulator for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.” PLoS ONE 15 (10): e0240403. https://doi.org/10.1371/journal.pone.0240403.

Sulheim, Dag, Even Fagermoen, Anette Winger, Anders M. Andersen, Kristin Godang, Fredrik Müller, Peter C. Rowe, and J. Philip Saul. 2014. “Disease Mechanisms and Clonidine Treatment in Adolescent Chronic Fatigue Syndrome: A Combined Cross-Sectional and Randomized Clinical Trial.” JAMA Pediatrics 168 (4): 351–60. https://doi.org/10.1001/jamapediatrics.2013.4647.

Sun, Haoyu, Edward J Calabrese, Zhifen Lin, Baoling Lian, and Xiaoxian Zhang. 2020. “Similarities Between the Yin/Yang Doctrine and Hormesis in Toxicology and Pharmacology.” Trends in Pharmacological Sciences 41 (8): 544–56. https://doi.org/10.1016/j.tips.2020.05.004.

Sun, Haoyu, Edward J Calabrese, Min Zheng, Dali Wang, Yong Pan, Zhifen Lin, and Ying Liu. 2018. “A Swinging Seesaw as a Novel Model Mechanism for Time-Dependent Hormesis Under Dose-Dependent Stimulatory and Inhibitory Effects: A Case Study on the Toxicity of Antibacterial Chemicals to Aliivibrio Fischeri.” Chemosphere 205: 15–23. https://doi.org/10.1016/j.chemosphere.2018.04.043.

Sun, Y., Z. Zhang, Q. Qiao, Y. Zou, L. Wang, T. Wang, B. Lou, et al. 2024. “Immunometabolic Changes and Potential Biomarkers in CFS Peripheral Immune Cells Revealed by Single-Cell RNA Sequencing.” Journal of Translational Medicine 22 (1): 925. https://doi.org/10.1186/s12967-024-05710-w.

Sunami, Y. et al. 2024. “Anti-GPCR Autoantibodies in POTS.” Immunological Medicine 48 (2): 141–48. https://doi.org/10.1080/25785826.2024.2370079.

Szklarski, M., H. Freitag, S. Lorenz, S. C. Becker, F. Sotzny, S. Bauer, J. Hartwig, et al. 2021. “Delineating the Association Between Soluble CD26 and Autoantibodies Against G-Protein Coupled Receptors, Immunological and Cardiovascular Parameters Identifies Distinct Patterns in Post-Infectious Vs. Non-Infection-Triggered Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.” Frontiers in Immunology 12: 644548. https://doi.org/10.3389/fimmu.2021.644548.

Tak, L. M., A. J. Cleare, J. Ormel, A. Manoharan, I. C. Kok, S. Wessely, and J. G. Rosmalen. 2011. “Meta-Analysis and Meta-Regression of Hypothalamic-Pituitary-Adrenal Axis Activity in Functional Somatic Disorders.” Biological Psychology 87 (2): 183–94. https://doi.org/10.1016/j.biopsycho.2011.02.002.

Tan, Cuiyan, Xiaobin Zheng, Fengfei Sun, Jianzhong He, Honglei Shi, Meizhu Chen, Changli Tu, et al. 2022. “Hypersensitivity May Be Involved in Severe COVID-19.” Clinical and Experimental Allergy 52 (2): 324–33. https://doi.org/10.1111/cea.14023.

Tavakoli, M., M. Ferdousi, I. N. Petropoulos, J. Morris, N. Pritchard, A. Zhivov, D. Ziegler, et al. 2015. “Normative Values for Corneal Nerve Morphology Assessed Using Corneal Confocal Microscopy: A Multinational Normative Data Set.” Diabetes Care 38 (5): 838–43. https://doi.org/10.2337/dc14-2311.

Terman, Julia M, Jessica M Awsumb, Joseph Cotler, and Leonard A Jason. 2020. “Confirmatory Factor Analysis of a Myalgic Encephalomyelitis and Chronic Fatigue Syndrome Stigma Scale.” Journal of Health Psychology 25 (14): 2352–61. https://doi.org/10.1177/1359105318796906.

Terman, Julia M, Joseph Cotler, and Leonard A Jason. 2019. “How Psychiatric Referrals Influence Stigmatization in Patients with Myalgic Encephalomyelitis and Chronic Fatigue Syndrome: An Examination of American and British Models.” Community Psychology in Global Perspective 5 (2): 19–29. https://doi.org/10.1285/i24212113v5i2p19.

Theoharides, T C, C Spanos, X Pang, L Alferes, K Ligris, R Letourneau, J J Rozniecki, E Webster, and G P Chrousos. 1995. “Stress-Induced Intracranial Mast Cell Degranulation: A Corticotropin-Releasing Hormone Mediated Effect.” Endocrinology 136 (12): 5745–50. https://doi.org/10.1210/endo.136.12.7588332.

Thorpe, D. W., L. A. Jones, A. M. Martin, R. A. Coleman, C. Allman, R. A. Peterson, and D. J. Keating. 2026. “The Role of Peripheral Serotonin in SARS-CoV-2 Infectivity, COVID-19 Treatment and Long COVID.” Immunology and Cell Biology 104 (4): 368–76. https://doi.org/10.1111/imcb.70097.

Tölle, Markus, Helma Freitag, Michaela Antelmann, Jelka Hartwig, Mirjam Schuchardt, Markus van der Giet, Kai-Uwe Eckardt, Patricia Grabowski, and Carmen Scheibenbogen. 2020. “Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Efficacy of Repeat Immunoadsorption.” Journal of Clinical Medicine 9 (8): 2443. https://doi.org/10.3390/jcm9082443.

Toricelli, Mariana, Sebastiana Ribeiro Evangelista, Hudson Sousa Buck, and Tania Araujo Viel. 2021. “Microdose Lithium Treatment Reduced Inflammatory Factors and Neurodegeneration in Organotypic Hippocampal Culture of Old SAMP-8 Mice.” Cellular and Molecular Neurobiology 41 (7): 1509–20. https://doi.org/10.1007/s10571-020-00916-0.

Tracey, Kevin J. 2002. “The Inflammatory Reflex.” Nature 420 (6917): 853–59. https://doi.org/10.1038/nature01321.

Treadway, Michael T, Joshua W Buckholtz, Robin L Cowan, Neil D Woodward, Rui Li, M Salah Ansari, Ronald M Baldwin, Ariel N Schwartzman, Ronald M Kessler, and David H Zald. 2012. “Dopaminergic Mechanisms of Individual Differences in Human Effort-Based Decision-Making.” Journal of Neuroscience 32 (18): 6170–76. https://doi.org/10.1523/JNEUROSCI.6459-11.2012.

Tsilioni, Irene, Benjamin Natelson, and Theoharis C. Theoharides. 2022. “Exosome-Associated Mitochondrial DNA from Patients with ME/CFS Stimulates Human Microglia to Release IL-1$\beta$.” European Journal of Neuroscience 56 (10): 5784–94. https://doi.org/10.1111/ejn.15828.

Tsilioni, Irene, and Theoharis C Theoharides. 2023. “SARS-CoV-2 Spike Protein Stimulates Human Microglia to Release MMP-9.” International Journal of Molecular Sciences 24 (17): 13256. https://doi.org/10.3390/ijms241713256.

Ussher, Jake. 2025. Understanding ME/CFS & Strategies for Healing. Self-published.

VanElzakker, Michael B. 2013. “Chronic Fatigue Syndrome from Vagus Nerve Infection: A Psychoneuroimmunological Hypothesis.” Medical Hypotheses 81 (3): 414–23. https://doi.org/10.1016/j.mehy.2013.05.034.

Vazquez, G., J. P. Abonia, J. Hallgren, J. M. Fahrenholz, A. M. Stevens, C. Akin, J. T. Lyden, et al. 2022. “Hereditary Alpha Tryptasemia Does Not Concentrate in Hypermobility Disorders.” Journal of Allergy and Clinical Immunology 149 (2): 416–426.e7. https://doi.org/10.1016/j.jaci.2021.09.036.

Vergés, Cristina, Ana Giménez-Capitán, Victòria Ribas, Elena Martínez-Pérez, M. José González, and Francesc March de Ribot. 2025. “Clinical and Genetic Profiling of Fibromyalgia-Associated Dry Eye: A Multifactorial Approach.” The Ocular Surface 38: 377–87. https://doi.org/10.1016/j.jtos.2025.10.012.

Verma, Poonam, Alpana Singh, Dominic Ngima Nthenge-Ngumbau, Usha Rajamma, Swagata Sinha, Kanchan Mukhopadhyay, and Kochupurackal P Mohanakumar. 2016. “Attention Deficit-Hyperactivity Disorder Suffers from Mitochondrial Dysfunction.” BBA Clinical 6: 153–58. https://doi.org/10.1016/j.bbacli.2016.10.003.

Walitt, Brian, Komudi Singh, Samuel R LaMunion, et al. 2024. “Deep Phenotyping of Post-Infectious Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.” Nature Communications 15 (1): 907. https://doi.org/10.1038/s41467-024-45107-3.

Walitt, Brian, Komudi Singh, Samuel R LaMunion, Mark Hallett, Sandra Jacobson, Kong Chen, Yoshihisa Enose-Akahata, et al. 2024. “Deep Phenotyping of Post-Infectious Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.” Nature Communications 15 (1): 907. https://doi.org/10.1038/s41467-024-45107-3.

Wallukat, Gerd et al. 2021. “Functional Autoantibodies Against GPCRs in Long COVID.” Journal of Translational Autoimmunity 4: 100100. https://doi.org/10.1016/j.jtauto.2021.100100.

Wang, L et al. 2025. “Prevalence of Circulating Autoantibodies Against g-Protein Coupled Receptors in Long COVID.” International Journal of Molecular Sciences 27 (4): 1787.

Wang, Yan, Xian Jiang, Jing Li, and Xue Li. 2025. “Predictive Value of Dry Eye Disease Signs and Corneal in Vivo Confocal Microscopy on Serological Activity in Primary Sjögren Disease.” Medicine 104 (14): e42054. https://doi.org/10.1097/MD.0000000000042054.

Watt, T., S. Oberfoell, R. Balise, M. R. Lunn, A. K. Kar, L. Merrihew, M. S. Bhangoo, and J. G. Montoya. 2012. “Response to Valganciclovir in Chronic Fatigue Syndrome Patients with Human Herpesvirus 6 and Epstein-Barr Virus IgG Antibody Titers.” Journal of Medical Virology 84 (12): 1967–74. https://doi.org/10.1002/jmv.23411.

Wawrzeniak, Keith, Gauri Gaur, Eva Sapi, and Alireza G Senejani. 2020. “Effect of Borrelia burgdorferi Outer Membrane Vesicles on Host Oxidative Stress Response.” Antibiotics 9 (5): 275. https://doi.org/10.3390/antibiotics9050275.

Weijs, P. J. M., and R. R. Wolfe. 2025. “Protein Requirement in Obesity.” Current Opinion in Clinical Nutrition and Metabolic Care 28 (3): 231–37. https://doi.org/10.1097/MCO.0000000000001087.

Weissman-Tsukamoto, Rachel, Kaitlin R Carroll, and Betty Diamond. 2025. “Diffuse Neuropsychiatric Lupus: Clinical Evidence, Immune-Mediated Mechanisms, and Therapeutic Insights.” Seminars in Immunology 78: 101981. https://doi.org/10.1016/j.smim.2025.101981.

Wendeln, Anna C., Katrin Degenhardt, Lisa Kauber, Martina Gertig, et al. 2018. “Innate Immune Memory in the Brain Shapes Neurological Disease Hallmarks.” Nature 556: 332–38. https://doi.org/10.1038/s41586-018-0023-4.

Weymann, K. B., L. J. Wood, X. Zhu, and D. L. Marks. 2014. “A Role for Orexin in Cytotoxic Chemotherapy-Induced Fatigue.” Brain, Behavior, and Immunity 37: 84–94. https://doi.org/10.1016/j.bbi.2013.11.003.

Widjaja, Anissa A, Wei-Wen Lim, Sivakumar Viswanathan, Sonia Chothani, Benjamin Corden, Chee M Dasan, Jolin W T Goh, et al. 2024. “Inhibition of IL-11 Signalling Extends Mammalian Healthspan and Lifespan.” Nature 632: 1–9. https://doi.org/10.1038/s41586-024-07701-9.

Wilding, J. P. H., R. L. Batterham, S. Calanna, M. Davies, L. F. Van Gaal, I. Lingvay, B. M. McGowan, et al. 2021. “Once-Weekly Semaglutide in Adults with Overweight or Obesity.” New England Journal of Medicine 384 (11): 989–1002. https://doi.org/10.1056/NEJMoa2032183.

Wilhelm, F, J Cadamuro, and S Mink. 2025. “Autoantibodies in Long COVID: A Systematic Review.” The Lancet Infectious Diseases, S1473-3099(25)00411-6. https://doi.org/10.1016/S1473-3099(25)00411-6.

Williams, Grant E, Sharon Hausman-Cohen, Maryelaine Sotos, Emily Gutierrez, Carol Bilich, Francis W Mueller, and Shaun Jagshi. 2025. “The Role of GCH1 Deficiency and Tetrahydrobiopterin in Mental Health.” International Journal of Molecular Sciences 26 (16): 8030. https://doi.org/10.3390/ijms26168030.

Wilson, F. C., D. J. Zangerle, L. E. Rozen, J. J. Fliess, A. A. Darakjian, K. A. Sacco, C. Hamilton, et al. 2026. “Mast Cell Score Associates with Wide-Spread Mast Cell Symptoms and Comorbidities in Patients with hEDS and HSD.” medRxiv [Preprint]. https://doi.org/10.64898/2026.05.31.26354552.

Wilson, Jeffrey M, Loren Erickson, Michael Levin, Samuel M Ailsworth, Scott P Commins, and Thomas A E Platts-Mills. 2024. “Tick Bites, IgE to Galactose-Alpha-1,3-Galactose and Urticarial or Anaphylactic Reactions to Mammalian Meat: The Alpha-Gal Syndrome.” Allergy 79 (6): 1440–54. https://doi.org/10.1111/all.16003.

Winkler, Andrea S., David Blair, John T. Marsden, Tim J. Peters, Simon Wessely, and Anthony J. Cleare. 2004. “Autonomic Function and Serum Erythropoietin Levels in Chronic Fatigue Syndrome.” Journal of Psychosomatic Research 56 (2): 179–83. https://doi.org/10.1016/S0022-3999(03)00514-8.

Winkler, B. et al. 2016. “Catecholamine Responses in Chronic Fatigue Syndrome.” Neurological Sciences 37 (12): 1933–39. https://doi.org/10.1007/s10072-016-2699-0.

Wirth, K. J., and C. Scheibenbogen. 2026. “Imbalance of Excitatory and Inhibitory Neurotransmitter Systems in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.” International Journal of Molecular Sciences 27 (9): 4041. https://doi.org/10.3390/ijms27094041.

Wirth, Klaus J., and Carmen Scheibenbogen. 2026. “Imbalance of Excitatory and Inhibitory Neurotransmitter Systems in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.” International Journal of Molecular Sciences 27 (9): 4041. https://doi.org/10.3390/ijms27094041.

Wirth, K., and M. Löhn. 2024. “Microvascular Capillary and Precapillary Cardiovascular Disturbances Strongly Interact to Severely Affect Tissue Perfusion and Mitochondrial Function in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Evolving from the Post-COVID-19 Syndrome.” Medicina (Kaunas) 60 (2): 194. https://doi.org/10.3390/medicina60020194.

Wollersheim, T., K. Haas, S. Wolf, K. Mai, C. Spies, E. Steinhagen-Thiessen, K. D. Wernecke, J. Spranger, and S. Weber-Carstens. 2017. “Whole-Body Vibration to Prevent Intensive Care Unit-Acquired Weakness: Safety, Feasibility, and Metabolic Response.” Critical Care 21 (1): 9. https://doi.org/10.1186/s13054-016-1576-y.

Wolpert, Lewis M., Mark R. Back, Kirk P. Mayer, Dennis F. Bandyk, and Gordon B. Zwald. 2020. “Iliac Vein Stenting in the Treatment of May-Thurner Syndrome: Long-Term Outcomes.” Journal of Vascular Surgery: Venous and Lymphatic Disorders 8 (2): 251–58. https://doi.org/10.1016/j.jvsv.2019.08.015.

Wong, A. C., A. S. Devason, I. C. Umana, et al. 2023. “Serotonin Reduction in Post-Acute Sequelae of Viral Infection.” Cell 186 (22): 4851–4867.e20. https://doi.org/10.1016/j.cell.2023.09.013.

Woo, Marcel S, Mohsin Shafiq, Antonia Fitzek, Matthias Dottermusch, Hermann Altmeppen, Behnam Mohammadi, Christina Mayer, et al. 2023. “Vagus Nerve Inflammation Contributes to Dysautonomia in COVID-19.” Acta Neuropathologica 146 (3): 387–94. https://doi.org/10.1007/s00401-023-02612-x.

Wu, Kevin Y., Omar Serhan, Antoine Faucher, and Simon D. Tran. 2024. “Advances in Sjögren’s Syndrome Dry Eye Diagnostics: Biomarkers and Biomolecules Beyond Clinical Symptoms.” Biomolecules 14 (1): 80. https://doi.org/10.3390/biom14010080.

Wyller, Vegard Bruun, Kristin Godang, Lars Mørkrid, Jerome Philip Saul, Erik Thaulow, and Lars Walløe. 2007. “Abnormal Thermoregulatory Responses in Adolescents with Chronic Fatigue Syndrome: Relation to Clinical Symptoms.” Pediatrics 120 (1): e129–37. https://doi.org/10.1542/peds.2006-2759.

Yang, L., T. W. Kim, Y. Han, M. S. Nair, O. Harschnitz, J. Zhu, P. Wang, et al. 2024. “SARS-CoV-2 Infection Causes Dopaminergic Neuron Senescence.” Cell Stem Cell 31 (2): 196–211.e6. https://doi.org/10.1016/j.stem.2023.12.012.

Yokokura, Masamichi, Kenji Takedera, Ken Kazumata, et al. 2021. “In Vivo Imaging of Dopamine D1 Receptor and Activated Microglia in Attention-Deficit/Hyperactivity Disorder: A Positron Emission Tomography Study.” Molecular Psychiatry 26 (9): 4958–67. https://doi.org/10.1038/s41380-020-0784-1.

Young, James L, Lucinda Bateman, Sonia Helliwell, Nancy G Klimas, Ilene S Ruhoy, and Thomas S Kilduff. 2025. “Solriamfetol Improves Daily Fatigue Symptoms in Adults with ME/CFS After 8 Weeks of Treatment.” Journal of Psychopharmacology 39 (11): 1268–76. https://doi.org/10.1177/02698811251368371.

Yu, Wen, Shuang Geng, Yan Suo, Xuejiao Wei, Qing Cai, Ben Wu, Xianzheng Zhou, Yuling Shi, and Baoxiang Wang. 2018. “Critical Role of Regulatory t Cells in the Latency and Stress-Induced Reactivation of HSV-1.” Cell Reports 25 (9): 2379–2389.e3. https://doi.org/10.1016/j.celrep.2018.10.105.

Zabriskie, Heather A. 2022. “Rationale and Feasibility of Resistance Training in hEDS/HSD: A Narrative Review.” Journal of Functional Morphology and Kinesiology 7 (3): 61. https://doi.org/10.3390/jfmk7030061.

Zhang, J., D. Chen, P. Deming, T. Srirangarajan, J. E. Theriault, P. A. Kragel, L. Hartley, K. M. Lee, K. McVeigh, and T. D. Wager. 2025. “Cortical and Subcortical Mapping of the Human Allostatic-Interoceptive System Using 7 Tesla fMRI.” Nature Neuroscience 28 (11): 2380–91. https://doi.org/10.1038/s41593-025-02087-x.

Zhang, Y., L. Cao, R. Zhang, W. Pi, V. Wee Yong, and M. Xue. 2026. “Oxidative Stress as the Orchestrator of the HIF Axis Switch in Intracerebral Hemorrhage.” Free Radical Biology and Medicine 244: 312–22. https://doi.org/10.1016/j.freeradbiomed.2025.12.011.

Zhang, Z, X Ma, Z Xia, J Chen, Y Liu, Y Chen, J Zhu, et al. 2017. “NLRP3 Inflammasome Activation Mediates Fatigue-Like Behaviors in Mice via Neuroinflammation.” Neuroscience 358: 115–23. https://doi.org/10.1016/j.neuroscience.2017.06.048.

Zhang, ZT, XM Du, XJ Ma, Y Zong, JK Chen, CL Yu, YG Liu, YC Chen, LJ Zhao, and GC Lu. 2016. “Activation of the NLRP3 Inflammasome in Lipopolysaccharide-Induced Mouse Fatigue and Its Relevance to Chronic Fatigue Syndrome.” Journal of Neuroinflammation 13 (1): 71. https://doi.org/10.1186/s12974-016-0539-1.

Zhu, J., D. Sun, G. Zeng, K. Wu, X. Yang, X. Zhu, D. Aierken, et al. 2026. “Histaminylation Alters Collagen Matrix Mechanics and Attenuates Cardiac Fibrosis Post-Myocardial Infarction via Mechanotransduction Signaling Axis.” Signal Transduction and Targeted Therapy 11 (1): 229. https://doi.org/10.1038/s41392-026-02721-5.